The Identification Of A Novel Mechanism By Which Vincristine Sulphate Causes Painful Peripheral Neuropathy by Old, Liz & Old, Elizabeth
This electronic thesis or dissertation has been 











The copyright of this thesis rests with the author and no quotation from it or information derived from it 
may be published without proper acknowledgement. 
 
Take down policy 
If you believe that this document breaches copyright please contact librarypure@kcl.ac.uk providing 
details, and we will remove access to the work immediately and investigate your claim. 
END USER LICENCE AGREEMENT                                                                         
This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 
International licence. https://creativecommons.org/licenses/by-nc-nd/4.0/ 
You are free to: 
 Share: to copy, distribute and transmit the work  
 
Under the following conditions: 
 Attribution: You must attribute the work in the manner specified by the author (but not in any 
way that suggests that they endorse you or your use of the work).  
 Non Commercial: You may not use this work for commercial purposes. 
 No Derivative Works - You may not alter, transform, or build upon this work. 
 
Any of these conditions can be waived if you receive permission from the author. Your fair dealings and 








The Identification Of A Novel Mechanism By Which Vincristine Sulphate Causes
Painful Peripheral Neuropathy
Old, Elizabeth Amy; Old, Elizabeth Amy
Awarding institution:
King's College London
Download date: 06. Nov. 2017
This electronic theses or dissertation has been 
downloaded from the King’s Research Portal at 
https://kclpure.kcl.ac.uk/portal/  
 Author: Elizabeth Old
The copyright of this thesis rests with the author and no quotation from it or 
information derived from it may be published without proper acknowledgement. 
Take down policy 
If you believe that this document breaches copyright please contact librarypure@kcl.ac.uk 
providing details, and we will remove access to the work immediately and investigate your claim. 
END USER LICENSE AGREEMENT  
This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivs 3.0 
Unported License. http://creativecommons.org/licenses/by-nc-nd/3.0/  
You are free to: 
Share: to copy, distribute and transmit the work 
Under the following conditions: 
Attribution: You must attribute the work in the manner specified by the author (but not in 
any way that suggests that they endorse you or your use of the work).  
Non Commercial: You may not use this work for commercial purposes. 
No Derivative Works - You may not alter, transform, or build upon this work. 
Any of these conditions can be waived if you receive permission from the author. Your fair dealings 
and other rights are in no way affected by the above. 
 
Title: The Identification Of A Novel Mechanism By Which Vincristine Sulphate Causes Painful 
Peripheral Neuropathy
1 
The Identification Of A Novel Mechanism By 
Which Vincristine Sulphate Causes Painful 
Peripheral Neuropathy 
Elizabeth Amy Old 
Thesis presented for the degree of 
Doctor of Philosophy 
at King’s College London 
Wolfson Centre for Age Related Diseases 






An estimated thirteen million new cancers are diagnosed every year and in many cases patients 
will be treated with chemotherapeutic agents, either with curative intent or to prolong life and 
alleviate symptoms. Historically the dose limiting side-effect of these compounds was immune- 
and myelosupression, however, as our ability to manage these has improved, a secondary dose-
limiting side-effect of these compounds has been revealed: neurotoxicity.  
 
Several anti-neoplastics, including the vinca alkaloids, cause a distal, bilateral and symmetrical 
painful peripheral neuropathy primarily affecting the longest neurons of the extremities. The key 
symptom of this condition is pain, yet current therapies are ineffective in alleviating this; the 
average patient rates their pain as a seven out of ten in severity and pain results cessation of 
treatment in up to 40% of patients.  
 
One of the main pitfalls in the development of analgesics for this condition is that little is 
understood about the mechanism by which chemotherapy causes neuropathy. Thus, I have aimed 
to delineate a novel pathway of the mechanism by which vincristine sulphate (VCR) induces 
painful peripheral neuropathy.  
 
The pathway delineated is based on the observation that there is significant monocyte-
macrophage infiltration of the peripheral nerves following VCR administration, in a temporal 
profile similar to that of the onset of mechanical allodynia (a painful response to normally 
innocuous stimuli) in the mouse, and that depletion of monocyte/macrophages prior to VCR 
administration attenuates allodynia. Whilst this depletion is not a viable therapeutic option for 
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patients, it has led us to investigate of the contribution to the development of pain of the CX3CR1 
receptor, the level of expression of which is the defining characteristic of monocyte/macrophages.  
 
We have established that CX3CR1 plays a critical role in the development of VCR-neuropathy; mice 
devoid of CX3CR1 exhibit a delay in the onset of allodynia and a reduction in VCR-induced nerve 
infiltration of CX3CR1
+ monocyte/macrophages. We have demonstrated that this infiltration is 
likely a result of up-regulation of monocyte adhesion molecules on the endothelial cells lining 
blood vessels. Furthermore, we suggest that at the blood-nerve interface CX3CR1
+ 
monocytes/macrophages are activated by CX3CL1, endogenously expressed on endothelial cells, 
promoting the production of reactive oxygen species, which subsequently activate the TRPA1 
receptor on sensory neurons. 
 
This work has led to the conclusion that CX3CR1 antagonists constitute new peripheral targets for 
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23B1. Chemotherapy  
 
Every year, worldwide, an estimated thirteen million new cancers are diagnosed; this number is 
expected to rise to over twenty million by 2030 (Ferlay et al., 2010). Whilst cancer accounts for 
approximately thirteen percent of deaths world-wide (Ferlay et al., 2010) in many cases, 
depending on the type and stage of cancer diagnosed, patients can be treated with 
chemotherapeutic agents, either with curative intent or to prolong life and alleviate symptoms. 
 
45B1.1. Chemotherapeutic Agents - Classes & Use 
 
Chemotherapy is the use of a standardised regime of the administration one or more cytotoxic 
anti-neoplastic compounds to kill cancerous cells. A large variety of anti-neoplastics are used in 
the clinic, either singly or in combination; the selection of a compound is based on type and stage 
of cancer. However these drugs can be broadly categorised into four main groups based on their 
mechanism of action: alkylating agents, anti-metabolics, natural compounds and molecular 
targeted therapies. 
 
102B .1.1. Alkylating Agents 
Alkylating agents impair cell function by forming covalent bonds with amino, carboxyl, sulfhydryl 
and phosphate groups in biologically important molecules, for example in DNA, RNA and proteins; 
guanine is particularly susceptible to this process. Alkylating agents are sub-classified according to 
their chemical structure and the mechanism by which the covalent bonds form; the compounds 
generally fall into one of three classes. Nitrogen mustards, such as cyclophosphamide, have highly 
reactive metabolites that are especially potent in the hematopoietic system. They are used in the 
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treatment of leukaemias, lung, testicular and bladder cancers. Nitrosourea compounds (e.g. 
carmustine) are metabolised into highly lipophilic compounds that can pass freely across 
membranes, making them ideal for treating brain cancers as they cross the blood brain barrier 
(BBB). Platinum compounds, such as oxaliplatin, are used to treat many gynaecological cancers 
and act by causing the formation of DNA cross-links that subsequently inhibit DNA, RNA and 
protein synthesis.  
 
103B .1.2. Anti-Metabolic Agents 
Anti-metabolic agents are structurally similar to the endogenous precursors or metabolites of DNA 
and RNA synthesis; thus they act as competitive inhibitors of key enzymes of this process. They are 
most active during the S-phase of the cell cycle and are most effective against rapidly growing 
tumours. Anti-metabolites can be sub-categorised into five main groups based on the endogenous 
metabolite to which they are similar: folate analogues such as methotrexate are used to treat 
leukaemia, lymphoma and a variety of solid mass cancers. Purine and adenosine analogues 
including mercaptopurine and pentostatin (respectively) are also used to treat leukaemias. 
Pyrimidine analogues for example capecitabine are used to treat breast, colorectal and gastro-
intestinal (GI) cancers. Finally substituted ureas, such as hydroxyurea, are used to treat head, neck 
and gynaecological cancers as well as leukaemia and melanoma. 
 
104B .1.3. Natural Compounds 
“Natural compounds” encompass a large group of compounds isolated or derived from naturally 
occurring substances, categorized by their origin. These compounds are pre-dominantly, although 
not exclusively, used to treat leukaemias; the class includes anti-tumour / cytotoxic antibiotics, e.g. 
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mitoxantrone, anthracyclines and mitomycin, epipodophyllotoxins which inhibit topoisomerase 
preventing RNA transcription (e.g. etoposide), microtubule agents such as the vinca alkaloids VCR 
and vinblastine which bind to tubulin and prevent microtubule polymerisation (thus inhibit mitotic 
spindle formation) and the taxanes (e.g. docetaxel and paclitaxel [PTX]) which stabilise 
microtubules and block cells in the mitosis phase of the cell cycle. 
 
105B .1.4. Molecular Targeted Therapies 
The final class of compounds contains drugs referred to as molecular targeted therapies. This class 
is, in general, the newest and fastest growing class of anti-neoplastics. These compounds are 
designed to be more specific that many other anti-cancer agents, targeting molecules highly 
expressed in cancer cells. They are sub-categorized into two groups: monoclonal antibodies and 
small-molecule targeted therapies. 
 
Monoclonal antibodies are designed to bind to a specific protein expressed by the cancer cell and 
either cause it to undergo apoptosis or identify the cell as a target for phagocytes. This family of 
compounds includes alemtuzumab, which recognises the CD52 antigen expressed on B-
lymphocytes and is used for the treatment of B-cell lymphocytic leukaemia, and bevacizumab 
which binds to vascular endothelial growth factor (VEGF), preventing receptor binding and 
activation which consequently prevents endothelial cells growth and angiogenesis in tumours 
which secrete high levels of VEGF (e.g. advanced colorectal cancers). Small-molecule targeted 
therapies are designed to selectively interact with the predominant signalling pathway in a given 
cancer; for example imatinib inhibits Bcl-Abl tyrosine kinase present in most cases of myelogenous 
leukaemia, whilst gefitinib, used for the treatment of non-small cell lung carcinoma, binds to the 
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ATP-binding site of the EGF receptor, blocking its kinase activity which is associated with cell 
proliferation and angiogenesis.   
 
46B1.2. Side-Effects and Their Management 
 
Whilst the type and severity of side-effects occurring as a result of chemotherapy vary between 
agents, several are common to many classes of drugs. These include anaemia, thrombocytopenia, 
neutropenia, enterotoxicity and neuropathy/neurotoxicity. 
 
106B .2.1. Anaemia 
Anaemia is defined as a deficiency in haemoglobin containing erythrocytes and is graded in its 
severity according to an individual’s haemoglobin level. Anaemia can range from mild (level 1; 10-
11g/dL) to life threatening (level 4; <6.5g/dL) (Groopman and Itri, 1999) and is a common side 
effect of both chemotherapy and cancer itself, occurring in between thirty to ninety percent of 
patients (depending on cancer type and treatment regime) (Knight et al., 2004). In the context of 
chemotherapy, anaemia primarily occurs as a result of the cytotoxic quality of anti-neoplastic 
agents which causes the suppression and/or death of rapidly dividing erythropoietic precursors in 
the bone marrow. Severe anaemia can be life threatening as it can lead to hypoxia and subsequent 
organ failure, and even mild to moderate anaemia can have a large impact on the quality of life of 
patients, causing fatigue, dyspnoea, tachycardia and headaches. Anaemia is most prevalent in 
patients treated with microtubule agents (vinca alkaloids and taxanes); however it can be well 
managed with red blood cell transfusions, which stabilise haemoglobin levels and restore quality 
of life (Groopman and Itri, 1999). Whilst transfusion is historically the treatment of choice, it is not 
without risk, infection and allergic reactions can occur and this has lead to the development of an 
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alternative therapy; recombinant human erythropoietin (EPO) (Tonia et al., 2012). EPO mimics the 
action of endogenous erythropoietin, a 34kDa cytokine produced by the kidneys in response to 
hypoxia that stimulates erythropoiesis in hematopoietic tissues, thus resulting in increased 
erythrocytes production in the bone marrow (Koury and Bondurant, 1990;Koury et al., 1988). 
 
107B .2.2. Thrombocytopenia 
Thrombocytopenia is defined as a decrease in platelets, typically a platelet count of less than 150 x 
109/L; however the condition is rarely symptomatic until a drop below 50 x 109/L is seen. A platelet 
count below 5 x 109/L is considered a haematological emergency (Gauer and Braun, 2012)). 
Thrombocytopenia is caused by either a decrease in platelet production (e.g. as the result of folic 
acid deficiency) or an increased destruction of platelets. In the context of chemotherapy, 
thrombocytopenia of varying severities occurs in up to seventy percent of patients (depending of 
treatment regime), but occurs predominantly following treatment with platinum based alkylating 
agents (Jardim et al., 2012). Chemotherapy-induced thrombocytopenia in this instance is generally 
moderate to severe, with the average platelet count of patients dropping to around 20 x 109 
platelets/L (Kenney and Stack, 2009), and is thought to be caused by the suppression of bone 
marrow stem cells and the direct destruction of megakaryocytes (Zeuner et al., 2007). Recent 
evidence suggests sinusoidal injury and splenic sequestration of platelets are also likely to 
contribute to thrombocytopenia, and supportively, this goes some way to explain the 
splenomegaly occasionally seen in patients treated with oxaliplatin (Jardim et al., 2012). Typically 
chemotherapy-induced thrombocytopenia manifests in patients as petechiae and bruising, 
however in severe cases spontaneous GI, pulmonary or intracranial haemorrhage may occur. In 
most instances blood platelet levels recover following cessation of treatment with the causative 
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agent, however when it does not, platelet transfusions are normally sufficient to restore platelet 
levels (Visentin and Liu, 2007). 
 
108B .2.3. Neutropenia 
Neutropenia is defined as a decrease in circulating neutrophils (typically below 2000 cells/mm3 but 
considered severe below 500 cells/mm3) and results in an increased susceptibility to infection 
(Saloustros et al., 2011). Chemotherapeutic agents cause this condition due to their ability to 
suppress the generation of blood cells, including neutrophils, within the bone marrow due to the 
rapid turnover of these cells; neutropenia to some degree is often unavoidable. In some cases, as a 
result of the extended duration and/or severity of neutropenia, patients may develop febrile 
neutropenia; a temperature in excess of 38oC occurring as a result of an infection secondary to 
neutropenia. This side-effect of chemotherapy is tolerated well by most patients; however those 
who do develop infections as a result are managed with infection-appropriate antibiotics. Patients 
identified as being at high risk of developing febrile neutropenia, such as those with low 
neutrophils counts prior to the onset of chemotherapy are given prophylactic granulocyte-colony 
stimulating factor (G-CSF) which has been demonstrated to decrease the incidents of febrile 
neutropenia in chemotherapy treated patients by stimulating the survival, proliferation and 
differentiation of both mature neutrophils and their precursors (Renner et al., 2012). 
 
109B .2.4. Enterotoxicity 
Also known as GI toxicity, enterotoxicity in a common occurrence in patients treated with a variety 
of chemotherapeutics and is routinely characterised by diarrhoea, constipation, colitis and 
nausea/vomiting. These symptoms arise through various mechanisms largely dependent on the 
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chemotherapeutic used, for example diarrhoea can occur in up to eight percent of patients (Coyle 
et al., 2013) but is especially common in patients treated with pyrimidine analogues or 
topoisomerase inhibitors such as irinotecan, as result of acute loss of epithelial cells and damage 
to the intestinal mucosa (Ikuno et al., 1995), whilst evidence suggests cisplatin, on the other hand, 
causes diarrhoea as a result of increased gastric emptying (Viana-Cardoso et al., 2011); emerging 
evidence suggests oxaliplatin induced constipation may arise as a result of damage to or loss of 
enteric neurons resulting in a decrease in gastric motility (Wafai et al., 2013). Diarrhoea and 
constipation following chemotherapy have a large impact on the quality of life of patients, 
however they can generally be well managed with drugs that increase or decrease gastric motility 
such as opioids (Benson, III et al., 2004) or osmotic salts (Tack, 2011) respectively. Nausea and 
vomiting as a result of chemotherapy occurs to some degree in an excess of ninety percent of 
patients (Kris et al., 1985), depending on the agent used, and is hypothesized to occur as a result 
of activation of abdominal vagal afferents following damage to the GI tract (by the cytotoxic 
compounds) and subsequent signalling to the emetic centre in the brainstem (Rojas and Slusher, 
2012). The neurotransmitters involved in this signalling pathway are understood and accordingly 
chemotherapy induced nausea/vomiting are generally well managed with 5-HT3 antagonists (e.g. 
ondansetron), dopamine antagonists (e.g. metaclopramide), corticosteroids (e.g. dexamethasone) 
and NK1 receptor antagonists (e.g. aprepitant) (Wickham, 2012).   
 
110B .2.5. Neuropathy 
Chemotherapy induced peripheral neuropathy (CIPN) is a dose-limiting side-effect associated with 
several classes of anti-neoplastic agents including vinca alkaloids, taxanes and platinum containing 
compounds; occurring in up to seventy percent of patients (Pachman et al., 2011). Symptoms of 
CIPN typically start within weeks of the onset of treatment and are predominantly, but not 
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exclusively, sensory in nature; they include pain, hypersensitivity and loss of sensation (Windebank 
and Grisold, 2008). Whilst in the majority of patients the prevalence of these symptoms decreases 
following cessation of treatment, this is not always the case, and there are many incidences where 
(cancer) treatment has to be halted prematurely as the neuropathy becomes severe. CIPN is 




24B . Physiological and pathophysiological pain signalling  
 
The International Association for the Study of Pain defines pain as “an unpleasant sensory and 
emotional experience associated with actual or potential tissue damage” (www.iasp-pain.org). 
Under physiological conditions pain is a vital protective mechanism and persists only for the 
duration of the nociceptive stimulus or tissue damage; functioning as a warning system against 
actual or further tissue damage. The fundamental importance of this system becomes apparent 
when we study those individuals with the rare phenotype of insensitivity to pain, which results is 
frequent inadvertent self-mutilation and injury throughout life (Cox et al., 2006). Should this 
system malfunction and the pain experienced outlive the causative stimuli and physiological role it 
is termed chronic. Generally chronic pain states fall into two broad categories: neuropathic, or 
inflammatory; whilst these categories are simplistic and imply distinct mechanisms, in reality a 





47B2.1. Pain Signalling 
 
Acute (or nociceptive) pain arises as a result of the stimulation of excitation, the ‘bare’ or ‘naked’ 
endings of primary afferent sensory neurons whose cell bodies lie in the dorsal root ganglia (DRG) 
and mediate the transmission of painful stimuli. Classification of primary afferents is based on the 
anatomical and electrophysiological characteristics of these neurons, and gives rise to three 
populations: Aβ fibres, Aδ fibres and C fibres. Aβ fibres are large diameter (>10µm), highly 
myelinated fibres with fast conduction velocities (30-100msec-1) and low activation thresholds 
(Millan, 1999). These fibres are predominantly low-threshold mechanoreceptors and respond to 
non-nociceptive stimuli such as light touch, and are responsible for the transduction of normal 
tactile sensation. In comparison, Aδ fibres are smaller (2-6µm) and less myelinated than Aβ fibres, 
thus they have slower conduction velocities (2-30msec-1), and also possess high activating 
thresholds meaning that, whilst they can convey non-nociceptive sensory information, they are 
predominantly activated by ‘painful’ stimuli (Millan, 1999). A fibres can be identified 
immunohistochemically by their expression of neurofilament 200 (NF200) and whilst both Aδ and 
Aβ fibres terminate in the deep lamina (III-V) of the dorsal horn of the spinal cord, Aδ also have 
terminations in the superficial dorsal horn (lamina I and II) (D'Mello and Dickenson, 2008) (see 
figure 1.1). Finally, C fibres are small diameter (0.4-1.2µm) unmyelinated fibres with low 
conduction velocities (<2msec-1) and high activating thresholds that respond to noxious stimuli 
(Lawson, 2002;Millan, 1999;D'Mello and Dickenson, 2008) (see figure 1.1). C fibers are then sub-
divided into two populations, peptidergic and non-peptidergic, based on their expression of 
neuropeptides. Peptidergic C fibres express substance P (SP) (McCarthy and Lawson, 1989) and 
calcitonin gene-related peptide (CGRP) (Lawson et al., 2002). These fibres express the TrkA 
receptor (Averill et al., 1995), respond to and are regulated by nerve growth factor (NGF) and 
project to the lamina I of the dorsal horn (Lewin et al., 1994;McMahon et al., 1995).  
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Figure 1.1. Schematic of primary afferent populations and their central terminations. Primary afferent fibers (Aβ [blue], Aδ [green] & C [red]) transmit signals 
from the periphery, through the dorsal root ganglia (DRG) to the dorsal horn of the spinal cord. Aβ and Aδ fibers have terminations in the deep lamina where 
they synapse on to wide dynamic range (WDR) neurons. Aδ fibers also have terminations in superficial lamina where along with C fibers they synapse onto 




As their name suggest, the non-peptidergic C fibres do not express these neuropeptides and 
down-regulate TrkA during the early postnatal phase. These fibres terminate in lamina II of the 
dorsal horn, and are instead characterised by their surface expression of isolectin B4 (IB4) and the 
purinergic receptor P2X3 (Vulchanova et al., 1998;Bradbury et al., 1998). Primary afferents possess 
a single axon that bifurcates to give rise to a peripheral and a central branch. The peripheral axon 
branch innovates peripheral targets, where activation of various receptors or ion channels (e.g. 
Transient Receptor Potential [TRP] channels) located on nerve terminals, initiates action potentials 
that are conducted to the CNS via the central branch of the primary afferent.  
 
As hinted to above, the spinal cord is organised into a series of laminae based on the anatomical 
characteristics of the neurons found there. Laminae I-VI make up the dorsal horn (although 
laminae VI exists only in the lumbosacral and cervical enlargements) and it is here that Aβ, Aδ and 
C fibre primary afferents synapse onto second order interneurons or projection neurons; laminae 
VII-IX make up the ventral horn and are involved predominantly in motor signalling (Rexed, 1952). 
 
 The majority of dorsal horn neurons are interneurons with axons that remain in the spinal cord 
and branches that terminate locally (Todd, 2010). These neurons can be broadly categorized by 
their excitatory (glutamatergic) or inhibitory (primarily GABA-ergic and/or glycinergic) nature. 
Interneurons can also be characterised by their responses to varying stimuli. Nociceptive-specific 
neurons are found predominantly in the superficial laminae and receive input from Aδ and C 
fibres. Non-nociceptive neurons are found mainly in the deeper laminae, III and IV, and respond to 
tactile information conveyed to the spinal cord by Aβ fibres (Light et al., 1979). Finally wide 
dynamic range (WDR) neurons, located primarily in lamina V, receive input from Aβ, Aδ and C 
fibres and therefore respond to a wide range of stimuli including mechanical, thermal and 
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chemical stimulation. WDR neurons also exhibit wind-up, a short-lasting form of synaptic plasticity 
where repetitive stimulation induces an increase in evoked response intensity and prolonged post-
discharge (D'Mello and Dickenson, 2008). 
 
Additionally, the dorsal horn contains a range of neurons that form descending projections as well 
as neurons whose projections ascend to supraspinal sites and a vast number of non-neuronal glial 
cells. These glial cells (astrocytes and microglia) were initially thought play simply structural and 
supportive roles, however in the last decade a wealth of evidence has identified a key role for 
these cells in the modulation of pain signalling under pathophysiological conditions. This is 
discussed below. 
 
To allow the propagation of an action potential from the primary afferent to the post-synaptic 
dorsal horn neuron, the electrical activity of the pre-synaptic neuron must be converted to a 
chemical signal; this activates the post synaptic neuron by activation of specific receptors on the 
neuron’s membrane. In the spinal cord glutamate is the principle mediator of excitatory signalling 
and is released from the pre-synaptic neuron in both physiological and pathophysiological states; 
the excitatory effect of glutamate is exerted by the activation of glutamate receptors, 
predominantly N-methyl-D aspartate (NMDA) and α-amino-3-hydroxy-5-methyl-4-
isoxazolepropionic acid (AMPA) receptors, although metabotropic (mGluR) and kainate (KA) 
receptors (KAR) are also located on the post-synaptic membrane. In the pre-synaptic terminal 
glutamate is synthesised and packaged into small synaptic vesicles, and released via exocytosis 
when membrane depolarisation causes an increase in intracellular calcium levels. Glutamate is 
quickly released from the central terminals of primary afferents following activation of these 
neurons by noxious stimuli; the excitatory post-synaptic potential (EPSP) resulting from a
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single action potential primarily arises a result of this glutamate activating AMPA and KA receptors 
(Yoshimura and Jessell, 1990;Li et al., 1999). AMPA receptors are ligand-gated cation channels 
composed of a combination of the subunits GluR1-4; the mRNA for all four subunits has been 
found in the spinal cord (Furuyama et al., 1993;Henley et al., 1993;Jakowec et al., 1995). The 
expression of GluR1 and GluR2 is mainly restricted to laminae I and II; GluR3 and GluR4 have a 
more widespread distribution, with moderate expression in the deep laminae of the dorsal horn 
and the laminae of the ventral horn and weak expression in the superficial dorsal horn (Nagy et al., 
2004). AMPA receptor activation on the other hand results in influx of the cations Na+ and K+; Ca2+ 
permeability is dependent on the presence of the GluR2 subunit in the receptor complex, which 
also determines the susceptibility of the channel to be blocked by polyamines (Hollmann and 
Heinemann, 1994;Tao, 2012). There are seven NMDA receptor subunits: NR1, NR2A-D and NR3A-
B. Receptors are formed of heteromeric complexes of these subunits and require the expression of 
NR1 and at least one NR2 subunit to be functional (Kew and Kemp, 2005). Under normal 
physiological conditions the NMDA receptor contributes little to the generation of EPSPs as these 
receptors are tonically blocked by extracellular Mg2+ ions, however if there is repetitive high 
frequency stimulation of nociceptors, NMDA receptors may become activated as the Mg2+ block 
dissociates due to prolonged depolarization of the membrane (Mayer et al., 1984). Following 
NMDA receptor activation by glutamate, there is an influx of Ca2+ ions which causes depolarisation 
of the post-synaptic neuron as well as activation of signalling molecules such as 
calcium/calmodulin dependent kinases, which contributes to long term potentiation and central 
sensitization (Malinow et al., 1989).  
 
Inhibitory synapses in the dorsal horn are chiefly glycine or GABA-ergic. GABA-ergic neurons are 
abundant throughout the dorsal horn of the spinal cord, especially within the superficial laminae 
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(Daniele and Macdermott, 2009;Todd and Sullivan, 1990;Oliva, Jr. et al., 2000), whilst glycinergic 
neurons are thought to be the predominant inhibitory interneurons of the deeper laminae 
(Inquimbert et al., 2007;Todd et al., 1996). These neurons evoke inhibitory post-synaptic 
potentials (IPSPs) via activation of their respective receptors; GABA (γ-Aminobutric Acid) exerts its 
inhibitory effects via the activation of the ligand-gated ion channel GABAA or the G-protein 
coupled GABAB receptor; glycine activates is own ligand-gated ion channel. Activation of these 
receptors depresses neuronal activity by hyperpolarisation of the post-synaptic membrane as a 
result of Cl- influx or the activation of K+ channels (leading to K+ efflux). 
 
Primary afferents, peptidergic C fibres in particular, also express a range of neuropeptides 
including SP and CGRP that are synthesised as precursors and packaged into large dense core 
vesicles (Merighi et al., 1991) and cleaved by proteases into active signalling molecules. SP is 
released from the central terminals of primary afferents following noxious stimulation, both 
electrical and chemical (capsaicin) (Go and Yaksh, 1987); once released, it exerts its effects via 
activation of the NK1 receptor, the highest expression of which is in lamina I, where over 75% of 
nociceptive projection neurons express the NK1 receptor (Cheunsuang and Morris, 2000). These 
neurons play a key role in transmission of highly noxious stimuli and hyperalgesic responses; 
specific ablation of NK1 expressing neurons in lamina I results in significant attenuation of 
responses to these types of stimuli but not to mild noxious stimuli (Mantyh et al., 1997). NK1 
receptors are also found on both the peripheral and central terminals of C fibres where their 
activation regulates the release of neuropeptides (Malcangio and Bowery, 1994;Lever et al., 2003). 
CGRP exerts its effects by modulating SP release in several ways: enhancing SP release (Oku et al., 
1987), blocking SP degradation (Le et al., 1985) and regulating the expression of the NK1 receptor 
(Seybold et al., 2003). CGRP activates the CGRP receptor, a G-protein coupled receptor (GPCR) 
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expressed extensively in neurons of the superficial dorsal horn (Ye et al., 1999). Additionally 
evidence suggests that SP and CGRP are co-released with glutamate from C fibres, with the 
subsequent receptor activation contributing to prolonged slow depolarizations that aid the 
removal of the Mg2+ block from NMDA receptors, facilitating wind-up in wide dynamic range 
neurons (Budai and Larson, 1996).   
 
Sensory output from the dorsal horn is relayed to higher processing centres in the brain by 
ascending pathways, comprised of spinal projection neurons (figure 1.2). Using antero- and 
retrograde tracing techniques these spinal projections have been extensively mapped; lamina I 
neurons form the spinoparabrachial tract, projecting supraspinally to high nociceptive processing 
centres including the parabrachial area (PBA) and the periaqueductal gray (PAG). These brain 
regions contain neurons that project to the hypothalamus and amygdala, activity in which 
contributes to the emotional aspects of pain. Lamina I neurons also project to the caudal 
venterolateral medulla (CVM), the nucleus of the solitary tract and to several nuclei of the 
thalamus (D'Mello and Dickenson, 2008;Todd, 2010). Approximately eighty percent of lamina I 
projection neurons are express the NK1 receptor (Todd et al., 2000), and the majority of these 
neurons project contralaterally (figure 1.2); this is not always the case, however, and there are 
many neurons that project bilaterally (Spike et al., 2003). Whilst it has been demonstrated that 
non-NK1 expressing projection neurons respond to noxious stimuli (Todd, 2002) little else is 
known about them. Projections from deeper laminae, typically IV-VI WDR neurons (and some 
projections from lamina I) cross the midline of the spinal cord to reach the contralateral white 
matter and project to the brainstem and thalamus (forming the spinothalamic tract). The 
spinothalamic tract sends further projections to several nuclei of the cortex, including the primary 
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and secondary somatosensory, insular, anterior cingulate and prefrontal cortices, collectively 
referred to as the ‘pain matrix’ (Tracey and Mantyh, 2007).  
 
These ascending pathways play a critical role in the transmission and modulation of pain in higher 
brain regions; however a number of descending pathways are also involved in the modulation of 
nociceptive transmission (figure 1.2). Early studies demonstrated that the electrical stimulation of 
specific brain regions resulted in analgesia (Reynolds, 1969), suggesting activity in these regions 
could inhibit nociceptive signalling; however it is now evident that descending pathways can also 
facilitate nociceptive transmission. The best characterised descending pathway is that connecting 
the PAG and dorsal horn, which contributes to environmental and opioid analgesia (Heinricher et 
al., 2009). As shown in figure 1.2 the PAG receives input from the limbic system (amygdala and 
hypothalamus) as well as the dorsal horn, first projecting to the rostral ventromedial medulla 
(RVM) which in turn relays the signal to the spinal cord (Tracey and Mantyh, 2007). Electrical 
stimulation of the RVM is analgesic and inhibits spinal neuron responses to noxious stimuli as does 
injection of the local anaesthetic lidocaine (Bee and Dickenson, 2007). This suggests that 
descending projections from the RVM both facilitate and inhibit nociceptive transmission; likely 
occurring due to the presence of several cell types in this brain region. Three cell types have been 
characterised in the RVM based on their response to a thermal stimuli: ‘on-cells’ showed increased 
discharge, ‘off-cells’ showed decreased discharge and ‘neutral-cells’ were unchanged by the 
stimuli. These cells also differ in their sensitivity to µ-opioids; ‘on-cells’ are inhibited whilst ‘off-
cells’ become continuously activated (Fields et al., 1983). This pattern of activity suggested that 
‘on-cells’ mediate descending facilitation whilst ‘off-cells’ mediate descending inhibition. Both ‘on-
cells’ and ‘off-cells’ project to the dorsal horn where they modulate nociceptive transmission 
directly by interacting with primary afferents, and indirectly by interacting with excitatory and 
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inhibitory interneurons and projection neurons (figure 1.2) (Fields et al., 1995), by forming both 
noradrenergic and serotonergic synapses (Yoshimura and Furue, 2006). 
 











Figure 1.2. Main ascending and descending pathways of nociceptive transmission between the dorsal 
horn and brain. Ascending pathways are shown in red and include the spinothalamic and spinoparabrachial 
tracts. Descending pathways are shown in green and include descending input from the PAG via the RVM. 
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48B2.2. Chronic Pain 
 
As mentioned above, chronic pain states fall into two categories: neuropathic and inflammatory. 
In both cases a combination of mechanisms results in enhanced nociceptive transmission due to 
peripheral and central sensitisation. Whilst variable in its aetiology, chronic pain typically 
manifests in a similar fashion in human patients and rodent models. It is characterised by the 
presence of a range of symptoms including sensory loss, spontaneous pain, paraesthesia 
(spontaneous or evoked abnormal sensation), hyperalgesia (increased sensitivity to noxious 
stimuli) and allodynia (a painful response to previously innocuous stimuli) (Woolf and Mannion, 
1999).  
 
The treatment of chronic pain remains a problem clinically as many patients do not experience 
sufficient pain relief with classical analgesics. Furthermore, no clear predictors of treatment 
response have been identified in chronic pain patients (Baron et al., 2010). The difficulty in 
treating the condition is likely a result of the heterogeneity of the mechanisms underlying the 
development and maintenance of chronic pain, however some classes of drugs, including the anti-
depressant selective serotonin reuptake inhibitors (SSRIs) and opiates have shown efficacy in 
clinical trials and meta-analyses (Baron et al., 2010;Dworkin et al., 2007;O'Connor and Dworkin, 
2009). Regardless of their efficacy these therapeutic approaches are symptomatic and much 
research is needed to better understand the mechanism by which these pain states are arising so 





111B2.2.1. Neuropathic Pain 
Neuropathic pain is that arising from neuropathy and occurring as a result of a lesion of the 
nervous system, be that as the result of physical trauma or disease. Typically neuropathy is 
associated with direct trauma to part of the nervous system, for example it may arise as a result of 
crushing stretching or severing of a peripheral nerve, or as a result of damage to the CNS such as a 
spinal cord injury. In addition to these processes, neuropathic pain can arise as a result of the 
pathogenesis of a disease, for example diabetes mellitus, viral infections and tumour growth are 
often associated with the development of neuropathy. Furthermore, neuropathy can occur 
following toxic insult; this may be a direct exposure to specific toxins, for example acrylamide, 
arsenic or thallium, or a side-effect of pharmacotherapy with neuropathy-causing agents e.g. anti-
retrovirals, metronidazole or certain chemotherapeutics (Baron et al., 2010).   
 
112B .2.2. Chronic Inflammatory Pain 
Inflammation is a complex yet protective response to harmful stimuli elicited by tissue injury or 
infection that, under physiological conditions, serves to destroy, dilute or provide a barrier against 
the damaging agent. It is characterized by the development of hyperalgesia (dolor), heat (color), 
redness (rubor) and swelling (tumor). On a more discrete level it involves a number of biological 
processes including increased blood flow and dilatation and increased permeability of blood 
vessels, the exudation of fluid and the migration of leukocytes; pain occurs as a result of the 
activation of peripheral sensory neurons by pro-nociceptive mediators released from damaged 
cells or infiltrating immune cells. The first pro-inflammatory mediator to be identified as capable 
of inducing hyperalgesia was bradykinin (Armstrong et al., 1953); a host of other mediators have 
since been observed to have a similar effect, they include (but are not limited to) prostaglandins, 
leukotrienes, chemokines and cytokines. Chronic inflammatory pain is typically associated with 
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inflammatory diseases, for example rheumatoid or psoriatic arthritis; in these patients the 
constant presence of these algogenic mediators results in the sensitisation of both the PNS and 
CNS which results in ongoing pain. Due to our developing understanding of this process a number 
of successful treatments for chronic inflammatory pain are emerging, targeting peripheral pro-
nociceptive inflammatory mediators e.g. tumour necrosis factor-α (TNFα; etanercept / infliximab) 
and interleukin-1 (IL-1; anakinra). These drugs reduce inflammation-evoked hyperalgesia by 
reducing nociceptor activation, and also reduce disease progression and immune cell infiltration of 
the joint, preventing further release of pro-nociceptive mediators (Schaible et al., 2010;Agarwal, 
2011;Mertens and Singh, 2009;Breedveld, 2002). 
 
113B 2.2.3. Animal Models 
Due to the limitations of studying the mechanisms underlying chronic pain states in humans, a 
number of animal models have been developed to aid research in this field. Many of the classical 
models of neuropathic pain involve the surgical injury of a peripheral nerve (see table 1.1.), usually 
the sciatic nerve or branch thereof. Such injuries induce a sustained pain phenotype in a single 
hind paw of the rodent, with the contralateral paw acting as an internal control. Likewise, a 
number of models of inflammatory pain have been developed in order to study the mechanisms 
by which this normal immune response becomes a persistent pathological condition. These 
models typically involve the direct administration of an exogenous algogenic compound, either a 
chemical irritant or an inflammatory mediator (see table 1.2.), that results in the inflammation of 






Table 1.1. Surgical models of neuropathy 
 
Model Surgical Paradigm Reference 
Chronic Constriction Injury 
(CCI) 
Loose ligation of the sciatic 
nerve. 
(Bennett and Xie, 1988)  
Partial Nerve Ligation (PNL) Tight ligation of 1/3-1/2 of the 
sciatic nerve. 
(Seltzer et al., 1990)  
Spinal Nerve Ligation (SNL) Ligation of the L5 and/or L6 
spinal nerve 
(Kim and Chung, 1992)  
Spared Nerve Injury (SNI) Transection of the tibial and 
common perineal (but not 
sural) nerves  
(Decosterd and Woolf, 2000)  
 
 
Table 1.2. Inflammatory models of chronic pain 
 
Model Inflammatory Agent Reference 
Complete Freud’s Adjuvant 
(CFA) 
Mineral oil containing 
Mycobacterium tuberculosis. 
(Freund, 1947)  
Zymosan Components of yeast cell wall. (Piller and Ecker, 1941)  
Carrageenan Extract from seaweed. (Vinegar et al., 1976)  
Formalin Formalin solution (Dubuisson and Dennis, 1977)  
 
 
Whilst use of these models has greatly enhanced our understanding of the mechanisms underlying 
chronic pain, they display little resemblance to most clinical occurrences; as a result a number of 
models have been developed that more closely mimic disease states that are associated with the 
development of chronic pain. As table 1.3 shows, these include models of viral infection, such as 
post-herpetic neuralgia and HIV-associated neuropathy, models of diabetic neuropathy, models of 
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bone cancer pain and models of chemotherapy-induced painful peripheral neuropathy induced by 
the repeated administration of specific chemotherapeutic agents.  
 
Typically the development of chronic pain in these models is assessed behaviourally in terms of 
alterations in responses to evoked pain, and involves the measurement of reflex flexion 
withdrawals to noxious stimuli. The majority of pain testing involves the application of mechanical 
or thermal stimuli to the effected paw where reflex withdrawals are spinally mediated and 
initiated by the activation of primary nociceptors, and are under descending control from 
supraspinal structures in the brain stem and midbrain (Fields and Heinricher, 1989). Furthermore 
the glabrous skin of the underside of the paw provides an area of accessible skin that most closely 





Table 1.3. Disease mimicking models of pain 
 
Model Disease Initiation Reference 
Bone Cancer Pain Inoculation of long bones with 
cancer cell line 
(Schwei et al., 1999;Sabino et 
al., 2002)  




(Aley et al., 1996;Polomano et 
al., 2001;Deng et al., 2012)  
 
Diabetic Neuropathy Intra-peritoneal injection of 
streptozocin 
(Wuarin-Bierman et al., 
1987;Malcangio and 
Tomlinson, 1998) 
HIV-associated Neuropathy Application of HIV-1 gp120 to 
sciatic nerve or intrathecal 
space 
Wallace et al, 2007 
Post-herpetic Neuralgia Infection with varicella-zoster 
virus 
Fleetwood-Walker et al, 1999 
 
 
First described by von Frey in 1986, the application of graded filaments to the skin is used to 
measure sensitivity to punctuate mechanical stimuli, and has subsequently been adapted to allow 
for the average calculation of a fifty percent paw withdrawal threshold (PWT), the force at which 
when applied to the paw, the paw is withdrawn on half of the occasions tested (Chaplan et al., 
1994). Sensitivity to thermal (heat) stimuli is predominantly tested using the Hargreaves’ method, 
developed by Hargreaves and colleagues in 1988 (Hargreaves et al., 1988); a heat source in the 
form of radiant light is directed at the plantar surface of the hind paw and the latency to 
withdrawal is recorded. Whilst these two approaches are the most common methods of 
assessment of pain behaviours in rodent models, several other have been developed and are used 
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regularly, these include paw-pressure assessment of mechanical sensitivity, hot-plate and tail 
immersion assessment of thermal sensitivity and cold-plate and acetone tests for assessment of 
cold sensitivity. It should be noted that these tests do not account for the development of 
spontaneous pain and results may be confounded by the loss of sensation that can accompany 
some models. 
 
114B2.2.4. Mechanisms of Chronic Pain 
The development of animal models of neuropathic and chronic inflammatory pain has led to a vast 
increase in the understanding of the pathogenic mechanisms by which these pain states arise. 
These can generally be categorised into one of the following, which are discussed below: 
1. Peripheral sensitisation and changes in peripheral nerves 
2. Central sensitisation and immune responses in the spinal cord 
3. Higher centre modulation 
 
189B2.2.4.1. Peripheral Sensitisation and Changes in Peripheral Nerves 
Peripheral sensitisation can be loosely defined as the response of primary afferents to a change in 
the local environment, which results in a characteristic electrophysiological response in the 
nociceptor of a reduction in activation threshold and an increase in responsiveness to supra-
threshold stimuli (Andrew and Greenspan, 1999;Koltzenburg et al., 1999;Kocher et al., 1987). The 
usually ordered composition of peripheral nociceptors shows substantial plastic changes following 
damage or exposure to inflammation. Due to tissue damage there is a dramatic change in the 
composition of the chemical milieu surrounding primary afferents; a multitude of molecules are 
released from the damaged cells, infiltrating immune cells and the nerve itself. These molecules 
include ATP, neurotransmitters (e.g. histamine and 5-hydroxytryptamine [5HT]), peptides (e.g. 
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substance P [SP], CGRP and bradykinin), neurotrophins (e.g. NGF), chemokines (e.g. CCL2), 
cytokines (e.g. TNFα and IL-1β) and proteases (e.g. Cathepsin S). Collectively these mediators are 
referred to as an ‘inflammatory soup’ and via receptors on the peripheral terminals of primary 
afferents, they can activate a host of intracellular signalling pathways that can directly alter 
neuronal conduction properties, induced further mediator release from the neuron or result in 
post- translational modification of various proteins involved in nociceptive transmission (Campbell 
and Meyer, 2006;Moalem and Tracey, 2006). There are also many longer-term consequences; 
following the activation of second messenger pathways there is activation of transcription factors 
such as ATF-3 (activating transcription factor-3), STAT (signal transducer and activator of 
transcription) and NFκβ (nuclear factor κβ), which leads to changes in the expression of various 
proteins. In fact, the upregulation of such transcriptional factors is often used as a unique marker 
of neuronal damage; ATF-3 activation/expression is induced in the cell body of almost every 
damaged fibre (Tsujino et al., 2000). 
 
Widespread changes in neuronal gene expression are observed following injury; as shown by 
micro-array studies, many of these genes encode signalling molecules, receptors and ion channels 
that are critically involved in the transmission of nociceptive stimuli (Costigan et al., 2002;Kubo et 
al., 2002;Uno et al., 2002). Whilst early work focused on the role of the damaged fibres and the 
idea that they become hyper-excitable and generate ectopic action potentials (leading to central 
sensitisation; (Devor, 2001), there is now a shift towards examining intact fibres as well; the 
blockade of signal transduction in intact roots, but the administration of local anaesthetic, reduces 
pain behaviour the spinal nerve ligation model of neuropathic pain (Yoon et al., 1996). Moreover, 
neuropathic pain like behaviours can be induced in the absence of axonal damage by the local 
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application of an inflammatory agent (Chacur et al., 2001;Eliav et al., 1999) , indicating that these 
fibres play a key role in dysfunction nociceptive transmission in these models. 
 
Many of the changes in the conduction properties of nociceptive afferents occur as a result of 
changes in ion channel expression or activation. Once of the best characterised of these is TRPV1 
(Transient Receptor Potential Vanilloid-1); this non-selective cation channel is upregulated in 
uninjured sensory fibres after nerve injury (Hudson et al., 2001). Furthermore, whilst 
physiologically expressed in smaller diameter fibres, nerve injury induces de novo expression of 
TRPV1 in large myelinated A-fibres (Hong and Wiley, 2006;Pabbidi et al., 2008) and likely 
contributes to the development of hyperalgesia, certainly inhibiting TRPV1 activity or decreasing 
its expression attenuates such pain behaviours in several rodent models of neuropathy (Christoph 
et al., 2006;Watabiki et al., 2011;Ta et al., 2010). TRPV1 is by far the only ion channel to be altered 
following injury; the expression of TRPA1 mRNA, a predominantly calcium permeable cation 
channel, is increased in the uninjured L4 DRG after an L5 spinal nerve ligation, and decreasing this 
expression by the administration of an antisense oligodeoxynucleotide suppresses injury induced 
cold allodynia (Obata et al., 2005). The expression of several voltage-gated sodium channels 
(VGSC) is increased in DRG neurons following injury. Several inflammatory mediators are able to 
increase the expression and phosphorylation state of the VGSC Nav1.8 that leads to an increase in 
Na+ current amplitude and a hyperpolarising shift in voltage dependent activation (Wood et al., 
2004). Additionally following nerve injury a change in the spatial distribution of Nav1.8 is seen from 
the cell body of the DRG to the axonal site of injury (Novakovic et al., 1998), and the antisense 
knock-down of Nav1.8 attenuates neuropathic behaviour in rodents (Lai et al., 2002). Conversely, 
however, neuropathic pain develops normally in Nav1.8 null mice (Akopian et al., 1999), arguing 
against a role for this channel in neuropathic pain states. The Nav1.7 subtype of VGSC is thought to 
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contribute significantly to inflammatory pain; if this ion channel is selectively knocked out in 
nociceptors, mice exhibit reduced or completely abolished pain responses to a range of 
inflammatory mediators (Nassar et al., 2004). In humans, gain of function mutations in the scn9a 
gene (which encodes the Nav1.7 channel protein) lead to altered pain sensitization, for example 
the hereditary disease early-onset erythromelalgia which is characterized by severe bilateral pain 
and cutaneous vasodilation (Yang et al., 2004;Dib-Hajj et al., 2005;Dib-Hajj et al., 2007;Drenth and 
Waxman, 2007). Several HCN (hyperpolarisation-activated cyclic nucleotide-gated) channels, 
responsible for generating an inward depolarizing current to allow subsequent action potentials, 
are upregulated following nerve injury. This reduces the refractory period of the neuron and 
contributes to hyperexcitability; pharmacological blockade of these channels are effective in 
reducing behavioural hypersensitivity as well as primary afferent ectopic activity (Lee et al., 
2005;Emery et al., 2011). Finally, several A-type potassium channels (Kv4.3, Kv3.4 and Kv9.1) that 
play a critical role in the regulation of neuronal excitability are down-regulated following nerve 
injury and inflammation, resulting in an overall enhancement of neuronal excitability (Chien et al., 
2007;Takeda et al., 2006;Takeda et al., 2008;Tsantoulas et al., 2012). 
 
Changes in ion channel expression are not the only examples of a phenotypic switch in neurons as 
a response to injury and/or inflammation; a similar phenomenon is seen in regards to 
neuropeptide expression in peripheral afferents. Physiologically SP expression is confined to a sub-
population of small diameter peptidergic neurons; however the expression of SP and its precursor 
(preprotacykinin) decrease here following injury (Noguchi et al., 1994). This is associated with 
concomitant de novo expression of SP in injured medium and large diameter fibres (Noguchi et al., 
1994;Marchand et al., 1994). CGRP and BDNF expression following injury undergo a similar 
change; physiological expression in small diameter peptidergic DRG neurons is decreased (Verge et 
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al., 1995;Cho et al., 1998;Michael et al., 1999), whilst de novo expression in large diameter 
neurons is evident (Michael et al., 1999;Cho et al., 1998). Several other neuropeptides show vastly 
increased expression in primary afferents following injury; these include galanin, cholecystokinin 
and neuropeptide Y (Verge et al., 1995). 
 
The injury to the nerve or surrounding tissue that ultimately leads to the development of chronic 
pain triggers a local inflammatory response. This is the body’s normal response to tissue damage 
and consists of two main phases; a pro-inflammatory phase in which there is clearance of 
pathogens and cellular debris to restore homeostasis, and a pro-resolution phase consisting of 
local tissue repair and the dampening of the damaging effects of a prolonged pro-inflammatory 
phase. The cells of the immune system (mast cells, macrophages, neutrophils and T-cells) are 
recruited to the site of injury due to release of pro-inflammatory mediators released from tissue 
resident immune cells which are the first to respond to the damage; typically these are tissue 




        
Figure 1.3. Key players in peripheral sensitization. Following tissue damage immune cells (mast cells, 
neutrophils and macrophages) infiltrate the area and along with the damaged tissue, release a host of 
pro-nociceptive mediators that are capable of triggering action potentials or altering protein 
expression in primary afferents. NO - nitric oxide, PG - prostaglandin, NGF - nerve growth factor, ATP - 
adenosine triphosphate (Adapted from (Marchand et al., 2005). 
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Schwann cells play a critical role in the inflammatory response to a damaged nerve; the Schwann 
cells that once myelinated the degenerating axon de-differentiate and taking on a phagocytic 
phenotype they begin to phagocytose myelin debris; this process of Wallerian degeneration 
creates a local environment distal to the injury that promotes regeneration  (Allodi et al., 2012). 
During this process Schwann cells synthesis and release a variety of potent inflammatory 
mediators including IL-1, TNF, IL-6, LIF ATP, prostaglandins and nitric oxide (NO) (Bergsteinsdottir 
et al., 1991;Murwani et al., 1996;Wagner and Myers, 1996;Bolin et al., 1995;Thacker et al., 2007) 
that as well as acting directly on the nerve, are able to induce the expression of CCL2 via an MEK-
ERK dependent signalling pathways (Perrin et al., 2005;Tofaris et al., 2002;Fischer et al., 2008b) 
that promotes the recruitment of macrophages; a reduction in CCL2 released from Schwann cells 
results in a substantial decrease in macrophage recruitment and an amelioration of neuropathic 
pain behaviours (Fischer et al., 2008a). After peripheral nerve injury tissue resident mast cells 
become activated and undergo degranulation (Zuo et al., 2003), resulting in the release of a 
number of pro-inflammatory mediators including histamine, proteases and cytokines (Galli et al., 
2005;Thacker et al., 2007) which contribute to the recruitment of immune cells. Histamine itself is 
pro-nociceptive via the activation of neuronal histamine receptors which are upregulated after 
nerve injury (Mizumura et al., 2000;Kashiba et al., 1999;Herbert et al., 2001). Prevention of mast 
cell degranulation by cell stabilization with sodium cromoglycate reduces macrophage and 
neutrophil infiltration at the site of injury, and attenuates the development of mechanical 
allodynia in animals with a peripheral nerve injury (Zuo et al., 2003). Similarly blocking the 
infiltration of neutrophils and macrophages by reducing available circulating cells, using an anti-
neutrophil antibody and liposomal clodronate respectively, significantly attenuates behavioural 




Following tissue injury neutrophils are one of the earliest cell types to infiltrate the affected area, 
peaking as little as 24 hours after injury (Perkins and Tracey, 2000), and acting as phagocytic cells 
as well as releasing pro-inflammatory mediators which can activate neurons and recruit 
macrophages (Witko-Sarsat et al., 2000). Significant neutrophil infiltration is seen in several 
models of nerve injury (Zuo et al., 2003;Clatworthy et al., 1995;Perkins and Tracey, 2000); current 
evidence suggests a role for these cells in the development of pain rather than its maintenance, as 
neutrophil blockade is successful only in preventing the development of hypersensitivity rather 
than reversing established pain (Perkins and Tracey, 2000). The contribution of macrophages to 
the development of peripheral sensitization and pain has been examined in several models of 
neuropathic pain; macrophage infiltration into the nerve occurs as a result of the release of 
chemoattractant mediators from tissue resident immune cells and neutrophils. An attenuation of 
pain behaviours has been shown following both the depletion of circulating 
monocyte/macrophages (Barclay et al., 2007;Liu et al., 2000) and in a mouse with delayed 
macrophage recruitment, which also demonstrated a retardation of Wallerian degeneration 
(Myers et al., 1996;Sommer and Schafers, 1998). Following activation these cells increase the 
synthesis and release of pro-inflammatory mediators including NO, free radical species and 
cytokines (e.g. TNFα, IL-1β and IL-6) (O'Shea and Murray, 2008;Dale et al., 2008). As well as 
causing the further recruitment and activation of macrophages, many of these factors are able to 
act directly on neurons to either trigger nociceptive action potentials or activate pathways that 





190B2.2.4.2. Central Sensitization and Immune Responses in the Spinal Cord 
In the spinal cord a variety of plastic changes occur in response to altered nociceptive transmission 
from the periphery that manifest as enhanced pain signalling. This process, often referred to as 
central sensitization, includes changes in synaptic strength, activation of glial cells and alterations 
in protein expression; this is summarised in figure 1.4.  
 
Input from the periphery is transmitted to second order dorsal horn neurons via the excitatory 
neurotransmitter glutamate. Under physiological conditions glutamate predominantly activates 
AMPA and KA receptors on the post-synaptic membrane inducing an ion flux that results in 
depolarisation; the contribution of NMDA receptors in this instance is minimum due to the 
presence of an Mg2+ block that requires repetitive input or slow sustained depolarisation to be 
removed. Sustained noxious stimuli associated with peripheral tissue injury results in a higher 
frequency of input to dorsal horn neurons; this results in temporal summation and the release of 
co-transmitters from the pre-synaptic primary afferent that provide a sufficient stimulus to 
remove the Mg2+ block. Subsequently NMDA receptor activation allows influx of Ca2+, boosting 
depolarization and activating calcium sensitive intracellular signalling cascades, such as those 
responsible for phosphorylation of NMDA and AMPA receptors and ion channels, as well as 
activation of transcription factors that initiates prolonged changes in neuronal excitability; thus 
NMDA receptors are often considered key mediators of pathological pain (Woolf and Salter, 2000). 
NR2B, the predominant NMDA subunit in nociceptive pathways, has been suggested as a target 
for the development analgesics for the treatment of neuropathic pain, and indeed there have 
been some successes in the use of NR2B antagonists for this condition; NR2B antagonists 
attenuate pain in animal models (Gogas, 2006), indicating NMDA receptor signalling does play a 
key role in the pathological changes associated with chronic pain. It has been demonstrated that 
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sustained noxious input from the periphery can alter membrane expression and subunit 
composition of AMPA receptors (Tao, 2012); painful stimulation results an increase in the 
expression of GluA1 at the neuronal membrane but a decrease in GluA2 (Park et al., 
2008;Collingridge et al., 2004), resulting in enhanced permeability to Ca2+ and facilitating 
nociceptive plasticity (Hartmann et al., 2004). Potentiating the effects of glutamate is not the only 
effect of neuropeptides in central sensitisation. The release of SP from the central terminals of 
primary afferents is enhanced by noxious peripheral stimulation (Go and Yaksh, 1987) which, in 
turn, leads to increased signalling through its receptor, NK1. The expression of NK1 on lamina I 
interneurons is substantial (Cheunsuang and Morris, 2000) and the activation of this GPCR 
enhances the release of peptide neurotransmitters (Malcangio and Bowery, 1994;Lever et al., 
2003) which contributes to wind up (Herrero et al., 2000). Additionally, approximately eighty 
percent of lamina I projection neurons express the NK1 receptor (Todd et al., 2000), and activation 
here results in an increase of nociceptive signalling to higher brain regions. CGRP, which shows de 
novo expression in the central terminals of medium and large A-fibres following injury, potentiates 
the effects of SP (Woolf and Wiesenfeld-Hallin, 1986), enhances BDNF release (Buldyrev et al., 
2006) and, via activation of post-synaptic CGRP receptors, activates PKA and PKC signalling 
pathways (Sun et al., 2003) that can alter protein transcription, thus resulting in the altered 
expression of various ion channels and receptors in dorsal horn neurons. BDNF, following 
activation of its receptors on neurons enhances NMDA receptor mediated transmission (Kerr et 
al., 1999) and activates several intracellular signalling pathways, including MAPK (Pezet et al., 
2002a), that contributes to altered neuronal protein expression. 
 
Although originally considered to only represent an increase in excitatory synaptic strength and 
neuronal excitability, it is now understood that central sensitization also consists of loss of 
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inhibition in the spinal cord (von Hehn et al., 2012). Peripheral nerve injury results in a loss of 
GABA-ergic currents in the dorsal horn (Janssen et al., 2011) thought to be due to the excitotoxic 
loss of GABA-ergic interneurons (Scholz et al., 2005); furthermore a reduction in glycinergic 
inhibitory currents is also observed in the dorsal horn (Moore et al., 2002), again attributed to a 
loss of inhibitory interneurons (Scholz et al., 2005). Additionally BDNF reduces the expression of 
the KCC2 ion transporter which results in the reduced inhibitory efficacy of GABA due to an 
alteration in neuronal anion gradient (Coull et al., 2005;Coull et al., 2003;Miletic and Miletic, 
2008), and an increase in nociceptive discharge to higher brain regions is associated with a loss 
descending inhibitory activity (Viisanen and Pertovaara, 2007;Saade and Jabbur, 2008). 
 
Whilst the neuronal changes occurring the in the CNS following peripheral nerve injury are 
pronounced, chronic pain states are no long considered to be diseases of purely neuronal origin, 
and the pro-nociceptive activation of glial cells within the spinal cord is now a hot topic. Glial cells 
constitute approximately seventy percent of the cells in the brain and spinal cord and consist of 
microglia (five to ten percent of the glial population) and macroglia (astrocytes and 
oligodendrocytes) (Vallejo et al., 2010;Milligan et al., 2003); however it is microglia and astrocytes 



























Figure 1.4. Key neuronal players involved in central sensitization. Enhanced pre-synaptic activity and phenotypic switching of primary afferents leads 
to the release of neurotransmitters and neuropeptides; these activate their specific receptors on the post-synaptic membrane and post-synaptic 
excitation is enhanced. Activation of TrkB by BDNF decreases KCC2 expression which alters the neuronal anion gradient and reduces the efficacy of 
GABA; this combined with a reduction in the expression of glycine receptors (GlyR) decreases post-synaptic inhibition. 
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Microglia are the resident macrophages of the CNS. These cells are of myeloid lineage and invade 
the CNS during embryogenesis, where they reside physiologically in a ‘resting’ or ‘quiescent’ state. 
Quiescent microglia are characterised by a small soma, expression of receptors for complement 
components (Fcγ receptor of IgG), low expression of cell surface antigens and the possession of 
highly motile ramified processes that perform immune surveillance of the surrounding area; it is 
this that is their main function (Nimmerjahn et al., 2005). In response to injury or insult microglia 
are rapidly activated, taking on a more amoeboid morphology, altering their expression of a 
number of cell surface proteins that play a critical role in immune responses, synthesising and 
releasing inflammatory mediators, and enhancing their proliferative and phagocytic capacity 
(Davalos et al., 2005;Nimmerjahn et al., 2005;Hanisch and Kettenmann, 2007). This microglial 
activation, also termed microgliosis, has been documented in a number of models of both 
inflammatory and neuropathic pain, and is visible immunohistochemically as early as three days 
after the peripheral injury (Echeverry et al., 2008); however real-time PCR analysis of spinal cord 
lysates is able to detect changes in the levels of microglial specific mRNA transcripts (e.g. CD11b, 
TLR4 and CD14) as little as four hours after injury (Tanga et al., 2004). Microgliosis is most 
abundant in the superficial dorsal horn ipsilateral to the injury in the periphery but is also seen in 
the ventral horn due to the combination of sensory and motor fibres in the damaged nerve. The 
temporal profile of microglial activation in the spinal cord following peripheral damage is 
concomitant with the presence of behavioural hypersensitivity (Zhang et al., 2007;Peters et al., 
2007b;Wodarski et al., 2009) and the administration of glial inhibitors attenuate pain in 
neuropathic models (Clark et al., 2007a;Tawfik et al., 2007), suggesting that microgliosis does 
indeed contribute to the development of pain. Spinal microglia are activated in a multitude of 
ways (see figure 1.5) and certainly in models of neuropathic pain it appears that the activating 
factors arises from an enhanced peripheral drive through primary afferent fibres, as nerve 
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conduction blockade via the application of local anaesthetic prevents microglial activation (Wen et 
al., 2007;Hathway et al., 2009;Suter et al., 2009). Microglia possess the receptors for both SP and 
BDNF (Rasley et al., 2002;Pezet et al., 2002b) that are increasingly released from the central 
terminals of primary afferents, NMDA and AMPA receptors that are exposed to glutamate 
released from activated pre-synaptic neurons (McMahon and Malcangio, 2009;Ransohoff and 
Perry, 2009) and several purinergic receptors, including P2X4 and P2X7 that are substantially 
upregulated after injury (Tsuda et al., 2003;Chessell et al., 2005). Following peripheral injury the 
cleavage of CX3CL1, expressed on neurons in the CNS, is increased; the concentration of the 
soluble forms of this chemokine in the cerebrospinal fluid of neuropathic animals is considerably 
higher than that of naive or sham operated animals (Clark et al., 2009). The CX3CL1 receptor, 
CX3CR1, is expressed predominantly on microglia in the brain and spinal cord where it is 
constitutively expressed and increased by injury (Verge et al., 2004;Milligan et al., 2004;Harrison 
et al., 1998). Activation of microglial CX3CR1 is known to be critically involved in the development 
of neuropathic mechanical allodynia as mice lacking this protein do not develop allodynia 
following a peripheral nerve injury neither do they show the associated microgliosis (Staniland et 
al., 2010). Activation of CX3CR1 results in calcium-dependent activation of P38 MAPK and 
subsequent release of several pro-nociceptive mediators, including IL-1β, IL-6 and NO (Milligan et 
al., 2004). Another chemokine, CCL2, has also been hypothesized to activate microglia. Under 
physiological conditions CCL2 mRNA is almost undetectable in the spinal cord (Zhang et al., 
2007;Zhang and De, 2006) (although it is constitutively expressed in DRG neurons (Dansereau et 
al., 2008)), however following injury CCL2 is upregulated in spinal microglia, astrocytes and small 
diameter non-peptidergic fibres in the DRG that co-express ATF-3 (Zhang et al., 2007;Dansereau et 
al., 2008;Abbadie et al., 2003;Ji et al., 2013;Old and Malcangio, 2012). Microglial expression of 
CCL2’s receptor, CCR2, is somewhat debated as recently a CCR2-red fluorescent protein knock-in 
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mice demonstrated a CCR2+ population of cells that did not co-express CX3CR1 (which is 
supposedly expressed by all microglia) (Olechowski et al., 2009;Saederup et al., 2010), however 
increased immunoreactivity for CCR2 has been reported in microglia after injury (Abbadie et al., 
2003) and CCL2 does increase microglial immunoreactivity for OX42 (Thacker et al., 2009). As with 
CX3CL1, CCR2 contributes to enhanced nociceptive transmission via the release of pro-nociceptive 
mediators. Furthermore it is able to enhance EPSCs and potentiates NMDA and AMPA currents 
within the spinal cord (Gao et al., 2009), and additionally may contribute to the development of 
deregulation of GABA-ergic transmission; co-exposure of DRG neurons to CCL2 and GABA results in 
a rapid concentration-dependent reduction of GABA-ergic induced inward current (Gosselin et al., 
2005;Old and Malcangio, 2012) .In addition, it has been demonstrated that several cytokines, such 
as those released from activated microglia themselves, can activate microglial cells, thus there 
may be positive feedback-dependent activation of microglia following injury. For example, the 
IFNγ receptor (IFNγR) co-localises with microglial markers in the spinal cord following an injury 
known to increase the expression of IFNγ (Tanga et al., 2005); furthermore it has been 
demonstrated that IFNγ can activate microglia in vitro (Hanisch and Kettenmann, 2007).  
Additionally, IFNγ induced hypersensitivity and microgliosis can be prevented by the 
administration of the microglial inhibitor minocycline and IFNγ-/- mice do not develop microgliosis 
following injury (Tsuda et al., 2009). 
 
The predominant intracellular pathway activated in microglia under neuropathic conditions is the 
MAP kinase pathway, a family of kinase proteins of which there are three members: ERK, P38 and 
JNK. Activation of both ERK and P38 is seen in microglia following injury; the expression of 
phosphorylated ERK (pERK) peaks approximately three days after injury (Zhuang et al., 2005) and 
the inhibition of its signalling pathway attenuates both injury-induced and diabetes-releated 
64 
 
hypersensitivity (Zhuang et al., 2007;Tsuda et al., 2008). The expression of phosphorylated P38 
(pP38) also peaks approximately three days after injury and remains elevated for several weeks, 
and whilst increased pERK can be seen in neurons and astrocytes as well as microglia following 
injury, pP38 is found solely in microglia (Jin et al., 2003;Tsuda et al., 2004;Clark et al., 2007b). The 
activation of both ERK and P38 proteins results in the activation of transcription factors that 
ultimately mediated an up-regulation of several molecules: IL-1, TNF, IL-6, IL-18, NO, CX3CL1, CCL2, 
prostaglandins and BDNF (McMahon and Malcangio, 2009); all of which are pro-nociceptive, this 
process is summarised below in figure 1.5. 
 
Under physiological conditions, astrocytes play a key role in the maintenance of homeostasis in 
the CNS. Astrocytes are the most abundant glial cell of the CNS; comprising approximately 40-50% 
of all glia (Aldskogius and Kozlova, 1998;Cahoy et al., 2008) these cells wrap around the soma of 
neurons and make contact with hundreds of dendrites (Halassa et al., 2007;Haydon, 2001). Due to 
the close contact between neurons and astrocytes, astrocytes are able to provide support and 
nourishment to these cells and assist in the regulation of the extracellular environment around 
synapses (Gao and Ji, 2010b). Astrocytes play an important role in the regulation of extracellular K+ 
and Ca2+, control extracellular neurotransmitter concentrations by actively up-taking any excess 
and assist in the maintenance of the blood brain barrier (BBB) (Cahoy et al., 2008) and provide 
neurons with a source of anti-oxidants (Pekny and Nilsson, 2005). In this ‘active’ state astrocytes 
possess many thin processes, however following activation, such as that occurring in chronic pain 
states, these cells undergo hypertrophy and increase their expression of several proteins, including 
glial fibrillary acid protein (GFAP), which is consequently used as a marker of astrocyte activation 
(Garrison et al., 1994;Vallejo et al., 2010), vimentin and S100β (a calcium binding peptide) (Ridet et 
al., 1997;Pekny and Nilsson, 2005); these astrocytes are referred to as ‘reactive’. As is the case for 
65 
 
microglia, the activation of astrocytes, often referred to as astrogliosis, has been demonstrated in 
several models of chronic pain (Garrison et al., 1991;Colburn et al., 1999;Sweitzer et al., 1999), and 
the administration of astrocytic inhibitors, such as fluorocitrate, attenuates pain behaviours in 
many of these models (Milligan et al., 2003;Watkins et al., 1997;Okada-Ogawa et al., 2009). 
Furthermore, mice deficient in the astrocytic protein GFAP develop a shorter lasting pain 
phenotype than wild-type mice and the administration of a GFAP anti-sense mRNA reverses 
established neuropathic pain (Kim et al., 2009), indicating that this protein, and astrocyte 
activation, play a critical role in the maintenance of a pain phenotype following injury. 
Supportively, astrogliosis typically occurs several days after injury and is much longer lasting than 
microgliosis (Colburn et al., 1999;Tanga et al., 2004;Romero-Sandoval et al., 2008). 
 
Astrocytes can be activated via a multitude of pathways. They possess a number of 
neurotransmitter receptors including NMDA, mGluR, SP and CGRP receptors (Porter and 
McCarthy, 1997) that allow them to be activated by increased transmitter release following injury. 
In fact it has been demonstrated that increased GFAP expression after injury or inflammation 
requires the NMDA receptor and neuronal activity (Guo et al., 2007;Garrison et al., 1994). 
Additionally astrocytes express several chemokine and cytokine receptors that can be activated by 
mediators released from activated microglia; IL-18 released from activated microglial activates the 
IL-18R on the surface of astrocytes which is upregulated following injury (Miyoshi et al., 2008) and 
TNFα, also released from microglia, activates astrocytic TNFR in a similar fashion (Gao et al., 

































Figure 1.5. Examples of 
mechanisms of microglial cell 
activation in models of pain. 
Activation of the IFNγ and CXCR3 
receptors leads to upregulation of 
the P2X4 ion channel, activation of 
which results in activation of MAPK 
signalling pathways that result in the 
release of pro-nociceptive 
mediators such as BDNF. Activation 
of CCR2, TLR4, CGRP and NK1 
receptors has similar results. CatS is 
released from microglial in a P2X7-
dependent manner; CatS cleaves 
neuronal CX3CL1 which in turn 
activates CX3CR1 on the microglial 
surface, which leads to downstream 
MAPK signalling. Microglia also 
possess NMDA and AMPA glutamate 
receptors which when activated 
lead to an increase in intracellular 
calcium levels and subsequent 
activation of signalling proteins. 
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Whilst astrocytes undergo many changes following activation, there are two that are likely to be 
responsible for the contribution of these cells to pain. Following an initial increase after nerve 
injury, the astrocytic expression of the glutamate transporters GLT1 and GLAST decreases (Sung et 
al., 2003;Wang et al., 2008;Xin et al., 2009;Tawfik et al., 2008), and as the inhibition of glutamate 
transporters causes an elevation in spinal extracellular glutamate concentrations (which elicits 
nociceptive hypersensitivity) (Liaw et al., 2005;Weng et al., 2006), it is reasonable to suggest that 
this decrease in expression contributes to pain via an increase extracellular concentration of this 
excitatory neurotransmitter. Additionally, reactive astrocytes express phosphorylated JNK (pJNK) 
and ERK (pERK) (Zhuang et al., 2006;Gao et al., 2010a;Weyerbacher et al., 2010) that, in a similar 
fashion to pERK and pP38 in microglia, stimulate the release of a variety of pro-inflammatory 
mediators via the activation of transcription factors. These mediators include IL-1β which 
regulates the phosphorylation of the NMDA receptor (Guo et al., 2007;Tsakiri et al., 2008) and 
increases COX-2 expression in neurons (Samad et al., 2001) and CCL2 which activates CCR2 on 
neurons (that is upregulated following injury) which increases the frequency of EPSCs and 
enhances NMDA and AMPA induced inward currents (Gao et al., 2009). JNK signalling in particular 
dominates pain-astrogliosis research as JNK activation in astrocytes regulates the expression and 
release of several cytokines and chemokines (Gao and Ji, 2010b). JNK phosphorylation in 
astrocytes has been demonstrated to increase the expression of COX-2 and iNOS as well as the 
release of NO, prostaglandin E2 and IL-6 (Falsig et al., 2004) all of which are pro-nociceptive. 
Increased expression of pJNK in astrocytes is seen in models of both neuropathic and 
inflammatory pain (Ma and Quirion, 2002;Svensson et al., 2007;Gao et al., 2010a) and its inhibition 
via the administration of the JNK inhibitors SP600125 or D-JNK1-1 can suppress pain behaviours in 
models of peripheral nerve injury and diabetes-induced neuropathic pain (Zhuang et al., 
2006;Daulhac et al., 2006).  
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191B2.2.4.3. Higher Centre Modulation 
Sensory output from the dorsal horn is relayed to higher processing centres in the brain by 
ascending pathways; however there are also a number of descending pathways from these regions 
that are involved in the modulation of pain transmission, and indeed many of these regions have 
been shown to contribute to the development and/or maintenance of neuropathic pain.  
 
Despite a wealth of evidence supporting the involvement of cerebral cortical and sub-cortical 
areas of the brain in humans in pain modulation, relatively few animal studies have attempted to 
example the role of these regions in chronic pain; however a number of regions have been shown 
to influence pain modulation in this setting (extensively reviewed in (Saade and Jabbur, 2008)). A 
transient reduction of thermal hyperalgesia and mechanical and cold allodynia has been 
demonstrated by blockade of signalling in the ventral orbital area, attributed to a reduction in 
dopaminergic transmission (Baliki et al., 2003). A similar effect can be observed by altering 
dopaminergic transmission in the insular cortex; here D1 and D2 receptors play a pro-nociceptive 
and anti-nociceptive role respectively, via reception of dopaminergic inputs from the amygdala 
and RVM (Jasmin et al., 2003a;Jasmin et al., 2003b;Ohara et al., 2003;Coffeen et al., 2008). The 
amygdala itself shows substantial plastic changes in neuropathic models, where amongst other 
mechanisms, fear reactions regulated in this region can enhance pain through inhibition of 
descending inhibitory pathways from the locus coeruleus (Viisanen and Pertovaara, 2007;Saade 
and Jabbur, 2008), which are themselves enhanced by an increase in nociception evoked 
discharges (Saade and Jabbur, 2008). Although the thalamus does not have descending projections 
to the brain stem or spinal cord, experimental evidence indicates a role for this brain region in 
chronic pain; thalamic electrical stimulation produces analgesia in both animals (Dickenson, 1983) 
and humans (Hosobuchi et al., 1973;Mazars, 1975). Furthermore, electrical stimulation of the 
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ventral posterolateral nucleus of the thalamus abolishes mechanical allodynia in a rat model of 
nerve injury without altering the nociceptive thresholds of the contralateral paw (Kupers and 
Gybels, 1993). One of the most understood descending pathways involved in nociceptive 
modulation is that of the PAG and RVM. A reduction in descending inhibition from the PAG has 
been demonstrated in neuropathic animals (Pertovaara et al., 1997), whilst prolonged exposure to 
noxious stimuli produces nociceptive facilitation in the RVM via an increase in discharge from ‘on-
cells’; it is thought that an alteration in the ratio of activated ‘on’ and ‘off’ cells contributes to 
hyperalgesia (Morgan et al., 1994;Morgan and Fields, 1994;Saade and Jabbur, 2008). Moreover, 
inhibition of this facilitation by the injection of lidocaine into the RVM attenuates pain behaviours 
in neuropathic animals (Pertovaara et al., 1996). Recent animal studies have identified a 
descending facilitatory projection from the PAG that relays pro-nociceptive signals to the RVM, by 
enhancing spinal transmission of inputs from the periphery; activation of this system has been 
associated with the development of hyperalgesia, for example by cholecystokinin (CCK) released 
from midbrain structures in response to chronic input from nociceptive pathways (Carlson et al., 
2007;Heinricher et al., 2004;Tillu et al., 2008;Lovick, 2008). An increase in CCK in the PAG is also 
thought to contribute to the development of morphine tolerance and its associated development 





25B3. Chemotherapy induced neuropathy 
49B3.1. Symptoms and Incidence 
 
Chemotherapy-induced neuropathy first came to light in the late 1960’s when clinicians observed 
evidence of neuropathy in leukaemia patients receiving treatment with vinca alkaloids (Sandler et 
al., 1969). Further study of such patients revealed a loss of the ankle-jerk reflex and paraesthesias 
(abnormal sensation e.g. tingling) in the fingers and toes that begun following VCR treatment and 
recovered somewhat with dose reduction (Casey et al., 1973). In the years that followed similar 
studies identified populations of patients treated with other chemotherapeutic agents, primarily 
taxanes and platinum containing compounds, which displayed similar symptoms despite their 
varying anti-neoplastic mechanisms. 
 
One of the most problematic symptoms, with all neuropathy-inducing agents, is pain (Tofthagen, 
2010). Two recent studies asked patients to describe the pain they were experiencing; the average 
patient rated it as a seven out of ten in severity (Dougherty et al., 2004) and assigned ‘throbbing, 
‘sharp’, and ‘burning’ properties to the pain (Dougherty et al., 2007). Pain reporting in 
chemotherapy-receiving patients is consistent and can occur as early as four days after the first 
administration of the chemotherapeutic agent (Loprinzi et al., 2011). Pain is described as both 
spontaneous (Tofthagen, 2010) and occurring as a result of a stimulus, typically cold and 
mechanical hypersensitivity (Binder et al., 2007). The most prevalent symptoms of chemotherapy-
induced painful peripheral neuropathy reported are paraesthesias and dysesthesia (loss of 
sensation) which occur consistently across varying chemotherapy treatment protocols (Kautio et 
al., 2011), and can be spontaneous or cold induced (Driessen et al., 2012;Attal et al., 2009). Also 
commonly reported is a loss of vibratory sensation (Berger et al., 1997), a general reduction in 
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sensory function in the hands (Kautio et al., 2011), alterations in taste (Strasser et al., 2008), 
thermal hyperalgesia (Binder et al., 2007), pharyngolarygeal dysesthesia (Argyriou et al., 2013b) 
and, in patients receiving very high doses of chemotherapeutics, muscle weakness (Tofthagen, 
2010). Symptoms are typically experienced in the hands and feet in what is described as a glove 
and stocking distribution (Dougherty et al., 2007) and commonly extend as far as the wrists and 
ankles. Additionally this tends to be symmetrical; patients report symptoms of equal severity on 
the left and right side of the body (Dougherty et al., 2004). Clinically neuropathy is graded based 
on its severity; the most commonly used scale to score chemotherapy-induced neuropathy is the 
National Cancer Institute Common Toxicity Criteria (NCI-CTC), which is summarised in the table 
below. 
 
The incidence of neuropathy occurrence following chemotherapy varies greatly across patient 
populations and studies, likely due to variation in the drugs themselves and the treatment 
regimens they are given as part of. Neuropathy resulting from treatment with taxanes has been 
reported in as few as 35% of patients in a study of patients receiving docetaxel for primary breast 
cancer (Eckhoff et al., 2011) and as many as 97% of patients in a study of those receiving PTX  for 
the same type of cancer (Tanabe et al., 2013). Chemotherapy-induced neuropathy has been 
reported in an excess of 85% of patients treated with the platinum-based oxaliplatin for colorectal 
cancer (Briani et al., 2013), and in a similar number of patients treated with the vinca alkaloid VCR 





Table 1.4. NIC-CTC neuropathy grading. (Adapted from (Postma and Heimans, 2000))  
 
Scale Neuropathy - Sensory Neuropathy - Motor 
Grade 0 Normal. Normal. 
Grade 1 Loss of deep tendon reflexes or 
paraesthesias (including tingling) but 
not interfering with function 
Subjective weakness, no objective 
findings. 
Grade 2 Objective sensory loss or paraesthesias 
interfering with function but not 
interfering with activities of daily living. 
Mild objective weakness interfering with 
function but not interfering with activities 
of daily life. 
Grade 3 Sensory loss or paraesthesias interfering 
with activities of daily living. 
Objective weakness interfering with 
activities of daily live. 





It was noted early in the study of this condition that the neurotoxicity associated with 
chemotherapeutics is dose related and cumulative (Legha, 1986), in fact the dose of 
chemotherapy received is one of the key factors in predicting the likelihood of a patient 
developing a neuropathy; patients receiving a high dose per cycle show a greater incidence of 
neuropathy than low dose receiving patients. For example a prospective study by Postma and 
colleagues identified neuropathic symptoms in 50% of patients receiving 135mg/m2/cycle of PTX 
for ovarian cancer, whilst 100% of patients treated with 250-300mg/m2/cycle of PTXl for breast 
cancer experienced neuropathy (Postma et al., 1995). The incidence of neuropathy increases with 
treatment duration (Augusto et al., 2008) and the number of cycles received. For example a 2004 
study of patients being treated for a variety of solid mass tumours found 15% of patients were 
experiencing neuropathy at the end of a single cycle of chemotherapy, 75% at the end of the 
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second cycle and 100% of patients experienced some degree of neuropathy by the end of a fourth 
cycle of their treatment (Dougherty et al., 2004). 
 
In addition to agent and dose, several factors have been suggested to increase the likelihood of a 
patient developing neuropathy following chemotherapy. Age is a frequently occurring factor in 
determining the incidence of chemotherapy-induced neuropathy; several studies have reported an 
increased incidence or increased severity of neuropathy in elderly patients, particularly those over 
70 years old (Cen et al., 2012;Johnson et al., 2011).The evidence however, is not conclusive; a 
recent study by Argyrious and colleagues reported no correlation between age and incidence in 
their cohort of patients (Argyriou et al., 2013a). The effect of diabetes on incidence is also 
debated; studies have provided both evidence for (Brunello et al., 2011) and against (Picozzi et al., 
2011) an increased incidence of chemotherapy-induced neuropathy in diabetic or hypoglycaemic 
patients. It has been suggested that malnourishment and hypoalbuminemia, common in cancer 
patients, may result in patients developing more severe neuropathy than better nourished 
patients (Arrieta et al., 2010). Several gene polymorphisms have been associated with the 
development of neuropathy as a result of chemotherapy. These include a greater incidence of a 
singly nucleotide polymorphism in the tac1 gene (encoding the tachykinin precursor) in patients 
with chemotherapy-induced neuropathy compared to non-neuropathic disease matched controls 
(Won et al., 2012), and a lower incidence in patients with a polymorphism in the cyb1b1*3 allele 
which is associated with taxane turnover in the liver. The results of this latter study is supported 
by evidence of inhibitors of the protein cytochrome p450 (which is involved in drug metabolism) 




Chemotherapy-induced neuropathy is a substantial clinical problem to both oncologists and 
patients. Neuropathic patients report worse quality of life scores, especially in physical function 
and pain categories, than non-neuropathic chemotherapy-receiving patients (Kim et al., 2010). In 
addition, the neuropathy can become severe enough to require dose reduction or complete 
cessation of treatment, which can directly impact a patient’s ability to survive the cancer. 
Neuropathy has been reported as the dose-limiting side effect in an excess of 70% of people in 
some patient populations (Postma et al., 1995), and causes treatment to be cessed in between 
20% (Briani et al., 2013;Dougherty et al., 2007) and 40% (Bennett et al., 2012) of patients receiving 
some treatment regimens. In those patients that don’t require cessation of treatment and 
subsequently survive their cancer, symptoms of neuropathy can persist and continue to have an 
effect on their quality of life. Symptoms of PTXl-induced neuropathy have been reported to persist 
for as long as 3 years after completion of treatment (Tanabe et al., 2013), VCR neuropathy as long 
as 4 years after treatment (Dougherty et al., 2007), and a 2009 study of oxaliplatin treated patients 
calculated the average half life of recovery from the neuropathy was a staggering 6.8 years 
(Brouwers et al., 2009). Treatment of chemotherapy-induced neuropathy is a critical part of the 
medical management of cancer patients, current treatment options are discussed below. 
 
50B3.2. Prevention and Treatment of Chemotherapy Induced Neuropathy  
 
As the mechanism by which chemotherapy-induced neuropathy (discussed below) has not been 
fully elucidated, the neuropathy itself cannot be treated; rather clinicians aim to manage the most 
problematic of symptoms, pain. This is primarily done with classical analgesics, however the 
efficacy in this condition is varied, and a number of patients continue to report pain. In fact the 
average pain score of patients receiving daily doses of gabapentin, paracetamol, naproxen, 
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codeine or morphine (in excess of 85mg/day) was three out of ten (Dougherty et al., 
2007;Dougherty et al., 2004) and only 75% of patients with bortezomib-induced neuropathy 
report decreased pain intensity whilst taking control release oxycodone (Cartoni et al., 2012). 
These statistics are supported by work in rodent models of chemotherapy pain (discussed below) 
where opioid treatment has mixed results; transiently attenuating some aspects of pain, such as 
tactile allodynia, in some studies (Park et al., 2013), but not all (Bujalska et al., 2009). However, 
there does appear to be a higher response rate to opiates in rodents than in humans, but this may 
be an artefact of the type of pain assessed; whilst rodents are assessed for stimulus induced pain, 
patients report spontaneous pain. 
 
Gabapentin and pregabalin, traditionally used as anti-epileptics, are used routinely to treat various 
chronic pain conditions, and chemotherapy-pain is no different. In various rodent models of this 
condition both gabapentin and pregabalin are able to attenuate established chemotherapy-
induced mechanical and cold allodynia (Guindon et al., 2013), however this does not translate fully 
into the clinic; whilst some patients respond well to this therapy, showing improvement of 1-2 
neuropathy grades (Saif et al., 2010), a substantial percentage of patients do not respond, and 
report post-gabapentin pain scores of four out of ten, no different to placebo treated patients 
(Vondracek et al., 2009;Rao et al., 2007). Several other anti-epileptic drugs, such as lacosamide, 
valproate, lamotrigine and oxcarbazepine have shown pain reducing efficacy in animal models of 
chemotherapy pain (Geis et al., 2011;Rodriguez-Menendez et al., 2008), but their results haven’t 
translated to patients, where these drugs are only partially successful in reducing neuropathy (Rao 
et al., 2008;Argyriou et al., 2006). SSRI (selective serotonin re-uptake inhibitor), SNRI (selective 
norepinephrine re-uptake inhibitor) and TCA (tricyclic) anti-depressants fair slightly better; these 
drugs decrease pain in many (Smith et al., 2013;Katsuyama et al., 2013;Kanbayashi et al., 2013), 
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although not all (Kautio et al., 2008) patients. Whilst they can have some undesirable side-effects 
such as nausea and tiredness, patients treated with anti-depressants report increases in quality of 
life score independent of successful pain management (Kautio et al., 2008). 
 
Trials of several other therapies have been undertaken for the treatment of chemotherapy 
induced pain with varying results, highlighting the difficulties clinicians face in treating this 
condition. Several studies have indicated infusions of calcium and magnesium could reduce the 
incidence of neuropathy in colorectal cancer patients treated with oxaliplatin by half and a recent 
meta-analysis has supported this; incidence of grade 3 (severe) neuropathy is significantly lower in 
patients that receive calcium/magnesium infusions than the control group without significant 
alterations in efficacy of the chemotherapy itself (Gamelin et al., 2004;Wen et al., 2013). On the 
other hand, whilst initial studies suggested glutathione treatment could prevent a decrease in 
nerve conduction velocity caused by cisplatin (Hamers et al., 1993) and reduce the incidence of 
neuropathy in oxaliplatin treated patients (Cascinu et al., 2002), a 2011 Cochrane review found 
that overall there was insufficient evidence to support a neuroprotective effect of glutathione 
(Albers et al., 2011). The same review found no neuroprotective effect for vitamin E, which had 
been observed in some (Pace et al., 2010;Argyriou et al., 2005a), but not all (Afonseca et al., 
2013;Kottschade et al., 2011) studies to reduce the incidence and severity of neuropathy occurring 
as a result of chemotherapy. Additionally, glutamine has been demonstrated to reduce the 
number of patients requiring chemotherapy dose-reduction as a result of neuropathy (Wang et al., 
2007), calcium channel blockers to decrease the incidence of acute neuropathy after oxaliplatin 
treatment (Tatsushima et al., 2013) and the anti-oxidant N-acetylcysteine to decrease the 
incidence of oxaliplatin neuropathies of all severities (Lin et al., 2006).  
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Despite these positive studies, chemotherapy pain patients are still poorly managed due to a lack 
of drugs with complete efficacy in treating the condition. The above studies look at improvement 
in the overall incidence of neuropathy, be it a reduction in sensory loss or stimulus induced pain, 
but patients still complain of spontaneous pain (Dougherty et al., 2004).  The underlying problem 
is that these drugs are primarily treating the symptoms of the neuropathy and are not treating or 
preventing the neuropathy itself. In order to develop drugs prevent the development of 
chemotherapy-induced painful peripheral neuropathy, we first need to understand the 
mechanism by which chemotherapeutic agents cause neuropathy, thus allowing the identification 
of novel drug targets that allow management of the neuropathy and subsequent pain, without 
interfering with the anti-neoplastic mechanisms of the chemotherapeutics. 
 
51B3.3. Modelling Chemotherapy Induced Neuropathy  
 
Patient studies have allowed us to gain some understanding of the pathophysiology occurring as a 
result of chemotherapy-induced neuropathy. Repeatedly patients report pain and mechanical and 
cold hypersensitivity and this appears to correlate with electrophysiological abnormalities; 
symptomatic VCR-neuropathy patients show an abnormal amplitude of sural sensory nerve action 
potentials and a decrease in sensory nerve conduction velocity which is not seen in patients that 
don’t experience symptoms of neuropathy (Krishnan et al., 2005). This is a common finding across 
chemotherapeutic regimens (Krarup-Hansen et al., 2007) and has been found to persist, along 
with pain, beyond the administration of the chemotherapeutic agent (Argyriou et al., 
2005b;Ramchandren et al., 2009). Often in patients that do not exhibit a decrease in conduction 
velocity electrophysiological abnormalities are evident; concentric needle electromyography has 
demonstrated evidence of denervation of the small muscles in the hand, which is associated with 
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prolonged mean distal latencies and decreased mean amplitudes of compound muscle action 
potentials (Pal, 1999). Conversely, nerve conduction and EMG studies have revealed evidence of 
sensory nerve hyper-excitability which is not reversed by carbamazepine (Pal, 1999;Wilson et al., 
2002). The physical properties of the nerves themselves are altered in neuropathic patients; sural 
nerve biopsies have provided evidence of a loss of large-diameter fibres with both axonal and 
myelin degeneration (Roelofs et al., 1984). Intraepidermal nerve fibre density is reduced in the 
distal limbs, where symptoms are most commonly reported (Burakgazi et al., 2011) and ultrasound 
assessment of the nerves of symptomatic patients has shown enlargement of the nerve at median 
and ulna entrapment site (Briani et al., 2013). 
 
Whilst this information gives us a starting point, and indicates that chemotherapeutic agents are 
indeed having a substantial effect on the nervous system, animal models are required to allow the 
underlying pathology associated with this condition to be studied in detail. Three models are 
commonly used in the laboratory for such work and are based on four different neuropathy 
causing agents; PTX, cisplatin or oxaliplatin and VCR. The features of these models are described 
below and are summarised at the end of the section in table 1.5. 
 
The PTX model of chemotherapy-induced peripheral neuropathy is primarily a rat model and is 
established by the repeated intraperitoneal administration of PTX. Two dosing regimens are 
common, both using a dose of between 0.5 and 2mg/kg given either on alternate (Polomano et al., 
2001) or consecutive days (Naguib et al., 2012). This results in mechanical and cold allodynia and 
hypersensitivity, without an effect on motor co-ordination (Polomano et al., 2001). PTX treated 
rats have decreased sensory nerve conduction velocities (Gilardini et al., 2012;Wozniak et al., 
2011), associated with both Aβ and C fibres (Zhang and Tuckett, 2008), a decrease in the 
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amplitude of sensory compound action potentials (Leandri et al., 2012) and an increase in 
spontaneous firing of both A and C fibres (Xiao and Bennett, 2008). PTX decreases the density of 
myelinated fibres and causes myelinated fibre degeneration in the sciatic nerve (Kawashiri et al., 
2009), as well as a loss of intraepidermal nerve fibres (Siau et al., 2006). This evidence, gathered 
approximately four weeks after PTX treatment, indicates neuronal damage; this is supported by an 
increase ATF3 (a neuronal stress marker) immunoreactivity in the DRG one week after treatment 
(Jamieson et al., 2007). 
 
Similarly the oxaliplatin and cisplatin models of chemotherapy-induced neuropathy, whilst 
possible in a mouse, are predominantly studied in the rat. Both oxaliplatin and cisplatin models are 
comparable to one another in their primary features due to these compounds being of the same 
class of chemotherapeutic agents. Typically given as a high dose once or twice a week for four 
weeks (Deng et al., 2012) or as a lower dose daily for up to three weeks (Di Cesare et al., 2012), 
the platinum compounds produce robust cold and mechanical allodynia without altering 
responses to heat (Guindon et al., 2013). As shown by electrophysiology studies these animals 
exhibit a decrease in sensory nerve conduction velocities (Gilardini et al., 2012), a reduction in 
sensory action potential amplitude (Renn et al., 2011) and spontaneous activity in wide dynamic 
range neurons (Cata et al., 2008). Oxaliplatin treatment has also been demonstrated to cause 
neuronal atrophy, increase eccentric nucleoli in DRG neurons (Renn et al., 2011) and reduce 
intraepidermal nerve fibre density in the skin (fifteen and thirty days after the onset of treatment) 
(Boyette-Davis and Dougherty, 2011). 
 
VCR can be used to cause chemotherapy-induced neuropathy in both the rat and mouse. In both 
instances it is administered daily for approximately two weeks (sometimes with a break to divide 
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treatment into two cycles) at a dose of between 0.1 and 0.5mg/kg/day intraperitoneally (mouse) 
or intravenously (rat) (Aley et al., 1996;Uceyler et al., 2006). In rodents VCR administration in this 
fashion causes severe dose-dependent mechanical allodynia and hyperalgesia (Aley et al., 
1996;Fukuizumi et al., 2003;Kiguchi et al., 2008b). Thermal hypersensitivity is common (Hansen et 
al., 2011;Uceyler et al., 2006) but not always present in these animals (Rahn et al., 2007). Similarly 
to PTX and the platinum-based compounds, VCR treatment is associated with altered 
electrophysiological properties of sensory nerve fibres. VCR causes a subset (41%) of C-fibres in 
the saphenous and cutaneous nerves to become hyper-responsive and fire in an irregular pattern 
with altered action potential timing (Tanner et al., 2003). A and C fibres show increased 
spontaneous firing (Xiao and Bennett, 2012) and a delayed F wave latency post VCR (Geis et al., 
2011). Additionally, it has been demonstrated that VCR causes decreased conduction velocity of 
(sciatic) sensory nerves (Alimoradi et al., 2012), a decrease in the amplitude of compound action 
potentials, reduction in myelin thickness and fibre diameter in the sciatic nerve (Callizot et al., 
2008) and a reduction in intraepidermal nerve fibre density (three weeks after VCR administration) 
(Siau et al., 2006). Furthermore, an increase in ATF-3 immunoreactivity in the DRG several weeks 




Table 1.5. A summary and comparison of the main features of chemotherapy-neuropathy in 
patients and animal models 
 
 
Feature Present in 
humans 




Present in VCR 
model 
Spontaneous pain  Not Known Not Known Not Known 
Mechanical 
hypersensitivity 
    
Thermal 
hypersensitivity 
    
Cold hypersensitivity     
Decreased 
conduction velocity 
in sensory nerves 
    
Spontaneous A 
and/or C fibre firing 
Not Known    
Reduction in action 
potential amplitude 
    




    
Neuronal atrophy Not Known Not Known  Not Known 
Increased ATF-3 
expression in the 
DRG 





52B3.4 The mechanism by which chemotherapeutics cause neuropathy 
 
Whilst chemotherapeutic agents have varying mechanisms of action, the neuropathic symptoms 
they produce in patients and animal models are similar. As such we can use these animal models 
to tease out mechanisms by which these agents may be causing the neuropathy independently of 
their anti-neoplastic effects. When the existing literature is examined several research areas are 
prevalent and will be discussed here; the endocannabinoid system, ion channels, reactive oxygen 
species and anti-oxidants, TRP channels and the contribution of the immune system, both 
peripheral and central.  
 
115B3.4.1 The endocannabinoid system in chemotherapy-induced neuropathy 
The endocannabinoid system has recently emerged as a source for novel analgesics for the 
treatment of chronic pain (Guindon and Hohmann, 2009;Rahn and Hohmann, 2009). To date the 
two best studied endocannabinoids are AEA (anandamide) and 2-AG (2-arachidonoylglycerol); 
both are arachidonic acid metabolites derived from phospholipids of the cell membrane. AEA and 
2-AG exert their biological actions by binding to and activating to the G-protein coupled CB1 or 
CB2 receptors.  CB1 receptors are found predominantly within the CNS, within areas of the brain 
associated with pain processing; these include the PAG, amygdala (Herkenham et al., 1991), 
thalamus (Matsuda et al., 1993) and DRG (Hohmann and Herkenham, 1999). The CB2 receptor on 
the other hand is found predominantly in the peripheral immune system (Howlett et al., 2004); 
however recent evidence has found this receptor to be expressed at low levels on both neurons 
and non-neuronal cells in the CNS and upregulated in chronic pain states (Beltramo et al., 
2006;Wotherspoon et al., 2005) . Agonists of both the CB1 and CB2 receptors are analgesic in 
models of chronic pain (Yu et al., 2010;Naguib et al., 2008) and antagonists of these receptors can 
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block this beneficial effect (Tumati et al., 2012;Romero et al., 2013). The synthesis of the 
endocannabinoids is well characterised; fatty-acid amide hydrolase (FAAH) is the principle 
catabolic enzyme for AEA (Cravatt et al., 1996), whilst 2-AG is hydrolysed (although not 
exclusively) by monoacylglycerol lipase (MAGL) (Blankman et al., 2007). Inhibiting the normal 
function of these enzymes, thus preventing endocannabinoid metabolism, attenuates pain 
behaviours in neuropathic (Kinsey et al., 2010) and inflammatory (Ghosh et al., 2013;Booker et al., 
2012) models of pain. 
 
Due to the clear involvement of the endocannabinoid system in chronic pain signalling, the role of 
this system in chemotherapy-induced pain has been investigated and the emerging evidence 
supports a contribution; chemotherapy alters endocannabinoid tone and its correction can 
attenuate pain. Cisplatin administration reduces AEA levels in the plantar paw skin and 
intradermal administration of AEA (following cisplatin) can locally attenuate subsequent 
mechanical hyperalgesia in these animals (Khasabova et al., 2012). Increasing the endogenous 
levels of AEA and 2-AG available to bind CB1 and CB2 receptors by administration of FAAH or 
MAGL inhibitors attenuates pain behaviours in cisplatin (Guindon et al., 2013) and VCR (Caprioli et 
al., 2012) treated rats. This effect is receptor dependent; pre-treatment with a CB1 or CB2 
antagonist prevents the anti-nociceptive effects of these inhibitors (Guindon et al., 2013), but has 
no effect on chemotherapy-induced pain when give alone (Khasabova et al., 2012). Evidence 
suggests both CB1 and CB2 receptors play a role in the analgesic effect of endocannabinoids in 
chemotherapy pain; the administration of both CB1 and CB2 agonists can prevent and reverse pain 




So how are the endocannabinoids modulating pain behaviour after chemotherapy treatment? One 
possible explanation is that the system provides neurons protection from the damaging effects of 
chemotherapeutic agents. In vitro experiments have demonstrated that incubation of DRG 
neurons with cisplatin causes a reduction in neurite length and that this effect can be blocked by 
pre-treatment with a CB1 agonist. Furthermore, in vivo cisplatin causes the conduction velocities 
of A-fibres to decrease, and increases TRPV1 and ATF-3 immunoreactivity in the DRG; this can be 
prevented by concomitant administration of a FAAH inhibitor (Khasabova et al., 2012). There is 
also evidence to suggest the endocannabinoids modulate pain by suppressing pro-nociceptive 
activity of non-neuronal cells in the CNS. PTX treatment is associated with an increase in CD11b 
(microglial marker) and GFAP (astrocytic marker) immunoreactivity in the spinal cord (Burgos et 
al., 2012;Naguib et al., 2012) that can be attenuated by pre-treatment of animals with the CB2 
agonist MDA7. This attenuation is prevented by prior administration of a specific CB2 antagonist, 
suggesting the effects of MDA7 are via direct activation of CB2 receptors (Naguib et al., 2012). The 
administration of PTX is associated with enhanced expression of iNOS, IL-1β, IL-6 and TNF-α in 
spinal glial cells (it is reduced by the glial inhibitor minocycline) that can be prevented by a mixed 
CB1/2 agonist (Burgos et al., 2012). Crucially the pro-nociceptive effects of cannabinoid 
modulators do not appear to interfere with the anti-neoplastic actions of chemotherapeutics; 
concomitant administration of CB1/2 agonists and PTX did not reduce cancer cell death compared 
to PTX treatment alone (Naguib et al., 2012). 
 
116B3.4.2 Sodium, Potassium and Calcium in chemotherapy-induced neuropathy 
The regulation of ion flux by specific channels is critical for the normal function of the nervous 
system in terms of both action potential propagation and intracellular signalling. Ion channels play 
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a key role in determining the excitability of nociceptive neurons, hence altered function leads to 
aberrant pain signalling such as that occurring in chronic pain states. 
 
Voltage-gated sodium channels (VGSC) are responsible for the propagation of action potentials, 
including those transmitting painful signals from the periphery to the CNS, which can be 
demonstrated by the anti-nociceptive effects of sodium channel blocking anaesthetics (Levinson et 
al., 2012). Moreover, altered expression and function of VGSCs is thought to contribute to 
neuronal hyperexcitability associated with pain following nerve injury (Docherty and Farmer, 
2009). Alterations in the properties of sodium channels have been documented in patients 
following chemotherapy treatment; patients assessed before and after a single dose of oxaliplatin 
exhibit altered refractoriness (associated with sodium channel inactivation/activation state) in 
both sensory and motor axons of the median nerve (Park et al., 2011;Krishnan et al., 2006). As 
such, sodium channel blockers can be used to attenuate pain in models of chemotherapy pain; 
they completely reverse both mechanical and cold allodynia in oxaliplatin treated rats (Egashira et 
al., 2010) and significantly attenuate mechanical hyperalgesia in VCR treated rats (Nozaki-Taguchi 
et al., 2001). The mechanism by which sodium channels become disregulated following 
chemotherapy is not known, however in models of nerve injury sodium channel activity can be 
altered by several cyto/chemokines (Belkouch et al., 2011;Guillouet et al., 2011) the expression of 
which can be upregulated by chemotherapeutics (Kiguchi et al., 2008a). 
 
Potassium channels are activated by altered membrane potential, allowing efflux of K+ ions to 
hyperpolarize the membrane back to its resting potential (Maljevic and Lerche, 2012). During the 
propagation of the action potential, potassium channels play a key role in nociceptive signalling, 
and their altered expression has been associated with chronic pain states (Tsantoulas et al., 
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2012;Costigan et al., 2010). Whilst evidence for an involvement of these channels in 
chemotherapy-pain is scarce, it has been reported that cisplatin administration causes membrane 
depolarization that can be partially prevented with the Kv7 agonist retigabine (Nodera et al., 
2011). Additionally pre-treatment with the potassium sparing diuretic amiloride reduces the 
severity of mechanical and cold hypersensitivity in VCR treated rats (Muthuraman et al., 2008). 
 
Calcium ions have several important functions in the nervous system. Calcium channels are 
involved in the propagation of action potentials, control of neuronal excitability and 
neurotransmitter release (Iftinca and Zamponi, 2009). Abnormal calcium homeostasis is thought 
to significantly contribute to the pain by altering sensory neuron function (Fernyhough and 
Calcutt, 2010). Increased activity of T-type calcium channels has been associated with neuropathic 
pain states (Todorovic and Jevtovic-Todorovic, 2007) and their knock-down has been reported to 
antagonise neuropathic pain (Choi et al., 2007). Ca2+ acts as intracellular signalling molecule; it is 
released from intracellular stores as a response to various stimuli including chemokine receptor 
signalling or enters the cell via ion channels e.g. NMDA receptors, and its signalling cascades can 
result in the release of pro-nociceptive mediators from both neuronal and non-neuronal cells (Old 
and Malcangio, 2012). Modulation of calcium function certainly appears to contributes to 
chemotherapy-induced pain; patients treated with calcium channel blockers exhibit a reduced 
incidence of the development of neuropathy (Tatsushima et al., 2013) and the T-type calcium 
channel antagonist ethosuximide significantly reverses established PTX-hyperalgesia in rats 
(Flatters and Bennett, 2004). It is likely that chemotherapeutics alter calcium function in terms of 
both channel activity/neuronal excitability and intracellular signalling, as calcium entry blockers 
prevent cisplatin-induced decreases in sensory nerve conduction velocities (Hamers et al., 1991) 
and platinum-containing compounds increase Ca2+/calmodulin dependent protein kinase II 
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(CaMKII) phosphorylation in the spinal cord, which can be attenuated by a calmodulin inhibitor 
(Shirahama et al., 2012). 
 
117B3.4.3 ROS, NOS and anti-oxidants in chemotherapy-induced neuropathy 
Reactive oxygen species (ROS) are generated physiologically as a by-product of normal cellular 
activity; however should an imbalance arise between the production of these species and ability of 
the system to reduce and detoxify them oxidative stress occurs, and ultimately leads to damage of 
the cell. Anti-oxidants are able to reduce pain and have beneficial effects on nerve conduction 
velocities in neuropathic patients (Sima, 2007), indicating oxidative stress may occur in the 
nervous system of these patients. This is supported by pre-clinical work which has demonstrated 
an overproduction of ROS in lumbar neurons following spinal cord injury that leads to symptoms 
of neuropathic pain in the hind paws of rats. Furthermore, this can be attenuated by the 
administration of ROS scavengers (Gwak et al., 2013). 
 
If the anti-oxidant status of patients is assessed before and after the commencement of 
chemotherapy significant changes are observed. Chemotherapy decreases total anti-oxidant status 
and decreases erythrocyte superoxide dismutase and glutathione peroxidase levels, indicative of 
an increase in ROS (Esfahani et al., 2012). 60% of patients with established PTX or cisplatin 
neuropathy showed an improvement of at least 2 neuropathy grades after 8 weeks of treatment 
with the anti-oxidant acetyl-L-carnitine, a naturally occurring amino acid derivative that plays a 
critical role in the transport of free fatty acids into mitochondria (Rebouche, 2004); patients 
reported less pain and chemotherapy-induced slowing of sensory nerve conduction velocities was 
partially reversed (Bianchi et al., 2005). This improvement is also seen in animal models of 
chemotherapy-pain, where acetyl-L-carnitine is able to prevent or attenuate neuropathic pain 
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behaviours and electrophysiological changes following PTX (Flatters et al., 2006), oxaliplatin 
(Pisano et al., 2003) and cisplatin (Ghirardi et al., 2005a;Ghirardi et al., 2005b), without any 
significant impact on the anti-neoplastic actions of the drugs (Ghirardi et al., 2005a). The 
administration of antioxidants aims to prevent oxidative stress by shifting the balance of pro- and 
anti-oxidants to favour the anti. An alternative method is to scavenge excess ROS before it can 
cause damage, and this is also effective in attenuating chemotherapy pain; the non-specific ROS 
scavenger PBN reduces both cold and mechanical hypersensitivity occurring as a result of PTX  
treatment when given as a delayed treatment, and prevented its onset when prophylactically 
(Fidanboylu et al., 2011). 
 
There are multiple sources of ROS production in nervous tissue, and whilst invading immune cells 
produce ROS as a mechanism of destroying pathogens, the major source of intracellular ROS is 
leakage from mitochondria (Schapira and Cooper, 1992). This leakage is likely to be increased 
following chemotherapy due to mitochondrial dysfunction. Following chemotherapy treatment in 
rats, nerve fibres exhibit an increase in abnormal, swollen mitochondria (Flatters and Bennett, 
2006) and deficits in mitochondrial electron transport chain complexes I and II are observed 
(Zheng et al., 2011;Zheng et al., 2012). Treatments with compounds that specifically inhibit these 
mitochondrial complexes dose-dependently attenuate pain behaviours (Joseph and Levine, 2006). 
Furthermore, if PTX or cisplatin are applied to cultured DRG neurons they cause mitochondrial 
dysfunction that manifests as a loss of membrane potential, and results in the formation of 
autophagic vacuoles in the cells (Melli et al., 2008). Peroxynitrite, the product of superoxide and 
nitric oxide, is increased in the spinal cord following chemotherapy which leads to nitration of GLT-
1 and glutamine synthase, rendering them ineffective at clearing glutamate from the synapse. 
This, in turn, leads to glutamate excitotoxicity. Targeting peroxynitrite formation directly or 
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indirectly (by reducing nitric oxide production with L-NAME [non-selective NOS inhibitor] or 
superoxide production with a NADPH oxidase inhibitor) prevents these effects and attenuates PTX-
induced mechanical allodynia (Doyle et al., 2012). In the CNS, NOS lies downstream of NMDA 
receptor activation, thus glutamate excitotoxicity as a result of protein nitration would contribute 
to a positive feedback mechanism that results in the production of NO, which in turn is available to 
react with superoxide to form peroxynitrite. Inhibition of this process by antagonism of the NMDA 
receptor reverses established oxaliplatin-induced mechanical allodynia (Tatsushima et al., 2011). 
Evidence of oxidation of proteins is also observed in oxaliplatin treated rats as an increase in 
plasma, spinal cord and peripheral nerve levels of carbonylated protein, a marker of protein 
oxidation. This oxidative damage can be prevented by the co-administration of antioxidants with 
the chemotherapeutic, which also attenuates both mechanical and thermal hypersensitivity (Di 
Cesare et al., 2012). 
 
118B3.4.4 TRP channels in chemotherapy-induced neuropathy 
The TRP family of proteins consists of 28 members sub-divided into 7 sub-families: TRPA, TRPC, 
TRPML, TRPN, TRPP and TRPV (Clapham et al., 2003;Montell et al., 2002). These channels are 
widely expressed in a variety of excitable and non-excitable cells within mammalian tissues and 
mediate flux of cations (Ca+/Na+) across the cell membrane (Ramsey et al., 2006). TRP channels 
can be activated by a broad range of ligands, including small organic molecules, lipids or 
productions of lipid metabolism (Ramsey et al., 2006) and even ROS (Andersson et al., 2008). A 
role for TRP channels in pain transduction was initially suggested based on evidence that indicated 
that TRPV1 is activated by noxious heat (Caterina et al., 1997), and subsequently several other TRP 
channels have been found to play a role in the transmission of thermal and pain sensation 
(Patapoutian et al., 2009). Under chronic and inflammatory pain conditions these channels can be 
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upregulated (Urano et al., 2012), for example NGF released as a result of inflammation activates 
p38 in sensory neurons leads to a down-stream increase in TRPV1 expression and transport of this 
protein to peripheral terminals (Ji et al., 2002). Knock-down or knock-out of TRPs can prevent the 
development of pain behaviours in animal models of chronic pain (Katsura et al., 2006;Kwan et al., 
2006;Caterina et al., 2000;Bolcskei et al., 2005).  As such these channels have become the target 
for the development of novel analgesics, and have had some success in pre-clinical models in 
chronic and inflammatory pain (Vilceanu et al., 2010;Eid et al., 2008). Additionally, in patients 
potent TRPV1 agonists, despite initially being noxious, cause desensitisation of the channel which 
reduces nociceptive transmission and sensitivity to heat (Novakova-Tousova et al., 2007;Simpson 
et al., 2008). 
 
As in neuropathic pain, there is evidence to suggest a role for TRP channels (specifically TRPA1, 
TRPV1, TRPV4 and TRPM8) in chemotherapy-pain. Following incubation with cisplatin or 
oxaliplatin, cultured DRG neurons increase their expression of TRPA1, V1 and M8; a similar 
increase in TRPA1 and TRPV1 expression is also observed in the trigeminal ganglia of cisplatin 
treated mice (Ta et al., 2010). In chemotherapy pre-treated cultures, DRG neurons exhibit a dose-
dependently reduction in neurite length, an increase in cAMP signal intensity and increased 
responses to a TRPV1 or TRPA1/M8 agonist (Anand et al., 2010). TRPA1 can be activated by ROS 
(Andersson et al., 2008) which are produced as a consequence of chemotherapy (see above), and 
it has been suggested that activation of TRPA1 by chemotherapeutic agents is indirect; indeed the 
calcium responses induced by oxaliplatin in TRPA1 transfected cells is ablated by a ROS scavenger 
(Nassini et al., 2011). Furthermore, the pain behaviours occurring as a result of chemotherapy 
treatment can be attenuated by both the blockade (Nassini et al., 2011;Materazzi et al., 
2012;Barriere et al., 2012) and knock-out of TRPA1 (Trevisan et al., 2013).  Antagonists of TRPV1 
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(Chen et al., 2011) and TRPV4 (Materazzi et al., 2012;Chen et al., 2011) are also able to reduced 
chemotherapy induced pain and TRPV4 knock-out mice exhibit less mechanical hypersensitivity 
after PTX treatment than wild-types (Alessandri-Haber et al., 2008). 
 
119B3.4.5 The contribution of non-neuronal cells and cyto/chemokines to chemotherapy-induced 
neuropathy 
As discussed above, neuropathic pain is no longer considered a disease purely of neuronal origin; a 
substantial body of evidence supports a critical role for non-neuronal cells of both the PNS and 
CNS in the development and maintenance of chronic pain states, and chemotherapy pain is no 
exception. In the periphery, following chemotherapy administration, macrophages infiltrate the 
nerve and DRG where they take on a hypertrophied activated appearance (Jimenez-Andrade et al., 
2006;Peters et al., 2007a;Uceyler et al., 2006). Whilst the signal for this infiltration is not yet fully 
understood, we do know that activated macrophages are capable of releasing a multitude of 
mediators, such as TNF-α (Niu et al., 2012;Dumitru et al., 2000), that can have a direct effect on 
sensory neurons (Pollock et al., 2002).  Within the spinal cord, chemotherapy administration 
causes the activation of astrocytes, demonstrated by an increase in the astrocytic marker GFAP 
(Warwick and Hanani, 2013;Naguib et al., 2012); this is associated with a down regulation of 
GLAST and GLT-1, proteins involved in the maintenance of glutamate homeostasis by astrocytes, 
and can be prevented by the systemic administration of minocycline, an inhibitor of cytokine 
synthesis (Zhang et al., 2012).  Spinal astrocyte gap junctions, that allow communication between 
cells, are likely to contribute to the activation of astrocytes in chemotherapy-pain as blockade with 
carbenoloxone dose-dependently attenuates mechanical hypersensitivity in a rat model of 
oxaliplatin-induced neuropathy (Yoon et al., 2013). In some chemotherapy-pain models 
microgliosis is evident; an increase in OX-42 immunoreactivity in the dorsal horns of the cervical 
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and lumbar spinal cord sections is observed in PTX treated rats (Ledeboer et al., 2007), and this 
can be suppressed by the phosphodiesterase and adenosine reuptake inhibitor propentofylline, 
which also attenuates pain behaviours following daily systemic administration (Sweitzer et al., 
2006). In fact in young animals severe gliosis correlates with neuropathic symptoms (Ruiz-Medina 
et al., 2013). 
 
As in many non-chemotherapy models of chronic pain, several cytokines and chemokines have 
been identified as possible contributors to pain following chemotherapy. Serum levels of IL-6 are 
elevated in patients following chemotherapy (Pusztai et al., 2004), especially in those experiencing 
neuropathic pain symptoms as a result. These patients have higher levels of the interleukin-6 
receptor (IL-6R) on CD14+ cells and lower serum levels of soluble gp130 (a protein that forms part 
of the function complex of the IL-6R) than patients with low neuropathy scores (Starkweather, 
2010). In animal models this increase in IL-6 expression is also present, and co-localises with 
macrophage markers in the peripheral nerve and DRG. Local injection of an IL-6 neutralising 
antibody attenuates pain behaviour (Kiguchi et al., 2008b); in support of this evidence for a role of 
macrophage derived IL-6 in the development of chemotherapy-induced pain, IL-6 knock-out mice 
show a reduced incidence of mechanical allodynia following VCR treatment in comparison to wild-
type littermate controls (Kiguchi et al., 2008b). Conversely, at low doses IL-6 treatment can 
prevent the behavioural and electrophysiological abnormalities caused by VCR (Callizot et al., 
2008), providing evidence for both pro- and anti-nociceptive effects of this cytokine in 
chemotherapy-pain. This is in keeping with the literature regarding this molecule; it can be 
neuroprotective (Akaneya et al., 1995) and in non-chemotherapy models of chronic pain there are 
reports of attenuation of pain with both treatment with IL-6 (Andriambeloson et al., 2006;Flatters 
et al., 2004;Flatters et al., 2003) and molecules that inhibit its function (Guptarak et al., 2013;Wei 
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et al., 2013). It has been reported that levels of TNF-α are unaltered in the spinal cord and brain of 
PTX treated animals (Zhang et al., 2012;Parvathy and Masocha, 2013). Indeed, patients receiving 
chemotherapy do not have an increased plasma TNF-α level (Pusztai et al., 2004) and treatment 
with etanercept, a competitive binder of TNF-α does not reverse established pain; however pre-
treatment with this compound can delay the onset of chemotherapy-pain (Park et al., 2013). 
Following chemotherapy plasma levels of IL-10 are significantly increased, however this is 
transient (Pusztai et al., 2004) and intrathecal administration of a plasmid that enhances the 
expression of this anti-inflammatory cytokine prevents is able to reverse established 
chemotherapy-induced mechanical allodynia (Ledeboer et al., 2007). Spinal levels of the 
chemokine CCL2 are upregulated following chronic PTX treatment and treatment with a CCR2 (but 
not CCR1) antagonist can attenuate pain behaviour (cold allodynia), whilst a CCL2 neutralising 
antibody can suppress chemotherapy-induced activation of microglia (Pevida et al., 2013). 
 
120B3.4.6 Other contributing factors 
Whilst the evidence discussed above constitute the majority of work attempting to determine the 
mechanism by which chemotherapy causes neuropathy, the use of various inhibitors/antagonists 
has suggested a great many other pathways may be involved, that don’t fit into such neat 
categories. 
 
Briefly, an increase in the mRNA of the bradykinin B1 receptor is observed in the thalamus and 
pre-frontal cortex seven days after administration of PTX, and both the administration of B1 or B2 
antagonists, or the double knock-out of the B1 and B2 receptors, reduces hyperalgesia in mice 
treated with this chemotherapeutic agent (Costa et al., 2011) or VCR (Bujalska et al., 2008b). 
Chronic oxaliplatin therapy has been associated with upregulation of PKCγ in the thalamus and 
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PAG of rats, and a supraspinally administered specific PKCγ inhibitor reverses hyperalgesia in these 
animals (Norcini et al., 2009). PKCε and PKA inhibitors are also anti-allodynic (Dina et al., 2001), as 
are 5HT3 antagonists (Whitaker-Azmitia et al., 1995). Alpha-1- and alpha-2-adrenoceptor 
antagonists are anti-nociceptive and delay the onset of hyperalgesia in a model of VCR-induced 
neuropathy (Bujalska et al., 2008a), Rho kinase inhibitors improve sural nerve conduction latencies 
and return sensory thresholds to pre-chemotherapy levels (James et al., 2010), and P38 and ERK 
inhibition reduce apoptosis of cisplatin-treated DRG neurons (Scuteri et al., 2009). 
 
Despite this wealth of evidence, the precise mechanism by which chemotherapeutic agents cause 
neuropathy remains elusive, preventing the development of an ideal compound for the prevention 





26B4. Thesis Aims 
 
The general aim of the work laid out in this thesis is to delineate the mechanism by which 
repeated cycles of the anti-neoplastic drug VCR cause pain, and to identify novel therapeutic 
targets for the treatment of this condition; in particular we hypothesis that infiltrating immune 
cells significantly contribute to the development of chemotherapy induced pain. The aim of 
chapter two is to characterise a mouse model of VCR-induced painful peripheral neuropathy and 
to establish the major changes occurring in both the PNS and CNS. In chapter three changes 
observed in the PNS are further explored, and the contribution of infiltrating 
monocyte/macrophages and the CX3CL1 receptor CX3CR1 is determined. Chapter four aims to 
ascertain the contribution CX3CL1 itself and changes in endothelial adhesion properties make to 
the development of pain in the model. In summary, the work in this thesis utilises a variety of in 
vivo and in vitro techniques such as behavioural assays, immunohistochemistry and western 
blotting to examine the hypothesis that it is the occurrence of a chain of peripheral non-neuronal 
changes that instigates the development of chemotherapy-induced painful peripheral neuropathy 
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53B1.1. Vincristine Sulphate: Origin, Clinical Use and Mechanism of Action 
 
Vincristine sulphate (VCR) is a naturally occurring plant alkaloid originally extracted from the 
leaves of the periwinkle plant, Catharanthus roseus. It has been known for its medicinal properties 
for centuries; extracts from the plant have been used historically to stop haemorrhage, treat 
scurvy and heal wounds and diabetic ulcers (Gidding et al., 1999). The potent chemotherapeutic 
nature of this compound was first identified in the late 1950’s following a observation by Noble 
and colleagues that rats treated with an extract of C.roseus caused peripheral granulocytopenia 
and bone marrow suppression (Noble et al., 1958). Additionally Svoboda et al demonstrated anti-
leukaemic properties of this extract (Svoboda, 1958), it was able to cure leukaemia and prolong 
life with an acceptable range of side-effects; this extract was demonstrated to be VCR (Svoboda et 
al., 1962).  
 
Initial studies in man proved promising (Costa et al., 1962) and VCR was approved by the FDA as 
Oncovin in 1969. VCR is a widely used and potent anti-neoplastic agent. Its primary use is in the 
treatment of Hodgkin’s and non-Hodgkin’s lymphoma and childhood and adult leukaemias such as 
acute lymphoblastic leukaemia (ALL). The response rate to VCR in the first-line treatment of these 
diseases is as high as 76-92 % if treatment is completed (Gidding et al., 1999;O'Brien et al., 2013). 
VCR is also used to treat a variety of solid mass tumours including small cell lung carcinoma (42% 




The primary mechanism by which VCR inhibits tumour growth is by binding to and stabilising 
tubulin, resulting in interference with mitotic spindle formation and leading to an inhibition of 
mitosis (Malawista et al., 1968;Himes et al., 1976;Owellen et al., 1976).  It has also been 
demonstrated that VCR can induce apoptosis of cancerous cells in vitro independent of cell cycle 
phase (Takano et al., 1993;Pittman et al., 1994) and can reduce tumour blood flow resulting in 
necrosis (Baguley et al., 1991;Hill et al., 1993). It is not yet understood if it is by similar 
mechanisms that VCR causes neuropathy. As well as forming mitotic spindles, tubulin is also a 
major component of microtubules which form the cytoskeleton of cells; in neurons these 
microtubules play a critical role in the axonal transport of survival factors to peripheral nerve 
terminals, and it has been hypothesised that disruption of this process results in neuronal death. 
Early evidence has suggested binding of VCR to microtubules causes a reduction in their number 
(Donoso et al., 1977) as well as disruption of their normally highly organised structure (Topp et al., 
2000).  Several electrophysiological changes in the peripheral nerves support a role for neuronal 
damage as the causative factor in the development of pain; following VCR administration rats 
exhibit a reduction in nerve conduction velocity (Alimoradi et al., 2012) and hyper-responsiveness 
develops in A and C fibres (Tanner et al., 2003). Furthermore, an increase in the expression of the 
neuronal stress factor ATF-3 has been observed in the DRG of VCR treated mice (Hansen et al., 
2011). However the precise mechanism by which VCR is inducing these changes is not known and 
using currently available immunohistochemical techniques neuronal damage has not been 
observed in the very early stages of the development of VCR-induced hypersensitivity. As such 
some of the focus of the research in this field has shifted to involvement of non-neuronal cells 
which as now known to significantly contribute to the development of pain in a number of models 




54B1.2. Non-Neuronal Cells in VCR-Induced Neuropathy 
 
As discussed in chapter one there is clear evidence for a role of non-neuronal cells, both centrally 
and peripherally in the instigation and maintenance of neuropathic pain. Here three key cell types 
will be discussed (macrophages, microglia and astrocytes) as there is evidence to suggest these 
cells contribute to VCR-induced hypersensitivity and/or allodynia. 
 
121B .2.1. Macrophages 
Macrophages are mononuclear phagocytic cells that differentiate from circulating peripheral 
blood mononuclear cells (PBMCs/monocytes) under steady state conditions to replenish tissue 
resident cells or in response to inflammation. PBMCs derive from a common myeloid progenitor in 





Figure 2.1. Macrophage derivation. Macrophages differentiate from monocytes, which originate in the bone 
marrow from a common haematopoietic stem cell (HSC) which undergo differentiation steps that commit 
them to a myeloid and then monocytic lineage via granulocyte/macrophage colony-forming units (GM-CFU) 
and macrophage colony-forming units (G-CFU). (Adapted from (Mosser and Edwards, 2008)). 
 
 






Monocytes are a heterogeneous population of cells and as such, so are macrophages; varying size, 
degree of granularity, nuclear morphology and expression of surface markers (Gordon and Taylor, 
2005). Tissue or resident macrophages play a predominantly homeostatic role; these mature cells 
are involved in immune surveillance. They are involved in the clearance of cellular debris following 
tissue damage or remodelling, maintaining healthy tissue by removing toxic materials and are able 
to recruit and activate lymphocytes (and other immune cells) in response to danger signals such as 
lipopolysaccharide components of bacterial cell walls. Tissue resident macrophages also play an 
important role in suppressing inflammation mediated by infiltrating inflammatory monocytes, thus 
restoring tissue homeostasis following injury or infection (Murray and Wynn, 2011). Resident 
macrophages are crucial for the early detection of tissue damage; however following injury or 
infection their numbers in tissue are insufficient to mount a full response and monocytes enter the 
damaged tissue (monocyte/macrophage heterogeneity and infiltration is discussed in detail in 
chapters three and four). Under physiological conditions, the cellular debris cleared by 
macrophages is primarily produced by apoptosis results in little or no production of inflammatory 
mediators (Kono and Rock, 2008), however following trauma or cellular stress, debris is produced 
by cells undergoing necrotic death. This has a marked effect on the activation state of 
macrophages as it contains danger signals such as nuclear proteins and cleaved components of the 
extracellular matrix (Zhang and Mosser, 2008).  
 
Two key macrophage subsets have been described based on their physiology following activation. 
Classically activated or M1 macrophages are primarily activated through toll-like receptors, PPARγ 
(peroxisome proliferator-activated receptor γ) signalling and interaction with the cytokines IFNγ 
(interferon-γ) and TNFα; these cells show enhanced microbicidal activity and increased synthesis 
and release of pro-inflammatory mediators including nitric oxide (NO), free radical species and 
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cytokines (e.g. TNFα, IL-1β and IL-6) (Murray and Wynn, 2011;Dale et al., 2008), a result of which is 
further macrophage activation.  Alternatively activated or M2 macrophages on the other hand are 
predominantly activated by IL-4 or IL-13 and express arginase-1, CD206 and, unsurprisingly, the IL-
4 receptor. These cells produce growth factors including TGFβ (transforming growth factor β) and 
PDGF (platelet-derived growth factor) (Barron and Wynn, 2011) and anti-inflammatory cytokines 
such as IL-10. They promote wound healing by producing matrix metalloproteinases (MMPs), thus 
contribute to the production of extracellular matrix components (Kreider et al., 2007) and as such 
have been referred to as ‘wound-healing macrophages’ (Mosser and Edwards, 2008).  
 
Current evidence suggests that macrophages contribute to the development of pain behaviours 
under pathological conditions. The infiltration of monocyte/macrophages into the peripheral 
nerve following injury is seen in both humans and rodents (Durrenberger et al., 
2006;Durrenberger et al., 2004;Lindenlaub and Sommer, 2000;Hu and McLachlan, 2002). Our 
laboratory has demonstrated that depletion of monocyte/macrophages by administration of 
liposome clodronate partially attenuates the mechanical and thermal hyperalgesia following 
peripheral nerve injury for as long as monocyte/macrophages are absent; once cell numbers are 
restored (examined in the spleen) this effect is lost (Barclay et al., 2007;Liu et al., 2000). 
Furthermore, the depletion of monocyte/macrophages in the knee joint of mice significantly 
reduces joint inflammation and the production of pro-inflammatory cytokines (Blom et al., 2004). 
In both human patients and animal models the peripheral administration of inhibitors of the pro-
inflammatory cytokines released by classically activated macrophages attenuates pain (Dahl and 
Cohen, 2008;Kato et al., 2009;Gabay et al., 2011). Selectively reducing cytokine/chemokine 
expressing macrophages in the nerve similarly impairs the development of neuropathic pain 
(Echeverry et al., 2013).  
102 
 
There is evidence for a role of macrophages in models of chemotherapy-induced pain. Following 
the administration of both VCR or PTX and increase in the number of macrophages in the sciatic 
nerve and DRG is observed (Jimenez-Andrade et al., 2006;Peters et al., 2007a;Uceyler et al., 2006). 
These cells take on a hypertrophied activated appearance; an increased in the expression of CD68, 
a lysosomal protein present in activated macrophages (Holness and Simmons, 1993) has been 
reported in the sciatic nerve of rats ten days after PTX treatment (Peters et al., 2007a). 
Furthermore these cells exhibit a hypertrophied and multi-vacuolated appearance (indicative of 
activated phagocytic macrophages) when compared to the small macrophages present in the 
nerves of vehicle treated animals (Peters et al., 2007a;Hu and McLachlan, 2002). Whilst it has not 
yet been possible to assess monocyte/macrophage infiltration in the peripheral nerves of 
chemotherapy-treated patients, an increased serum level of IL-6 has been reported in patients 
treated with the agents PTX, 5-fluorouracil and doxorubicin (Pusztai et al., 2004); this cytokine is 
released from classically activated macrophages (Mosser and Edwards, 2008), and suggests these 
cells may be activated in chemotherapy-treated patients. Despite this evidence, the signal for 
macrophage infiltration as a result of chemotherapy has not been elucidated, and the temporal 
profile of infiltration is not known.  
 
122B .2.2. Microglia 
Microglia are specialised macrophages of the CNS and constitute between 5-20% of the total glial 
cell population (depending on the region examined) (Saijo and Glass, 2011). Similarly to 
macrophages they are of a myeloid lineage; this has been confirmed conclusively by their absence 
from the CNS in PU.1-null mice (McKercher et al., 1996). PU.1 is a key transcription factor in the 
control of myeloid cell differentiation (Beers et al., 2006). Recent findings suggest microglia 
originate from macrophages in the foetal yolk sac that migrate into the CNS early on during 
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embryonic development (Saijo and Glass, 2011); however there is also evidence from postnatal 
rodent studies using fluorescently labelled cells that suggest that, at least in the early stages of 
postnatal development, microglia can differentiate from monocytes entering the CNS from the 
circulation (Perry et al., 1985). In adult rodents circulating monocytes are able to enter the CNS 
under conditions where there is disruption to the blood brain barrier (BBB) (King et al., 2009), 
however evidence obtained from immune-irradiated mice indicate that CNS colonisation by these 
cells is transient and does not contribute to the resident microglial cell pool (Ajami et al., 2011). 
The resident microglia population is maintained by proliferation of existing microglia rather than 
by infiltration of monocytes; thymidine labelling of cells demonstrates that the cells are able to 
undergo DNA synthesis and divide (Lawson et al., 1992). Regardless, some uncertainty remains in 
this area. 
 
Under physiological conditions microglia exist in a ‘resting’ or ‘quiescent’ state, characterised by a 
small soma, expression of receptors for complement components (Fcγ receptor of IgG), low 
expression of cell surface antigens and possession of highly motile ramified processes that 
perform immune surveillance of the surrounding area (Nimmerjahn et al., 2005); as a result of this 
function the new terminology of ‘surveying’ microglia has been suggested (Hanisch and 
Kettenmann, 2007) as this important function means these cells are far from resting. Several 
mechanisms by which these cells maintain a quiescent state have been suggested, including 
interaction of microglial CX3CR1 with its neuronal ligand CX3CL1 (Callizot et al., 2008), and 
inhibitory signalling through the microglial cell surface proteins (typically integrins/lectins) CD172, 
CD200R and CD45 with their neuronal ligands CD47, CD200 and CD22 respectively (Ransohoff and 
Cardona, 2010). In response to injury or pathological insult, such as the presence of pathogens or 
neurotoxic levels of glutamate for example, microglia quickly become activated and proliferate to 
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expand their population. Activated microglia are morphologically distinct from quiescent cells; 
they appear more amoeboid, with a hypertrophied cell body and thick retracted processes. 
Following activation these cells alter their expression of a number of cell surface antigens that play 
a critical role in immune responses; for example expression of MHC class II is increased allowing 
the presentation of antigens by microglia. These cells have an enhanced proliferative and 
phagocytic capacity (McMahon and Malcangio, 2009), and once activated synthesise and secrete a 
variety of pro-inflammatory mediators into the extra-cellular environment including cytokines (e.g. 
TNFα and IL-1β), chemokines (e.g. CCL2 and CX3CL1), reactive oxygen species (ROS) and nitric 
oxide (NO). Current evidence does suggest that the activation state of microglia is somewhat 
flexible; different stimuli activating different receptors may result in varied downstream cascades, 
for example glutamate activating mGLUR2 results in the production of TNFα, whilst activation of 
P2Y receptors by UDP leads cells to adopt a predominantly phagocytic phenotype (Clark et al., 
2012;McMahon and Malcangio, 2009;Calvo and Bennett, 2012;Ellis and Bennett, 2013;Graeber 
and Christie, 2012;Milligan et al., 2001;Inoue and Tsuda, 2009). 
 
The evidence for a role of microglia (and astrocytes) in the development and maintenance of 
chronic pain is extensive, has been reviewed umpteen times in the past decade and has been 
summarised in chapter one (Inoue and Tsuda, 2009;Clark et al., 2012;McMahon and Malcangio, 
2009;Calvo and Bennett, 2012;Ellis and Bennett, 2013;Schomberg and Olson, 2012;Vallejo et al., 
2010). Briefly, in models of peripheral nerve injury (Colburn et al., 1997;Coyle, 1998;Beggs and 
Salter, 2007), inflammatory pain (Clark et al., 2007a;Hua et al., 2005) and disease pathology (Tsuda 
et al., 2008;Wodarski et al., 2009;Clark et al., 2012) there is substantial evidence of microgliosis 
(the activation and proliferation of microglia) in the dorsal horn of the spinal cord. Inhibiting 
microgliosis with the glial inhibitor minocycline prevents or attenuate mechanical and thermal 
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hypersensitivity in these models (Ledeboer et al., 2005;Lin et al., 2007;Raghavendra et al., 
2003;Hua et al., 2005) indicating that this process is critical to the development and/or 
maintenance of hypersensitivity following peripheral nerve damage. The attenuation of 
hypersensitivity occurring as a result of peripheral nerve damage has also been demonstrated in 
animals deficient of key microglial proteins, such as CX3CR1 (Staniland et al., 2010) and by the 
intrathecal administration of inhibitors of pro-nociceptive mediators released from activated 
microglia (Clark et al., 2007b).  
 
As with macrophages, there is evidence to support a role for microglia in the development and/or 
maintenance of chemotherapy-induced pain. Following administration of PTX the 
immunoreactivity of the microglial marker OX-42 is increased in the dorsal horns of cervical and 
lumbar spinal cord sections (Ledeboer et al., 2007). This can be suppressed by the 
phosphodiesterase and adenosine reuptake inhibitor propentofylline, which also attenuates 
mechanical allodynia following systemic administration (Sweitzer et al., 2006). Additionally 
chemotherapy-induced mechanical allodynia can be reversed by intrathecal administration of IL-
1RA, the receptor antagonist of IL-1β, which is released from microglia following their activation 
(Ledeboer et al., 2007). However, microgliosis has not been reported in all models of 
chemotherapy-induced neuropathy and the involvement of microglia in the pathogenesis of this 
condition remains controversial.  
 
123B .2.3. Astrocytes 
Astrocytes are the most abundant of the glial cells in the CNS and have traditionally been 
considered to provide little more than structural and homeostatic support to neurons; however as 
research in the field has evolved the potential of astrocytes as critical participants in intercellular 
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communication has been recognised, in fact astrocytes have now been implicated to play a role in 
almost all processes that occur in the CNS (Volterra and Meldolesi, 2005). Derived from the 
neuroectoderm, these star shaped cells envelope the many neuronal elements, including 
synapses, axons and dendrites, with each astrocyte able to make contact with several neurons 
(Halassa et al., 2007;Haydon, 2001), and have an intimate relationship with the endothelial cells of 
the blood brain barrier (BBB) (Abbott et al., 2006). Astrocytes play a key role in the maintenance of 
extracellular K+ concentrations ([K+]o); physiological fluctuations in [K
+]o are normal and occur as a 
result of neuronal activity, however this must be tightly regulated to prevent a pathological build 
up of K+ that could cause hyperexcitability in neurons (Scemes and Spray, 2012). [K+]o is regulated 
by astrocytes via several methods of uptake including various ion channels and transporters 
(predominantly by Na-K-ATPase pumps or Na-K-Cl co-transporters), or by spatial buffering, a 
process whereby highly K+ permeable cells (astrocytes) transfer K+ ions from regions of high [K+]o 
to regions of low [K+]o (Kofuji and Newman, 2004). Astrocytes respond to the accumulation of K
+ 
that results from increased uptake by altering their metabolism; this can be achieved via several 
mechanism, for example by enhancing glycolysis by the activation of pyruvate carboxylase 
(Subbarao et al., 1995). One of the features of astrocytes that allows spatial buffering of K+ is the 
presence of gap junctions. Gap junctions are intercellular connections comprising two hemi-
channels formed of connexin subunits that allow ions and small molecules to pass between cells. 
In the adult connexins (Cx) 43 and 30 are the predominant connexins found in astrocytes 
(Dermietzel et al., 1991;Giaume et al., 1991;Nagy and Rash, 2000); dye coupling experiments have 
demonstrated that no intercellular communication occurs in Cx43/Cx30 double knock-out mice 
(Wallraff et al., 2006;Rouach et al., 2008). K+ regulation is not the only homeostatic mechanism 
that astrocytes play a key role in; they also play a major role in the regulation of extracellular 
glutamate levels. The majority of glutamate is released into the extracellular space from neurons 
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as a neurotransmitter following depolarisation, whilst a small quantity is thought to come from 
astrocytes themselves; recent evidence has demonstrated glutamate release from astrocytes as a 
result of both Ca2+ dependent and independent mechanisms (Araque et al., 2000;Hamilton and 
Attwell, 2010;Santello et al., 2011). Glutamate is removed from the extracellular space by 
excitatory amino acid transporters (EAATs), of which two (GLAST and GLT1) are preferentially 
expressed on astrocytes (Coulter and Eid, 2012). If for any reason this system fails or its capacity is 
reduced glutamate excitotoxicity can occur; this phenomenon was first described in retinal 
neurons by Lucas and Newhouse in 1957 (LUCAS and NEWHOUSE, 1957) and later in CNS neurons 
by Olney and Sharpe in 1969 (Olney and Sharpe, 1969); it describes the process whereby 
prolonged activation of glutamate receptors leads to cell death. 
 
The contribution of astrocytes to the development of pain subsequent to peripheral nerve damage 
has been reviewed in chapter one. Briefly, in terms of pain processing, astrocytes have a clear 
signalling role, forming the pain triad with neurons and microglia (Scholz and Woolf, 2007). This 
role is not surprising; astrocytes are considered to be excitatory cells, albeit not in the classical 
sense that describes the activity of neurons; they can however be activated by internal and 
external signals and release a variety of factors (Volterra and Meldolesi, 2005). Astrocytes express 
a large number of neurotransmitter receptors and can themselves release neurotransmitters (e.g. 
glutamate and ATP) as a consequence of an increase in intracellular calcium concentration 
(Hansen and Malcangio, 2013). A substantial number of non-neurotransmitter receptors are 
expressed on the surface of astrocytes; these include cytokine (e.g. TNFR and IL-18R) and 
chemokine receptors (e.g. CCR2) and purinergic receptors (e.g. P2X7), the substrates for which are 
all known to be released by neurons and glia in the CNS following injury. Activation of these 
receptors triggers intracellular signalling cascades such as the activation of PLC-β and subsequent 
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release of Ca2+ from intracellular store via IP3 (inositol triphosphate) and phosphorylation (and 
activation) of MAPK proteins; these are involved in cell survival, transcriptional regulation and the 
release of pro-nociceptive/inflammatory mediators (Old and Malcangio, 2012). For example the 
expression of CCL2 is increased in spinal astrocytes after injury, and following its release in a JNK-
dependent fashion, activates the CCR2 receptor on the surface of neurons, where it enhances 
spontaneous EPSCs and potentiates NMDA- and AMPA-induced currents (Gao et al., 2009).  
Additionally the expression IL-1β is increased in spinal astrocytes in models of both diabetic 
neuropathy and peripheral nerve injury (Liao et al., 2011;Weyerbacher et al., 2010); release of this 
protein and its subsequent activation of IL-1 receptors on the surface of neurons potentiates 
NMDA-induced currents through phosphorylation of the NMDA receptor (Oka et al., 
1993;Weyerbacher et al., 2010). Furthermore, IL-1β can activate microglia, causing downstream 
phosphorylation of MAPK proteins and consequential release of pro-nociceptive mediators (Okuno 
et al., 2004). Astrogliosis, the activation of astrocytes, occurs within the spinal cord as a result of 
injury that leads to the development of a chronic pain state. Typically demonstrated by an increase 
in the immunoreactivity of glial fibrillary acid protein (GFAP), astrogliosis occurs within days of 
nerve damage following in models of peripheral nerve injury (Colburn et al., 1997;Chen et al., 
2012;Zhang et al., 2011b), inflammatory pain (Gao et al., 2010a;Tenorio et al., 2013) and disease 
pathology (Zhang et al., 2011a;Bas et al., 2012). As with microglia, inhibition of astrocytic activity is 
able to reverse mechanical allodynia arising as a result of peripheral nerve injury (Gao and Ji, 
2010a) and inflammatory hyperalgesia (Guo et al., 2007) and prevent mechanical allodynia when 
administered prior to nerve transection (Sweitzer et al., 2001). This evidence indicates that 
astrocyte activation plays a crucial role in the development and/or maintenance of neuropathic 
and inflammatory pain. Within the spinal cord, astrogliosis (demonstrated by an increase in GFAP 
immunoreactivity) is evident within a week of the systemic administration of PTX or VCR (Naguib 
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et al., 2012;Ji et al., 2013;Kiguchi et al., 2008a). As figure 2.2 illustrates, this is associated with an 
increase in the expression of the pro-nociceptive mediators CCL2 and TNF (Zhang et al., 
2013;Kiguchi et al., 2008a), the post-translational nitration of glutamate transporter proteins 
which reduces their functional capacity (Doyle et al., 2012) and IL-1β induced phosphorylation of 
the NMDA receptor (Zhang et al., 2008;Weyerbacher et al., 2010). Furthermore, spinal astrocyte 
gap junctions are likely to contribute to astrocytic activation in chemotherapy-pain as blockade 
with carbenoloxone dose-dependently attenuates mechanical hypersensitivity in a rat model of 
oxaliplatin-induced neuropathy (Yoon et al., 2013). Whilst chemotherapy-induced neuropathy 
appears to be more heavily associated with astrogliosis than microgliosis, there is still much to 









Figure 2.2. Schematic representation of spinal cord changes that contribute to enhanced nociceptive 
transmission in models of chemotherapy-pain. Activation of spinal glial cells leads to the release of pro-
nociceptive cytokines and chemokines which are able to further activate microglia and astrocytes with a 
positive feedback outcome. Furthermore IL-1 released from astrocytes, microglia and neurons activates the 
IL-1 receptor on neurons which leads to the down-stream phosphorylation of the NMDA receptor, 
potentiating excitatory signalling. Additionally post-translational nitration of astrocytic glutamate 
transporters reduces glutamate scavenging by astrocytes, increasing extracellular glutamate which activates 





55B1.3. Chapter aims 
 
Despite a recent increase in research into the treatment of chemotherapy-induced pain, there is 
still a lack of clinically effective compounds available for treating this condition; the pain 
experienced by patients undertaking chemotherapy treatment is inadequately managed. It is likely 
that this stems from a lack of understanding of the underlying mechanism by which the 
neuropathy occurs. Whilst there is evidence for an involvement of neuronal damage, peripheral 
immune cell activation and activation of spinal glial cells, the precise mechanism by which VCR 
causes painful peripheral neuropathy has not yet been elucidated. As a result there is still a lack of 
viable therapeutic targets for the development of a prophylactic treatment of this dose-limiting 
side effect. To allow an investigation into this mechanism we must first establish and characterise 
a model of VCR-induced neuropathy. Here we hypothesise that systemic administration of VCR 
causes mechanical and cold hypersensitivity and activation of non-neuronal cells in the spinal cord 
and peripheral nerve. Thus, the aims of this chapter are: 
 To examine the temporal profile of the development of mechanical and cold 
hypersensitivity occurring as a result of systemic VCR administration.  
 To examine the cell bodies of sensory neurons in the DRG for evidence of neuronal 
damage/stress occurring as a result of VCR administration. 
 To examine the temporal profile of the activation of non-neuronal cells occurring as a 
result of VCR administration, both centrally in the dorsal horn or the spinal cord and 





28B . Methods 
 
56B2.1. Establishing a Mouse Model of VCR-Induced Painful Peripheral Neuropathy 
 
124B .1.1. Animals 
Unless otherwise stated, all experiments were performed using adult male C57Bl/6 mice (10-14 
weeks of age and 22-27g from Harlan UK), in accordance with The Animals Scientific Procedures 
Act (ASPA) 1986, United Kingdom Home Office regulations and institutional guidelines. Animals 
were individually housed (to prevent aggressive behaviour) on a 12 hour light / 12 hour dark cycle 
at 21-22oC, with food and water ad libitum. 
 
125B .1.2. Drug administration 
192B .1.2.1. VCR 
VCR (Sigma, UK) was dissolved in sterile saline and 0.5mg/kg was injected into the peritoneal 
cavity (intraperitoneally[ i.p.]), using a 30G needle, daily for five days per cycle, for two cycles 
before treatment was cessed (figure 2.3). This dosing protocol has been used successfully to cause 
VCR-induced mechanical allodynia in C57Bl/6 mice by Uceyler et al (Uceyler et al., 2006). 
 
193B2.1.2.2. Fluorocitrate (glial inhibitor) 
Fluorocitrate (Sigma, UK) was dissolved in sterile saline and injected intrathecally at 0.1nmol in 
5µl. Mice were tightly restrained in a sock and intrathecal injections were performed by lumbar 
puncture, inserting a 30G 3/8” needle connected to a Hamilton syringe between the L4 and L5 





Figure 2.3. Experimental schedule for behavioural assessment and VCR dosing to induce painful peripheral 
neuropathy. Blue boxes represent cycles of VCR treatment (cycle 1: days 0-4, cycle 2: days 7-11), green 
arrows represent study days during which cold sensitivity was assessed and red arrows represent study days 
during which mechanical sensitivity was assessed. Behavioural tests were performed 1 hour after dosing. 
 
126B .1.3. Behavioural testing 
194B2.1.3.1. Assessment of Mechanical Sensitivity 
Static mechanical withdrawal thresholds were assessed by applying von Frey filaments (Linton 
Instruments, UK) to the plantar surface of the hind paw. Unrestrained animals were acclimatised 
in acrylic cubicles (8 x 5 x10cm) above a wire mesh for 60 minutes prior to testing. Calibrated von 
Frey filaments (flexible nylon fibres of increasing diameter that exert defined levels of force 
ranging between 0.008 and 1.2g) were applied to the plantar surface of both hind paws of the 
mouse until the fibre bent, and then held in place for 3 seconds or until the paw was withdrawn in 
a reflex not associated with movement or grooming. Filaments were applied alternately to the left 
and right hind paws. A 50% paw withdrawal threshold was calculated using the ‘up-down’ method 
(Chaplan et al., 1994) starting with the 0.6g filament. If a positive response was observed, the next 
lower force hair was applied and if a negative response was observed, the next higher force hair 
was applied. Responses to four subsequent hairs were assessed according to the up-down 
sequence. Data are expressed as the average 50% paw withdrawal threshold for both hind paws, 
in grams, calculated using the method described by Dixon (Dixon, 1980). 






195B2.1.3.2. Assessment of Cold Sensitivity 
Cold sensitivity of the hind paws was assessed as described by Gentry et al (Gentry et al., 2010). A 
cold plate (Ugo-Basile, Milan) was set according to predetermined calibration data, using a surface 
temperature probe to correlate set temperature with actual surface temperature, and allowed to 
stabilize at the set temperature for 5 minutes before use. Paw withdrawal latency (PWL) was 
determined with the actual temperature of the cold plate at 10oC. Mice were lightly restrained 
with their hind paws free to move. In turn, each hind paw was placed onto the surface of the cold 
plate and the time taken for the mouse to withdraw each paw noted as the end point. Withdrawal 
was counted as complete removal of the paw from the surface of the cold plate. A maximum cut-
off of 30 seconds was set to prevent tissue damage. Data are expressed as the average withdrawal 
latencies for both paws in seconds. [Performed by Clive Gentry]. 
 
196B2.1.3.3. Statistical analysis of behavioural data 
Statistical analysis of behavioural data was carried out on raw data, using SigmaPlot 12.0 software 
(Systat Software Inc, UK). Data are shown as mean ± standard error of the mean (SEM) and were 
analysed using a two-repeated measures analysis of variance (ANOVA) followed by Holm Sidak 
post-hoc test. A p value of less than 0.05 (P<0.05) was considered significant (*), less than 0.01 
(P<0.01) moderately significant (**) and less than 0.001 (P<0.001) highly significant (***). 
 
57B2.2. Immunohistochemistry 
127B .2.1. Tissue preparation 
Mice, under pentobarbital anaesthesia (Sodium pentobarbital, 200mg/ml; Euthatal; Merial Animal 
Health, UK), were transcardially perfused with saline (0.9% NaCl [VWR, UK] w/v, 0.1% heparin 
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sodium [5000units/ml, Leo Laboratories Ltd, UK]), followed by 4% paraformaldehyde in 0.1M 
phosphate buffer (containing 1.5% picric acid [Sigma, UK]). The lumbosacral spinal cord was 
exposed by laminectomy and the lumbar enlargement and L3, L4 and L5 DRG excised. The sciatic 
nerves of the animal were exposed by an anterior to posterior incision along the thigh and 10-
20mm segments excised. Tissues were post-fixed for 2 hours in the perfusion fixative and 
subsequently cryoprotected in 20% sucrose (VWR, UK) in 0.1M phosphate buffer at 4oC for a 
minimum of 72 hours. Following cryoprotection tissues were embedded in optimum cutting 
temperature embedding medium (OCT [VWR, UK]) and frozen in liquid nitrogen. Tissue sections 
were cryostat cut (Bright Instruments, UK) (table 2.1) and thaw-mounted onto glass microscope 
slides (VWR, UK). Slides were stored in cryoprotectant (PBS containing 20% w/v sucrose [VWR, UK] 
and 30% v/v ethylene glycol [VWR, UK]) at -20oC until use. 
 
Table 2.1. Thickness and orientation of tissues prepared for immunohistological analysis 
 
Tissue Thickness Orientation 
Spinal cord 20µm Transverse 
DRG 15 µm Transverse 
Sciatic nerve 15 µm Longitudinal 
 
 
128B .2.2. Immunohistochemical staining 
Slides were washed six times for 5 minutes in 0.1M phosphate buffered saline (PBS)and incubated 
over night at room temperature with a primary antibody for a specific cell marker (table 2.2) in 
PBS containing 0.2% TritonX-100 (Sigma, UK) and 0.1% sodium azide (Sigma, UK). Slides were then 
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washed three times for 5 minutes in PBS and incubated at room temperature, in the dark, with an 
appropriate secondary antibody (table 2.3) for 2.5-3 hours. Following three further PBS washes 
slides were cover-slipped with Vectashield mounting media with DAPI (Vector Laboratories, USA) 
and visualised under a Zeiss Axioplan 2 fluorescent microscope (Zeiss, UK). 
 
Table 2.2. Immunohistochemistry primary antibodies 
 
Primary Antibody Cellular Marker Concentration Supplier 
Rabbit anti-activating 
transcription factor 3 C-
19 (ATF3) 
N/A 1:500 Santa Cruz 
Biotechnology Inc, UK 
Mouse anti-βIII tubulin Neurons 1:1000 Promega, UK 
Rat anti-mouse F4/80 Monocytes/Macrophages 1:200 AbD Serotec, UK 
Rabbit anti-ionized 
calcium binding adaptor 
molecule 1 (Iba1) 
Microglia  
1:1000 
WAKO Pure Chemical 
Industries, Germany 
Rabbit anti-glial fibrillary 
acidic protein (GFAP) 




Table 2.3. Immunohistochemistry secondary antibodies 
 
Secondary antibody Concentration Supplier 
Goat anti-rabbit IgG-conjugated Alexa Fluor 488TM 1:1000 Molecular Probes, USA 
Goat anti-rabbit IgG-conjugated Alexa Fluor 546TM 1:1000 Molecular Probes, USA 
Donkey anti-mouse IgG-conjugated Alexa Fluor 546TM 1:1000 Molecular Probes, USA 
Goat anti-rat IgG-conjugated Alexa Fluor 488TM 1:1000 Molecular Probes, USA 




129B .2.3. Quantification of immunohistochemistry 
197B2.2.3.1. Cell numbers 
The number of positive cells for each immunohistochemical marker was determined. Three tissue 
sections per animal were selected at random with experimental group blinded. Four boxes 
measuring 100 by 100µm (area 104µm2) were spaced equally across the superficial laminae of the 
dorsal horn, for spinal cord sections, or were spaced equally across the tissue for nerve or DRG 
sections. The number of cells positive for the given marker was counted (with experimenter blind 
to condition). 
 
198B2.2.3.2. Fluorescence intensity 
Quantitative assessment of immunoreactivity was carried out by determining the 
immunofluorescence intensity within a fixed area of the superficial dorsal horn. Three L4-L5 spinal 
cord sections were chosen at random from each animal, with experimental group blinded. Four 
boxes measuring 100x100µm were spaced equally across the superficial laminae of the dorsal 
horn. Mean grey intensity each of the boxed areas was determined using Axiovision LE 4.2 
software. The background intensity for each tissue section was determined using an area of 
50x50µm, and subtracted from the intensity values determined and an average value for 
immunofluorescence intensity across the superficial dorsal horn was calculated (with 




199B2.2.3.3. Counts in DRG sections 
The number of βIII-tubulin+ cells per section was determined and represents the total number of 
DRG cells present per section. The total number of ATF3+ cells was then determined and the 
percentage of ATF3 positive DRG cells calculated (with experimenter blind to condition). 
 
200B .2.3.4. Statistical analysis of immunohistochemical data 
Statistical analysis of immunohistochemical data was carried out on raw data, using SigmaPlot 12.0 
software (Systat Software Inc, UK). For both immunofluorescence intensity and cell numbers an 
average value was obtained for each animal. A mean value for each experimental group was then 
calculated, and the groups compared to one another using a one-way analysis of variance 
(ANOVA) followed by Tukey post-hoc test. Group difference with a P value of less than 0.05 






Mounting evidence indicates that in rodents, as in humans, the repeated systemic administration 
of the chemotherapeutic agent VCR results in the development of severe mechanical allodynia and 
cold hypersensitivity. Additionally rodent models have demonstrated that subsequent to VCR 
treatment macrophages infiltrate the peripheral nerve, the cell bodies of neurons within the DRG 
up-regulate their expression of the neuronal stress factor ATF3, and glia cells within the dorsal 
horn of the spinal cord become activated; however the temporal profile of this response is poorly 
understood. Thus we set out to determine the temporal profile of these responses.  
 
95% of mice survived both cycles of VCR treatment with no significant weight loss (figure 2.4) or 
signs of ill health. Until tested VCR treated mice were indistinguishable from saline treated control 
animals; they feed and groom normally and do not display signs of piloerection, excess 








Figure 2.4. Repeated systemic administration of VCR does not cause weight loss in wild-type mice. 
Repeated i.p. VCR (0.5mg/kg/day) administration for two cycles of five days each (0-4 and 7-11; black 
horizontal bars); total dose approximately 125µg/mouse. Vehicle group received an equal volume of saline. 
Animals were weighed prior to any dosing or behavioural assessment, and had been in their cages with ad 
libitum access to food and water for a minimum of 20 hours prior to weighing. N=8 per group, data shown 
are mean ± SEM. No significant difference between saline and VCR treated groups. 
 
58B3.1. In mice, repeated systemic administration of VCR induces a severe mechanical and 
moderate cold hypersensitivity that recovers upon cessation of treatment 
 
The administration of VCR (0.5mg/kg i.p.) for five consecutive days (days 0-4; first cycle, 
cumulative dose 2.5mg/kg), followed by a two day pause and then a second cycle of treatment 
(five consecutive days; 7-11, cumulative dose 5.0mg/kg) was associated with the rapid 
development of significant and severe hind-paw mechanical hypersensitivity (allodynia), which 
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26.35% ± 13.89 of baseline threshold). The hypersensitivity was well established throughout and 
following the first cycle of treatment (days 1-4) and was maintained throughout the second cycle 
(days 5-11; reduction in PWT 98.00% ± 0.21). Mechanical hypersensitivity was sustained at this 
severity for several days beyond the cessation of treatment (until day 17) before gradually 
recovering and returning to baseline pre-treatment levels twenty-four days after the first 
administration (figure 2.5A). Area under the curve analysis of this data reveal a highly significant 
difference in the allodynia index (mechanical allodynia) of VCR treated mice compared to saline 
treated controls across the duration of the study, the first cycle of VCR alone, the second cycle of 
VCR and during the recovery phase; in this analysis a decreased allodynia index value represents a 
greater degree of allodynia (figure 2.5B).  
 
With a comparable time frame, the administration of two five day cycles of VCR was associated 
with the development of a moderate hypersensitivity to cold stimuli; a statistically significant 
decrease in withdrawal latency to a cold stimulus was observed on day 3, after four 
administrations of VCR (31.27% ± 5.92 reduction of baseline PWL; figure 2.6A). However, area 
under the curve analysis demonstrates that the reduction in allodynia index (cold allodynia) that is 
observed over the duration of the study (figure 2.6B; all time) does not occur during the first cycle 
of VCR treatment (figure 2.6B; first cycle). Cold allodynia resulting from VCR treatment is less 
severe than the mechanical allodynia observed in these mice and the onset is more gradual; 
however the maximal difference from baseline was observed at the end of the second cycle of VCR 
(figure 2.6A; day 11, 60.00% ± 3.97 reduction in PWL). As with mechanical allodynia, a sustained 
period of cold hypersensitivity was observed, lasting until day 17, before thresholds gradually 





Figure 2.5. Repeated systemic administration of VCR causes severe mechanical allodynia in mice. 
Development of mechanical allodynia following i.p. VCR (0.5mg/kg/day) administration for two cycles of five 
days each (0-4 and 7-11; black horizontal bars); total dose approximately 125µg/mouse. Vehicle group 
received an equal volume of saline. (A) Time course of the development of mechanical allodynia shown as 
50% paw withdrawal threshold (PWT), data shown as mean ± SEM. N=8 per group, ***P<0.001 compared to 
baseline threshold, ### P<0.001 compared to saline threshold, two-way repeated measures ANOVA with 
poct-hoc Holm-Sidak test. (B) Area under the curve (AUC) analysis showing data expressed as allodynia index 
where a lower value represent more severe allodynia. All time is the analysis of AUC for baseline-day 24, 
first cycle baseline-day 4, second cycle day 7-day 11 and recovery day 11-day 24. Data shown are mean ± 
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Figure 2.6. Repeated systemic administration of VCR causes moderate cold allodynia in mice. 
Development of cold allodynia following i.p. VCR (0.5mg/kg/day) administration for two cycles of five days 
each (0-4 and 7-11; black horizontal bars); total dose approximately 125µg/mouse. Vehicle group received 
an equal volume of saline. (A) Time course of the development of cold allodynia shown as paw withdrawal 
latency (sec; PWL) to a 10oC stimulus, data shown as mean ± SEM. N=8 per group, *P<0.05 and ***P<0.001 
compared to baseline threshold, ### P<0.001 compared to saline threshold, two-way repeated measures 
ANOVA with poct-hoc Holm-Sidak test. (B) Area under the curve (AUC) analysis showing data expressed as 
allodynia index where a lower value represent more severe allodynia. All time is the analysis of AUC for 
baseline-day 24, first cycle baseline-day 4, second cycle day 7-day 11 and recovery day 11-day 24. Data 
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59B3.2. Repeated systemic administration of VCR is not associated with a sustained 
significant increase in the neuronal stress factor ATF3 in the sensory neurons 
 
Direct damage to sensory neurons has been proposed as a mechanism for VCR induced 
neuropathy; here we assessed the expression of ATF3 in cell bodies of sensory neurons in the 
lumbar dorsal root ganglia (DRG) following VCR administration. ATF3 is a member of the ATF/CREB 
family of transcription factors that are activated as part of a range of stress responses (e.g. 
oxidative stress) (Hai et al., 1999) and inflammatory reactions (Gilchrist et al., 2006) when damage 
to the cell has occurred; ATF3 is upregulated in several surgical models of peripheral nerve 
damage and is associated with neuronal damage (Braz et al., 2011;Allchorne et al., 2012). 
 
The representative images in figure 2.7A show ATF3+ cells in the L5 DRG of saline and VCR (day 11) 
treated mice. Following the completion of the first cycle of VCR (day 4) a slight but significant 
increase in ATF3 expression was observed in the cell bodies of sensory neurons in the L5 DRG 
when compared to the DRG of saline treated control animals (percentage of ATF3+  cell bodies: 
saline 0.71% ± 0.24; day 4 VCR 1.93% ± 0.40; figure 2.7B). A similar increase in ATF3 expression 
was measured in the L5 DRG of mice that had received two full cycles of VCR (day 11; VCR 1.60% ± 





Figure 2.7. Repeated systemic administration of VCR does not cause an increase in ATF3 expression in the 
lumbar dorsal root ganglia. (A) Representative images showing activating transcription factor 3 (ATF3) 
expression in L5 dorsal root ganglion (DRG) following vehicle (SAL) or two cycles of VCR (days 0-4, 7-11; 
0.5mg/kg/day i.p.) where ATF3 is shown in red and Beta-III tubulin (B-III tubulin) is shown in green. Scale 
bars equal 100 µm. (B) Quantification of ATF3 expression in neuronal cell bodies in the DRG, where the 
number of ATF3 positive cells is given as a percentage of total neuronal cell bodies. Data shown are mean ± 
SEM and N=4 per group, *P<0.05.  
 
 
61B3.3. Repeated systemic administration of VCR is associated with increased 
monocyte/macrophage infiltration into the sciatic nerve and the lumbar DRG 
 
Using an immunohistochemical approach, we assessed monocyte/macrophage infiltration into 
both the sciatic nerve and the L5 (lumbar) DRG of the mouse following repeated systemic 
administration of VCR. This approach was quantitative, with the number of F4/80+ cells in a given 




































The representative images in figure 2.8A show F4/80+ cells in the sciatic nerve of saline and VCR 
treated mice. In the sciatic nerve the administration of a five day cycle of VCR (0.5mg/kg i.p.; days 
0-4; first cycle), followed by a two day pause and second cycle of treatment (days 7-11) was 
associated with a significant increase in F4/80+ cells, suggestive of monocyte/macrophage 
infiltration of the peripheral (sciatic) nerve. Specifically, an 83.58% (± 11.48 increase; day 1; figure 
2.7A/B) in number of F4/80+ cells per 104µm2 was observed twenty-four hours after the first VCR 
administration. The number of F4/80+ cells continued to increased throughout the first cycle of 
treatment (100.79% ± 15.97 increase; day 3; figure 2.8A/B), the break between treatment cycles 
(135.21% ± 6.62 increase; day 5; figure 2.8A/B) and the second cycle of VCR treatment (141.19% ± 
25.73 increase; day 11; figure 2.8A/B), peaking at day 14 (186.85% ± 7.21 increase; day 14; figure 
2.8A/B) despite cessation of VCR treatment. We then observed F4/80+ cell numbers return to 
baseline pre-treatment values twenty-four days after the first administration concomitantly with 
recovery of mechanical allodynia.  
 
Similarly, figure 2.9A shows representative images of F4/80+ cells in the L5 DRG of saline and VCR 
treated mice. An increase in F4/80+ cells in the L5 DRG was observed following the administration 
of two cycles of VCR treatment, indicative of monocyte/macrophage infiltration. Specifically, an 
11.73% (± 2.32; day 1; figure 2.9A/B) increase in number of F4/80+ cell per 104µm2 in lumbar DRG 
was observed twenty-four hours after the first administration of systemic VCR, this increase 
continued throughout the duration of treatment, reaching significance at the end of the first cycle 
(51.55% ± 3.56 increase; day 4; figure 2.9A/B) and remaining so for the second cycles of VCR 








Figure 2.8. Repeated systemic administration of VCR causes macrophage infiltration of the sciatic nerve. 
(A) Representative images showing macrophages in the sciatic nerve following vehicle (SAL) or two cycles of 
VCR administration (days 0-4, 7-11; 0.5mg/kg/day i.p.) where macrophages are visualised as F4/80+ cells. 
Scale bars equal 100µm. (B) Quantification of the number of F4/80+ cells/macrophages in the sciatic nerve, 
shown as number of F4/80+ cells per 104µm2. Data shown are mean ± SEM and N=4 per group. ### P<0.001 












































Figure 2.9. Repeated systemic administration of VCR causes macrophage infiltration of the dorsal root 
ganglia. (A) Representative images showing macrophages in the L5 dorsal root ganglia (DRG) following 
vehicle (SAL) or two cycles of VCR (days 0-4, 7-11; 0.5mg/kg/day i.p.) where macrophages are recognised as 
F4/80+ cells and shown in green. βIII-tubulin, a neuronal marker, is shown in red. Scale bars equal 100µm. (B) 
Quantification of the number of macrophages in the DRG, shown as number of F4/80+ cells per 104µm2. Data 
shown are mean ± SEM and N=4 per group. ### P<0.001 compared to saline threshold, one-way ANOVA 




































64B3.4. Repeated systemic administration of VCR causes astrogliosis but not the 
microgliosis in the lumbar spinal cord 
 
To test the hypothesis that injury to the peripheral nerve induced by VCR causes activation of glial 
cells in the dorsal horn of the spinal cord (suggestive of central sensitisation), we next examined 
this area for changes in glial cells number or activation state, taking an immunohistochemical 
approach to do so.  
 
The representative images in figure 2.10A (top panels) show Iba1+ cells in the L5 dorsal horn of the 
spinal cord of saline and VCR (day 11) treated mice; they demonstrate that the repeated systemic 
administration of VCR was not associated with microgliosis in the dorsal horn of the lumbar spinal 
cord. No increase in the number of Iba1+ cells in the dorsal horn was observed at any time point 
examined during and after the first and second cycles of VCR treatment (figure 2.10B). The 
morphology of microglia within the dorsal horn did not change as a result of VCR treatment; as the 
high magnification panels (bottom panels) in figure 2.10A show, in both saline and VCR (day 11) 
treated mice, the microglia in the dorsal horn have a ‘quiescent’ morphology; they possess a small 
soma and long branching processes. Furthermore, as the images in figure 2.11A demonstrate, the 
expression of pP38 does not increase subsequent to VCR treatment; pP38 is frequently used as a 
marker of microglial cell activation in chronic pain models as it is rapidly activated my several pro-
inflammatory mediators. No increase in the number of pP38+ Iba1+ cells in the dorsal horn was 
observed at any time point examined during and after the first and second cycles of VCR 




Despite the lack of microgliosis observed in this model, spinal cord changes were seen following 
cyclical administration of VCR. Astrogliosis, the change in number and activation state of 
astrocytes, in the lumbar dorsal horn of the spinal cord was assessed by quantifying the level of 
immunoreactivity of the astrocytic marker GFAP. The representative images in figure 2.12A show 
GFAP+ cells in the L5 dorsal horn of the spinal cord of saline and VCR (days 5 and 11) treated mice; 
they demonstrate that the repeated systemic administration of VCR was associated with an 
increase in the immunofluorescence of this protein that recovers following the cessation of 
treatment (day 24). Specifically, the administration of VCR for five consecutive days (days 0-4; first 
cycle), followed by a two day pause and second cycle of treatment (days 7-11) was associated with 
an increase GFAP immunoreactivity in the dorsal horn; this increase was significant following one 
cycle of treatment (96.21% ± 30.11 increase; day 5; figure 2.12B) remained elevated during the 
second cycle of VCR (114.80% ± 23.68 increase; day 11; figure 2.11B), and for several days beyond 
the cessation of treatment (82.85% ± 9.00 increase; day 17; figure 2.12B), before gradually 
recovering and returning to baseline pre-treatment levels concomitantly with mechanical 







Figure 2.10. Repeated systemic administration of VCR does not cause microgliosis in the dorsal horn of the 
lumbar spinal cord. (A) Representative images showing microglia in the L5 dorsal horn following vehicle 
(SAL) or two cycles of VCR (days 0-4, 7-11; 0.5mg/kg/day i.p.) where microglia are visualised as Iba1+ cells. 
Scale bars equal 100µm. (B) High magnification images of microglia in the L5 dorsal horn. Scale bars equal to 
10µm. (C) Quantification of the number of microglia/ Iba1+ cells in the dorsal horn shown as number of Iba1+ 
cells per 2.25x104µm2. Data shown are mean ± SEM and N=4 per group. No significant difference between 

















































                                           
 
 
Figure 2.11. pP38 is expressed within microglia in the spinal cord but is not increased by repeated 
systemic administration of VCR.  (A) Representative images showing pP38 expression in the L5 dorsal horn 
following vehicle (SAL) or two cycles of VCR administration (days 0-4, 7-11; 0.5mg/kg/day i.p.). pP38 (red) 
co-localises exclusively with Iba1 (green), a marker of microglial cells. Scale bars equal 100µm and 10 µm in 
high magnification images. (B) Quantification of the number of pP38+ microglia in the dorsal horn shown as 
number of pP38+ Iba1+ cells/104µm2. Data shown are mean ± SEM and N=4 per group. No significant 



































Figure 2.12. Repeated systemic administration of VCR causes astrogliosis in the dorsal horn of the lumbar 
spinal cord. (A) Representative images showing astrocytes in the L5 dorsal horn following vehicle (SAL) one 
(day 5) or two cycles (day 11) of VCR administration (days 0-4, 7-11; 0.5mg/kg/day i.p.) or following 
recovery, where astrocytes are visualised as GFAP+ cells. Scale bars equal 100µm. (B) Quantification of the 
intensity of GFAP staining in the dorsal horn shown as relative GFAP intensity (relative to saline treatment) 
per 104µm2. Data shown are mean ± SEM and N=4 per group. ### P<0.001 compared to saline value with 
one-way ANOVA with post-hoc Tukey test. 
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67B3.5. Astrogliosis is not required for the maintenance of mechanical hypersensitivity 
following repeated systemic administration of VCR  
 
 We then sought to establish the contribution of astrocytes to pain mechanical allodynia in the 
VCR model of painful peripheral neuropathy by intrathecally injecting fluorocitrate (FLC). FLC is an 
irreversible inhibitor of aconitase, an enzyme that plays a critical role in the citrate cycle of glia but 
not neurons (Hassel et al., 1992). In mice that had received the full first cycle of VCR (day 5) the 
single administration of 0.1nmol FLC in 5μl did not attenuate mechanical allodynia one hour after 
administration (figure 2.13A +1; figure 2.13b VCR-post). However, as demonstrated by the 
representative images in figure 2.14A, the single administration of 0.1nmol fluorocitrate in 5μl 
reversed the increase in GFAP immunoreactivity observed following the full first cycle of VCR, to a 
level comparable to that of saline treated animals. When this is quantified we show that there is 
no significant different between the GFAP immunoreactivity of saline treated and VCR-FLC treated 







Figure 2.13. Single intrathecal administration of FLC does not attenuate mechanical allodynia in VCR 
treated mice. Repeated i.p. VCR (0.5mg/kg/day) administration for a full cycle of five days each (0-4; black 
horizontal bar), with or without i.t. FLC (0.1nmol in 5µl. Vehicle group received an equal volume of saline. 
(A) Time course of the development of mechanical allodynia shown as 50% paw withdrawal threshold 
(PWT), data shown as mean ± SEM. N=8, ***P<0.001 compared to baseline threshold, ### P<0.001 
compared to saline threshold, two-way repeated measures ANOVA with post-hoc Holm-Sidak test. No 
significant difference between VCR-SAL and VCR-FLC treated groups. (B) VCR produced a significant 
decrease in PWT compared to saline vehicle, as represented by pre-dose data. This threshold was not 
altered by FLC administration, as represented by post-dose data. Data shown as mean ± SEM, N=8 per group 























































































Figure 2.14. VCR-induced astrogliosis in the dorsal horn of the lumbar spinal cord can be suppressed by 
FLC. (A) Representative images showing astrogliosis in the L5 dorsal horn following vehicle (SAL) or one 
cycles of VCR administration (0.5mg/kg/day i.p.) with (VCR-FLC) or without (VCR-SAL) i.t. FLC ( 0.1nmol in 
5µl), where astrocytes are recognised by their expression of GFAP. Scale bars equal 100µm. (B) 
Quantification of the intensity of GFAP staining in the dorsal horn shown as relative GFAP intensity (relative 
to SAL-SAL) per 104µm2. Data shown are mean ± SEM and N=4 per group. ### P<0.001 compared to saline 







































30B4. Discussion  
 
The introduction and development of chemotherapeutic regimes during the twentieth century has 
dramatically increased the rate of survival of cancer patients. However these drugs are not 
without serious side-effects; these stem from the fact that cells with a high turnover, such as those 
in the bone marrow, are highly susceptible to the toxic effects of chemotherapeutics. The 
successful management of many of these side-effects, including anaemia, thrombocytopenia and 
neutropenia has allowed treatment regimens to be advanced but has also exposed a secondary 
dose-limiting effect: neurotoxicity (Windebank and Grisold, 2008). The symptoms of the 
chemotherapy-induced neuropathy are predominantly sensory in nature, with patients reporting 
the most problematic symptom to be pain (Tofthagen, 2010). A number of animal models of 
chemotherapy pain have been developed in recent years; these exhibit similar sensory 
abnormalities and symptoms to those observed in patients, specifically a decrease in sensory 
nerve conduction velocity, mechanical allodynia and cold hypersensitivity. From the evidence 
obtained from a number of recent studies we know that, at least superficially, the development of 
VCR-induced neuropathy in rodents is similar to that in man. The neurotoxicity of VCR in both 
rodent and man is cumulative; symptoms are experienced following multiple doses of this anti-
neoplastic agent and become progressively more severe as therapy is continued. Both rodent and 
man experience a neuropathy that is predominantly sensory and that is associated with altered 
electrophysiological properties of sensory nerves; the decrease in conduction velocity (Alimoradi 
et al., 2012;Krishnan et al., 2005) and amplitude of action potentials (Pal, 1999;Callizot et al., 2008) 




The development of mechanical allodynia following VCR administration is well documented in the 
rat; daily intraperitoneal administration of this agent for two weeks causes a rapid decrease in 
nociceptive threshold. This is dose-dependent and cumulative; higher doses cause a more severe 
phenotype. Following the cessation of VCR treatment, mechanical allodynia is sustained for 
several days; nociceptive thresholds return to baseline values approximately three and half weeks 
after the commencement of the study (Aley et al., 1996). This rat model of chemotherapy-induced 
mechanical allodynia provides a suitable model for the testing of potential analgesics, due to its 
large therapeutic window and reproducible results. However, the mouse model of this condition is 
more appealing for the study of the molecular mechanisms underlying the neuropathy, due to the 
availability of genetically modified strains. A mouse model of VCR-induced neuropathy has been 
established in C57Bl/6 mice (Uceyler et al., 2006) however its characterisation is far from 
complete, hence the need for the current study. Furthermore, despite the wealth of evidence 
obtained from both human and rodent studies/models, the precise mechanism by which 
chemotherapeutic agents cause neuropathy remains elusive. 
 
Here, in this chapter, we set out to characterise a mouse model of VCR-induced neuropathy; 
considering the development of behavioural symptoms of the neuropathy and assessing the 
temporal profile of non-neuronal cell involvement both peripherally and centrally, as these cells 
are known to play a key role in the development of pain in a number of models of neuropathy. The 
principle finding of the work described here is that repeated systemic administration of VCR 
results in the development of severe and sustained mechanical allodynia and mild cold 
hypersensitivity. Furthermore, the development of these pain behaviours is associated with 
changes to non-neuronal cells; specifically macrophage infiltration of the sciatic nerve and DRG 
and astrogliosis (but not microgliosis) in the dorsal horns of the lumbar spinal cord.  
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We have demonstrated here that the temporal profile of mechanical allodynia exhibited by mice 
following VCR administration is actually quite similar to that seen in rats. VCR treated mice 
develop significant mechanical allodynia within 24 hours of first administration of the drug; by the 
end of the first cycle of treatment (5 administrations) this allodynia is extremely severe, is 
sustained throughout a second cycle of VCR and persists for several days after the cessation of 
treatment before recovery. This temporal profile of allodynia is likely accurate as it is consistent 
with previous studies of VCR-induced neuropathy in mice, where onset of allodynia is rapid and 
sustained beyond the cessation of treatment (Uceyler et al., 2006;Hansen et al., 2011;Gauchan et 
al., 2009;Kiguchi et al., 2008b).  
 
In addition to the development of mechanical allodynia, hypersensitivity to cold is a common 
complaint in chemotherapy patients (Binder et al., 2007). Here we were able to demonstrate the 
development of cold hypersensitivity in mice following VCR treatment. Consistent with previous 
literature (Park et al., 2012;Geis et al., 2011;Thibault et al., 2008), this is not as robust as the 
development of mechanical allodynia and thresholds are much more varied between animals. 
Whilst the change in threshold to a cold stimulus is significant for the majority of subsequent 
studies we have concentrated on mechanical allodynia as a behaviour indication of the 
development of neuropathy as the data obtained is more consistent that of cold hypersensitivity. 
It is important to note that whilst the behavioural phenotype observed is severe, no weight loss 
was evident in VCR treated animals, suggesting this treatment protocol was not overwhelmingly 
toxic to the animals.  
 
As discussed in chapter one, it has previously been suggested that VCR may cause neuropathy by 
binding to tubulin and disrupting the normal function of neurons; this hypothesis is supported by 
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an increase in expression of the neuronal stress factor ATF3 that is reported in models of VCR-
induced neuropathy (Hansen et al., 2011). In a study by Hansen et al. a significant increase in ATF3 
immunoreactivity (from approximately 5% to 17% of DRG neurons) is reported in the lumbar DRG 
19 days after the commencement of VCR treatment. Here we examined ATF3 expression at day 4 
(following the completion of the first VCR cycle) and day 11 (at the end of the second cycle) after 
the commencement of treatment; we observed a small but significant increase in the ATF3 
expression of L5 DRG neuronal cell bodies at the earlier time point but not the latter. However, 
the expression values obtained fall within the previously published values of ATF3 expression in 
naive or control mice (0.001% (Ogbonna et al., 2013) to 5% (Hansen et al., 2011;Kim and Moalem-
Taylor, 2011). To put this increase into perspective, following a severe peripheral nerve injury an 
increase of approximately 20% is observed in our hands (Ogbonna et al., 2013). It is possible that if 
tissue was taken at later time points, such as study day 19 or 20 for example, an increase in ATF3 
may have been seen in our model, however this seems unlikely, as pain behaviour had reached 
peak levels by both time points examined, and if a neuronal stress response was the causative 
factor in this, an ATF3 increase should have been apparent. Further to this, Ja’afer et al recently 
demonstrated that whilst there is evidence of myelin sheath alterations in the rat sciatic nerve 
following VCR treatment, there is no axonal loss in the sciatic or tail nerves (Ja'afer et al., 2006); 
this is consistent with work by Authier et al who reported that whilst there is a decrease in nerve 
conduction velocity in VCR treated animals, few degenerated fibres are found in the sciatic nerve 
(Authier et al., 2003). However, the infiltration of the nerve by macrophages is indicative of 
neuronal damage as these immune cells are recruited to sites of tissue damage; it is possible that 
the histochemical techniques currently available to use are not sensitive enough to detect the 




As well as an increase in neuronal ATF3, Hansen et al have also reported an increased number of 
macrophages in the DRG of VCR animals (Hansen et al., 2011). This was examined at a single time 
point, but inspired us to assess the temporal profile of macrophage infiltration, and indeed we 
observe a comparative number of macrophages in the DRG by the end of the treatment protocol. 
Furthermore, by examining two earlier time points, day 1 (24 hours after the first administration) 
and day 4 (following a full cycle of VCR), we have established that this increased in macrophage 
number in the DRG is gradual, unlike the infiltration we see in the peripheral nerve. Analysis of 
macrophage infiltration of the sciatic nerve has demonstrated that there is a rapid increase in the 
number of these cells in the nerve just 24 hours after the commencement of treatment. This 
number continues to rise following subsequent doses of VCR and peaks just after the cessation of 
treatment, before decreasing back to baseline levels concomitantly with the recovery of the 
behavioural phenotype. In fact the temporal profiles of mechanical allodynia and macrophage 
infiltration of the nerve are very similar, and combined with the evidence from previous work in 
the laboratory, that demonstrates that in a model of peripheral nerve injury depletion of these 
cells delays the onset of allodynia (Barclay et al., 2007), we hypothesise that these cells play a 
considerable role in the development of chemotherapy-pain; these experiments are presented in 
chapter three. 
 
In contrast to the changes in macrophages, the morphology and number of microglia in the dorsal 
horn of the spinal cord remained unchanged following VCR treatment. This observation, whilst 
unexpected, is not surprising. Microgliosis in models of chemotherapy pain remains controversial; 
there is considerable inter-model variation and microgliosis tends to be reported in rat models 
rather than mouse (Ledeboer et al., 2007).  Astrogliosis, on the other hand, was observed; a 
significant increase in GFAP immunoreactivity was detected five days after the commencement of 
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treatment (end of cycle one) and this continued to increase during the second cycle of VCR 
administration, before declining back to baseline levels concomitantly with the recovery of pain 
related behaviours. This is also consistent with previous studies which have documented 
astrogliosis at varying time points (Ji et al., 2013;Kiguchi et al., 2008a). Activation of spinal glial 
cells is indicative of central sensitization, which classically occurs as a result of damage to 
peripheral nerves, thus the activation of astrocytes in this models provides further, albeit indirect, 
evidence for neuronal damage in our mice occurring as a result of VCR treatment. 
 
Due to the similarities in the temporal profiles of astrocyte activation and mechanical allodynia, 
and concomitant recovery of astrogliosis and mechanical hypersensitivity following the cessation 
of VCR treatment, we hypothesised that astrogliosis might contribute to the maintenance of VCR-
induced hypersensitivity. To investigate this we administered a glial inhibitor to mice exhibiting 
well established VCR-induced mechanical allodynia, to see if this behaviour could be attenuated. It 
has previously been demonstrated that centrally administered glial inhibitors have efficacy in 
models of chemotherapy-pain, suggesting glial cells do contribute to the behavioural phenotype 
observed in these animals. Minocycline, a tetracycline derivative that possesses anti-inflammatory 
properties, has been reported to preferentially inhibit the function of microglia (rather than 
astrocyte or neurons) (Tikka and Koistinaho, 2001), but is capable of attenuation of cold 
hyperalgesia induced by PTX. In these animals significant microgliosis has been demonstrated and 
this too is attenuated by minocycline (Pevida et al., 2013). Moreover, minocycline is also able to 
prevent the development of mechanical hypersensitivity in oxaliplatin treated rats (Boyette-Davis 
and Dougherty, 2011). Propentofylline, a third generation glial inhibitor that decreases both 
microglial and astrocytic activation (by inhibition of phosphodiesterase cAMP generation) (Tawfik 
et al., 2008), suppresses spinal glial activation and mechanical allodynia in PTX treated animals. 
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Here we intrathecally administered FLC; this is a selective inhibitor of the aconitase enzyme found 
in the tricarboxylic acid cycle (TCA) of glia but not neurons (Hassel et al., 1992). At the time of 
experimentation a dosing regimen for FLC treatment in mice had not been established and the use 
of compound in models of chemotherapy pain had not been published. However we have 
demonstrated that the single intrathecal administration of 1nmol FLC in 10µl suppresses glial 
activation and reverses hyperalgesia in rat models of chronic pain, with a peak behavioural effect 
occurring one hour after administration (Clark et al., 2007a). Due to the smaller intrathecal space 
of mice, we administered 1nmol FLC in 5 µl to mice that had received a full cycle (five 
administrations; day 5) of VCR. Unfortunately these mice experienced seizures; as a result they 
were unsuitable for behavioural assessment and we culled in accordance with Home Office 
Regulations. A reduced dose of FLC (0.1nmol in 5µl) was well tolerated by both saline and VCR 
treated mice, and it is this dose that was used in the study presented here. We had not previously 
demonstrated efficacy of FLC at this dose, however, immunohistochemical analysis of the spinal 
cord following treatment demonstrates that it was able to reverse activation of astrocytes , as 
demonstrated by a reduced GFAP immunoreactivity of VCR-FLC compared to VCR-SAL treated 
mice. No behavioural effect was observed; FLC did not attenuate mechanical allodynia in VCR 
treated mice. Whilst there was initially some concern as to whether this could be attributed to a 
sub-optimal dose of FLC, Morioka et al have recently demonstrated efficacy in the suppression of 
astrocytic metabolism at this same dose (Morioka et al., 2012). Thus, these data suggest that 
whilst cycle administration of VCR is associated with the development of astrogliosis in the dorsal 
horn of the spinal cord, activation of astrocytes in the spinal cord is not required for the 
maintenance of mechanical allodynia in these animals. Also, as the development of astrogliosis 
occurred several days after a reduction in mechanical thresholds was first apparent; our data 
suggest that the activation of astrocytes do not contribute to the initiation or development of 
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mechanical allodynia. However as the existing literature shows efficacy of glia inhibitors in PTX and 
oxaliplatin induced neuropathies (Pevida et al., 2013;Boyette-Davis and Dougherty, 2011), this 
result may be specific to VCR neuropathy, and suggests that chemotherapeutics with differing 






31B5. Introduction to Chapter 3 
 
In this chapter, we provide evidence for macrophage infiltration of the peripheral nervous system 
occurring concomitantly with the significant development of pain behaviours in VCR treated mice. 
Thus, we sought to determine the contribution of these cells to the development of VCR-induced 
mechanical allodynia. To investigate the hypothesis that macrophage infiltration of the PNS is a 
critical step in the development of VCR-induced mechanical allodynia, we have not only depleted 
circulating monocytes (thus preventing the infiltration of macrophages into the nerve), but have 
also used two genetically altered mouse strains to establish the contribution made by differing 
populations of macrophages. Macrophages are a heterogeneous population of cells, existing as 
tissue resident macrophages and differentiating from circulating monocytes upon entry into the 
tissue following danger signals from the immune system. These experiments are presented in 
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Macrophages were introduced in chapter two as a heterogeneous population of cells that 
differentiate from circulating monocytes and function as phagocytic cells, involved in the clearance 
of cellular debris following tissue damage or remodelling. Here we will discuss the origin, 
heterogeneity and function of these cells in more detail and then focus on one particular 
chemokine receptor expressed by these cells: CX3CR1. 
 
68B1.1. Monocyte / Macrophages; Origin, Function & Heterogeneity 
 
 
Macrophages (first recognised by Metchnikoff in his 1908 Nobel Prize winning work) can be found 
in all tissues, and circulate in the blood as monocytes, constituting a significant portion of the 
peripheral blood mononuclear cells (PBMCs) / leukocytes.  Monocytes constitute approximately 
10% of circulating leukocytes in man and 4% in the mouse (Auffray et al., 2009), and under steady 
state conditions do not proliferate. Monocytes can differentiate into inflammatory dendritic cells 
or macrophages under inflammatory (and sometimes steady-state) conditions (Geissmann et al., 
2010;Mosser and Edwards, 2008). They differentiate from committed myeloid progenitors and, as 
shown by radioisotope labeling of blood and bone marrow cells, are the precursors for 
macrophages in all tissues. This process is regulated by several growth factors, the most important 
of which is CSF1 (colony stimulating factor-1; also known as M-CSF). In vitro CSF1 stimulates 
proliferation and differentiation of progenitors (monoblasts, promonoblasts and monocytes) to 
macrophages. The CSF1 receptor is expressed by all mononuclear phagocytic cells under the 
control of the transcription factor PU.1 and the CSF-1 protein itself is produced by cells of 
mesenchymal lineage including endothelial cells, fibroblasts and myoblast; most tissues are able to 
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produce this protein (Pollard, 2009;Gow et al., 2010;Sweet and Hume, 2003). Additionally 
macrophages can differentiate from monocytes in the presence of GM-CSF although the 
phenotype of mice lacking this protein is not as extreme as those lacking either CSF-1 or PU.1 
(Pollard, 2009). The full process of macrophage differentiation from bone marrow progenitor is 
summarised in figure 3.1.  
 
In humans monocytes show substantial morphological heterogeneity but were first identified by 
their expression of CD14. Subsequent identification of the antigenic marker CD16 allowed two 
distinct monocyte populations to be determined: CD14+CD16- monocytes, also known as classically 
activated or inflammatory monocytes, and the alternatively activated or resident CD14+CD16+ 
monocytes, which resemble tissue resident macrophages (Passlick et al., 1989;Ziegler-Heitbrock et 
al., 1993). In vitro transmigration assays have revealed that these cells are able to differentiate 
into either dendritic cells or macrophages given the appropriate stimulus, although CD14+CD16+ 
monocytes showed a preference for differentiation to dendritic cells and CD14+CD16- monocytes 
to macrophages (Randolph et al., 2002). Additionally, since their initial identification these two 
differing populations have been found to have distinct chemokine receptor expression profiles, 




             
Figure 3.1. The mononuclear phagocytic system development. During development there are cells that 
derive from the yolk sac that have a macrophage like phenotype, possessing the macrophage marker CD11b. 
In later developmental stages haematopoiesis in the liver becomes the source of macrophages that bare 
considerable resemblance to those seen in the adult. As in adults these cells originate from a common 
haematopoietic stem cell (HSC) which undergoes differentiation steps that commit them to a monocytic 
lineage via granulocyte/macrophage colony forming units (GM-CFU) and macrophage colony forming units 
(M-CFU). In adults haematopoiesis occurs in the bone marrow but includes similar steps as in the foetal liver 
with monocytes migrating into the blood stream where they act as a source of precursors of the 
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Table 3.1. Antigen expression on human monocytes of the two best-characterised subsets. (Adapted from 
Gordon and Taylor, 2005)  
 
Antigen / Receptor Expression in Human 
CD14+CD16+ ‘resident’ 
monocytes 
Expression in Human 
CD14+CD16- ‘inflammatory’ 
monocytes 
CD14 + + 
CD16 + - 
F4/80 Not determined Not determined 
CD11b + + 
Ly6C Not determined Not determined 
CX3CR1 High Intermediate 
CCR2 - + 
 
As in humans, two phenotypically distinct monocyte populations can be seen in the mouse, albeit 
based on different antigen expression. In mice monocytes are differentiated from other leukocyte 
populations by their F4/80+CD11b+ phenotype and as in humans can also be subdivided according 
to their expression of the chemokine receptors CX3CR1 and CCR2, as shown in table 3.2 (Gordon 
and Taylor, 2005). The expression of these chemokine receptors appears to be critical for the 
survival and trafficking of monocytes. The role of CX3CR1 is discussed in detail below but it appears 
that this receptor is vital for survival of resident Ly6C-CX3CR1
high monocytes; in CX3CR1 knock-out 
mice a lack of CX3CR1-CX3CL1 interaction results in a reduction in the number of these monocytes 
found in the circulation (but no change in inflammatory monocyte numbers) and a decrease in 
absolute monocyte numbers in these animals (Jung et al., 2000). CCR2 deficiency on the other 
hand results in retention of Ly6C+CX3CR1
int monocytes in the bone marrow, indicating that CCR2-
CCL2 interaction is required for extravasation of these cells from here (Serbina and Pamer, 2006). 
In fact CCR2 knock out results in a marked reduction of inflammatory monocyte trafficking in 
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general; following a thioglycollate inflammatory challenge far fewer cells are recovered from the 
peritoneum of CCR2-/- mice compared to wild-type controls, and this recruitment deficit is specific 
to monocyte/macrophages (Kurihara et al., 1997). 
 
Table 3.2. Antigen expression on mouse monocytes of the two best-characterised subsets. (Adapted from 
Gordon and Taylor, 2005) 
 
 Antigen / Receptor Expression in Mouse  
‘resident’ monocytes 
Expression in Mouse  
‘inflammatory’ monocytes 
CD14 Not determined Not determined 
CD16 Not determined Not determined 
F4/80 + + 
CD11b + + 
Ly6C - + 
CX3CR1 High Intermediate 
CCR2 - + 
 
As well as this phenotypic distinction, these subsets of monocytes can also be distinguished 
functionally using adoptive transfer of GFP-expressing monocytes from a CX3CR1 knock-in mouse. 
Geissmann et al determined that Ly6C+CX3CR1
intCCR2+ inflammatory monocytes were short lived 
after adoptive transfer to irradiated wild-type mice, however in models of disease these cells are 
rapidly recruited to sites of inflammation, whilst Ly6C-CX3CR1
highCCR2- resident monocytes, on the 
other hand, persisted and could be seen in tissues (Geissmann et al., 2003). As a result of their 
three key functions (antigen presentation, phagocytosis and immunomodulation) 
monocyte/macrophages play a critical role in maintaining tissue homeostasis and supporting the 
adaptive immune response. Examples of resident monocyte/macrophage function are summarised 
in figure 3.2 below.  
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Figure 3.2. Macrophage location and function. Macrophages are found in most tissues where they have 
specialised functions and sometimes known by specific names. In the brain microglia are involved in 
neuronal survival, connectivity and repair.  In the skin Langerhan cells play an important immune 
surveillance role and control keratinocyte proliferation and differentiation. In the heart cardiac macrophages 
are involved in healing and remodelling of cardiac tissue. Splenic macrophages are immune surveyors as are 
alveolar macrophages in the lungs and crypt macrophages in the small and large intestines. In the liver 
Kupffer cells clear debris from the blood and contribute to tissue regeneration after injury. Pancreatic 
macrophages have an important role in islet development whilst in the kidney macrophages are involved in 
ductal development. In the bone marrow macrophages contribute to erythropoiesis whilst in the rest of the 
bone osteoclasts are critical for normal bone remodelling. Macrophages found in the eye contribute to 
vascular remodelling, in the uterus they are involved in cervical ripening and finally in the ovaries and testis 

















Homeostatically monocyte/macrophages ingest waste material, including that arising from the 
aging of red blood cells (they phagocytically clear approximately 2 x 1011 erythrocytes per day) 
(Mosser and Edwards, 2008) and clean up debris at the side of tissue damage or infection (Geske 
et al., 2002). In comparison to their polymorphonuclear companions, neutrophils, 
monocyte/macrophages are relatively long lived. This is clinically very important especially in 
cancer patients where they provide protection in those at risk of fatal infection following 
chemotherapy, as they are not depleted as severely as other immune cells by this treatment (Dale 
et al., 2008). Under physiological conditions tissue resident macrophages survey their local 
environment and are responsible for mounting a response to invading pathogens. These are 
detected via their interaction with pattern-recognition receptors on the surface of macrophages, 
leading subsequently to activation of the cell and the release of various mediators that recruit 
other cells of the immune system. A key example of this is activation of toll-like receptors (TLRs). 
TLRs recognise various pathogen related molecules, such as lipopolysaccharide. Ligand-binding to 
this receptor results in downstream activation of the transcription factor NF-κB and release of pro-
inflammatory cytokines and chemokines (Dale et al., 2008) which are able to modulate the 
immune response by recruiting and activating further immune cells. Importantly resident 
macrophages phagocytose pathogens and release CCL2 which induces the chemotaxis of 
inflammatory monocytes. Monocyte/macrophages have a huge capacity for phagocytosis and can 
internalise almost any antigen which is digested by the fusion of the phagosome with lysosomes. 
The antigens are then presented on major histocompatability complex (MHC) proteins of class I 
(predominantly endogenous antigens) or class II (exogenous antigens) and mediate the activation 
of T-cells (Trombetta and Mellman, 2005). Following their recruitment to inflamed tissues, 
inflammatory monocyte/macrophages become activated, be it by pro-inflammatory mediators 
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released from resident monocyte/macrophages or from damaged tissues; they show enhanced 
microbial activity and begin to secrete high levels of pro-inflammatory mediators themselves. 
 
69B1.2. Experimental macrophage depletion 
 
Liposomes are artificially prepared lipid vesicles comprised of concentric phospholipid bilayers 
(figure 3.3), and were first identified by British haematologist Alec Bangham in the early 1960’s 
(Bangham et al., 1962;Horne et al., 1963;Bangham and Horne, 1964). The entrapment of an 
aqueous compartment by this bilayer allows these vesicles to act as a cross-membrane delivery 
system for highly hydrophilic molecules dissolved in an aqueous solution; due to the 
hydrophobicity of the membrane the solutes are unable to readily pass through the lipid 
membrane, rather they are delivered to their target site by fusion of the lipid bilayer with similar 
structures, such as those comprising the cell membrane, and consequent release of the contents 
into the target cell or organelle. Whilst there is ongoing research into specific targeting of 
liposomes by the introduction of specific surface markers or antibodies, the typically fate of 
liposomes is to be phagocytosed by mononuclear phagocytes. As a result liposomes offer a 
valuable tool for targeting compounds to these cells to manipulate their function. A number of 
liposome encapsulated drugs are already in use, designed to reduce the toxicity of existing 
formulations; for example liposome-encapsulated doxorubicin (Myocet) has been trialled and 
approved for the treatment of solid tumours and has been shown to have a longer half-life with 
less free drug available for tissue distribution than conventional doxorubicin (Mross et al., 2004). 
Here the specific example of liposome-encapsulated clodronate (LCL) is discussed.  Clodronate, 
also known as dichloromethylene-bisphosphonate (Cl2BMP) is used extensively in the treatment of 
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osteolytic bone disease where it exerts anti-bone-resorptive action via cytotoxic effects on 
osteoclasts (monocyte-derived bone specific macrophages) (Rogers et al., 2000), but has also been 
reported to have analgesic efficacy independent of this mechanism (Kim et al., 2013). The 
phagocytosis of LCL by phagocytes results in the development of a phagosome within the cell 
(figure 3.4A/B), which subsequently fuses with phospholipase containing lysosomes (figure 
3.4C/D) which in turn disrupt the phospholipid bilayers of the liposome causing the clodronate, 
which is dissolved in the aqueous compartments between bilayers, to be released into the cell 
(figure 3.4E). Clodronate accumulates in the cell (it is strongly hydrophilic and unable to cross the 
cell membrane) and causes the cell to undergo apoptosis (figure 3.4F/G); the exact mechanism by 
which this occurs has not yet be unravelled, however the most prevalent suggestion is based upon 
the mechanism by which non-nitrogen containing bisphosphonates act upon osteoclasts; 
clodronate is metabolised into a non-hydrolysable methylene-containing analogue of ATP by 
aminoacetyl-tRNA synthetase enzymes that accumulates in the cell, subsequently triggering 
apoptosis (figure 3.4E) (Frith et al., 1997;Frith et al., 2001). When administered to non-phagocytic 
cells in vitro LCL has no effect on growth or function of the cells (Claassen et al., 1990). In fact 
evidence suggest that when administered systemically LCL affects only macrophages and their 
direct monocyte precursors (Huitinga et al., 1992); despite their phagocytic potential neutrophils 
appear neither morphologically or functionally  affected by LCL (Qian et al., 1994). 
 
Using this method of macrophage depletion, a role for these cells in the pathophysiology of a 
number of inflammatory and pain-inducing diseases has been established. Depletion of the 
macrophages in the knee joints of mice by intra-articular injection of LCL before the induction of 
rheumatoid arthritis significantly reduces osteophyte formation (Blom et al., 2004), joint 
disruption, joint inflammation and pro-inflammatory cytokine (IL-1β and TNFα) production (van 
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Lent et al., 1996); blockade of IL-1β and TNFα signalling in arthritis models is anti-hyperalgesic 
(Sachs et al., 2011). Reduction of circulating monocyte/macrophages reduces infiltration of these 
cells into the nerve following injury to this tissue; this both reduces thermal hyperalgesia and 
protects nerve fibres against degeneration, confirming a role for monocyte/macrophages in the 
development of neuropathy following nerve injury (Liu et al., 2000). Preventing spinal cord 
infiltration of macrophages following spinal cord injury, by LCL induced depletion preserves fibre 
myelination, reduces cavity size and encourages enhanced sprouting and behavioural recovery 
(Popovich et al., 1999). Macrophage depletion prevents infiltration of the nerve by these cells and 
significantly attenuates disruption of the blood nerve barrier following chronic nerve compression 
(Gray et al., 2007), reduces nerve-injury induced mechanical hypersensitivity (Barclay et al., 2007) 
and delays the onset of diabetes induced mechanical allodynia (Mert et al., 2009). 
 
  
                                                
 
 
Figure 3.3. Schematic representation of liposome encapsulated clodronate. Concentric phospholipid 





Figure 3.4. Schematic representation of the mechanism of monocyte/macrophage depletion by liposome 
encapsulated clodronate. The phagocytosis of LCL by phagocytes results in the development of a 
phagosome within the cell (A/B), which subsequently fuses with phospholipase containing lysosomes (C/D) 
which in turn disrupt the phospholipid bilayers of the liposome causing the clodronate, which is dissolved in 
the aqueous compartments between bilayers, to be released into the cell (E). Clodronate accumulates in the 














Chemokines or ‘chemoattractant cytokines’ are a family of small proteins that obtain their name 
from their first described function as mediators of leukocyte migration. First discovered in the late 
1980’s, the chemokines are now a large family of structurally and functionally similar molecules 
named according to the organisation of cysteine residues on their N-terminal region and are 
divided into four sub-families: C, CC, CXC and CX3C. Chemokines with each subclass have a 
promiscuous relationship with their receptors of which there are over twenty; as a result receptor 
nomenclature is based on the sub-family of ligands it binds, e.g. CC chemokines bind but CC 
receptors. The exception to this rule is the interaction between CX3CL1 and its receptor CX3CR1 
which is a monogamous relationship. The structure, expression and function of CX3CR1 are 
discussed here, whilst the protein ligand, CX3CL1, is discussed in detail in chapter four. 
 
130B .3.1. Structure 
CX3CR1 was first identified as the orphan receptor V28, however PCR screens of human PBMCs 
demonstrated that the amino acid sequence of V28 displayed a number of features also present in 
several known chemokine receptors, including seven hydrophobic regions, a 20 amino acid region 
highly conserved in the G-protein coupled receptor super-family and a short sequence in the 
second cytoplasmic loop which is particularly conserved in the chemokine receptors. In fact 81% of 
the amino acid sequence of V28 was found to be identical to that of the MIP-1α and MCP-1 
receptors (Raport et al., 1995). The genes encoding the chemokine receptors (and their protein 
ligands) are clustered in the human genome (Maho et al., 1999); CX3CR1 has been mapped to the 
3p21.3 region (Samson et al., 1996;Maho et al., 1999) were it is encoded by a single exon (Raport 
et al., 1995). Like all of the chemokine receptors, CX3CR1 is a seven-transmembrane domained G-
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protein coupled receptor. The regions of the protein critical for ligand binding by CX3CR1 have 
been identified using equilibrium binding analyses of various protein mutants; two acidic amino 
acid residues, Asp25 located in the N-terminal domain and Glu254 in the third extracellular loop, 
are crucial for ligand binding; their substitution with alanine abolishes the ligand binding capacity 
of CX3CR1. Additionally an N-terminal tyrosine (Tyr14) is implicated in binding affinity as its 
substitution significantly impacts ligand binding; together this suggests the N-terminal domain and 
third extracellular loop are involved in ligand binding (Chen et al., 2006). Structural analysis of 
CX3CL1 has implicated several positively charged amino acid residues in the chemokine function of 
this protein (Mizoue et al., 1999;Mizoue et al., 2001;Harrison et al., 2001).  Additionally, Chen et al 
determined the amino acid residues of CX3CR1 responsible for ligand binding are also essential for 
the stimulation of receptor mediated cellular responses; mutant receptors with a deficient ligand 
binding capability failed to induced cellular migration in a CX3CL1 chemotactic assay . Furthermore, 
several mutants with unaffected ligand binding showed an unexpected deficit in chemotactic 
response, suggesting high affinity ligand binding alone is not sufficient for receptor activation 
(Chen et al., 2006). One of the intracellular consequences of CX3CL1-induced activation of CX3CR1 
is the phosphorylation of the mitogen-activated protein kinase ERK1/2 (Cambien et al., 2001), 
which is necessary for CX3CR1-dependent chemotaxis (Chen et al., 2006); independent mutation of 
the residues Glu13 and Asp16 in the N-terminal domain and Asp266 in the third extracellular loop 
results in significant impairment of the ability of CX3CR1 to induce ERK activation 
(phosphorylation) which subsequently impairs chemotaxis (Chen et al., 2006), suggesting that 
these regions necessitate signal transductions as well as ligand binding. 
 
Human genetic studies have identified two CX3CR1 polymorphisms that are risk factors for 
coronary artery disease; an isoleucine (Ile) substitution at Val249 (V249I) and a methionine (Met) 
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substitution at Thr280 (T280M) which are located in the sixth and seventh transmembrane domain 
respectively (McDermott et al., 2001;Moatti et al., 2001;Ghilardi et al., 2004). Functional analysis 
of leukocytes possessing CX3CR1 with these mutations demonstrated that this is a result of a 
decreased number of CX3CL1 binding sites and defective chemotactic responses for CX3CL1, with 
the T280M mutation contributing to activation independently of binding (Faure et al., 
2000;McDermott et al., 2003); however it still unclear whether CX3CL1 interacts directly with these 
transmembrane residues. 
 
131B .3.2. Expression 
Raport et al initially demonstrated using Northern blotting that the expression of V28, now known 
as CX3CR1, is highest in the spleen and peripheral blood leukocytes. High levels of expression were 
also observed in several neural tissues including the medulla (and multiple other brain regions) 
and the spinal cord. Examination of the RNA from myeloid and lymphoid cell lines found V28 to be 
highly expressed in THP.1 cells (monocytic cell line) and to a lesser extent U937 (macrophage cell 
line) and HL60 (myeloid precursor) cells of the myeloid lineage, but not expressed at all in 
lymphoid cells. Analysis of mRNA from freshly isolated peripheral blood leukocytes demonstrated 
V28 was expressed mainly by CD16+ natural killer (NK) cells, but the mRNA could also be detected 
at lower levels in CD3+ T cells (which could be increased with IL-2 treatment), CD14+ monocyte and 
granulocytes, but barely in CD19+ B cells. When the levels of functional protein was assessed in 
these cells a slightly different expression pattern was revealed; almost all (92%) of NK cells 
expressed functional V28 protein, which was expected from the mRNA analysis, however, slightly 
unexpectedly, the majority (79%) of CD14+ monocytes expressed functional V28. The CD3+ positive 
T cells found to express functional V28 was predominantly CD8+, although some CD4+CD8+ T cells 
expressed V28. The expression of the V28 functional protein in CD19+ B cells was equal to that of 
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the mRNA expression, in that its expression was barely detected. Conversely, unlike mRNA, 
virtually no V28 protein was detected in granulocytes (Raport et al., 1995). The expression of 
CX3CR1 in T-cells was examined in more detail by Foussat and colleagues several years later. Using 
a series of flow cytometry studies they demonstrated that approximately 8% of CD4+ and 14% of 
CD8+ T-cells express CX3CR1 on their surface, the majority of which were CD45RO
+ memory T-cells; 
however there were some CD8+ cytotoxic and CD4+ helper T-cells that expressed this protein. They 
observed that CD8+ T-cells expressed CX3CR1 under both resting and activated states, whilst CD4
+ 
helper T-cells expressed the protein only when activated. The CX3CR1 protein is functional in these 
cells; CX3CL1 causes migration of CD8
+ memory, CD8+ cytotoxic and CD4+ memory T-cells via the 
induction of either transient or sustained actin polymerization (Foussat et al., 2000). 
 
The rat homologue of CX3CR1, RBS-11 was identified in the late 1990’s based on its sequence 
homology to V28. Radio-ligand binding analysis confirmed highly specific binding of this receptor 
to CX3CL1 with no competitive binding by other chemokines. Analysis of mRNA expression found 
RBS-11 to be relatively abundant in the brain; expression of RBS-11 mRNA in cultured primary 
microglia was ten-fold higher than that of whole brain samples suggesting the signal seen in these 
samples was from microglial RBS-11 mRNA. FACS analysis of cortical microglia demonstrated that 
these cells express the RBS-11 protein on their surface as well as the mRNA; this was confirmed to 
be functional as treatment of these cells with CX3CL1 induced calcium mobilization and chemotaxis 
that could be blocked with an anti-RBS-11 antibody (Harrison et al., 1994). 
 
The development of a transgenic mouse by Jung et al, in which the CX3CR1 gene was mutated to 
contain a green fluorescent protein (GFP) reporter gene, allowed the pattern of CX3CR1 expression 
in the mouse to be analysed in depth. Reverse transcription PCR analysis of these mice 
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demonstrated the presence of chimeric transcripts in CX3CR1-GFP mice and the absence of wild-
type transcripts in CX3CR1
gfp/gfp mice; thus heterozygous mice (CX3CR1
+/gfp) expressed both the GFP 
reporter and functional CX3CR1, whilst homozygous CX3XR1-GFP mice (CX3CR1
gfp/gfp) expressed 
only the GFP reporter and no functional CX3CR1 protein. Using the heterozygous mice Jung et al 
were able to use FACS analysis to determine which murine cell populations express CX3CR1; this 
protein was confirmed to be functional by demonstrating that these cells were able to bind a 
CX3CL1 fusion protein that could easily be visualised (NTN-Fc). In accordance with data collect from 
human peripheral blood cells, murine blood contained a population of monocytes (CD11b+ Gr1low) 
that expressed CX3CR1, as did approximately 5-30% of NK cells in the mouse; these could be found 
in the peripheral blood as well as lymphoid and non-lymphoid organs such as the liver. B-
lymphocytes, on the other hand, were CX3CR1 negative. In contrast to human data, murine T-
lymphocytes, both resting and active, were CX3CR1 negative. Other peripheral blood cells of 
myeloid lineage (eosinophils and CD11b+ Gr1high neutrophils) did not express functional CX3CR1; 
however some neutrophils expressed low levels of GFP, attributed to residual expression from the 
CX3CR1 positive granulocyte-macrophage colony forming precursor from which these cells derive. 
Jung et al also characterised the expression of CX3CR1 on dendritic cells and found this protein to 
be expressed on CD8α- (myeloid) and CD8α+ (lymphoid) dendritic cells as well as CD11clow F4/80+ 
cutaneous Langerhans cells. Similar to data collected on the expression of CX3CR1 in the rat, 
microglial cells in the mouse CNS were positive for CX3CR1 but the protein was not seen in 
astrocytes or oligodendrocytes (Jung et al., 2000). More recently it has been suggested that 
CX3CR1 is also expressed on GFAP
+ satellite glial cells in the DRG based on the observation that in 
an inflammatory model pain (carrageenan) there is an increase in satellite cell activation in the 
DRG in comparison to control, that could be attenuated by treatment with either the glial inhibitor 
FLC or an antibody against CX3CR1. However protein expression of CX3CR1 in the DRG is not shown 
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by this group (immunohistochemically or otherwise) (Souza et al., 2013) and it may be possible to 
attribute the effect of the CX3CR1 antibody to the suppression of CX3CL1-CX3CR1 signalling in 
macrophages in the DRG, which are known to express CX3CR1. Additionally, Yang et al have 
demonstrated that both the CX3CR1 protein and mRNA are present in endothelial cells (human 
coronary artery endothelial cells [HCAECs] and human umbilical vein endothelial cells [HUVECs]); 
the protein appears functional as treatment of these cells with soluble CX3CL1 results in an 
increase in adhesion molecule (ICAM-1) expression shown to be dependent on a CX3CL1-CX3CR1 
interaction; this increase in ICAM-1 was attenuated in cells transfected with a CX3CR1-interferring 
RNA that knocked down the expression of CX3CR1. These cells were, however, in an in vitro setting 
and the expression of CX3CR1 in endothelial cells was not confirmed in vivo (Yang et al., 2007). 
 
Furthermore there is evidence to suggest pathophysiological changes may alter the expression 
profile of CX3CR1. In a rat model of temporomandibular joint inflammation Wang et al 
demonstrate CX3CR1 expression in NeuN
+ (neurons) and GFAP+ (astrocytes) cells in the trigeminal 
nucleus caudalis, a subdivision of the trigeminal nucleus of the medulla, that receives pain 
information conveyed from the ipsilateral face. The activation of these receptors by CX3CL1 
increases GFAP immunoreactivity, suggestive of astrocyte activation, and exacerbates pain in 
these animals (Wang et al., 2012). Double immunofluorescence labelling of coronary arteries from 
patients with atherosclerotic plaques/lesions with antibodies against CX3CR1 and smooth muscle 
actin has demonstrated that CX3CR1 is expressed by smooth muscle cells in the lesions of these 
patients, which were often adjacent to CX3CL1 positive cells. Coupled with the observation that 
cultured smooth muscle cells undergo chemotaxis to CX3CL1 it is suggested that CX3CR1 is 
functional in these cells (Lucas et al., 2003). This data supports previous work by Wong et al, who 
have reported co-localization of CX3CR1 with a smooth muscle cell marker (α-smooth muscle actin) 
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in the coronary arteries taken from patients with diabetes mellitus and atherosclerosis (Wong et 
al., 2002). It has been demonstrated that CX3CR1 is expressed by several kinds of cancer cells 
including renal carcinoma cells (Yao et al., 2013), pancreatic ductal adenocarcinoma cells (Zhao et 
al., 2012) and non-small cell lung cancer cells (Mauri et al., 2012), as well as in astrocytoma, 
oligodendroglioma and glioblastoma cells, to name just a few. In these cells it is thought that the 
receptor may contribute to cell migration and metastasis (Yao et al., 2013;Zhao et al., 2012), 
leading some to hypothesis that high CX3CR1 expression may be a marker of poor prognosis (Xu et 
al., 2012); CX3CR1 positivity is significantly associated with stage and number of metastatic sites 
(Mauri et al., 2012). 
 
132B .3.3. Function and contribution to disease 
201B .3.3.1. Peripheral Physiological Functions of CX3CR1 
The development of CX3CR1 functional knock-out mice has allowed the function of this receptor to 
be extensively evaluated. One of these (described above in terms of its use to evaluate the 
expression of CX3CR1) is an mouse containing GFP reporter in which mice of the homozygous 
phenotype CX3CR1
gfp/gfp do not possess functional CX3CR1. Jung et al compared the CX3CR1
+ cell 
populations from the chimeric CX3CR1
+/gfp to the GFP+ populations of the CX3CR1
gfp/gfp mouse and 
found that none of these were absent or significantly altered in the absence of functional CX3CR1 
(Jung et al., 2000). However a later paper by the same group has since reported that expression of 
functional CX3CR1 is critical for the survival of Gr1
lowCX3CR1
high monocytes; the absence of CX3CR1-
CX3CL1 interaction results in a specific reduction in the number of circulating Gr1
low CX3CR1
high 
monocytes (but no change in Gr1high CX3CR1
low monocyte numbers) and a decrease in absolute 
monocyte numbers in these animals. Adoptive transfer of CX3CR1
+/gfp monocytes into CX3CR1 
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knock-out animals restored monocyte number, whilst the same process using CX3CR1
gfp/gfp 
monocytes could not, suggesting impaired survival of these cells. Enforced expression of the anti-
apoptotic factor Bcl2 was able to rescue monocyte numbers in CX3CR1
gfp/gfp mice; a pronounced 
increase in Gr1low CX3CR1
high monocytes was demonstrated and it was suggested that CX3CR1-
CX3CL1 interaction promotes activation of Bcl2, preventing apoptosis. This was confirmed with a 
series of experiments using cultured monocytes in which addition of CX3CL1 to the media could 
prevent cell death induced by serum starvation; the effect of CX3CL1 was blocked by treatment of 
the monocytes with pertussis toxin which blocks Gα signalling associated with CX3CR1 (Landsman 
et al., 2009). 
 
So CX3CR1 function is critical to the survival of CX3CR1
high cells, but what other functions does it 
have? In circulating monocytes the key function of CX3CR1 appears to be its role in adhesion of 
these cells to the endothelium. The adhesive property of monocytes provided by CX3CR1 was 
established early on. In their 1997 paper, Imai et al demonstrate rapid immobilization of V28 
(CX3CR1) transfected cells on glass plates coated with a FKN-SEAP fusion protein (CX3CL1 fused 
with the secreted form of placental alkaline phosphatase that allows chemokines to retain their 
binding capacity whilst allowing quantitative determination of specific binding), but not to plates 
coated with SEAP lacking FKN (fractalkine/CX3CL1). The adhesion was stable and not affected by 
depletion of divalent cations. The adherence also occurred in cells in which calcium mobilization 
after CX3CL1 treatment did not occur despite transfection with V28, suggesting that adherence via 
CX3CR1 does not require an intracellular calcium response (Imai et al., 1997). To create a more 
physiological setting, Fong et al added the element of shear stress to similar experiments and 
observed that despite this additional factor, immobilised CX3CL1 still rapidly captured leukocytes 
without rolling. They also demonstrated that if a mixed population of PBMCs was subjected to this 
167 
 
assay approximately 62.5% of the captured cells were CD14+ monocytes and another 30% were 
CD8+ T-cells, which is to be expected given our understanding of CX3CR1 expression in human 
leukocytes. Finally, they confirmed the observation made by Imai and colleagues that this 
adherence occurs independently of calcium mobilization (Fong et al., 1998). Later Haskell et al 
used chimeras of the mucin stalk of CX3CL1 and the soluble receptor binding domains of other 
chemokines to demonstrate that the adhesive property of the CX3CR1-CX3CL1 interaction occurs as 
a result of the specific conformation of CX3CL1, as opposed to the presence of a chemokine with a 
mucin stalk tethering the soluble domain to a cell membrane (Haskell et al., 2000). Interestingly, 
the presence of this chemokine domain alone is not sufficient to induce adhesion, repetition of 
FKN-SEAP experiments using fusions of SEAP to individual domains of CX3CL1 determined that, 
whilst monocytes adhere efficiently to immobilised FKN-SEAP, they could not adhere to a version 
of the fusion protein containing only the mucin stalk (mucin-SEAP) or only the chemokine domain 
(CX3C-SEAP) (Goda et al., 2000). Despite evidence to suggest that the interaction between CX3CL1 
and its receptor is alone enough to cause monocyte adherence, the contribution of integrins 
should not be overlooked. In fact it is likely that CX3CL1-CX3CR1 interactions impacts integrins 
mediated monocyte adhesion. Monocytes are able to adhere to the endothelial layer by 
interaction with the integrins VCAM-1 and ICAM-1, but the addition of soluble CX3CL1 (chemokine 
domain) and subsequent activation of CX3CR1 greatly enhance adherence via these integrins 
(Goda et al., 2000).  
 
Using intravital microscopy Auffray et al have shown that Gr1lowCX3CR1
high monocytes 
constitutively exhibit a crawling type of motility which is not seen with CX3CR1
int cells under steady 
state conditions. In CX3CR1-deficient mice the number of crawling monocytes is reduced by 
approximately two thirds; it’s possible to suggest that this crawling behaviour is conveyed, at least 
168 
 
in part, by the intrinsic adhesion function of CX3CR1, along-side a significant contribution by β2-
integrins and LFA-1. The patrolling monocytes provide immune surveillance of the endothelium 
and surrounding tissues; in response to tissue damage they quickly extravasate and invade the 
affected tissue providing an early inflammatory immune response to the damage by releasing 
TNFα and IL-1β, contributing to the recruitment of Gr1highCX3CR1
int cells (Auffray et al., 2007).  
 
The evidence presented above demonstrates that CX3CR1 is critically involved in the adhesion of 
CX3CR1
high monocytes to the endothelium, occurring independently of receptor activation. 
Following adhesion, monocytes transmigrate across the endothelium to infiltrate the underlying 
tissue. This process is also heavily dependent on CX3CR1 and three key regions of the receptor 
have been identified. Firstly, a NPX(2-3)Y sequence (asparagine-proline-X(2-3)-tyrosine where X 
represents leucine, isoleucine & valine) in the seventh transmembrane domain is required for 
ligand binding. Secondly, serine residues within the intracellular C-terminus contribute to receptor 
trafficking. Finally, and most critically for transmigration, a DRY (asparate-arginine-tyrosine) 
sequence in the second intracellular loop is required for the activation of the receptor and G-
protein that leads to calcium mobilization; mutation of these regions results in a receptor that is 
unable to induce transmigration of the monocyte (Schwarz et al., 2010). It is likely that this 
transmigration is induced by polymerization of actin filaments, which has been observed in 
migrating dendritic cells following a CX3CL1 stimulus (Dichmann et al., 2001); actin reorganization 
is a prerequisite for leukocyte migration after a chemokine stimulus and can be inhibited by the 
addition of pertussis toxin which blocks Gi signalling (Tenscher et al., 1997;Aspinall et al., 2010). 
Indeed CX3CR1 mediated migration can be inhibited by blocking Gi signalling, and requires 
cleavage of membrane bound CX3CL1 by ADAM10 or ADAM17, to produce a soluble chemokine 
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domain that is able to activate intracellular signalling pathways downstream of CX3CR1 (Schwarz et 
al., 2010).  
 
As well as providing a mechanism by which monocytes can adhere to and migrate into the 
endothelium to provide immune surveillance of surrounding tissues, CX3CR1 can recruit NK cells in 
a similar fashion (El-Shazly et al., 2013), and also promotes the development of dendritic cells 
under steady state conditions. Expression of CX3CR1 is a marker of myeloid monocyte/dendritic 
cell precursors, and whilst it has been demonstrated that deficiency of CX3CR1 does not result in 
an obvious deficiency in dendritic cell differentiation (Jung et al., 2000), the results of a series of 
adoptive transfer experiments performed by Lyszkiewicz et al indicate that CX3CR1 signalling 
promotes dendritic cell differentiation under physiological conditions, and that progenitors that 
are deficient of CX3CR1 perform poorly at giving rise to dendritic cells in comparison to wild-type 
progenitors (Lyszkiewicz et al., 2011). Additionally there is evidence to support a role for CX3CR1 in 
the maintenance of bone homeostasis through the regulation of osteoblasts and osteoclasts. 
Osteoclasts are a type of specific tissue resident macrophage that express CX3CR1 as a result of 
their differentiation from circulating monocytes; they are involved in the demineralization and 
breakdown of bone. CX3CR1-deficient mice exhibit a decrease in osteoclast number resulting in 
deregulation of bone homeostasis that leads to an increase in bone formation rate and bone 





202B1.3.3.2. Central Physiological Functions of CX3CR1 
Within the brain CX3CR1 is exclusively expressed in microglia, where its interaction with CX3CL1 
contributes to the suppression of an inflammatory state in these cells; CX3CL1 is able to limit the 
release of pro-inflammatory mediators, reducing production of NO and TNFα (Mizuno et al., 
2003;Lyons et al., 2009). This would suggest the CX3CR1-CX3CL1 interaction is protective and there 
is certainly in vivo evidence to support this. It has been demonstrated that in the brain the CX3CR1-
CX3CL1 interaction is neuroprotective; CX3CR1-deficient mice show enhanced neuronal loss in a 
model of both amyotrophic lateral sclerosis when compared to wild-type littermate controls; a 
similar effect has been shown in a model of Parkinson’s disease (Cardona et al., 2006). Additionally 
when this model of Parkinson’s disease was established in wild-type mice an increase in CX3CR1 
protein was seen and associated with microgliosis and parkinsonian-like behaviours that could be 
reverse with treatment with an anti-CX3CR1 antibody (Shan et al., 2011).  Likewise, in a model of 
experimental auto-immune uveitis (inflammation within the eye) CX3CR1
-/- animals show increased 
disease severity and neuronal loss suggesting a neuroprotective role for this receptor. This effect 
was partially attributed to an inability of monocytes to fully transmigrate, causing clustering of 
semi-differentiated cells (Dagkalis et al., 2009); this is not surprising considering all we have learnt 
regarding the role of CX3CR1 in leukocyte extravasation. Furthermore a protective role for this 
interaction  can be deduced from studies of age-related retinal disease; Seidler et al observed that 
in human monocytes CX3CR1 expression decreases with age (Seidler et al., 2010) and a lack of 
CX3CR1 in mice is associated with enhanced accumulation of hypertrophied microglia in the sub-
retinal space (Combadiere et al., 2007;Chinnery et al., 2012;Raoul et al., 2008), that contribute to 
the development of age-related macular degeneration (Combadiere et al., 2007). This suggests 
that the CX3CR1-CX3CL1 interaction may contribute to the maintenance of a resting morphology in 
these cells; however this research is still controversial and enhanced retinal degeneration in 
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CX3CR1 knock-out mice is not seen by all groups (Luhmann et al., 2013b;Luhmann et al., 2013a). A 
possible mechanism for the neuroprotective effect of CX3CR1 is the induction of neurogenesis or 
long term potentiation (LTP) both of which are important in learning and memory; young CX3CR1 
knock-out mice display motor learning deficits and impaired associative and spatial memory 
associated with decreased hippocampal neurogenesis and alterations in the induction of LTP 
(Rogers et al., 2011). CX3CL1 enhances hippocampal NMDA receptor function, via the activation of 
adenosine receptor type A2 (A2AR) and the release of D-serine from glia, which increases NMDA-
field excitatory post-synaptic potentials (Scianni et al., 2013). Conversely a neurotoxic effect of 
CX3CR1-CX3CL1 signalling has also been proposed following the observations that CX3CR1-
deficiency correlates with reduced ischemic damage in a model of stroke; CX3CR1
-/- mice show 
enhanced functional recovery and a reduction in infarct size and pro-inflammatory mediator 
expression in comparison to wild-type controls (Denes et al., 2008). However it is possible that this 
effect is a result of reduced leukocyte infiltration and subsequent release of pro-inflammatory 
mediators as opposed to a direct neurotoxic effect; these mice do indeed appear to have fewer 
apoptotic and infiltrating leukocytes in the lesion (Denes et al., 2008).  Additionally a similarly 
neurotoxic effect for CX3CR1 has been demonstrated in a model of spinal cord injury where 
deficient CX3CR1 signalling promotes recovery by limiting the recruitment and activation of Ly6C
-
CX3CR1
high monocytes, which would otherwise synthesise and release a host of inflammatory 




203B1.3.3.3. Pathophysiological Functions of CX3CR1 
209B1.3.3.3.1. Cardiovascular Disease 
Physiological CX3CR1-CX3CL1 signalling is certainly a necessity; survival of immune surveying 
monocytes depends on it and in its absence show reduced survival to a number of infections 
including herpes simplex virus (Boivin et al., 2012) and vaccinia virus (Bonduelle et al., 2012), and 
demonstrate reduced bacterial clearance (Ishida et al., 2008b). However, it has also become 
evident that aberrant CX3CR1-CX3CL1 signalling can contribute significantly to the pathogenesis of 
a number of chronic diseases, perhaps unsurprising given the role of this protein pair in immune 
and inflammatory processes. Early examination of patients with polymorphisms of the gene 
encoding CX3CR1 identified a reduced risk of atherosclerosis in those with alterations that resulted 
in the expression of a receptor with a reduced binding capacity (Moatti et al., 2001;McDermott et 
al., 2001). Following an inflammatory stimuli endothelial cells up-regulate their expression of 
CX3CL1, promoting enhanced CX3CR1
high monocyte transmigration (Harrison et al., 1999). As these 
cells differentiate into macrophages in the tissue they begin to accumulate lipids and release 
chemokines that lead to further immune cell recruitment. Interestingly, as discussed previously, 
under atherosclerotic conditions smooth muscle cells being to express CX3CR1, leading to their 
recruitment to the developing lesion due to the chemotactic effects of CX3CL1 (Lucas et al., 
2003;Wong et al., 2002). The contribution of CX3CR1/L1 to the pathogenesis of cardiovascular 
disease is significant; an increased number of CX3CR1
high monocytes alone is sufficient to act as a 
predictor of plaque rupture (Ikejima et al., 2010), and, as to be expected from the human 
polymorphisms, mice deficient in CX3CR1 show a decreased prevalence of atherosclerosis (Lesnik 
et al., 2003). In fact these mice show an 83% decrease in arteriolar leukocyte adhesion (Rius et al., 
2013). Indeed CX3CR1 appears to contribute to the pathology of several diseases based on its role 
in leukocyte migration. Patients with coronary artery disease have increased plasma levels of 
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soluble CX3CL1 and an increased number of circulating CX3CR1
+ PBMCs, due to an expansion of the 
CX3CR1
+CD8+ T-cell subset; this is associated with enhanced chemotaxis and adhesion of 
leukocytes and is treated with aggressive statin therapy, which decreases both CX3CR1 and CX3CR1 
expression in these patients (Damas et al., 2005).  
 
210B .3.3.3.2. Wound Healing 
Normal wound healing is heavily dependent in the infiltration of immune cells to the site of injury; 
here they play a key role in the phagocytosis of pathogens and support angiogenesis. In CX3CR1 
deficient animals there is a delay or decrease in myeloid recruitment to the injury site. This is 
accompanied by a reduced magnitude of neovascularisation and an inability to maintain new 
vessels, likely due to a reduction in macrophage TGF-β and VEGF release and reduced deposition 
of α-smooth muscle actin and collagen (Ishida et al., 2008a). The overall effect of this is a pro-
longed temporal profile of wound healing (Clover et al., 2011;Khan et al., 2013); these effects can 
all be reversed and normal wound healing restored by the adoptive transfer of wildtype (CX3CR1-
expressing) macrophages (Ishida et al., 2008a).  
 
211B .3.3.3.3. Kidney Disease 
CX3CL1 expression is elevated in the endothelium of the nephritic/fibrotic kidney and is associated 
with enhanced infiltration of CX3CR1
+ leukocytes (Feng et al., 1999;Oh et al., 2008). These cells 
contribute to the developing pathology occurring in this disease state; blockade of CX3CR1-
mediated leukocyte infiltration by the administration of an anti-CX3CR1 antibody dramatically 
debilitates leukocyte infiltration and is functionally protective; reducing renal pathology and 
increasing renal function (Oh et al., 2008;Feng et al., 1999). This protective effect of CX3CR1 
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signalling deficiency is also demonstrated in the CX3CR1 knock-out which shows both a reduction 
in monocyte recruitment and injury severity in a model of ischemic kidney injury, which can be 
reversed by the adoptive transfer of CX3CR1-expressing monocytes (Li et al., 2008), and a 
reduction in renal inflammation and fibrosis in a model of diabetes-induced kidney damage (Song 
et al., 2013).  
 
212B .3.3.3.3. Arthritis 
Similarly enhanced CX3CR1
high monocyte migration is seen in models of arthritis; high levels of 
CX3CR1
high monocytes are seen in the synovium of rheumatoid arthritis patients (Yano et al., 2007), 
as is the upregulation of CX3CL1 (Ruth et al., 2001). Systemic treatment with an anti-CX3CL1 
antibody, that blocks CX3CR1-CX3CL1 interaction, reduces disease severity and immune cell 
infiltration in animal models of this condition (Nanki et al., 2004). CX3CR1-deficient mice 
demonstrate a similar reduction in disease severity and clinical score in comparison to wild-type 
mice (Tarrant et al., 2012). Furthermore, intrathecal administration of an antibody against CX3CR1 
is able to suppress the activation of spinal microglia that is frequently seen in arthritis models 
(Clark et al., 2012), concomitantly with delaying the onset of both mechanical allodynia and 
thermal hypersensitivity, suggesting a role for CX3CR1/CX3CL1 in pain modulation (Sun et al., 
2007).  
 
213B .3.3.3.4. Chronic Pain 
Current evidence indicates that CX3CR1 contributes significantly to pain processing in a number of 
chronic pain conditions through a microglial mechanism. As discussed in chapter two, microglia 
are specialised macrophages of the CNS. These cells are CX3CR1




+ monocytes of the periphery, they play an immune surveillance role under physiological 
conditions and are believed to maintain this phenotype via interactions between CX3CR1 and 
CX3CL1 (Saijo and Glass, 2011). This changes, however, when microglia detect an immune 
challenge, be it injury or infection; microglia take on an ‘activated’ phenotype, becoming 
hypertrophied and retracting their processes, as well as altering their expression of cell surface 
proteins to allow antigen presentation, undergoing proliferation and synthesizing and secreting a 
number of pro-inflammatory mediators.  
 
Several models of chronic pain show evidence for microglial activation. For example Zhuang et al 
have demonstrated that following spinal nerve ligation, a marked reduction in paw withdrawal 
threshold is seen that is associated with microgliosis and enhanced expression of CX3CR1 in the 
ipsilateral dorsal horn of the spinal cord (Zhuang et al., 2007). Additionally we have previously 
shown in our laboratory that microgliosis occurs subsequent to partial ligation of the sciatic nerve 
and induction of peripheral inflammation that is, again, associated with the development of 
thermal and mechanical hypersensitivity (Staniland et al., 2010). The interaction between CX3CR1 
and CX3CL1 is critical for these responses. Mice deficient in CX3CR1 do not develop thermal 
hyperalgesia and/or mechanical allodynia in these models, and show reduced microgliosis and 
activation of the P38 MAPK (Staniland et al., 2010). Likewise both the behavioural and microglial 
responses to peripheral nerve injury can be attenuated by the intrathecal administration of a 
CX3CR1 neutralizing antibody (Zhuang et al., 2007;Milligan et al., 2004;Milligan et al., 2005a), 
whereas activation of CX3CR1 by administration of soluble CX3CL1 has the opposing effect (Zhuang 
et al., 2007;Milligan et al., 2005a;Milligan et al., 2004). The same effect is true for the 
development of bone cancer pain; the development of pain in animals with experimental bone 
cancer occurs concurrently with microgliosis and an increase in the expression of microglial 
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CX3CR1 and pP38; the onset of this can be significantly delayed by the intrathecal administration of 
a CX3CR1 neutralizing antibody (Hu et al., 2012) despite a lack of efficacy in suppressing bone 





71B .4. Chapter aims 
 
The evidence presented above clearly establishes a role for CX3CR1 in the development and/or 
maintenance of chronic pain and in the pathogenesis of peripheral diseases, in which migrating 
leukocytes make a substantial contribution. Data presented in chapter two confirms that there is 
indeed macrophage infiltration of the peripheral nerve following the induction of chemotherapy-
induced neuropathy; however what has not yet been demonstrated is the contribution to pain 
made by peripheral CX3CR1 and its mediation of leukocyte transmigration into the nerve. Here we 
hypothesise that nerve infiltrating monocyte/macrophages contribute significantly to the 
generation of a pain phenotype in our model of VCR-induced pain and that this process is CX3CR1 
dependent; thus, the aims of this chapter are: 
 To determine the significance of macrophage infiltration in this model; do these cells 
contribute to the pain phenotype? 
 To characterise the population of macrophages that infiltrates the nerve in model of 







72B .1. Animals 
 
Unless otherwise stated, all experiments were performed using adult male C57Bl/6 mice (22-27g; 
10-14 weeks from Harlan UK or bred in house), in accordance with The Animals Scientific 
Procedures Act (ASPA) 1986, United Kingdom Home Office regulations and institutional guidelines. 
Animals were individually housed (to prevent aggressive behaviour) on a 12 hour light / 12 hour 
dark cycle at 21-22oC, with food and water ad libitum. 
 
133B2.1.1. Generation and breeding of CX3CR1-GFP mice 
The original CX3CR1-GFP mice were created by the manipulation of the murine CX3CR1 locus by 
targeted replacement of the gene with cDNA encoding EGFP. In the mutant locus the egfp gene 
replaces the first 390bp of the second cx3cr1 exon encoding the N-terminus. Genomic fragments 
flanking the cx3cr1 gene were used to construct a cx3cr1 targeting vector. Following homologous 
recombination and isolation of cell clones that harboured the expected replacement of cx3cr1 
with egfp, the loxP site-flanked neo gene was excised and the targeting cell clones were injected 
into blastocysts to generate chimeric mice. Germ line transmission of the mutant allele yielded 
heterozygous mutants, CX3CR1
+/gfp. These animals were cross-breed to generate CX3CR1
gfp/gfp mice, 
which were subsequently, in our hands, bred with wildtype C57Bl/6 mice to generate 
experimental heterozygous mice that possessed both CX3CR1-GFP and functional CX3CR1 protein 
(Jung et al., 2000). Litters were weaned at 21 days and group housed (up to 5 per cage) in single 
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sex cages. Both male and female animals were used for behavioural studies from eight weeks old, 
at which time they were singly housed and allowed to acclimatise to their new cage for one week.  
 
134B2.1.2. Generation of CX3CR1-/- mice 
The original CX3CR1 knock-out mice (Taconic, USA) were created by the insertion of a neomycin 
resistance cassette into the wild-type cx3cr1 gene, causing an interruption of the transcription of 
the gene. Two homologous recombinants were identified by southern blot and microinjected into 
C57Bl/6 blastocysts. Chimeric mice were then mated with wildtype C57Bl/6 mice to produce 
heterozygous mice which were then backcrossed three times on the C57Bl/6 background 
(Combadiere et al., 2003). These transgenic mice were backcrossed a further ten times with 
C57Bl/6 mice (Harlan, UK) to obtain heterozygous breeding pairs. These breeding pairs were used 
to obtain litters for experimental use with a heterozygous (+/-): homozygous knockout (-/-): 
homozygous wildtype (+/+) ratio of 2:1:1. Litters were weaned at 21 days and group housed (up to 
5 per cage) in single sex cages. Animals were used for behavioural studies from ten weeks old, at 
which time they were singly housed and allowed to acclimatise to their new cage for one week. 
Both male and female animals were used, with wild-type littermates serving as a control. 
 
135B2.1.3. Macrophage depletion 
Prior to VCR treatment, the circulating monocyte/macrophage population was depleted as 
described previously (Barclay et al., 2007;Van and Sanders, 1994). Liposome-encapsulated 
clodronate (LCL; 10µl/g of a 5mg/ml solution [Rooijen, Netherlands]) or control liposome-
encapsulated PBS was administered to mice on two occasions, three and one days before the 
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commencement of VCR treatment, via injection into the peritoneal cavity with a 30G needle. This 
schedule is shown diagrammatically in figure 3.5 below. 
 
136B2.1.4. Vincristine induced painful peripheral neuropathy 
VCR-neuropathy was induced as described previously described by Sommer et al (Uceyler et al., 
2006). Vincristine sulphate (VCR [Sigma, UK]) was dissolved in sterile saline (0.9% NaCl [VWR, UK]) 
and 0.5mg/kg was injected into the peritoneal cavity (intraperitoneally [i.p.]), using a 30G needle, 
daily for five days per cycle, for up to 2 cycles, shown below in figure 3.5. 
              
 
Figure 3.5.: Experimental schedule for behavioural assessment and VCR (and LCL) dosing. (A) Macrophage 
depletion study: blue boxes represent cycles of VCR treatment, the grey arrows represent LCL dosing and 
red arrows represent study days during which mechanical sensitivity was assessed. (B) CX3CR1
-/- study: blue 
boxes represent cycles of VCR treatment and red arrows represent study days during which mechanical 















73B2.2. Behavioural testing 
137B2.2.1. Assessment of mechanical sensitivity 
Static mechanical withdrawal thresholds were assessed as previous described in chapter two. Data 
are expressed as 50% paw withdrawal threshold, in grams, calculated using the method described 
by Dixon (Dixon, 1980). 
 
138B2.2.2. Statistical analysis of behavioural data 
Statistical analysis behavioural data was carried out on raw data, using SigmaPlot 12.0 software 
(Systat Software Inc, UK). Data are shown as mean ± standard error of the mean (SEM) and 
analysed by two way repeated measures analysis of variance (ANOVA) followed by Tukey post-hoc 
test. A p value of less than 0.05 (P<0.05) was considered significant (*), less than 0.01 (P<0.01) 
moderately significant (**) and less than 0.001 (P<0.001) highly significant (***). 
 
74B2.3. Genotyping 
139B2.3.1. Ear biopsy 
 Transgenic mice were identified by individual ear marks made by taking a 1.5mm punch biopsy 
(Harvard Apparatus, UK) from the ear. The punch biopsies were performed when the mice were 
10-21 days of age and the samples were collected in individual 0.5ml Eppendorf tubes (Starlab, 




140B2.3.2. DNA extraction 
Each ear biopsy was incubated with 30µl of ear lysis buffer (67mM Tris [Sigma, UK], 16mM 
(NH4)2SO4 [Sigma, UK], 6.7mM MgCl2 [Sigma, UK], 0.2% v/v TritonX-100 [Sigma, UK], 0.1% v/v  β-
mercaptoethanol [Sigma, UK], 0.4mg/ml Proteinase K [VWR, UK] in dH2O) for 60 minutes at 55
oC 
followed by 5 minutes at 95oC. Samples were then vortexed for 30 seconds and centrifuged at 
12,000g for 1 minute, with the resulting supernatant containing the DNA used for PCR. 
 
141B2.3.3. CX3CR1-GFP PCR 
A single PCR reaction was performed for each DNA sample. A PCR reaction master mix was made 
consisting of 2mM MgCl2 (Promega, UK), 20% (v/v) 5x reaction buffer (Promega, UK), 300µM dNTP 
(Promega, UK), 50 units/ml Taq DNA polymerase (Promega, UK) and 1µM oligonucleotide primers 
(Sigma, uk). The forward wild-type and GFP and reverse oligonucleotide primers had the 
sequences 5’CAACAGGGTTCCAAGCAAG 3’, 5’ GGACAGGAAGATGGTTCCAA 3’ and 
5’TGGTGCAGATGAACTTCAGG 3’ respectively. Each reaction consisted of 2µl of 1:10 diluted DNA 
and 23µl of PCR master mix. The PCR reaction was performed in a TC412 Flexigene thermal cycle 
(Techne, UK) with an initial denaturation step of 94oC for 5 minutes, followed by 35 cycles with 
denaturation at 94oC for 30 seconds, annealing at 60oC for 30 seconds and polymerisation at 72oC 
for 30 seconds. This was then followed by a final extension step at 72oC for 5 minutes. The 





142B .3.4. CX3CR1 
-/- PCR 
A separate wildtype and knockout PCR reaction was performed for each DNA sample. A PCR 
reaction master mix was made for each allele (wild-type and knock-out) consisting of 1.5mM 
MgCl2 (Promega, UK), 20% (v/v) 5x reaction buffer (Promega, UK), 0.2mM dNTP (Promega, UK), 50 
units/ml Taq DNA polymerase (Promega, UK),0.1µM antisense oligonucleotide primer and 0.1µM 
wild-type or knock-out oligonucleotide primer (Sigma, UK). The antisense, wild-type and knock-out 
oligonucleotide primers had the sequences 5’ TGGGGTGACGCCACTAAGA 3’, 5’ 
GGCCTGTTATTTGGGCGACAT 3’ and 5’ GACCGCTTCCTCGTGCTTTA 3’ respectively. Each reaction 
consisted of 1.5µl DNA and 18.5µl of PCR master mix. The PCR reaction was performed in a TC412 
Flexigene thermal cycle (Techne, UK) with an initial denaturation step of 96oC for 3 minutes, 
followed by 25 cycles with a denaturation at 94oC for 30 seconds, annealing at 60oC for 30 seconds 
and polymerisation at 72oC for 30 seconds. This was then followed by a final extension step at 
72oC for 10 minutes. The expected sizes of the end products were 440bp for the wild-type cx3cr1 
gene and 600bp for the knock-out cx3cr1 gene.  
 
143B2.3.5. Gel electrophoresis and band visualisation 
To visualise the PCR products a gel electrophoresis was performed. Post- PCR samples were loaded 
onto, and run down, a 2% agarose gel containing 100µg/ml ethidium bromide (Sigma, UK), at 100V 
for 25 minutes using a Power Pac 200 (BioRad, UK). A 1kb DNA ladder (Promega, UK) was also run 
down each gel to allow for the sizes of the products to be easily determined. The gels were viewed 
using a GeneGenius system (Syngene, UK) and images collected using the GeneSnap programme 
(Syngene, UK). All samples from experimental and breeding animals underwent a repeat analysis 





144B2.4.1. Tissue preparation 
Tissue for immunohistochemical staining was prepared as described in chapter two. 
145B2.4.2. Immunohistochemical staining 
Slides were washed six times for 5 minutes in 0.1M PBS and incubated over night at room 
temperature with a primary antibody for a specific cell marker (table 3.3) in PBS containing 0.2% 
TritonX-100 (Sigma, UK) and 0.1% sodium azide (Sigma, UK). Slides were then washed three times 
for 5 minutes in PBS and incubated at room temperature, in the dark, with an appropriate 
secondary antibody (table 3.4) for 2.5-3 hours. Following three further PBS washes slides were 
cover-slipped with Vectashield mounting media with DAPI (Vector Laboratories, USA) and 
visualised under a Zeiss Axioplan 2 fluorescent microscope (Zeiss, UK). 
 
 
Table 3.3: Immunohistochemistry primary antibodies 
 
Primary Antibody Cellular Marker Concentration Supplier 
Rabbit anti-ionized 
calcium binding adaptor 
molecule 1 (Iba1) 
Microglia  
1:1000 
WAKO Pure Chemical 
Industries, Germany 
Rabbit anti-glial fibrillary 
acidic protein (GFAP) 
Astrocytes 1:1000 DAKO Cytomation, 
Denmark 
Rat anti-mouse F4/80 Monocytes/Macrophages 1:200 AbD Serotec, UK 
Mouse anti-NeuN Neurons 1:100 Chemicon, UK 
Mouse anti-βIII-tubulin Neuronal β-tubulin 1:1000 Promega, UK 





Table 3.4: Immunohistochemistry secondary antibodies 
 
Secondary Antibody Concentration Supplier 
Goat anti-rabbit IgG-conjugated Alexa Fluor 488TM 1:1000 Molecular Probes, USA 
Goat anti-rabbit IgG-conjugated Alexa Fluor 546TM 1:1000 Molecular Probes, USA 
Donkey anti-mouse IgG-conjugated Alexa Fluor 488TM 1:1000 Molecular Probes, USA 
Donkey anti-mouse IgG-conjugated Alexa Fluor 546TM 1:1000 Molecular Probes, USA 
Donkey anti-goat IgG-conjugated Alexa Fluor 546TM 1:1000 Molecular Probes, USA 
Goat anti-rat IgG-conjugated Alexa Fluor 488TM 1:1000 Molecular Probes, USA 
Goat anti-rat IgG-conjugated Alexa Fluor 546TM 1:1000 Molecular Probes, USA 
 
 
146B2.4.3. Quantification of immunohistochemistry 
204B .4.3.1. Fluorescence intensity 
Quantitative assessment of immunoreactivity was carried out by determining the 
immunofluorescence intensity within a fixed area of the superficial dorsal horn. Three L4-L5 spinal 
cord sections were chosen at random from each animal, with experimental group blinded. Four 
boxes measuring 104µm2 were spaced equally across the superficial laminae of the dorsal horn. 
Mean grey intensity each of the boxed areas was determined using Axiovision LE 4.2 software 
(Zeiss, UK). The background intensity for each tissue section was determined using an area of 
104µm2, and subtracted from the intensity values determined. An average value for 
immunofluorescence intensity across the superficial dorsal horn was then calculated. 
 
205B .4.3.2. Cell numbers 
The number of positive cells for each immunohistochemical marker was determined. Three tissue 
sections per animal were selected at random with experimental group blinded. Four boxes 
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measuring 104µm2 were spaced equally across the superficial laminae of the dorsal horn, for spinal 
cord sections, or were spaced equally across the tissue for nerve sections. The number of cells 
positive for the given marker was counted. 
 
206B .4.3.3. Statistical analysis of immunohistochemical data 
Statistical analysis for immunohistochemistry was carried out on raw data, using SigmaPlot 12.0 
software (Systat Software Inc, UK). For both immunofluorescence intensity and cell numbers and 
average value was obtained for each animal. A mean value for each experimental group was then 
calculated, and the groups compared to one another using a one-way analysis of variance 
(ANOVA) followed by Tukey post-hoc test. Group difference with a P value of less than 0.05 
(P<0.05) was considered significant. 
 
76B2.5. Monocyte/Macrophage Harvest 
 
Monocyte/macrophage infiltration of the peritoneal cavity was encouraged by the instigation of 
sterile inflammation, by injection of 1ml of 2% polyacrylamide bio-gel beads (Bio-Rad, UK) into the 
peritoneal cavity four days prior to harvest. To harvest the cells, animals were first euthanised by 
exposure to increasing concentrations of CO2 until breathing cessed. A small incision was made 
along the midline of the abdomen and the skin manually retracted.  A syringe connected to a 20G 
3/8” needle was then used to inject 5ml of cold harvest media (sterile PBS [Sigma, UK], 3mM EDTA 
[Sigma, UK]) into the peritoneal cavity of the mouse, and the abdomen lightly massaged to allow 
movement of the fluid. Using the same syringe and needle the fluid was aspirated, moving the 
needle away from the viscera to cause tenting of the peritoneal wall to prevent visceral damage. 
The peritoneal exudate was filtered through 75µm nylon mesh filters (BD Falcon, UK) and a second 
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peritoneal wash performed. The exudates were centrifuged at 400g for 10 minutes and 
resuspended in antibody solution for FACs analysis (see below). 
 
77B2.6. Flow Cytometry Analysis 
 
All antibodies were obtained from eBioscience (Hatfield, UK). Monocyte/macrophages from 
CX3CR1
+/+ mice were stained with FITC-conjugated Gr-1 (clone RB6-8C5) and APC-conjugated F4/80 
(clone BM8) antibodies, and monocyte/macrophages from CX3CR1gfp/+ mice with APC-conjugated 
Gr-1. Cells were incubated on ice for 30 minutes then washed twice with PBS containing 1.5% BSA 
(Sigma, UK) and re-suspended before analysis on a BD FACS calibur flow cytometer (Becton 





34B . Results 
 
As discussed in chapter one, repeated systemic administration of VCR causes 
monocyte/macrophage infiltration of the peripheral (sciatic) nerve with a temporal profile similar 
to that of the onset of mechanical hypersensitivity. Here we have performed a series of 
experiments to elucidate the role these cells play in the development of VCR induced painful 
peripheral neuropathy, and whether or not they constitute a viable target for analgesic 
development. 
 
78B3.1. Pre-treatment with liposome encapsulated clodronate prevents the development of 
mechanical hypersensitivity and monocyte/macrophage infiltration of the sciatic nerve that 
occurs following repeated systemic administration of VCR 
 
To determine the contribution made by monocyte/macrophages to the development of VCR-
induced mechanical allodynia, these cells were depleted by administration of two doses of 
liposome encapsulated clodronate (LCL) prior to VCR dosing; this alone had no effect on the 
mechanical thresholds of mice, which remained at baseline levels subsequent to treatment (figure 
3.6A; LCL-SAL mice). As described previously, in chapter two, the administration of VCR (0.5mg/kg 
i.p.) for five consecutive days (days 0-4; first cycle, cumulative dose 2.5mg/kg), followed by a two 
day pause and second subsequent cycle of treatment (days 7-11, cumulative dose 5.0mg/kg) was 
associated with significant and severe hind-paw mechanical hypersensitivity (allodynia) in PBS-VCR 
treated mice. In LCL pre-treated mice, however, the onset of VCR induced mechanical allodynia 
was significantly delayed, with the thresholds remaining at baseline levels (LCL-VCR), during the 
first cycle of VCR treatment (figure 3.6A). This is most apparent when an area under curve (AUC) 
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analysis is completed (figure 3.6B); a significant difference is seen in the allodynia index between 
PBS-VCR and PBS-SAL treated animals, however the difference between LCL-VCR and LCL-SAL 
treated animals is much smaller in comparison (figure 3.6B; decrease in allodynia index calculated 
from area under curve; PBS-VCR 57% ± 3.3, LCL-VCR 3% ± 3.2%). Allodynia index of VCR treated 
mice is significantly reduced by pre-treatment with LCL. Interestingly, as the representative images 
in figure 3.7A demonstrate, immunohistochemical analysis of sciatic nerves taken from LCL-VCR 
treated animals at the end of this first VCR cycle, demonstrate that monocyte/macrophage levels 
at this time are comparable to that of control tissue (day 4; figure 3.7A/B); no increase in the 
number of F4/80+ cells is observed. This suggests that the VCR-induced infiltration of these cells 
that usually occurs has not happen, consistent with the circulating population of 
monocyte/macrophages having been depleted with the LCL; thus not being available to infiltrate. 
 
Following a second cycle of VCR, as expected, PBS-VCR treated mice maintained severe 
mechanical hypersensitivity which recovered several days following the cessation of treatment. At 
this time the mechanical thresholds of LCL-VCR treated mice began to decline, reaching levels 
comparable to PBS-VCR mice following the commencement of the second cycle of VCR treatment 
(figure 3.6; LCL-VCR) and became indistinguishable from PBS-VCR mice throughout the second 
cycle and recovery period, as demonstrated by AUC analysis (figure 3.6B). Sciatic nerve tissue 
samples were taken for immunohistochemical analysis at the end of the second VCR cycle, and it 
was observed that the number of F4/80+ cells present in the tissue of LCL pre-treated animals (LCL-
VCR) had increased to a level comparable to PBS-VCR treated mice (figure 3.7C/D), indicating that 






Figure 3.6. Pre-treatment with LCL delays the onset of mechanical allodynia induced by repeated systemic 
administration of VCR.  Development of mechanical allodynia in mice pre-treated with either liposome 
encapsulated clodronate (10µl/g of a 5mg/ml solution [Rooijen, Netherlands]) or PBS control, with or 
without i.p. VCR (0.5mg/kg/day; 0-4 and 7-11; black horizontal bars) (A) Temporal profile of mechanical 
allodynia development shown as 50% PWT, data shown as mean ± SEM. N=8 per group, ***P<0.001 
compared to baseline threshold, ### P<0.001 compared to saline threshold, ††† P<0.001 LCL-VCR threshold 
compared to PBS-VCR threshold, two-way RM ANOVA with post-hoc Holm-Sidak test. (B) Area under the 
curve (AUC) analysis with data expressed as allodynia index where a lower value represent more severe 
allodynia. All time = day 0-day 24, first cycle= day 0- 4, second cycle = 7-11, recovery = 11-24. Data shown 
are mean ± SEM. N=8 per group, ### P<0.001 compared to saline index, ††† P<0.001 LCL-VCR compared to 
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Figure 3.7. Pre-treatment with LCL delays the onset of macrophage infiltration of the sciatic nerve induced 
by repeated systemic administration of VCR. (A/C) Representative images showing macrophages in the 
sciatic nerve following vehicle (SAL) or one (A; day 4) or two (B; day 11) cycles of VCR (0.5mg/kg/day i.p.) 
with (LCL) or without (PBS) liposome clondronate pre-treatment, where macrophages are visualised by their 
expression of F4/80. Scale bars equal 100µm. (B/D) Quantification of the number of macrophages in the 
sciatic nerve, shown as number of F4/80+ cells per 104µm2. Data shown are mean ± SEM and N=4 per group. 
*** P<0.001 compared to saline, ###P<0.001 compared to PBS-VCR, one-way ANOVA with post-hoc Tukey 
test. 
 
80B3.2. No difference in the severity of VCR induced mechanical allodynia is seen between male and 
female mice 
 
The study described above suggests that the monocyte/macrophages invading the nerve following 
systemic VCR administration play a critical role in the generation of mechanical allodynia. In the 
mouse, as in the human, monocyte/macrophages show substantial heterogeneity and whilst LCL is 































































































depletion does not allow one to use it to target specific subpopulations of 
monocyte/macrophages. One of the key differences between the two most well characterised 
populations of monocyte/macrophages in the mouse is the level of expression of the chemokine 
receptor CX3CR1; by using mice in which this protein has been genetically modified we can study 
the role of CX3CR1 expressing monocyte/macrophages and the receptor itself in VCR-induced 
neuropathy to see if a mechanism for the involvement of these cells can be teased out. Here we 
made use of two CX3CR1 modified mouse strains. The first of these is a GFP knock-in mouse in 
which the addition of an egfp reporter gene in the second exon of the CX3CR1 gene causes the 
expression of CX3CR1 tagged with GFP; this allows CX3CR1
+ cells to be easily visualised. Secondly 
we used a CX3CR1 knock-out mouse that lacked functional CX3CR1 protein, this is discussed further 
below. 
 
The initial characterization we performed of the mouse model of VCR-induced painful peripheral 
neuropathy was carried out on male mice; however to allow for larger group sizes in colony bred 
mice it would be ideal to use both male and female mice. Recent evidence has suggested a 
difference in the development of pain phenotypes between sexes in mouse models of chronic pain 
states (recently reviewed in (Bartley and Fillingim, 2013)). Falk et al have demonstrated earlier 
onset of pain related behaviours in female mice compared to males in a model of bone cancer 
pain (Falk et al., 2013); consistently Sorge et al have presented evidence for a sex difference in the 
occurrence of LPS-induced mechanical allodynia, with only male mice developing a pain 
phenotype. However this does seem to be a spinal cord specific response as this difference was 
only seen with intrathecally and not intracrainally or subcutaneously administered LPS (Sorge et 
al., 2011). This sex difference has not been noted in our laboratory previously (unpublished data), 
however to determine whether or not sex would be an influencing factor in the development of 
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VCR-induced mechanical allodynia, we assessed the mechanical thresholds of both male and 
female wild-type mice. As shown by figure 3.8A repeated systemic administration of VCR results in 
the rapid development of severe persistent mechanical allodynia in both male and female wild-
type C57Bl/6 mice. The mechanical thresholds of all mice are significantly reduced (P<0.001) from 
24 hours (day 1) after the first dose of VCR and remain so for all further time points assesses. 
Furthermore, area under curve (AUC) analysis (figure 3.8B) demonstrates that there is no 
significant difference (or even trend) between the mechanical thresholds of male and female mice; 
an equal reduction in threshold due to VCR treatment is seen overall and in both VCR cycles 
individually. This data is indicative of a lack of sex variation in the development of VCR-induced 








Figure 3.8. No difference in VCR-induced mechanical allodynia is seen between male and female mice. 
Development of mechanical allodynia following i.p. VCR (0.5mg/kg/day) administration for two cycles of five 
days each (0-4 and 7-11; black horizontal bars). Vehicle group received an equal volume of saline. (A) Time 
course of the development of mechanical allodynia shown as 50% paw withdrawal threshold (PWT), data 
shown as mean ± SEM. N=8 per group, two-way repeated measures ANOVA with post-hoc Holm-Sidak test. 
(B) Area under the curve (AUC) analysis showing data expressed as allodynia index where a lower value 
represent more severe allodynia. All time = BL-day 24, first cycle = BL-day 4, second cycle = day 7-11 Data 
shown are mean ± SEM. N=8 per group, ### P<0.001 compared to saline threshold with one way ANOVA 
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81B3.3. Use of a transgenic mouse expressing GFP tagged CX3CR1 demonstrates that early 
infiltrating monocyte/macrophages are CX3CR1 positive 
 
We next set out to phenotype the monocyte/macrophages infiltrating the peripheral nerve 
following VCR administration. To do this we used a CX3CR1-GFP expressing mouse in which all 
CX3CR1
+ cells are also GFP+.  The mice used in these experiments were heterozygous for GFP 
tagged CX3CR1 (CX3CR1
+/gfp); at this stage we did not wish to determine the role of CX3CR1 in the 
infiltration of monocyte/macrophages into the nerve and its effect on mechanical allodynia, and it 
has been demonstrated by Jung et al that due to the nature of the genetic modification 
homozygous mice (CX3CR1
gfp/gfp) are a functional knock-out of CX3CR1; the presence of the egfp 
gene in both alleles of the CX3CR1 gene prevents the transcription and translation of any 
functional protein.  
 
Prior to all experiments, mice were genotyped to confirm expression of wild-type CX3CR1 protein 
and CX3CR1-GFP protein. As figure 3.9, demonstrates wildtype mice (CX3CR1
+/+) express a single 
transcript of approximately 440bp and homozygous GFP (CX3CR1
gfp/gfp) mice express a single, larger 
transcript of approximately 570bp, whilst heterozygous CX3CR1
+/gfp mice express one wild-type 
(440bp) and one GFP transcript (570bp). Genotyping was performed twice (to remove false 
positives) and only heterozygous mice were selected for experimentation. 
 




                                        
 
Figure 3.9. Genotyping electrophoresis of PCR samples from CX3CR1-GFP mice. Representative image of 
agarose gel following electrophoresis of PCR products with homozygous knock-in mice (lane 1) yielding a 
570bp product, wild-type mice (lane 3) yielding a 440bp product, and heterozygous mice yielding both (lane 
2). 
 
We then conducted a series of immunohistochemical studies in naïve CX3CR1
+/gfp mice to confirm 
that the expression of CX3CR1-GFP was restricted to myeloid cells as previous literature predicts 
(Jung et al., 2000). Figure 3.10 shows representative high magnification images demonstrating 
expression of CX3CR1-GFP in the spinal cord. Here, CX3CR1-GFP co-localised exclusively with the 
microglial marker Iba1 (figure 3.10; top three panels); no co-localization with the astrocytic marker 
GFAP (figure 3.10; middle panels) or neuronal marker NeuN (figure 3.10; bottom panels) was 
observed. In a similar fashion, in the DRG CX3CR1-GFP was only observed to co-localise with the 
macrophage marker F4/80 (figure 3.11; third row); no co-localization with the neuronal marker βIII-
tubulin (figure 3.11; top row), satellite cell marker GFAP (figure 3.11; second row) or endothelial 
cell marker CD31 (figure 3.11; bottom row) was observed. Finally in the trunk of the sciatic nerve 
CX3CR1-GFP was observed only to co-localise with the macrophage marker F4/80 (figure 3.12; 
third row); no co-localization was observed with the neuronal marker βIII-tubulin (figure 3.11; top 
row), satellite cell marker GFAP (figure 3.11; second row) or endothelial cell marker CD31 (figure 










Figure 3.10. In the spinal cord CX3CR1-GFP is only expressed in Iba1
+ cells. Representative low and high 
magnification images demonstrating expression of CX3CR1-GFP in the dorsal horn of the (L5) spinal cord. 
CX3CR1-GFP (green) co-localises with Iba1 (red), but not with GFAP (red) or NeuN (red). Scale bars equal to 








Figure 3.11. In the DRG CX3CR1-GFP is expressed in F4/80
+ cells. Representative low and high magnification 
images demonstrating expression of CX3CR1-GFP in the L5 DRG. CX3CR1-GFP (green) co-localises with F4/80 
(red), but not with βIII-tubulin (red), GFAP (red) or CD31 (red). Scale bars equal to 50µm and 20µm in low 
and high magnification images respectively. 
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Figure 3.12. In the nerve trunk CX3CR1-GFP is expressed in F4/80
+ cells. Representative low and high 
magnification images demonstrating expression of CX3CR1-GFP in the sciatic nerve. CX3CR1-GFP (green) co-
localises with F4/80 (red), but not with βIII-tubulin (red), GFAP (red) or CD31 (red). Scale bars equal to 50µm 













Whilst previous assessment of the migration patterns of CX3CR1
+/gfp monocyte/macrophages has 
suggested that the function of CX3CR1 is not affected in heterozygous mice, we have provided 
evidence that suggests the development of pain in our model is monocyte/macrophage sensitive. 
Thus we first assessed the mechanical thresholds in CX3CR1
+/gfp mice to ensure the expression of 
GFP was not influencing the function of these cells in terms of their involvement in the 
development of VCR-induced mechanical allodynia.  As our previous data has suggested, the 
repeated systemic administration of VCR was associated with the development of severe and 
sustained hind-paw mechanical allodynia  in CX3CR1-GFP mice (figure 3.13A); mechanical 
thresholds and allodynia indices (AUC analysis; figure 3.13B) were comparable to those of all 
previously tested wild-type mice (see figure 2.4 in chapter two and figure 3.8. above), as was the 
maximum reduction in thresholds (CX3CR1
gfp/+ 97.63% ± 0.55, CX3CR1
+/+ 98.00% ± 0.21 reduction in 
PWT). 
 
As mentioned above, mouse monocytes can be categorised into two distinct populations based on 
their expression of CX3CR1. The first of these is a population of Ly6C
-CX3CR1
high resident cells which 
are long lived and have the primary function of surveying their local environment for signs of 
danger; the second is a population of Ly6C+CX3CR1
int “classical” inflammatory monocytes that are 
comparably short lived and are rapidly recruited to sites of inflammation (Auffray et al., 
2007;Geissmann et al., 2003;Yona et al., 2013). Due to this patrolling/surveying nature of the Ly6C-
CX3CR1
high monocytes it is likely that these cells comprise the myeloid infiltrate seen in the sciatic 






Figure 3.13. Heterozygous CX3CR1-GFP expressing mice develop severe sustained mechanical allodynia 
following VCR treatment. Development of mechanical allodynia following i.p. VCR (0.5mg/kg/day) 
administration for two cycles (days 0-4 and 7-11; black horizontal bars). Vehicle group received an equal 
volume of saline. (A) Time course of the development of mechanical allodynia shown as 50% paw 
withdrawal threshold (PWT), data shown as mean ± SEM. N=8 per group, ***P<0.001 compared to baseline 
threshold, ### P<0.001 compared to saline threshold, two-way repeated measures ANOVA with post-hoc 
Holm-Sidak test. (B) Area under the curve (AUC) analysis showing data expressed as allodynia index where a 
lower value represent more severe allodynia. All time = BL-day 11, first cycle = BL-day 4, second cycle = day 

































































































































Using mice expressing CX3CR1-GFP we tested this hypothesis that the infiltrating cells were 
CX3CR1
+. The analysis of CX3CR1-expressing cells in the sciatic nerves of CX3CR1
+/gfp revealed that 
both GFP+ (CX3CR1
+) and F4/80+ (monocyte/macrophage) cells were present in enhanced numbers 
following VCR treatment compared to their vehicle treated counterparts (figure 3.14A/B). 
Specifically the number of monocyte/macrophages (F4/80+ cells) was elevated 24 hours after the 
first administration of VCR (figure 3.14B; day 1) and remained so for the duration of VCR 
treatment (day 4 end of first cycle and day 10 end of second cycle); consistent with the analysis of 
F4/80+ cells in wild-type mice described in chapter two (figure 2.7). More interestingly the number 
of GFP+ (CX3CR1
+) cells concomitantly peaked 24 hours after the first administration of VCR (figure 
3.14B; day 1), was slightly reduced at the end of the first cycle of treatment (figure 3.14B; day 4) 
and was significantly lower (than day 1) by the end of the second cycle of chemotherapy (figure 
3.14B; day 11). These data indicate that CX3CR1
+ monocyte/macrophages infiltrate and populate 
the peripheral nerve immediately after the commencement of and during the first cycle of VCR 





                             
 
Figure 3.14. VCR administration induces infiltration of CX3CR1
+ monocyte/macrophage into the nerve. (A) 
Representative images showing F4/80+ (red) and GFP+ / CX3CR1
+ (green) cell infiltration into the sciatic nerve 
in vehicle (SAL) and VCR (day 1/4/11) treated animals (VCR i.p. 0.5mg/kg; days 0-4 and 7-11). Scale bars 
equal 100µm. (B) Quantification of the number of F4/80+ or GFP+ cells per 104µm2. Data shown are mean ± 
SEM and N=4per group. *** P<0.001 compared to saline, ###P<0.001 compared to day 1, one-way ANOVA 
with post-hoc Tukey test. 
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To further analyse, by FACS, the effect of VCR on the trafficking and/or phenotype of 
monocyte/macrophages, a peritoneal lavage was performed to collect these cells from the 
peritoneal cavity of CX3CR1
gfp/+ mice following a single cycle of VCR. Intraperitoneal administration 
of VCR caused a notable increase in the total number of monocyte/macrophages infiltrating the 




                                                      
 
Figure 3.15. VCR administration increases the number of monocyte/macrophages infiltrating the 
peritoneal cavity. Counts of F4/80+ cells in the fluid recovered from peritoneal lavage of saline (SAL) and 
VCR treated (VCR) mice (VCR i.p. 0.5mg/kg; days 0-4). Data shown are mean ± SEM and N=3 per group. 




























 Interestingly FACS analysis of these cells demonstrated that not only was there this increase in cell 
infiltration, the cells that infiltrated underwent a phenotypic shift as a result of VCR treatment. 
Figure 3.16A/B shows typical FACS plots obtained from these experiments, as the quantification 
shows (figure 3.16C/D) in both CX3CR1
+/+ and CX3CR1
+/gfp saline treated animals the majority (97% 
and 87% respectively) of cells are Gr-1- (thus Ly6C- monocyte/macrophages). Analysis of these cells 
from the CX3CR1
+/gfp mouse shows they do indeed express GFP (CX3CR1), suggesting that these 
cells are likely to be the Ly6C-CX3CR1
high cells considered ‘resident’ monocyte/macrophages. In 
CX3CR1
+/+ mice there is a shift towards a larger proportion of the cells being Gr-1+ (Ly6C+) following 
VCR treatment; suggesting a shift towards a Ly6C+CX3CR1
int monocyte/macrophages population 











                       
Figure 3.16. FACS analysis of peritoneal monocyte/macrophages shows a phenotypic shift following VCR 
treatment. (A/B) Representative dot-plot / FACS plots analysis of Gr-1 and F4/80 or GFP expression in 
vehicle (SAL) and VCR treated mice (VCR i.p. 0.5mg/kg; days 0-4). (C) Cumulative data of relative percentage 
of Gr-1+ and Gr-1- cells in the F4/80+ population in CX3CR1
+/+ mice. Data shown are mean ± SEM and N=3 per 
group. **P<0.01 compared to saline treated with post-hoc Student t-test. (D) Cumulative data of relative 
percentage of Gr-1+ and Gr-1- cells in the GFP+ population in CX3CR1
+/gfp mice. Data shown are mean± SEM 










































































82B3.4. The CX3CR1 receptor is critical for the development of VCR-induced mechanical 
hypersensitivity 
 
These last studies have demonstrated that the majority of infiltrating monocyte/macrophages 
express CX3CR1 to some degree, especially in the early stages of this chemotherapy-pain model, 
where infiltrating cells are likely to be patrolling/resident Ly6C-CX3CR1
high monocyte/macrophages. 
It is well established that CX3CR1 expression is vital for the survival of this population of cells and 
that its function as an adhesion molecule means that it plays a critical role in migration of cells 
from the blood into tissues. As data obtained from our liposome clodronate study has suggested 
that the infiltration of monocyte/macrophages into the nerve is a crucial step in the development 
of chemotherapy-induced mechanical allodynia, this receptor (CX3CR1) constitutes an attractive 
candidate as a target for therapeutic intervention in this condition. As such, we went on to 
evaluate the importance of this receptor in the development of VCR-induced mechanical allodynia. 
The role of CX3CR1 was elucidated using a second transgenic mouse tool; a CX3CR1 knock-out 
(CX3CR1
-/-). These animals completely lack functional CX3CR1 due to the insertion of a neomycin 
cassette that results in disrupted transcription of the protein, as shown by the presence of a 
smaller PCR product (figure 3.17). Additionally we assessed monocyte/macrophage numbers in 
CX3CR1 knock-out and wild-type mice by stimulating peritoneal cavity infiltration of 
monocyte/macrophages by the intraperitoneal administration of sterile bio-gel beads; the 
peritoneal cavity of wild-type (CX3CR1
+/+) contained approximately 14 x 106 cells/ml. The number 
of cells obtained from the peritoneal cavity of CX3CR1 knock-out was significantly lower (9.5 x 10
6 





                   
                                      
 
Figure 3.17. Genotyping electrophoresis of PCR samples from CX3CR1 knock-out and wild-type mice. 
Representative pictograph of agarose gel following electrophoresis of PCR products with homozygous 
knock-out mice (lane 1) yielding a 600bp product, wild-type mice (lane 3) yielding a 440bp product, and 




                                                          
 
Figure 3.18. Fewer F4/80+ cells are present in the CX3CR1
-/- mice. Counts of F4/80+ monocyte/macrophages 
in the fluid obtained from the peritoneal cavity of CX3CR1
+/+ (WT) and CX3CR1
-/- (KO) mice under sterile 
inflammatory conditions. Data shown are mean ± SEM and N=3 per group. #P<0.05 compared to WT with 









We first evaluated the development of VCR-induced mechanical allodynia in CX3CR1
-/- mice 
compared to wildtype littermate controls (CX3CR1
+/+). As figure 3.19A demonstrates, in contrast to 
CX3CR1
+/+ mice, the thresholds of CX3CR1
-/- mice remained unchanged (at baseline levels) for the 
duration of the first VCR cycle (until day 4). Area under curve analysis (figure 3.19B) for the first 
cycle shows a dramatic difference in allodynia index between VCR treated CX3CR1
+/+ and CX3CR1
-/- 
mice. Interestingly, following the first cycle of treatment and during the second the paw 
withdrawal thresholds of CX3CR1
-/- mice fall to a level comparable to that of CX3CR1
+/+ mice (day 7: 
CX3CR1
+/+ 98.00% ± 0.37, CX3CR1
-/- 96.89% ± 0.49 reduction in PWT). Indeed, the area under curve 
analysis for the second cycle of treatment (figure 3.19B) confirms that there is no significant 
difference in allodynia index between CX3CR1
+/+ and CX3CR1
-/- mice at this time. Thus this data 
suggests that CX3CR1-deficiency delays the onset of mechanical hypersensitivity following 
repeated systemic VCR administration. 
 
In a similar fashion to the study performed in LCL pre-treated animals, we then performed 
immunohistochemical analysis of the sciatic nerve of VCR treated CX3CR1
+/+ and CX3CR1
-/- mice. 
This revealed that the number of F4/80+ cells (monocyte/macrophages) in the nerve of CX3CR1
-/- 
mice had remained unchanged following the first cycle of VCR (day 4; figure 3.20A/B), in contrast 
to the increased number of monocyte/macrophage seen in the nerve of wildtype (CX3CR1
+/+) mice. 
However, by the end of the second VCR cycle (day 11) the number of F4/80+ cells 
(monocyte/macrophages) in the sciatic nerves of CX3CR1
-/- mice had increased to a level 
significantly higher than that of saline treated mice, although still lower than in VCR treated 
CX3CR1






Figure 3.19. CX3CR1-deficiency delays the onset of mechanical allodynia induced by repeated systemic 
administration of VCR.  Development of mechanical allodynia in CX3CR1
-/- (KO) mice or CX3CR1
+/+ (WT) 
control receiving i.p. VCR (0.5mg/kg/day; days 0-4 and 7-11; black horizontal bars) or equal volume of 
vehicle (SAL). (A) Temporal profile of mechanical allodynia development shown as 50% PWT, data shown as 
mean ± SEM. N=8 per group, ***P<0.001 compared to baseline threshold, ### P<0.001 compared to saline 
threshold, ††† P<0.001 compared to wild-type threshold, two-way RM ANOVA with post-hoc Holm-Sidak 
test. (B) Area under the curve (AUC) analysis data expressed as allodynia index where a lower value 
represent more severe allodynia. All time = BL-day 24, first cycle= BL-day 4, second cycle = 7-11, recovery = 
11-24. Data shown are mean ± SEM. N=8 per group, ### P<0.001 compared to saline index, ††† P<0.001 LCL-
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Figure 3.20. CX3CR1-deficiency delays the onset of macrophage infiltration of the sciatic nerve induced by 
repeated systemic administration of VCR. (A/C) Representative images showing macrophages in the sciatic 
nerve following vehicle (SAL) or one (day 4) or two cycles (day 11) of VCR treatment (0.5mg/kg/day i.p; days 
0-4 and 7-11.) in CX3CR1
+/+ (WT) and CX3CR1
-/- (KO) mice, where macrophages are visualised by their 
expression of F4/80. Scale bars equal 100µm. (B/D) Quantification of the number of macrophages in the 
sciatic nerve, shown as number of F4/80+ cells per 104µm2. Data shown are mean ± SEM and N=4 per group. 


































































































84B3.5. CX3CR1 deficiency does not influence spinal glial activation following repeated systemic 
administration of VCR 
 
As well as being expressed on monocyte/macrophages in the periphery, CX3CR1 is expressed 
exclusively on microglia in the central nervous system, where its interaction with CX3CL1 
contributes to the maintenance of homeostasis by limiting the release of pro-inflammatory 
mediators (Mizuno et al., 2003;Lyons et al., 2009). Under pathophysiological conditions the 
expression of CX3CR1 in microglia is enhanced and its activation contributes to enhanced 
nociceptive signalling (Zhuang et al., 2007;Staniland et al., 2010). Whilst we have previously 
established that the repeated systemic administration of VCR does not induce microgliosis in the 
spinal cord (chapter two figure 2.9), it was important for us to determine whether central changes 
in microglia could contribute to the phenotype we have observed in the CX3CR1 knock-out mouse 
following VCR administration. As shown previously, CX3CR1
+/+ mice exhibited no increase in the 
number of microglia (Iba1+ cells) in the dorsal horn of the spinal cord following repeated VCR 
administration (figure 3.21A/B; WT SAL/WT VCR) at either the end of the first cycle of treatment 
(day 4) or the second (day 11). Furthermore, as the high magnification inserts in figure 3.21A 
demonstrate, these cells did not exhibit a change in morphology associated with activation. In 
addition, no difference in the number or morphology of microglia in CX3CR1
-/- mice was observed 
in either saline or VCR treated mice irrespective of VCR cycle (figure 3.21A/B; KO SAL/KO VCR) and 
no distinction could be seen between CX3CR1
+/+ and CX3CR1





                                
Figure 3.21. Microgliosis does not occur in the spinal cord of CX3CR1
+/+ or CX3CR1
-/- mice following 
repeated systemic administration of VCR. (A) Representative images showing low and high magnification 
images of microglia in the dorsal horn of the spinal cord following administration of vehicle (SAL) or one (day 
4) or two cycles (day 11) of VCR (0.5mg/kg/day i.p.; days 0-4 and 7-11) in CX3CR1
+/+ (WT) and CX3CR1
-/- (KO) 
mice, where microglia are visualised by their expression of Iba1. Scale bars equal 100µm and 20 µm in 
inserts. (B) Quantification of the number of microglia in the dorsal horn of the spinal cord, shown as number 
of F4/80+ cells per 2.25 x 104µm2. Data shown are mean ± SEM and N=4 per group. No significant difference 
seen with one-way ANOVA with post-hoc Tukey test. 
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As shown previously CX3CR1
+/+ mice developed significant astrogliosis following VCR treatment, as 
demonstrated by an increase in GFAP immunoreactivity in the dorsal horn of the spinal cord 




-/- mice exhibited astrogliosis (increased 
GFAP immunoreactivity) equivalent to that of CX3CR1
+/+ mice at both the end of the first cycle of 
chemotherapy (day 4) and at the end of the second cycle (day 11). This is in line with the lack of 
effect of FLC in wild-type mice; taken together these data suggest the CX3CR1-deficiency does not 




                         
 
Figure 3.22. Astrogliosis occurs equally in the spinal cord of CX3CR1
+/+ and CX3CR1
-/- mice following 
repeated systemic administration of VCR. (A) Representative images showing astrocytes in the dorsal horn 
of the spinal cord following administration of vehicle (SAL) or one (day 4) or two cycles (day 11) of VCR 
(0.5mg/kg/day i.p.; days 0-4 and 7-11) in CX3CR1
+/+ (WT) and CX3CR1
-/- (KO) mice, where astrocytes are 
visualised by their expression of GFAP. Scale bars equal 100µm and 20 µm in inserts. (B) Quantification of 
the intensity of GFAP staining in the dorsal horn shown as relative GFAP intensity (relative to saline 
treatment) per 104µm2. Data shown are mean ± SEM and N=4 per group. * P<0.05 compared to saline value 





























































In chapter two we demonstrated that following repeated systemic administration of VCR there is 
an increase in the number of F4/80+ cells in the trunk of the sciatic nerve, indicative of 
macrophage infiltration. Furthermore, the temporal profile of the infiltration we observed was 
similar to that of the development of mechanical allodynia in these mice. This data is synergistic to 
previous work by both the Mantyh and Sommer laboratories who have demonstrated macrophage 
infiltration of the sciatic nerve and lumbar DRG following chemotherapy, where they take on a 
hypertrophied activated morphology (Peters et al., 2007a;Jimenez-Andrade et al., 2006;Uceyler et 
al., 2006). It has been hypothesised that macrophages contribute to the development of 
chemotherapy-pain through the release of pro-nociceptive mediators; the expression of IL-6 is 
increased in macrophages in the sciatic nerves of mice as a consequence of chemotherapy 
treatment and local administration of an IL-6 neutralising antibody attenuates VCR-induced 
mechanical allodynia (Kiguchi et al., 2008b). However, unlike in models of surgical nerve injury and 
diabetic neuropathy, the contribution of macrophages to the development of pain has not been 
fully elucidated. Thus, here in this chapter we set out to characterise the nerve infiltrating 
monocyte/macrophages present in VCR treated mice, and to determine the contribution these 
cells make to the development of VCR-induced mechanical allodynia. To achieve this we utilised 
three tools; liposome encapsulated clodronate (LCL) induced depletion of 
monocyte/macrophages, a CX3CR1-GFP reporter mouse and a CX3CR1
-/- mouse. 
 
The principle finding of this set of experiments is that monocyte/macrophages contribute 
significantly to the development of pain following administration of VCR; depletion of these cells 
prevents the onset of the mechanical allodynia normally observed in this model. Additionally the 
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evidence we have gathered suggests that the mechanism by which these cells are pro-nociceptive 
is CX3CR1 dependent; when phenotypically characterised it is apparent that a significant portion of 
these cells are CX3CR1 expressing and, in a similar temporal profile to monocyte/macrophage 
depleted animals, mice deficient in CX3CR1 experience a delay in the onset of VCR-induced 
mechanical allodynia in comparison to wild-types. 
 
The depletion of monocyte/macrophages by the systemic administration of liposome LCL had no 
effect on the baseline paw withdrawal thresholds of wild-type C57Bl/6 mice and no reduction in 
the number of tissue resident macrophages counted in these animals. This is to be expected; LCL 
was administered systemically but is unable to cross the blood nerve barrier (BNB), thus it is 
phagocytosed by, and depletes only circulating monocyte/macrophages. LCL reduces the number 
of monocyte/macrophages available to migrate into tissues rather than decreasing pre-existing 
tissue resident cells. The rapid onset of a severe and sustained mechanical hypersensitivity 
previously observed in VCR-treated mice was, interestingly, not present in LCL pre-treated 
animals. In these animals paw withdrawal thresholds remained at a level comparable to both 
baseline and vehicle animals for the first cycle of VCR chemotherapy, before declining to reach a 
level comparable to PBS-VCR treated mice by the start of the second cycle of treatment. When the 
sciatic nerves of these animals are examined immunohistochemically, we observed that infiltration 
of monocyte/macrophages into the sciatic nerve of LCL pre-treated mice is absent at a time point 
when these animals do not experience mechanical allodynia (day 4), but it is present at a later 
time point when the animals display severe mechanical hypersensitivity (day 11). These data 
indicate that monocyte/macrophage infiltration into the peripheral nerve is associated with the 
development of mechanical allodynia; mice that do not exhibit mechanical allodynia do not display 
an increased number of monocyte/macrophages in the sciatic nerve. Additionally these data 
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appear to indicate that the effect of macrophage depletion on the development of mechanical 
allodynia is transient; however we must consider the repopulation capacity of these cells. Our 
laboratory has shown previously that the systemic administration of LCL is associated with a 
reduction of splenic macrophages of approximately 90%, but that this is not permanent; 8 days 
after the administration of LCL this cell population has recovered fully (Barclay et al., 2007). Indeed 
this idea is well supported; following LCL-induced depletion of Kupffer macrophages in the liver, 
repopulation begin within a week and given that bone marrow precursors are unaffected, due to 
the inability of the liposomes to migrate into tissue, depleted cells are ultimately replaced (Van 
and van Kesteren-Hendrikx, 2002). Furthermore, the temporal profile of the attenuation of 
mechanical allodynia observed in our model of chemotherapy pain is comparable to that 
previously reported by ourselves (Barclay et al., 2007) and others (Liu et al., 2000). 
 
Whilst LCL induced depletion of monocyte/macrophages is a useful tool experimentally, it is not an 
attractive therapeutic option. Not only is the depletion transient but these cells play an important 
role in the immune system and are critical for the maintenance of homeostasis in relation to 
detecting and responding to infection; thus depletion of the cell population as a whole would 
leave patients immune suppressed and vulnerable to infection.  
 
In the mouse, as in the human, monocyte/macrophages show substantial heterogeneity, and it is 
possible that a similar reduction in hyperalgesia could be achieved by the suppression of only a 
single subpopulation, whilst maintaining an effective immune response. In order to assess this as a 
viable therapeutic option, our pro-nociceptive nerve infiltrating monocyte/macrophages must first 
be characterised. One of the key differences between the two most well characterised phenotypes 
of monocyte/macrophages in the mouse is the level of expression of the chemokine receptor 
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CX3CR1. This receptor is expressed highly in Ly6C
- resident monocyte/macrophages (Ly6C-
CX3CR1
high) but is expressed at a lower level in Ly6C+ inflammatory monocytes/macrophages (Ly6C-
+CX3CR1
int). We hypothesised that the cells infiltrating the nerve early on in the development of 
VCR-neuropathy were Ly6C-CX3CR1
high monocyte/macrophages, and evaluated the expression of 
CX3CR1 in monocyte/macrophages of VCR-treated mice. This was achieved by utilizing a 
genetically modified mouse, in which an egfp reporter gene had been inserted into the second 




To enable these experiments we obtained homozygous CX3CR1-GFP mice and breed them with 
wild-type mice to produce heterozygous (CX3CR1
+/gfp) offspring. We had previously characterised 
the VCR model of chemotherapy-pain only in male mice, however to enhance the number of 
offspring from these breeding pairs that could be used experimentally, we performed a 
comparative study of male and female wild-type mice; assessing development of mechanical 
allodynia in VCR treated animals to determine whether or not sex was an influencing factor. In 
contrast to some previous work which has demonstrated a sex difference in the development of 
neuropathic pain following the induction of bone cancer (Falk et al., 2013) and chronic 
inflammatory pain arising as the result of LPS administration (Sorge et al., 2011), no difference was 
seen in the paw withdrawal thresholds of male and female mice at any stage during the 
development or maintenance of VCR-induced mechanical allodynia. Thus in subsequent 
experiments both male and female mice were used.  
 
Whilst the current literature suggests that the function of CX3CR1 is unaffected in CX3CR1-GFP 
mice, the evidence we have gathered so far suggest the development of mechanical allodynia in 
220 
 
our model is dependent on a normal infiltration capacity of monocyte/macrophages. We, 
therefore, assessed the development of mechanical hypersensitivity in CX3CR1-GFP heterozygous 
mice and have demonstrated that these mice do indeed develop mechanical 
hypersensitivity/allodynia to the same degree as wild-type mice. We then set out the test the 
hypothesis that the majority of infiltrating monocyte/macrophages are CX3CR1
+ (thus GFP+). Sciatic 
nerve sections were taken at various time points from VCR treated CX3CR1
+/gfp mice. At all of these 
time points mice had a significant reduction in their paw withdrawal thresholds indicative of 
mechanical hypersensitivity. Immunohistochemical analysis of these nerve sections demonstrated 
that significant infiltration of F4/80+ cells (monocyte/macrophages) occurs concurrently to an 
increase in CX3CR1-GFP
+ cells, suggesting that these infiltrating cells are CX3CR1
+ 
monocyte/macrophages. Interestingly, whilst this increased number of F4/80+ cells remains 
consistently elevated, a gradual decrease in CX3CR1-GFP
+ cells is seen over the course of the two 
cycles of VCR. On first glance, this suggests that at later time points the infiltrating cells may be 
CX3CR1
- (GFP-), however it is likely an artefact of the earlier infiltrating monocytes settling in the 
tissue and differentiating fully into macrophages following their migrating and activation, which 
causes them to decrease their expression of CX3CR1 (Yona et al., 2013). We have provided 
evidence further to support the idea that VCR induces monocyte/macrophage infiltration of 
peripheral tissues; systemically administered VCR induces infiltration of these cells into the 
peritoneal cavity. 
 
Our data demonstrate that in saline treated wild-type mice the majority of 
monocyte/macrophages extracted from the peritoneal cavity are Gr-1- ‘resident’ 
monocyte/macrophages. The same conclusion was drawn following the examination of 
monocyte/macrophages extracted from the peritoneal cavity of CX3CR1
+/gfp mice. Following a 
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single cycle of VCR, however the ratio of Gr-1- to Gr-1+ monocyte/macrophages in both wild-type 
and CX3CR1
+/gfp shifted; whilst the Gr-1- population still dominated in both, a substantial increase in 
the proportion of Gr-1+ cells was seen (approximately 20%) in both genotypes. This represents a 
shift towards a Ly6C+ ‘inflammatory’ phenotype and this observation leads us thus to suggest that 
monocyte/macrophages infiltrating the nerve may be able to produce pro-inflammatory 
mediators which can activate neurons and evoke pain. We will return to this idea and investigate it 
further in chapter four. 
 
The data obtained from the experiments conducted with CX3CR1-GFP expressing mice indicates 
that the majority of infiltrating monocyte/macrophages express CX3CR1 to some degree. 
Unfortunately we are currently unable to distinguish between Ly6C-CX3CR1
high and Ly6C+CX3CR1
int 
monocyte/macrophages with the tools currently available to us. Both populations of cells express 
CX3CR1, however they differ in their level of expression of this protein; this is high and 
intermediate respectively (as opposed to high verses low) and it is not possible to visually 
differentiate the two populations. Fortunately the expression of CX3CR1 is crucial for the survival 
of only one of the population’s cells, and this distinction can be utilised to distinguish the 
populations and their contribution to the development of VCR-induced mechanical allodynia. 




monocytes; the absence of CX3CR1-CX3CL1 interaction results in a specific reduction in the number 
of circulating Gr1low CX3CR1
high monocytes and a decrease in absolute monocyte numbers in these 
animals. This is via a Gα-Bcl2 dependent mechanism; forced expression of the anti-apoptotic 
factor Bcl2 rescues monocyte numbers in CX3CR1 deficient mice and a pronounced increase in 
Gr1lowCX3CR1
high monocytes is observed, indicating that CX3CR1-CX3CL1 interaction promotes 
activation of Bcl2, preventing apoptosis. Additionally the pro-survival effect of CX3CR1-CX3CL1 is 
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blocked by treatment of the monocytes with pertussis toxin which blocks Gα signalling associated 
with CX3CR1 (Landsman et al., 2009). Due to the necessity of the CX3CR1-CX3CL1 interaction for the 
survival of Ly6C-CX3CR1
high monocyte/macrophages CX3CR1
-/- mice lack this population of cells. 
Thus these CX3CR1 knock-out mice provided us with a tool with which we can examine the specific 
role of Ly6C-CX3CR1




+/+) mice rapidly develop a severe and persistent mechanical 
hypersensitivity as a result of VCR treatment. Fascinatingly, in a pattern comparable to that of LCL-
VCR treated animals, this does not occur in CX3CR1
-/- animals. In these animals paw withdrawal 
thresholds remains consistently at levels comparable to both baseline and vehicle treated animals 
for the first cycle of VCR chemotherapy. As this cycle nears completion, the mechanical thresholds 
of CX3CR1
-/- animals begin to decline, reaching a level comparable to that of CX3CR1
+/+ mice by the 
start of the second cycle of treatment; as with LCL-VCR and PBS-VCR treated mice, CX3CR1
+/+ and 
CX3CR
-/- show an equal decline in allodynia index during the second cycle of VCR chemotherapy. 
These data suggest that Ly6C-CX3CR1
high monocyte/macrophages make a significant contribution to 
the development of mechanical allodynia occurring subsequent to VCR treatment; when these 
cells are absent the onset of mechanical allodynia is substantially delayed. Indeed an increase in 
the number of monocyte/macrophages infiltrating the nerve is not observed in following a single 
cycle of VCR treatment in CX3CR1 knock-out mice, when these mice do not exhibit mechanical 
allodynia. In the nerves of these and vehicle treated CX3CR1 knockout mice a small population of 
monocyte/macrophages is present in the nerve. At present we do not possess the tools to fully 
characterise this remaining population, however it is possible that the population of 
Ly6C+CX3CR1




-/- animals, and take on an immune surveillance role. Perhaps 
unsurprisingly as the mechanical thresholds of CX3CR1
-/- mice decline during the end of the first 
cycle and for the duration of the second cycles of treatment, monocyte/macrophages began to 
infiltrate the sciatic nerve, and a significantly higher number of these cells is observed in the nerve 
in VCR treated knock-out mice compared to their vehicle treated counterparts at the end of the 
second cycle of treatment. Again, whilst we do not currently possess the tools to precisely 
determine the phenotype of these infiltrating cells, they are likely to be Ly6C+CX3CR1
intCCR2+ 
inflammatory monocyte/macrophages as the survival of this population of cells is not influenced 
by CX3CR1-deficiency (Landsman et al., 2009). 
 
We also provide data that indicates, as in wild-type mice, CX3CR1 knock-out mice develop 
astrogliosis, but not microgliosis, following systemic administration of VCR. Astrogliosis is present 
in knock-out animals in the absence of mechanical allodynia, and occurs despite removal of a key 
peripheral component that likely drives central glial activation this process. Thus it possible to 
suggest that astrocytic activation is not occurring as a result of neuronal activation by pro-
nociceptive mediators from monocyte/macrophages; rather it is an indication of direct activation 
of sensory neurons by VCR via a mechanism not yet determined. However, as we’ve shown in 
chapter two, suppression of glial activation by the aconitase inhibitor FLC is not sufficient to 
attenuate mechanical allodynia in the VCR-neuropathy model so the contribution made to the 





36B5. Introduction to Chapter 4 
 
 
In this chapter, we provide evidence that demonstrates that the infiltration of 
monocyte/macrophages of the peripheral nerve that occurs as a consequence of systemic VCR 
administration is a critical step in the development of VCR-induced mechanical allodynia. 
Additionally we have demonstrated that the majority of these infiltrating cells are CX3CR1
+, and 
that the rapid development of mechanical hypersensitivity after the administration of VCR 
requires the expression of this receptor and the presence of circulating Ly6C-CX3CR1
high 
monocyte/macrophages. Thus CX3CR1 is an attractive target for a novel therapeutic intervention 
for the treatment of chemotherapy induced pain. Next we must ask the question, if CX3CR1 is so 
critical for the development of pain in these circumstances, what role is its ligand CX3CL1 playing? 
In the next set of experiments we set out to test the hypothesis that CX3CL1 contributes to the 
development of VCR induced mechanical allodynia by activating monocyte/macrophages via 
CX3CR1, causing these cells to produce pro-nociceptive mediators that have the capacity to 
activate neurons. To do this we have utilised a CX3CL1-mCherry reporter mouse and have 
established an in vitro assay to assess the expression of CX3CL1 in the endothelium. We have also 
used a primary macrophage culture system to determine the effect of CX3CL1-CX3CR1 interaction 
on the production of pro-nociceptive mediators by these cells. These experiments are presented in 









13BChapter 4:  
14BThe Contribution Of Endothelial CX3CL1 And TRPA1 








Chapter three introduced the protein CX3CR1; a chemokine receptor expressed on the surface of 
cells of a myeloid linage, which plays an important role in the transmigration of these cells into 
tissue. Here we will discuss this receptors ligand, CX3CL1 and the endothelial cells on which it is 





As we mentioned previously in chapter three, chemokines are a family of proteins critically 
involved in the migration of leukocytes. CX3CL1, also known as fractalkine (FKN), is no exception to 
this; as determined by structure (see figure 4.1), it is the only member of the CX3C family of 
chemokines and was first described by Bazan et al as a potent attracter of T-cells and monocytes 
(Bazan et al., 1997).  The protein can exist in two forms, each of which mediates distinct biological 
actions: a membrane tethered protein and a soluble chemokine domain (Bazan et al., 1997). 
Membrane bound CX3CL1 serves as an adhesion protein, promoting the firm adhesion of 
leukocytes without the activation of integrins (Fong et al., 1998), whilst soluble CX3CL1 is a potent 
chemoattractant for monocytes, NK cells, T cells and B cells (Imai et al., 1997;Corcione et al., 
2009). 
 
147B .1.1. Structure 
In 1997 two groups independently described a novel chemokine that differed from those 
previously described (of the C, CC and CXC families), as it possessed a unique cysteine motif in its 
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Figure 4.1. Classification of chemokines according to the organization of N-terminal cysteine residues. 
 
chemokine domain: Cys-X-X-X-Cys (CX3C). This new chemokine was identified from sequence 
analysis of a cDNA library of the murine choroid plexus; a specific sequence clone, pT1, had a 
sequence quite similar to that of MCP-1 (CCL2) and was named neurotactin (Pan et al., 1997). The 
1194 base pair neurotactin gene was localised to chromosome 16q and encodes a 397 amino acid 
protein with several key regions. The first of these is the chemokine domain; made up of amino 
acids 23-92, alignment analysis of this region showed remarkable homology to the chemokine 
domain of many known chemokines, with the exception of the CX3C region. Based on this 


























structure of this chemokine domain is now well established; the N-terminal region contains 7 
amino acids residues prior to the first cysteine residue (Cys-8), the sequence of which does not 
seem to be of much relevance to function (with the exception of Lys-7, see below). Following Cys-8 
is a long loop, a three stranded anti-parallel β sheet (residues 24-51) and a tightly packed C-
terminal α–helix (residues 56-67) (Mizoue et al., 1999); this forms a globular protein domain of 
approximately 3nm in diameter that is maintained by two disulphide bridges (Fong et al., 1998). 
Secondly, CX3CL1 possesses a stalk segment of approximately 26nm in length (comprised of 241 
amino acid residues) (Fong et al., 2000), that database comparison has identified as a mucin-like 
chain, defined by extensive O-glycosylation of serine and threonine residues in short tandem 
repeats of varying length (Imai et al., 1997;Fong et al., 1998). CX3CL1 possesses a 
juxtamembranous dibasic arginine motif (Thr-Arg-Arg-Gln) believed to be the primary site of 
cleavage, and finally this protein possesses an uninterrupted stretch of 18 hydrophobic residues 
that form a transmembrane link to a 37 amino acid intracellular tail (Bazan et al., 1997;Pan et al., 
1997). 
 
As has been done with the receptor, CX3CR1, mutational analysis of CX3CL1 has identified which of 
these regions are the most critical for function. For example Harrison et al, using mutation of the 
length of the mucin-like stalk, have demonstrated that the affinity and efficacy of chemokine 
domain binging is independent of stalk length (Harrison et al., 2001). Cells possessing the entire 
mucin-line domain are more efficient at capturing leukocytes than cells possessing the chemokine 
domain alone (Fong et al., 2000), however it is possible that is as a result of the increased length of 
the protein rather than a function of the mucin-like stalk itself, as the adhesive function of CX3CL1 
is retained at full capacity when the mucin-like stalk is replaced with E-selectin (Fong et al., 2000). 
Additionally, CX3CL1 with mutations of basic residues in the chemokine domain and glycosylation 
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consensus sequence display reduced binding potency (although those that bound retained 
receptor activating capabilities). Residues Lys-7 and Arg-47 were found to be of particular 
importance in this respect (required for receptor binding); mutation of these residues renders the 
protein ineffective at both binding and stimulating chemotaxis (Harrison et al., 2001). 
Furthermore, there is remarkable cross-species conservation in the CX3CL1 protein; significant 
sequence homology is observed between all of the key domains of this protein when the sequence 
of the rat protein is compared to that of mice and humans, as table 4.1 below demonstrates 
(Nishiyori et al., 1998). 
 
Table 4.1. Sequence homology of rat, mouse and human CX3CL1 amino acid sequence 
 
Rat sequence compared to… Mouse sequence Human sequence 
Total protein 85.5% homology 66.1% homology 
Chemokine domain 85.5% homology 82.7% homology 
Mucin-like domain 79.9% homology 53.9% homology 
Transmembrane domain 100% homology 100% homology 
Intracellular domain 100% homology 91.9% homology 
 
148B .1.2. Expression 
The in vivo expression pattern of CX3CL1 is generally considered to be less well defined than that 
of the ligand’s receptor, CX3CR1 (Kim et al., 2011). Pan et al originally described cx3cl1 gene 
expression to be most abundant in the brain and heart, but it was present in all other tissues 
tested, with the exception of peripheral blood leukocytes; expression in endothelial cells was 
found to be constitutive and enhanced by exposure to LPS, whilst in the brain 
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immunohistochemical analysis demonstrated localization of CX3CL1 to capillary walls and 
microglia. Expression here was also increased by exposure to LPS and in a model of multiple 
sclerosis (Pan et al., 1997). However, more recently it has been determined, using in situ 
hybridization and immunohistochemical analysis, that neurons are in fact the principle CX3CL1 
expressing cells of the CNS, and microglia and endothelial cells in the brain actually show little or 
no expression of this protein or its mRNA (Hughes et al., 2002;Nishiyori et al., 1998;Tarozzo et al., 
2003). Additionally, Schwaeble et al reported that CX3CL1 mRNA is not increased in mouse model 
of multiple sclerosis (Schwaeble et al., 1998). These data supported the in vitro evidence provided 
by Maciejewski-Lenoir and colleagues; they reported that CX3CL1 mRNA was not expressed by 
microglia (either constitutively or cytokine/toxin induced) but was constitutively expressed by 
both hypothalamic and cortical neurons (but was not increased by cytokine or toxic insult). 
Additionally low levels of CX3CL1 mRNA were found in astrocytes, but this was robustly increased 
following exposure of these cells to the cytokines IL-1β or TNFα (Maciejewski-Lenoir et al., 1999). 
Consistently, Hughes et al have demonstrated minimal expression of CX3CL1 in a small subset of 
astrocytes associated with blood vessels and pia mater in the dorsal hippocampus, thalamic and 
cortical regions that is significantly upregulated in the late stages of prion infection, but is not 
associated with an increase in neuronal CX3CL1 (Hughes et al., 2002).  More detailed analysis of 
CX3CL1 expression in the brain reveals that expression varies between brain regions and indicates 
that discrete subsets of neurons expression the cx3cr1 gene (Feng et al., 1999). Tarozzo et al used 
semi-quantitative PCR analysis to demonstrate high levels of CX3CL1 mRNA expression in the 
cortex, hippocampus and striatum, intermediate expression within the olfactory bulb, thalamus, 
hypothalamus and brainstem and low levels of expression in the cerebellum. The results of a 
series of in situ hybridization studies confirmed this expression profile, as did 
immunohistochemical analysis; the protein was present in these locations, not just mRNA, and the 
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expression is, as expected, neuronal (Tarozzo et al., 2003). Furthermore, immunohistochemical 
studies have recently demonstrated localization of cytoplasmic glutamate containing vesicles 
within CX3CL1 positive neurons, suggesting CX3CL1 is expressed in excitatory glutamatergic 
neurons (Tong et al., 2000). In the spinal cord both CX3CL1 immunoreactivity and mRNA 
expression are observed in spinal neurons and afferents from DRG neurons under physiological 
conditions, and this is not altered by the induction of a chronic pain state (Verge et al., 2004;Lindia 
et al., 2005). 
 
The evidence for endothelial expression of CX3CL1 presented by Pan et al does appear to be well 
supported, and indeed endothelial and epithelial cells are likely the predominant CX3CL1-
expressing cells in the periphery. In cardiac tissues CX3CL1 is localised to cells surrounding the 
luminal side of coronary vessels and the endocardium lining of the ventricle chambers (Harrison et 
al., 1999). CX3CL1 is also found within endothelial cells of the blood vessels in the dermis of normal 
human skin and in Langerhan cells of the epidermis (Papadopoulos et al., 2000;Papadopoulos et 
al., 1999). In small intestinal and colonic tissues, CX3CL1 mRNA is expressed in epithelial cells; 
CX3CL1 expressed by intestinal epithelial and endothelial cells is significantly upregulated during 
the active phase of Crohn’s disease and can be upregulated in these cells by exposure to pro-
inflammatory cytokines (Muehlhoefer et al., 2000). 
 
Any controversy in the expression profile of CX3CL1 has been quashed by the recent development 
of a CX3CL1 reporter mouse. The CX3CL1 reporter mouse was generated by Kim et al, who utilised 
BAC transgene generation to produce mice possessing a fluorescent reporter gene embedded in 
the cx3cl1 gene, thus expressing a CX3CL1 protein that was mCherry tagged. These mice 
demonstrate that CX3CL1 (mCherry) expression in the brain almost exclusively co-localises with the 
232 
 
neuronal marker NeuN, and confirmed that in the steady state there is abundant expression in the 
hippocampus, striatum and cortex (primarily cortical layer II). Additionally, Kim et al demonstrated 
CX3CL1 expression in neurons of the spinal cord (but not in CGRP
+ cell bodies of the DRG). 
Expression of CX3CL1 in these mice is completely restricted to non-hematopoietic cells. 
Peripherally CX3CL1-mCherry can be found on both alveolar and bronchial epithelial cells in the 
lung, tubular epithelial cells and glomeruli in the kidney and mucus secreting goblet cells of the 
epithelial layer in the intestinal lamina propria (Kim et al., 2011). Interestingly, within many cells 
CX3CL1 appears to be present in two distinct cellular compartments, being expressed diffusely on 
the plasma membrane as well as in a punctuate juxtanuclear compartment. CX3CL1 exists in 
equilibrium between these compartments, being actively recycled as required. The juxtanuclear 
compartment shares features with recycling endosomes; CX3CL1 expressed here co-localises with 
VAMP-3 and syntaxin-13, the luminal pH is approximately 6.3 and addition of brefeldin-A causes 
the compartment to collapse (Liu et al., 2005). The cytoplasmic tail of CX3CL1 is recognised as the 
region of the protein critical for facilitating the internalization of the protein; two adaptor protein-
2 (AP-2) binding motifs are found here and their mutation results in decreased CX3CL1 
internalization. The process of internalization is both dynamin and clathrin dependent; inhibition 
of the function of these proteins by the addition of targeted siRNAs prevents CX3CL1 endocytosis 
(Huang et al., 2009). Endosomal recycling of CX3CL1 occurs constitutively and has been 
hypothesised to serve three main purposes: providing a mechanism by which the protein can be 
rapidly down-regulated, protecting pre-synthesised CX3CL1 from degradation and to expose 
CX3CL1 to intracellular ADAMs (a disintegrin and metalloproteases domain; enzymes responsible 
for the cleavage of CX3CL1), allowing intracellular cleavage and accumulation of CX3CL1 to allow 
accelerated exocytosis of the chemokine domain to enhance chemotaxis (Liu et al., 2005;Huang et 
al., 2009). Additionally, the majority of CX3CL1 located at the plasma membrane is clustered; BRET 
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analysis demonstrates that CX3CL1 is able to behave as an aggregating protein which enhances the 
proteins ability to capture leukocytes, as well as allowing the establishment of a gradient for 
chemotaxis (Hermand et al., 2008;Proudfoot et al., 2003). Aggregation of chemokines for this 
purpose is quite normal; however whilst most soluble chemokines accomplish this by binding 
sulphated glycosaminoglycans in the extracellular matrix and on the surface of endothelial cells, 
the clustering behaviour of CX3CL1 is unique in that it is the transmembrane domain of the protein 
that is critical for the process (Proudfoot et al., 2003). Whilst the precise sequence responsible is 
not known, knowledge of the clustering behaviours of other proteins that aggregating via a 
transmembrane domain suggests a combination of a glycine motif, leucine zipper and/or a 
phenylalanine dimer interface are likely responsible (Hermand et al., 2008). 
 
149B .1.3. Cleavage/Shedding 
CX3CL1 exists and functions as both a membrane bound and soluble chemokine (likely in several 
forms due to cleavage by different proteases), with the latter being produced by the enzymatic 
cleavage of the chemokine domain of the former by the metalloproteases ADAM10 and ADAM17 
and the cysteine protease Cathepsin S (Clark et al., 2011). 
 
Cathepsin S (CatS) is a lysosomal enzyme of the papain family of cysteine proteases and was first 
purified from bovine lymph nodes (Turnsek et al., 1975) as a single chain molecule with a 
molecular weight of approximately 24kDa (Kirschke et al., 1986). CatS falls into the endopeptidase 
family of proteases as it catalyses the hydrolysis of peptide bonds within a polypeptide chain (as 
opposed to exopeptidases which cleave at the N or C terminus of the polypeptide) and is 
expressed by epithelial cells (Beers et al., 2005) as well as by antigen presenting cells including 
macrophages and microglia, where its secretion is enhanced by a number of pro-inflammatory 
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mediators including cytokines (Liuzzo et al., 1999a;Liuzzo et al., 1999b) and is likely P2X7 
dependent (Clark et al., 2010). CatS has been strongly implicated in antigen presentation, however 
this is by no means its only function and several pieces of evidence have been presented to 
suggest CatS is responsible, at least in part, for the cleavage of neuronal CX3CL1 in the spinal cord. 
Our laboratory has previously observed that the intrathecal administration of both CatS and 
soluble CX3CL1 are similarly pro-nociceptive, and that a CX3CL1 neutralizing antibody is able to 
prevent the development of mechanical hyperalgesia and microgliosis induced by CatS (Clark et 
al., 2009;Clark et al., 2007b). 
 
The shedding of soluble CX3CL1 from endothelial and epithelial cells is both constitutive and 
inducible, and the metalloproteases ADAM-10 (a disintegrin and metalloproteases domain-10) and 
ADAM-17 (a disintegrin and metalloproteases domain-17, also known as TACE; tumor necrosis 
factor-α converting enzyme) play a key role in this process. Constitutive shedding of the soluble 
chemokine domain of CX3CL1 has been demonstrated to be predominantly ADAM-10 dependent; 
an inhibitor of both ADAM-10 and ADAM-17 blocks both inducible and constitutive 
shedding/cleavage of soluble CX3CL1 in vitro, however a preferential ADAM-10 inhibitor reduced 
constitutive shedding only. Additionally, over-expression of ADAM-10 in endothelial cells enhances 
constitutive cleavage, which is believed to play a role in the regulation of leukocyte recruitment 
adhesion under steady state conditions, as specific ADAM-10 inhibition results in increased 
monocyte adhesion and prevents de-adhesion of bound cells (Hundhausen et al., 
2003;Hundhausen et al., 2007). Inducible shedding, on the other hand, is thought to be ADAM-17 
dependent. Inducible shedding generally refers to the enhanced shedding of soluble CX3CL1 
observed following incubation of CX3CL1 expressing cells with the phorbol ester PMA, which has 
been repeatedly demonstrated to increase the soluble CX3CL1 content of the media of treated 
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cells. In a similar fashion to the experiments used to determine ADAM-10 as the metalloproteinase 
responsible for constitutive cleavage, the use of ADAM-17 specific inhibitors has demonstrated 
this protease to be able to reduce inducible shedding only and no PMA induced shedding occurs in 
CX3CL1 transfected ADAM-17/TACE
-/- cells. Additionally, it is thought that the activity of ADAM-17 
is dependent on the presence of divalent cations, as the addition of EDTA to cell media decreases 
CX3CL1 shedding (Garton et al., 2001;Tsou et al., 2001). Interestingly, it also seems that ADAM-10 
and ADAM-17 may cleave CX3CL1 at different locations; ADAM-10 cleaves CX3CL1 at a dibasic 
juxtamembrane sequence (Thr-Arg-Arg-Gln) (Bazan et al., 1997), however mutation of the arginine 
residues to alanine has no effect on PMA induced shedding of CX3CL1; the CX3CL1 cleavage site of 
CatS has not yet been determined and it’s likely that soluble CX3CL1 exists in several forms (Garton 
et al., 2001;Tsou et al., 2001). It should be noted that ADAM-10 and ADAM-17 are able to cleave 
proteins other than CX3CL1, TNFα for example, however a full review of ADAM-10/17 activity is 
beyond the scope of this introduction. 
 
150B .1.4. Function and Contribution to Disease 
The majority of functions of CX3CL1 are discussed in chapter three in terms of the function of 
CX3CL1-CX3CR1 interactions; membrane bound (full length) CX3CL1 is primarily responsible for the 
capture and adhesion of leukocytes, while soluble (cleaved) CX3CL1 establishes a chemotactic 
gradient and activates leukocytes via CX3CR1. Additionally, the interaction between CX3CL1 and 
CX3CR1 is critical for the survival of CX3CR1
high monocytes via the activation of the anti-apoptotic 
factor Bcl2. The contribution made by this receptor-ligand interaction to a number of pathologies 
has also been discussed, thus here only the involvement of CX3CL1 in inflammation and pain are 





Inflammation is a complex protective response to harmful stimuli elicited by injury or infection 
that serves to destroy, dilute or provide a barrier against the damaging agent. It is characterised by 
the development of hyperalgesia (dolor), heat (color), redness (rubor) and swelling (tumor). On a 
more discrete level it involves a number of biological processes including increased blood flow and 
dilatation and increased permeability of blood vessels, the exudation of fluid and the migration of 
leukocytes. The process of acute inflammation is typically initiated by cells present in the affected 
tissue, such as tissue resident macrophages or dendritic cells that, when activated, release a host 
of pro-inflammatory mediators such as cytokines, chemokines, bradykinin, histamine and NO that 
contribute to the development of the characteristic biological responses. Chemokines, or 
chemoattractant cytokines, as their name suggests act as a chemoattractant for infiltrating 
leukocytes, in particular monocyte/macrophages.  
 
Like other chemokines, CX3CL1 acts as a chemoattractant during inflammation, but also plays a key 
role in the process by which recruited cells transmigrate into inflamed tissues (see below). With 
CX3CL1 playing such a vital role in recruitment of cells critically involved in the inflammatory 
process, it is of no surprise that CX3CL1 has been suggested to contribute to a variety of 
inflammatory conditions. In fact upregulation of CX3CL1, be it the mRNA or actual protein, has 
been observed in inflammatory conditions affecting almost all organs of the body: in the 
endometrial foci of endometriosis patients (Bellelis et al., 2013), in the lung fibroblasts of chronic 
obstructive pulmonary disease (COPD) patients (Dagouassat et al., 2013), in the conjunctiva in a 
rodent model of toxic ocular surface inflammation (Denoyer et al., 2012), in the plasma and tissues 
of animals experiencing septic shock (Raspe et al., 2013), in the serum of patients with acute 
pancreatitis (Uchida et al., 2013), in synovial fibroblasts of rheumatoid arthritis (RA) patients 
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(Jones et al., 2013) and in atheroma and smooth muscle cells of patients and rodents with 
arthrosclerosis (Gan et al., 2013;Lucas et al., 2003). Indeed tissue specific changes in CX3CL1 mRNA 
expression have been suggested as a diagnostic marker for diseases associated with chronic 
inflammation (Mehta et al., 2012). CX3CL1 largely contributes to inflammation and pathogenesis 
by recruiting monocyte/macrophages which in turn release a host of inflammatory mediators; as 
mentioned previously coronary artery disease patients with increased plasma levels of CX3CL1 
have elevated numbers of CX3CR1
+ cells and therapies that reduce this (increase in of CX3CR1
+ 
cells) are effective at treating the condition (Damas et al., 2005). Furthermore, the blockade of 
CX3CR1
+ cell recruitment in a model of renal failure dramatically reduces fibrosis and increases 
function (Feng et al., 1999;Oh et al., 2008). Monocyte/macrophages are by no means the only cell 
type influenced by CX3CL1/R1 under inflammatory conditions; in patients with allergic asthma and 
rhinitis soluble CX3CL1 levels are increased and notably contribute to the recruitment of CD4
+ T-
lymphocytes (Rimaniol et al., 2003). Furthermore both CX3CL1 and CX3CR1 have been detected on 
a variety of cell types (including monocyte/macrophages, T-helper cells and dendritic cells) within 
the joints of rheumatoid arthritis patients (D'Haese et al., 2010;D'Haese et al., 2012). 
 
This wealth of evidence for a pro-inflammatory and pro-pathogenic action of CX3CL1 suggests 
compounds blocking both the synthesis and release of CX3CL1 or its signalling via CX3CR1 are likely 
to be advantageous in the treatment of many chronic inflammatory conditions; indeed this 
certainly seems to be the case as CX3CR1 knock-out animals show reduced pathology in models of 
inflammatory diseases. For example CX3CR1
-/- mice show reduced atherosclerotic plaque 
formation compared to CX3CR1
+/+ controls (Lesnik et al., 2003). Furthermore, administration of an 
anti-CX3CL1 or anti-CX3CR1 antibody attenuates leukocyte adhesion to inflamed endothelial cells 




If we examine CX3CL1 in the context of pain, we find it to be pro-nociceptive; intrathecal 
administration of soluble CX3CL1 causes mechanical allodynia and thermal hypersensitivity (Sun et 
al., 2013;Clark et al., 2007b;Milligan et al., 2004;Milligan et al., 2005a). Similarly injection of 
CX3CL1 in the PAG region of the brain, an area of that plays a key role in the descending 
modulation of pain, is also pro-nociceptive (Chen et al,. 2007). The administration of an anti-
CX3CL1 antibody attenuates the pain behaviours of both neuropathic and arthritic animals (Clark 
et al., 2007b;Clark et al., 2012). The central expression of CX3CL1 is substantially upregulated in 
models of arthritis (Yang et al., 2012), in some cases de novo expression in astrocytes is observed 
(Lindia et al., 2005), and compounds that are able to reduce CX3CL1 expression are analgesic (Yang 
et al., 2012). As the above mentioned anti-CX3CL1 antibodies are given intrathecally, in these 
instances it is neuronal CX3CL1 in the CNS that is contributing to pain; we can also determine that 
it is soluble rather than membrane bound CX3CL1 that is pro-nociceptive as the intrathecal 
administration of the irreversible CatS inhibitor LHVS attenuates pain to a similar degree as an 
anti-CX3CL1 antibody (Clark et al., 2012;Clark et al., 2007b). As expected from the expression 
profile of CX3CR1, CX3CL1 does not have a direct affect on neurons (Zhuang et al., 2007), instead 
following its liberation from neurons, CX3CL1 induces nociceptive behaviours via activation of the 
CX3CR1 receptor on microglia, stimulating the activation of p38 MAPK-mediated pathways (this 
release is assumed based on the anti-nociceptive effects of blockers of CX3CL1 signalling) (Clark et 
al., 2007b;Zhuang et al., 2007) and the release of a variety of pro-nociceptive mediators, including 
IL-1β, IL-6 and NO (Milligan et al., 2005b), that are able to sensitise neurons e.g. the induction of a 





Conversely, Holmes et al have demonstrated an anti-nociceptive effect of CX3CL1 in the periphery; 
pre-injury intraneural injection of CX3CL1 attenuated neuropathic pain related behaviours in a 
spared nerve injury model, and CX3CR1 knock-out mice were reported to show more pronounced 
allodynia than wild-types in the same model (Holmes et al., 2008); however these observations 
were made at a single time point and used a considerably higher dose than is required in the 
spinal cord to cause hypersensitivity (400ng vs 30ng (Holmes et al., 2008;Clark et al., 2007b)). This 
data might suggest a striking difference between the relationship between CX3CL1 and pain 
centrally and peripherally, however evidence from a recent human study suggests the contribution 
of CX3CL1 to pain may not be solely a central effect; unstable angina pectoris, partially defined as 
experiencing ischemic chest pain, is associated with elevated serum levels of CX3CL1 (Yao et al., 
2011). So what is responsible for this pronounced difference? In a recent review from our 
laboratory, we suggested this may be the result of a mouse strain variation; it has previously been 
demonstrated that mouse strains vary in their sensitivity to pain, and in fact the specific strain 
used by Holmes and colleagues (Balb/c) has been shown to have a significantly lower microglial 
response to CNS injury than C57Bl/6 mice typically used (Clark et al., 2011;Mogil et al., 
1999a;Mogil et al., 1999b;Kigerl et al., 2006). 
 
Whilst considering the suitability of CX3CL1 and CX3CR1 as targets for the development of 
analgesics it is important to consider the protective effects of the interaction between these two 
proteins; in the brain CX3CL1-CX3CR1 interaction certainly seems to be neuroprotective in models 
of both amyotrophic lateral sclerosis (ALS) and Parkinson’s disease (Cardona et al., 2006), and in a 
cohort of ischemic stroke patients higher plasma CX3CL1 levels were associated with better 
survival outcome at a six month assessment point (Donohue et al., 2012). Peripherally this 




monocyte/macrophages, wound healing and cell transmigration for immune surveillance, thus 
when developing analgesics that target this interaction it might be worth considering either a 
centrally acting compound or a compound such as a CatS inhibitor that targets the shedding of 
soluble CX3CL1 leaving the membrane bound CX3CL1 intact. 
 
 
86B1.2. The endothelium, adhesion molecules and the transmigration of leukocytes 
 
151B .2.1. Endothelial function and the transmigration of leukocytes 
The endothelium lines the entire vascular system and is composed of a monolayer of endothelial 
cells linked together by adhesive structures or cell to cell junctions (tight junctions, adheren 
junction and gap junctions (Michiels, 2003). A versatile and multifunctional organ, the 
endothelium acts as a semi-permeable barrier as well as having many synthetic and metabolic 
functions, including the regulation of thrombosis and thrombolysis, regulation of platelet 
adhesion, modulation of vascular tone and regulation of immune and inflammatory responses (via 
the control of immune cell trafficking). Endothelial cells produce and release several vaso-active 
substances (e.g. prostacyclin and NO) that cause vasodilation and inhibit the adhesion and 
aggregation of platelets; these substances are released in response to a range of chemical stimuli 
as well as changes in hemodynamic forces such as alterations in blood pressure. Additionally these 
cells can be activated by stimuli, including thrombin and histamine, which cause a shift towards a 
pro-thrombotic/pro-proliferative/vasoconstricting phenotype (Sumpio et al., 2002). 
 
The rapid migration of leukocytes from the vasculature to a target tissue is an essential process in 
the normal function of the immune system. The migration of these cells is commonly initiated 
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through the local generation of inflammatory mediators, such as chemokines, that induce 
circulating cells to being the process of leukocyte-endothelial adhesion. The process, shown in 
figure 4.2, begins with the adhesion of leukocytes to the endothelium; a process that involves 
tethering and rolling of leukocytes captured from the blood stream. This leads to firm attachment 
of leukocytes and subsequent transmigration.  
 
Whilst leukocytes are able to migrate under both physiological and pathophysiological conditions, 
the interaction of resting endothelial cells with leukocytes is minimal, as under these conditions 
endothelial cells sequester leukocyte interactive proteins such as P-selectin (and chemokines) in 
specialised secretory vesicles (Weibel-Palade bodies), and the transcription of several important 
adhesion molecules such as E-selectin, VCAM-1 and ICAM-1 is suppressed (Pober and Sessa, 2007). 
The activation of the endothelium can occur in two ways: type I activation, a rapid process 
occurring independently of changes in gene expression, and type II activation, a slower response 
that is dependent on the alteration of gene expression. Type I activation is typically mediated by 
ligand-dependent activation of G-protein coupled receptors, such as histamine receptors (H1), 
typically coupled to G-αq proteins (Pober and Cotran, 1990), the activation of which leads to the 
activation of phospholipase C (PLC) and subsequent release of Ca2+ from intracellular stores (Pober 
and Sessa, 2007). A rise in intracellular calcium in endothelial cells in this way contributes to a 
number of functions of the cells, but plays an especially important role in leukocyte recruitment. 
Calcium dependent activation of myosin light chain initiates the exocytosis of Weibel-Palade 
bodies, thus moving leukocyte interactive proteins (e.g. P-selectin) to the luminal surface of the 









Figure 4.2. The leukocyte transendothelial migration pathway.  This simplified schematic shows the various stages of leukocyte migration through the 
endothelium. The capture and rolling of leukocytes is mediated by selectins; during this time the cells are activated by chemokines expressed on the 
endothelial surface. The leukocytes then undergo an arrest step and subsequent firm adhesion to the endothelium which is mediated by integrins and 
supersedes crawling before the final process of migration occurs (adapted from (Ley et al., 2007)). 






activation than type I, and is typically mediated by TNFα or IL-1β derived from activated 
leukocytes. The activation of TNF receptor 1 (TNFR1) and the IL-1 receptor (IL-1R) by these 
cytokines results in the activation of downstream signalling pathways that ultimately lead to the 
activation of transcription factors that stimulate the transcription and translation of new 
genes/proteins. As with type I activation, type II activation of endothelial cells contributes to many 
of the functions of these cells, but in terms of leukocyte recruitment it triggers the increased 
expression of a number chemokines and leukocyte adhesion molecules, such as E-selectin, ICAM-1 
and VCAM-1, on the luminal surface of the cell (Pober and Sessa, 2007;Collins et al., 1995). 
 
The capture, tethering and rolling of leukocytes to the endothelium is mediated by the weak and 
reversible interactions of selectins (McEver et al., 1995). These adhesive transmembrane 
glycoproteins are a family of three molecules each with an N-terminal Ca2+-dependent lectin 
domain, an EGF domain, a transmembrane domain and a cytoplasmic tail. L-selectin is expressed 
constitutively on the surface of most leukocytes, P-selectin is rapidly mobilised from secretory 
granules in endothelial cells, and E-selectin is expressed on endothelial cells under the 
transcriptional regulation of inflammatory mediators. Selectins bind to sialylated and fucosylated 
oligosaccharides, the terminal components of glycoproteins expressed on both leukocytes and 
endothelial cells (Cines et al., 1998). E-selectin binds preferentially to ESL-1 (E-selectin ligand-1), 
whilst L- and P-selectin bind preferentially to PSGL-1 (P-selectin glycoprotein ligand-1). Under 
inflammatory conditions, when all three selectins are present, they work cooperatively to allow 
leukocyte rolling by binding reversibly to their ligands; this slows down leukocytes which facilitates 
the binding of chemokines and lipid autocoids on the surface of endothelial cells with their 
receptors on leukocytes. These mediators transduce signals that cooperate with those produced 
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by activated leukocytes interacting with selectins (Weyrich et al., 1995) to enable the expression 
and activation of integrins on the surface of the cells (Cines et al., 1998).  
 
The firm adhesion of leukocytes to the activated endothelium is primarily mediated by three 
integrins: LFA-1 (αLβ2/CD11a), Mac-1 (αMβ2/CD11b) and VLA4 (α4β1); LFA-1 is the predominant 
integrin for lymphocyte emigration, Mac-1 for neutrophils adhesion and VLA4 is the predominant 
integrin expressed on monocytes (although they also constitutively express LFA-1) (Hynes, 
1992;Stewart et al., 1995). LFA-1 has the highest affinity for the endothelial ligand ICAM-2 
(intercellular adhesion molecule-2); however it can also bind ICAM-1 (intercellular adhesion 
molecule-1) which is the primary endothelial ligand of Mac-1. The constitutive expression of ICAM-
1 is low expression but shows significant up-regulation following the exposure of the endothelium 
to inflammatory cytokines (Klein et al., 1995;Scholz et al., 1996). Similar to the ICAMs is VCAM-1 
(vascular cell adhesion molecule-1), an Ig like protein also found on the surface of cytokine-
activated endothelial cells, that selectively binds β1-integrins, i.e. VLA4 (Pober and Cotran, 1990). 
Additionally the interaction of integrins can cause leukocyte-induced clustering of ICAM-1 and 
VCAM-1 at the leukocyte-endothelial cell interface that serves as a platform for firm adhesion 
(Barreiro et al., 2008;Nourshargh et al., 2010). The transendothelial migration of leukocytes is also 
mediated by integrins. This process requires continuous cycles of adhesion and detachment; new 
adhesive contacts form at membrane protrusions at the leading edge of the cell, whilst at the rear 
of the cell integrins are down-regulated. Chemokines and shear stress promote the formation of 
these membrane protrusions (filopodia); the expression of integrins here is high and it is thought 
that the cell uses these filopodia to crawl along the endothelial layer in search of emigration sites 
(Nourshargh et al., 2010). Furthermore, the interaction of integrins with their ligands causes a rise 
in calcium in endothelial cells, which activates myosin light chain kinase and subsequently causes 
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contraction of the cell, promoting the passage of the leukocyte (Michiels, 2003). The migration of 
leukocytes across the endothelium at cell-cell junctions is also in part regulated by 
platelet/endothelial cell adhesion molecule-1 (PECAM-1/CD31) which is expressed on both 
leukocytes and endothelial cells. Evidence suggests that a homophilic interaction between 
leukocyte PECAM-1 and endothelial PECAM-1 guides leukocytes through endothelial junctions 
(Muller, 2003;Nourshargh et al., 2006) and contributes to the enhanced expression of leukocyte 
integrins (Dangerfield et al., 2002;Wang et al., 2005). Blockers of PECAM-1 suppress leukocyte 
transmigration through cytokine stimulated endothelial cells in vitro (Muller et al., 1993) and 
suppress leukocyte accumulation in the inflamed peritoneum of rats (Vaporciyan et al., 1993), 
suggesting this protein does indeed contribute to leukocyte migration. However observations 
made in a PECAM-1 knock-out mouse have failed to find a significant deficit in this process 
(Duncan et al., 1999). 
 
As well as mediating the activation of integrins, some chemokines can also directly mediate the 
arrest of leukocytes. Soluble chemokines, such as CXCL8 and CCL2, bind to heparin sulphate on the 
surface of endothelial cells and become immobilised, providing a site for leukocyte adhesion 
(Weber et al., 1999;Michiels, 2003). Furthermore the membrane bound chemokine CX3CL1, 
expressed on endothelial cells, is able to cluster, enhancing this proteins ability to capture 
leukocytes (Hermand et al., 2008;Proudfoot et al., 2003). CX3CL1 might aid leukocyte adhesion 





152B .2.2. Endothelial dysfunction following chemotherapy 
The endothelium is a dynamic organ that responds to a variety of stimuli by undergoing activation. 
This process is critical for the maintenance of homeostasis; but also allows the endothelium to 
contribute to the pathogenesis of vascular disease. Indeed endothelial dysfunction, the shift 
towards a chronically activated state, is associated with most forms of cardiovascular disease, 
including atherosclerosis, coronary artery disease and diabetes (Endemann and Schiffrin, 2004). 
For example, in atherosclerosis the morphologically abnormal endothelium is dysfunctional and 
contributes to the propagation of atherosclerotic lesion formation via several mechanisms, 
including the enhanced recruitment of monocytes that subsequently differentiate into foam cells 
(Ross, 1993;McGorisk and Treasure, 1996). 
 
Several cardiovascular complications of chemotherapy have been identified; these include 
acceleration of coronary artery disease, cardiomyopathy and congestive heart failure. 
Experimental studies have suggested potential mechanisms to account for these complications 
and include the dysfunction or damage of endothelial cells (Daher and Yeh, 2008). The treatment 
of patients with 5-fluorouracil, for example, is associated with acute cardiac toxicity and venous 
thromboembolic disease. It has demonstrated that this chemotherapeutic agent decreases 
endothelial cell DNA synthesis and increases prostacyclin release in a fashion consistent with 
endothelial cell injury (Cwikiel et al., 1996) and inhibits VEGF-induced tubule formation in 
endothelial cells as well as angiogenesis (Basaki et al., 2001;Drevs et al., 2004). Bevacizumab, a 
monoclonal antibody against VEGF used for the treatment of a variety of solid tumors, is 
associated with the worsening of hypertension in patients as well as an increased incidence of 
both arterial and venous thrombosis (Gordon and Cunningham, 2005;Kabbinavar et al., 2003). 
Indeed, mice specifically deficient in endothelial VEGF show progressive endothelial degeneration 
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and apoptosis, as well as diffuse vascular thrombosis that led to organ failure and death (Lee et al., 
2007). Bevacizumab-associated thrombotic events are hypothesised to occur as a result of this 
endothelial disruption, which leads to exposure of the extracellular matrix, platelet activation and 
reduced levels of thrombomodulin and NO (also thought contribute to bevacizumab-associated 
hypertension) (Verheul and Pinedo, 2007;Kamba and McDonald, 2007). Cisplatin treatment is 
associated with coronary ischemia, delayed onset hypertension and left ventricular hypertrophy 
(Berliner et al., 1990;Daher and Yeh, 2008); whilst the mechanism by which this occurs is not yet 
known, case-reports of coronary spasm suggest abnormal function of cardiovascular tissue 
contributes (Doll et al., 1986;Daher and Yeh, 2008). Furthermore, in rats the administration of 
microtubule disrupting agents such as VCR is associated with cardiotoxicity that manifests as 
development of vascular endothelial lesions comprised of apoptotic cells (Tochinai et al., 2013). In 
an in vitro setting VCR inhibits VEGF secretion and this is hypothesised to contribute to the 
cardiotoxicity seen in vivo (Avramis et al., 2001). 
 
87B1.3. The TRPA1 Receptor 
 
153B .3.1. TRPA1 structure 
The TRP (transient receptor potential) group of proteins is a large family of ion channels that share 
several characteristics: a six transmembrane domain structure with a pore loop between the fifth 
and sixth transmembrane segments, and permeability to cations. Despite these structural 
similarities the TRP channels are a diverse family displaying a wide array of cation selectivities and 
specific activation mechanisms. The TRP channels contribute to responsiveness to all major classes 
of external stimuli inducing light, sound, chemical, temperature and touch, as well as providing 
individual cells with the ability to detect changes in the local environment. Within the TRP super-
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family, the channels are divided into seven subfamilies that include five group 1 TRP channels: 
TRPA, TRPC, TRPM, TRPN (not found in mammals) and TRPV, and two group 2 TRP channels: 
TRPML and TRPP. The separation of the two groups is based on sequence and topological 
differences and the subfamilies are named based on the name of the original receptor described in 
that subfamily, i.e. TRPV1 (transient receptor potential vanilloid-1) which is activated by the 
inflammatory vanilloid compound capsaicin. The mechanism through which a TRP channel is 
activated generally cannot reliably be predicted based on its subfamily assignment, however the 
recurring theme amongst the TRP channels is that they are activated through a diverse range of 
mechanisms, which a single receptor often responding to a variety of stimuli (Venkatachalam and 
Montell, 2007).  
 
TRPA1 (transient receptor potential ankyrin-repeat-1) is the only known member of the TRPA 
subfamily and gains its name due to its possession of a series of N-terminal ankyrin repeats, as 
shown in figure 4.3. It was first identified in a screen for genes down-regulated following the 
oncogenic transformation of fibroblasts (Jaquemar et al., 1999), although the effects of the 
classical TRPA1 agonist, mustard oil, were described much earlier than the receptor itself 
(Koltzenburg and McMahon, 1986). The gene encoding this protein spans 55.7kbp of the human 
chromosome 8q13 and has been highly conserved across species for around 500 million years 
(Nilius et al., 2012;Kang et al., 2010). The trpa1 gene encodes an 1100 amino acid protein of 
approximately 120kDa that comprises, as expected, six transmembrane segments with a putative 
ion permeable site located between transmembrane segments five and six. The long N-terminal 
domain contains up to eighteen ankyrin repeat domains formed of 33 amino acids that are 
thought to be involved in protein-protein interaction and channel trafficking to the membrane; 
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deletion of these domains negatively affects insertion of the channel into the membrane (Nilius et 
al., 2012).  
 
                                
 
Figure 4.3. Schematic representation of the TRPA1 receptor. The TRPA1 receptor is comprised of six 
transmembrane domains, represented by the rectangular bars. Between the fifth and sixth transmembrane 
domains lies the pore domain. At the N-terminal end of the protein are a series of ankyrin repeat domains, 
represented by the grey ovals; it is these that give the TRPA1 receptor its name. 
 
Site-directed mutagenesis studies have identified cysteine and lysine residues in the N-terminal 
domain as critical for the covalent bonding of agonists and subsequent activation of the receptor 
(Hinman et al., 2006;Macpherson et al., 2007). Additionally TRPA1 possesses a number of Ca2+ 
binding sites and an EF hand motif (helix-loop-helix structure) that allow Ca2+-dependent 







studies have revealed that TRPA1 activates quite slowly following ligand binding; likely a reflection 
of the need for the agonist to penetrate the cell membrane to reach the intracellular agonist 
binding site (Macpherson et al., 2007;Koivisto, 2012). Recently Karashima and colleagues used 
advanced electrophysological techniques to predict a pore diameter for TRPA1 of at least 11A with 
a relative basal PCa/PNa of around 5 that increases to approximately 9 in the presence of an agonist, 
indicating this ion channel possesses a relatively large pore with higher calcium permeability than 
most other TRP channels (Karashima et al., 2010). 
 
154B .3.2. TRPA1 expression  
Within the nervous system TRPA1 activation is associated with pain; TRPA1 was originally 
described as a nociceptive channel and can be found on small myelinated Aδ and unmyelinated C 
fibres with their cell bodies in the dorsal root and trigeminal ganglion. Approximately 25% of 
TRPA1 containing neurons are peptidergic and release substance P and CGRP; however generally 
TRPA1 is expressed in neurons that also express the nerve growth factor (NGF) receptor TrkA and 
the heat and capsaicin sensitive ion channel TRPV1 (Story et al., 2003;Bautista et al., 2007;Nagata 
et al., 2005;Nilius et al., 2012). Quantification of TRPA1 positive neurons indicates that under 
normal conditions TRPA1 is expressed by approximately 55% of TRPV1 positive neurons, but that 
this can be increased to approximately 80% by treatment with NGF (Kobayashi et al., 
2005;Diogenes et al., 2007). Additionally there is likely a small population of TRPA1 positive 
neurons that are not TRPV1 positive, as a small population of TRPA1 positive neurons have been 
identified that do not respond to the TRPV1 agonist capsaicin (Salas et al., 2009). Recent evidence, 
however, indicates that TRPA1 expression is not confined to sensory neurons. TRPA1 is also found 
extensively in the brain; it is found in the hippocampus, neurons of the nucleus supraopticus and 
in the brain stem (Nilius et al., 2012). Furthermore, this ion channel has been found in other 
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neuronal tissues including sympathetic neurons (Andrade et al., 2008) such as the vagal fibres 
innovating the heart, where TRPA1 contributes to vasovagal reflexes (Pozsgai et al., 2010) and in 
the pelvic nerve innovating the colon where activation of TRPA1 contributes to the inhibition of 
contractility (Poole et al., 2011). 
 
Additionally TRPA1 expression has been observed outside of the nervous system. In the 
cardiovascular system TRPA1 is found in endothelial cells concentrated at myo-endothelial 
junctions; here its activation contributes to endothelium-dependent smooth muscle cell 
hyperpolarization and vasodilatation, thus contributing to the maintenance of vascular tone 
(Earley et al., 2009;Yanaga et al., 2006;Andrade et al., 2012). TRPA1 is expressed in the epithelial 
cells of a number of structures in the urinary tract in both rodents and humans (Nagata et al., 
2005;Streng et al., 2008;Gratzke et al., 2010), and is up-regulated in patients with outlet 
obstruction (Du et al., 2007); furthermore the intravesicular administration of TRPA1 agonists can 
cause urinary bladder over-activity (Du et al., 2007;Streng et al., 2008). The TRPA1 receptor is 
expressed in synovial cells responsible for maintaining the integrity of synovial tissue (Kochukov et 
al., 2006), in odontoblasts where it is hypothesised to contribute to the transmission of external 
stimuli signals to nearby nerves (El Karim et al., 2011;Byers, 1984), and is expressed by endocrine 
cells of the gastrointestinal (GI) tract where it contributes to serotonin release and subsequent 
modulation of GI motility (Kellum et al., 1999;Gershon, 2003;Nozawa et al., 2009). As well as being 
found in the nerves innovating the skin, TRPA1 is also expressed in non-neuronal skin cells such as 
keratinocytes and fibroblasts, where its activation mediates the secretion of eicosanoids (Jain et 
al., 2011) and induces an increase in proliferation related growth factors and inflammatory 




155B .3.3. TRPA1 Activation 
 TRPA1 is primarily activated chemically with a variety of compounds that occur naturally, such as 
allyl isothiocyanate (AITC; mustard oils), cinnamaldehyde and allicin (garlic oil extract) (Bautista et 
al., 2013). It should be noted that several of these naturally occurring compounds that are able to 
activate TRPA1 are also able to activate other TRP channels, mainly members of the TRPV family. 
For example mustard oil has recently been observed to activate mouse and human recombinant 
TRPV1 as well as TRPV1 in sensory neurons (Everaerts et al., 2011). Additionally TRPA1 can be 
activated by menthol and icillin, chemicals that induce a cooling sensation; this has lead to the 
proposition that TRPA1 is able to act as a cold receptor (Story et al., 2003). Indeed, when 
exogenously expressed in vitro TRPA1 is activated by noxious cold (<17oC) (Story et al., 
2003;Bandell et al., 2004), however the examination of the phenotype of TRPA1 knock-out mice 
regarding noxious cold sensation remains controversial (see below). More recently a number of 
synthetic drugs were identified as activators of TRPA1; these include the inhalational anaesthetic 
isoflurane (Matta et al., 2008), the antipsychotic chlorpromazine (Hill and Schaefer, 2007) and 
antifungal and antiprotozoal drug clioquinol (Andersson et al., 2009). Additionally the TRPA1 
receptor can act as a sensor for environmental irritants and pollutants including, but not limited 
to, acrolein and α,β-unsaturated aldehyde that is present in tear gas, vehicle exhaust and smoke 
(Andrade et al., 2012). Emerging evidence has implicated that TRPA1 can also be activated by the 
endogenous products of metabolism and oxidative stress; a large number of reactive oxygen 
species (ROS) including those that cause cysteine oxidation and/or disulfide formation, reactive 
nitrogen species (RNS) that cause S-nitrosylation and reactive carbonyl species (RCS) are all 
potential TRPA1 activators (Takahashi et al., 2008;Nilius et al., 2012;Andersson et al., 2008). These 
products of oxidative stress directly activate TRPA1 due to their electrophilic properties; the 
activation of TRPA1 by electrophilic compounds results in large inward currents and the 
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abolishment of outward currents, whereas following activation with non-electrophilic compounds 
this receptor demonstrates predominantly outward rectification (Nilius et al., 2012;Andrade et al., 
2012). The induction of inward currents is a result of the electrophilic modification of N-terminal 
cysteine residues of the protein that results in the dilation of the pore. The products of oxidative 
stress are produced as a result of an imbalance of the production and neutralization of oxidative 
substances, and the interaction between them and TRPA1 is an important mechanism for 
detecting tissue damage under inflammatory conditions. 
 
Due to the expression of TRPA1 on sensory neurons, this receptor has been implicated in both 
mechanotransduction and the transmission of cold sensitivity, especially at noxious thresholds. 
TRPA1 knock-out mice show deficits in the sensation of noxious punctuate mechanical stimuli 
(Kwan et al., 2006), as well as deficits in the mechanosensory function of nociceptors in the pelvic 
and splanchnic nerves which contribute to the maintenance of GI motility (Brierley et al., 2009). In 
models of gastric distension the up-regulation of TRPA1 is accompanied by visceral 
hypersensitivity which can be attenuated by the administration of a selective TRPA1 antagonist 
(Yang et al., 2008;Kondo et al., 2009).  The contribution of TRPA1 to the transmission of cold 
sensitivity is more controversial. Two separate knock-out animals have been developed; whilst in 
both instances the portion of the gene knocked out was the same (a sequence encoding a region 
between the fifth and sixth transmembrane domains required for ion conduction), Bautista et al 
working with one knock-out have reported normal responses to cold temperatures in vivo and in 
vitro (Bautista et al., 2006), whilst Kwan et al working with a second knock-out have reported that 
these mice have a significant deficit in cold sensation (Kwan et al., 2006). This deficit has been 
confirmed by a second group using this same mouse; TRPA1-/- mice showed longer latencies for 
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paw withdrawal from a 10oC (noxious) stimulus than wild-type litter mates and cold 
hypersensitivity induced by methanol was absent in these animals (Gentry et al., 2010).  
 
Due to its role in the transmission of noxious stimuli, and its activation by a number of irritants and 
products of tissue damage, TRPA1 has been suggested as a viable target for the development of 
analgesics for both inflammatory and neuropathic pain. Following the induction of an 
inflammatory injury (intraplantar CFA), TRPA1 mRNA is up-regulated at sites distant to the original 
injury, such as the DRG; this is associated with increased sensitivity to noxious cold (hyperalgesia) 
that, interestingly, cesses to occur as TRPA1 expression returns to pre-injury levels (da Costa et al., 
2010;Obata et al., 2005). Additionally the development of both cold and mechanical hyperalgesia 
can be prevented in the CFA inflammatory model by the systemic administration of the selective 
TRPA1 antagonists AP-18 and HC-030031 (da Costa et al., 2010;Petrus et al., 2007;Eid et al., 2008), 
and in models of inflammatory arthritis TRPA1 knock-out mice showed a reduction in the 
development of mechanical hyperalgesia (Fernandes et al., 2011). It should be noted that TRPA1 
does not appear to contribute to the inflammatory process itself, rather it contributes to 
nociceptive transmission; the inflammatory components of these models, such as articular 
inflammation, mononuclear cell infiltration and bone erosion are not reduced in TRPA1 knock-out 
mice (Fernandes et al., 2011), but TRPA1 antagonists are able to reduce the response of wide 
dynamic range neurons to noxious pinch and decrease the spontaneous firing of neurons in 
arthritis-inflamed rats (McGaraughty et al., 2010). The mechanism by which TRAP1 is upregulated 
in these inflammatory states is thought to be NGF-p38 MAPK dependent; p38 MAPK is activated 
by noxious cold and sensitizes TRPA1 causing, in turn, TRPA1-dependent hyperalgesia (Obata et 
al., 2005). NGF is one of many growth factors found to be upregulated in peripheral tissues in 
response to injury (Malin et al., 2006;Stucky et al., 2009).  
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In a similar fashion to that of an inflammatory injury, the expression of TRPA1 is elevated by nerve 
injuries that result in the development of neuropathic pain, for example spinal nerve ligation, 
where the over-expression of TRPA1 is essential for the development of cold hyperalgesia (Obata 
et al., 2005). However rather than occurring in the DRG that corresponds to the damaged nerve, 
TRPA1 is up-regulated in nearby uninjured DRG, suggesting a compensatory effect (Katsura et al., 
2006). The increased expression of TRPA1 mRNA following nerve injury does correspond to an 
increase in function protein; TRPA1 protein is over-expressed in Aδ fibres and its pharmacological 
antagonism attenuates cold hyperalgesia caused by nerve injury without altering noxious cold 
sensitivity in uninjured animals (Chen et al., 2011;Ji et al., 2008). 
 
156B .3.4. TRPA1 in chemotherapy pain 
Following incubation with cisplatin or oxaliplatin cultured DRG neurons show an increased 
expression of TRPA1, in a pattern similar to the increase in expression of this receptor observed in 
the trigeminal ganglia of cisplatin treated mice (Ta et al., 2010). Additionally oxaliplatin is able to 
induce calcium responses in TRPA1 transfected cells CHO cells (Nassini et al., 2011) and the 
mechanical and cold allodynia occurring as a result of bortezomib, PTX or oxaliplatin treatment are 
attenuated in TRPA1 knock-out mice (Trevisan et al., 2013) or by blockade of the receptor with the 
TRPA1 antagonist HC-030031 (Nassini et al., 2011;Materazzi et al., 2012). Interestingly the ability 
of chemotherapeutics to activate TRPA1 may not be direct, rather they may occur as a result of an 
increase in reactive oxygen species that in turn activate the TRPA1 receptor; oxaliplatin or cisplatin 
induced and increase in intracellular calcium levels in TRPA1 transfected CHO cells are ablated by 
the addition of the anti-oxidant ROS scavenger glutathione (Nassini et al., 2011). Peroxynitrite is 
increased in nervous tissues of animals receiving PTX, and the reduction of superoxide production 
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by the administration of an NADPH-oxidase inhibitor attenuates chemotherapy induced 
mechanical allodynia (Doyle et al., 2012), as does the administration of the anti-oxidant acetyl-L-
carnitine (ALC) (Flatters et al., 2006;Ghirardi et al., 2005a;Ghirardi et al., 2005b) . These studies 
have led to the suggestion that targeting either TRPA1 or reactive oxygen species are likely to be 
beneficial in reducing the pain related behaviours that develop following chemotherapy 





88B1.4. Chapter aims 
 
The attenuation of mechanical allodynia by the CatS inhibitor LHVS and in CX3CR1 knock-out mice 
establishes a role for CX3CL1 signalling in the development and/or maintenance of chronic pain 
following nerve injury. Additionally an association of this chemokine with leukocyte 
transendothelial migration has been discussed, and an association between treatment with 
chemotherapeutic agents and endothelial dysfunction has been suggested. Here we hypothesise 
that VCR activates endothelial cells, which is associated with the increased expression of adhesion 
molecules and the chemokine CX3CL1. Furthermore, we hypothesise that CX3CL1 activates 
monocytes as they transmigrate across the endothelium, causing them to release pro-nociceptive 
mediators; thus, the aims of this chapter are: 
 To establish the effect of inhibiting CX3CL1 cleavage on the development of VCR-induced 
mechanical allodynia in mice. 
 To determine the effect of VCR treatment of the protein expression and morphology of 
endothelial cells in vivo and in vitro. 
 To determine the effect of CX3CL1 treatment on the production of pro-nociceptive 
mediators from monocyte/macrophages. 
 To ascertain the suitability of TRPA1 as a therapeutic target for the prevention of VCR-







89B2.1. Induction of vincristine induced painful peripheral neuropathy and drug treatment 
 
157B2.1.1. Animals 
Unless otherwise stated, all experiments were performed using adult male C57Bl/6 mice (22-27g; 
10-14 weeks from Harlan UK or bred in house), in accordance with The Animals Scientific 
Procedures Act (ASPA) 1986, United Kingdom Home Office regulations and institutional guidelines. 
Animals were individually housed (to prevent aggressive behaviour) on a 12 hour light / 12 hour 
dark cycle at 21-22oC, with food and water ad libitum. 
 
158B2.1.2. Generation and breeding of CX3CL1-mCherry mice 
To produce experimental CX3CL1-mCherry heterozygous mice, an original breeding stock of 
CX3CL1-mCherry homozygous mice (CX3CR1
mCherry/mCherry) was kindly gifted to us by Dr Steffen Jung 
(Weizmann Institute of Science). The original CX3CR1-mCherry mice were generated using a RedET 
recombination system to replace the first exon of the cx3cl1 gene with a gene encoding a 
monomeric mcherry reporter gene. The desired transgene was extracted and injected into 
fertilised CB6F1 oocytes to establish transgenic mice. These were then back-crossed onto a 
C57Bl/6 background for a minimum of 8 generations. CX3CL1
mCherry/mCherry homozygous mice were 
mated with wild-type C57Bl/6 mice to produce heterozygous (CX3CL1
+/mCherry) offspring (Kim et al., 
2011). Litters were weaned at 21 days and group housed (up to 5 per cage) in single sex cages. 
Both male and female animals were used for behavioural studies from ten weeks old, at which 
time they were singly housed and allowed to acclimatise to their new cage for one week.  
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159B2.1.3. Generation and breeding of TRPA1-/- mice 
An experimental cohort of TRPA1-/- mice was kindly gifted to us by Professor Stuart Bevan; these 
mice were breed from heterozygous breeding pairs provided by Dr Kelvin Kwan and Dr David 
Corey (Harvard Medical School). The original TRPA1-/- mice were generated by the insertion of a 
targeting vector (containing an internal ribosomal entry site and a placental alkaline phosphatase 
gene [IRES PLAP]) into the exon encoding the pore domain of TRPA1. To prevent the production of 
a truncated TRPA1 product an endoplasmic reticulum retention signal and stop codon were 
inserted upstream of the IRES PLAP cassette; this results in the deletion of the pore-forming region 
and renders the channel non-conducting. This newly created vector was transfected into murine 
embryonic stem cells. These were subsequently injected into blastocysts to generate germ-line 
chimeric mice that were then mated with wild-type C57Bl/6 mice to generate heterozygous 
(TRPA1+/-) offspring (Kwan et al., 2006). Breeding pairs were then established to produce offspring 
of various genotypes (homozygous wild-type [TRPA1+/+], heterozygous [TRPA1+/-] and homozygous 
knock-out [TRPA1-/-]) in a ratio of 1:2:1. Litters were weaned at 21 days and group housed (up to 5 
per cage) in single sex cages. Animals were used for behavioural studies from ten weeks old, at 
which time they were singly housed and allowed to acclimatise to their new cage for one week. 
Both male and female animals were used, with wild-type littermates serving as a control. 
 
160B2.1.4. Vincristine induced painful peripheral neuropathy 
VCR neuropathy was induced as previously described in chapter two; briefly VCR (Sigma, UK) was 
dissolved in sterile saline and 0.5mg/kg was injected into the peritoneal cavity (intraperitoneally 








Figure 4.4. Experimental schedule for behavioural assessment and drug dosing. Blue boxes represent 
cycles of VCR treatment, green boxes represent cycles or LHVS treatment and red arrows represent study 
days behavioural phenotype was assessed. Behavioural tests were performed approximately 1 hour after 




162B .1.5. Cathepsin S inhibitor (LHVS) treatment 
The irreversible Cathepsin S inhibitor LHVS (morpholinurea-leucine-homophenylalanine-vinyl 
sulfone-phenyl [NeoMPS Inc, USA]) was dissolved in sterile saline containing 20% cremophor (v/v) 
and 30mg/kg was injected into the peritoneal cavity (intraperitoneally[ i.p.]), using a 30G needle, 
















twice daily (am and pm) for five days one hour prior to VCR treatment, as shown in figure 4.4A 
above. [Performed by Tom Pitcher]. 
 
90B2.2. Behavioural testing 
163B2.2.1. Assessment of mechanical sensitivity 
Mechanical sensitivity was assessed as described in chapter two. Data are expressed as 50% paw 
withdrawal threshold, in grams, calculated using the method described by Dixon (Dixon 1980). 
 
164B2.2.2. Assessment of cold sensitivity 
Cold sensitivity was assessed as described in chapter two. Data are expressed as withdrawal 
latencies in seconds. [Performed by Clive Gentry]. 
 
165B2.2.3. Statistical analysis of behavioural data 
Statistical analysis behavioural data was carried out on raw data, using SigmaPlot 12.0 software 
(Systat Software Inc, UK). Data are shown as mean ± standard error of the mean (SEM) and 
analysed by two-repeated measures analysis of variance (ANOVA) followed by Tukey post-hoc 
test. A p value of less than 0.05 (P<0.05) was considered significant (*), less than 0.01 (P<0.01) 




166B2.3.1. Ear biopsy and DNA extraction 
Ear biopsies and DNA extraction were performed as described in chapter three. 
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167B2.3.2. CX3CL1-mCherry PCR 
A single PCR reaction was performed for each DNA sample. A PCR reaction master mix was made 
for each allele (wild-type and knock-out) consisting of 3mM MgCl2 (Promega, UK), 20% (v/v) 5x 
reaction buffer (Promega, UK), 100µM dNTP (Promega, UK), 50 units/ml Taq DNA polymerase 
(Promega, UK) and 0.1µM forward and reverse oligonucleotide primer (Sigma, UK). The forward 
and reverse oligonucleotide primers had the sequences 5’CCAGCCGCGAGTGACTAC 3’ and 5’ 
CCCCAGGGAGATGCAGTC 3’ respectively. Each reaction consisted of 2µl of 1:10 diluted DNA and 
23µl of PCR master mix. The PCR reaction was performed in a TC412 Flexigene thermal cycle 
(Techne, UK) with an initial denaturation step of 95oC for 5 minutes, followed by 34 cycles with a 
denaturation at 94oC for 30 seconds, annealing at 60oC for 30 seconds and polymerisation at 120oC 
for 30 seconds. This was then followed by a final extension step at 72oC for 5 minutes. The 
expected sizes of the end products were 300bp for the wild-type CX3CL1 gene and 1000bp for the 
CX3CL1-mCherry gene. 
 
168B2.3.3. Gel electrophoresis and band visualisation 
To visualise the PCR products a gel electrophoresis was performed. Post- PCR samples were loaded 
onto, and run down, a 2% agarose gel containing 100µg/ml ethidium bromide (Sigma, UK), at 100V 
for 25 minutes using a Power Pac 200 (BioRad, UK). A 1kb DNA ladder was also run down each gel 
to allow for the sizes of the products to be easily determined. The gels were viewed using a 
GeneGenius system (Syngene, UK) and images collected using the GeneSnap programme 
(Syngene, UK). All samples from experimental and breeding animals underwent a repeat analysis 
to reduce the likelihood of both false positive and false negative results. 
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92B .4. Assessment of CX3CL1 in plasma 
169B2.4.1. Blood collection 
Approximately one hour after their last dose of VCR (or vehicle) mice were euthanised by 
exposure to an increasing concentration of CO2. Using a 25G 25mm (VWR, UK) needle attached to 
a 1ml syringe (VWR, UK) a cardiac puncture was performed; the needle was inserted into the chest 
wall, at the approximate level of the diaphragm, through the sternum, and approximately 0.8ml of 
blood drawn. This was then transferred to a 1.5ml Eppendorf containing heparin coated beads 
(Sarstedt, Germany) before gently shaking. Samples were stored on ice and then centrifuged at 
2000g for 20 minutes to separate plasma from cells. Plasma (supernatant) was transferred to fresh 
tubes and stored at -20oC. 
 
170B2.4.2. CX3CL1 ELISA 
CX3CL1 content of plasma samples was assessed by ELISA using a Quantikine CX3CL1/fractalkine 
ELISA kit (RnD Systems, UK) as per manufacturer’s instructions. Briefly assay diluents and plasma 
samples or kit supplied standards (0.62-40ng/ml) or controls were added to the plate and 
incubated for two hours before washing. Mouse CX3CL1 conjugate was subsequently incubated in 
the wells for two hours prior to further washing. Substrate solution was added to the wells and 
incubated, protected from light, for 30 minutes before a stop solution was added and the optical 
density analysed at 450nm wavelength (with wavelength correction at 540nm) using a Flexstation 
plate reader (Molecular Devices, USA). All standards, controls and samples were run in duplicate. 
Optical density for each sample was calculated by averaging the duplicate values. Statistical 
analysis was carried out on raw data, using SigmaPlot 12.0 software (Systat Software Inc, UK) and 
data are shown as mean ± standard error of the mean (SEM). Data was analysed for statistical 
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significance by one-way analysis of variance (ANOVA) followed by Dunnett post-hoc test. A p value 
of less than 0.05 (P<0.05) was considered significant (*), less than 0.01 (P<0.01) moderately 
significant (**) and less than 0.001 (P<0.001) highly significant (***). 
 
93B2.5. Immunohistochemistry 
171B2.5.1. Tissue preparation 
Mice, under pentobarbital anaesthesia (Sodium pentobarbital, 200mg/ml; Euthatal; Merial Animal 
Health, UK), were transcardially perfused with saline solution (0.9% NaCl [VWR, UK] w/v, 0.1% 
heparin sodium [5000units/ml, Leo Laboratories Ltd, UK]), followed by 4% paraformaldehyde in 
0.1M phosphate buffer (containing 1.5% picric acid [Sigma, UK] v/v). The sciatic nerves were 
exposed by an incision from knee to hip and a 15-20mm section excised. Nerves were post-fixed 
for 2 hours in the perfusion fixative before being cryoprotected in 20% sucrose in 0.1M phosphate 
buffer at 4oC for a minimum of 72 hours. Following cryoprotection tissues were embedded in 
optimum cutting temperature embedding medium (OCT) (VWR, UK) and frozen in liquid nitrogen. 
Transverse sections of the nerve were cryostat cut (Bright Instruments, UK) at 15µm thick and 
thaw-mounted onto glass microscope slides (VWR, UK). Slides were stored in cryoprotectant (PBS 
containing 20% w/v sucrose [VWR, UK] and 30% v/v ethylene glycol [VWR, UK]) at -20oC until use. 
 
172B .5.2. Immunohistochemical staining 
Slides were washed six times for 5 minutes in PBS and incubated over night at room temperature 
with a primary antibody, mouse anti-mCherry (1:500, Abcam [UK]) or goat anti-CD31 (1:500, R&D 
Systems [UK]), in PBS-Tx-Az. Slides were then washed three times for 5 minutes in PBS and 
incubated at room temperature, in the dark, with an appropriate secondary antibody (1:1000 
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donkey anti-mouse IgG-conjugated Alexa Fluor 546TM, Molecular Probes [USA] or donkey anti-goat 
IgG-conjugated Alexa Fluor 488TM, Molecular Probes [USA])  for 2.5-3 hours. Following three 
further PBS washes slides were cover-slipped with Vectashield mounting media with DAPI (Vector 
Laboratories, USA) and visualised under a Zeiss Axioplan 2 fluorescent microscope (Zeiss, UK). 
 
173B2.5.3. Quantification of immunohistochemistry 
The number of positive cells for each immunohistochemical marker was determined. Three tissue 
sections per animal were selected at random with experimental group blinded. The number of 
cells positive for the given marker was counted in the total nerve area. 
 
174B2.5.4. Statistical analysis of immunohistochemical data 
Statistical analysis for immunohistochemistry was carried out on raw data, using SigmaPlot 12.0 
software (Systat Software Inc, UK). An average cell number per animal was calculated and 
subsequently a mean value for each experimental group. The groups compared to one another 
using a one-way analysis of variance (ANOVA) followed by Tukey post-hoc test. Group difference 
with a P value of less than 0.05 (P<0.05) was considered significant. 
 
94B2.6. Culture of endothelial cells 
175B2.6.1. Endothelial cell culture 
A primary HUVEC (human umbilical vein endothelial cells) line was obtained from HPA culture 
collections and cultured in accordance to their guidelines. Briefly cells were maintained in 
endothelial cell culture media (40% DMEM, 40% HAM-12, 20% FBS [Invitrogen, UK] containing 
50mg/L endothelial growth supplement [AbD Serotec, UK], 100mg/L heparin sodium [Sigma, UK] 
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and 1% penicillin/streptomycin [Invitrogen, UK]) at 37oC and 5% CO2 until they reached 
approximately 95% confluency. Cells were then passaged by removal of the media and incubation 
with 0.25% tyrpsin-EDTA (Invitrogen, UK) for 1 minute. An equal volume of FBS (Invitrogen, UK) 
was added and the resulting suspension centrifuged at 220g for 5 minutes. The supernatant was 
removed and the cell pellet resuspended in endothelial media before cells were plated as a 1:4 
split. 
 
176B2.6.2. Endothelial cell treatment 
For Western blot experiments cells were plated in 6-well plates (Nunc, UK), for ELISA experiments 
cells were plated in 24-well plates (Nunc, UK) or for immunocytochemistry cells were plated on 
glass cover-slips in 24-well plates (Nunc, UK). Cells were grown to approximately 95% confluency 
for Western blot and ELISA experiments, approximately 90% confluency for immunocytochemistry 
and 75% confluency for live-dead analysis. A stock solution of VCR (1mg/ml VCR; Sigma, UK) was 
made by dilution of the salt in sterile PBS (Invitrogen, UK), this was subsequently diluted in 
endothelial cell culture media to the required concentration and cells incubated in this at 37oC and 
5% CO2. 
 
177B2.6.3. Live-dead assay 
The Live/Dead cell viability assay (Invitrogen, UK) was performed as described in the 
manufacturer’s guidelines. Briefly, following treatment of HUVEC cultures with VCR or 70% 
methanol as a positive ‘dead’ control, culture media was removed and the cells washed once with 
sterile PBS. Cells were incubated in PBS containing 1µm calcein (green) and 2µm EthD-1 (red) dyes 
at room temperature for 30 minutes whilst protected from light. Following incubation cell cover-
267 
 
slips were mounted onto glass microscope slides, using the assay solution as a mounting medium, 
and the cells visualised using a Zeiss Axioplan 2 fluorescent microscope (Zeiss, UK). Five areas of 
the cover-slip were selected at random and an image taken at x20 magnification; these images 
were used for quantification by counting the total number of cells stained red (dead) and green 
(live). Statistical analysis of the data was performed on raw data using SigmaPlot 12.0 software 
(Systat Software Inc, UK). An average percentage of live cells per cover-slip (equal to one well) was 
calculated and subsequently an average for the treatment group per experiment. Five cover-slips 
per group were analysed in each culture experiment and the experiment repeated in triplicate. 
Data presented are mean ± SEM of each experiment; groups are compared to one another using a 
one-way analysis of variance (ANOVA) followed by Tukey post-hoc test. Group difference with a P 
value of less than 0.05 (P<0.05) was considered significant. 
 
178B2.6.4. Endothelial cell morphology assessment 
Following treatment with VCR, cells were fixed by incubation in 4% PFA solution (4% 
paraformaldehyde [Sigma, UK] in 0.1M phosphate buffer) for 30 minutes followed by 3 minutes in 
cold methanol (Sigma, UK). Following 3 washes with PBS cells were incubated in a primary 
antibody solution (goat anti-β-tubulin 1:200 [Sigma, UK]) for 2.5 hours followed by a 45 minute 
incubation in secondary antibody solution (anti-goat IgG-conjugated Alexa Fluor 488TM 1:1000 
[Molecular Probes, USA]). Cover-slips were mounted onto glass microscope slides with Vectashield 
mounting media with DAPI (Vector Laboratories, USA) and visualised under a Zeiss Axioplan 2 
fluorescent microscope (Zeiss, UK).  
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179B2.6.5. CX3CL1 ELISA 
Cells were treated with vehicle or VCR when they reached approximately 95% confluency in a total 
volume of 210µl. CX3CL1 content of media samples was assessed by ELISA using a Quantikine 
CX3CL1/fractalkine ELISA kit (RnD Systems, UK) as per manufacturer’s instructions, and as 
described above. Statistical analysis was carried out on raw data, using SigmaPlot 12.0 software 
(Systat Software Inc, UK) and data are shown as mean ± standard error of the mean (SEM). Data 
was analysed for statistical significance by one-way analysis of variance (ANOVA) followed by 
Dunnett post-hoc test. A p value of less than 0.05 (P<0.05) was considered significant (*), less than 
0.01 (P<0.01) moderately significant (**) and less than 0.001 (P<0.001) highly significant (***). 
 
180B2.6.6. HUCEV phenotyping FACs 
For these experiments use of primary HUVEC was approved by the East London & The City 
Research Ethics Committee (REC Ref 06/Q0605/40 ELCHA, UK). Cells were seeded into 12-well 
plates coated with gelatin and incubated in DMEM (Invitrogen, UK) containing 10% FBS 
(Invitrogen, UK) overnight until confluency was reached. HUVEC were then treated with either 
10ng/ml human TNFα (R & D Systems Ltd, UK) or 10nM VCR (Sigma, UK) for 18 hours. Cells were 
then gently trypsinised (0.25% trypsin-EDTA [Invitrogen, UK] 1-2 minutes), re-suspended in 
complete Medium-199 (GE Healthcare, UK), washed and stained with either PE-conjugated ICAM-
1 (clone HA58; eBioscience, UK), FITC-conjugated VCAM-1 (clone 1.G11B1; AbD Serotech, UK) or 
PE-conjugated CD31 (clone WB59; Biolegend, UK). Cells were incubated on ice for 30 minutes then 
washed twice with PBS containing 1.5% BSA (Sigma, UK) and re-suspended before analysis on a BD 




95B2.7. Primary macrophage culture 
181B2.7.1. Primary macrophage culture 
To encourage monocyte/macrophage infiltration of the peritoneal cavity 1ml of polyacrylamide 
biogel beads (BioRad, UK) was injected into the peritoneal cavity of CX3CR1 wild-type (CX3CR1
+/+) 
or knock-out (CX3CR1
-/-) mice to induced a sterile inflammation. After four days the cell infiltrate 
was collected by peritoneal lavage; the peritoneal cavity was flushed with 8ml of cold sterile PBS 
(Invitrogen, UK) containing 3mM EDTA (Invitrogen, UK) by injection into the cavity with a 25G 
needle, avoiding perforation of the bowel. The abdomen was gently massaged and the fluid 
aspirated, filtered through a 75µm nylon mesh and the cells collected on ice. Cell suspensions 
were centrifuged at 220g for 10 minutes and resuspended in macrophage culture medium (DMEM 
[Invitrogen, UK] containing 10% FBS [Invitrogen, UK] and 1% penicillin/streptomycin [Invitrogen, 
UK]) for seeding onto culture plates.  
 
182B .7.2. ROS Production 
Macrophages from both CX3CR1 wild-type (CX3CR1
+/+) and knock-out (CX3CR1
-/-) mice were seeded 
at 2 x 105 cells/well in 96-well plates (Nunc, UK) and left to adhere in RPMI-1640 media (GE 
Healthcare, UK) containing 10% FBS (Invitrogen, UK) at 37oC for 1 hour. Cells were washed with 
warm PBS and incubated with freshly prepared RPMI-1640 media supplemented with 10% FBS and 
60µM luminol (Sigma, UK). Macrophages were then treated with either phorbol-12-myristate-13-
acetate (PMA 100ng/ml; Sigma, UK) or CX3CL1 (recombinant mouse CX3CL1 chemokine domain 
aa25-105; R&D Systems, UK). ROS production was monitored on a Novostar plate reader (BMG 
Labtech) at 37oC. [Performed by Dr Suchita Nadkarni]. 
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96B2.8. Western Blotting 
183B2.8.1. Sample preparation 
Following treatment, media was removed from cells and 130µl of lysis buffer consisting of 20 mM  
tris(hydroxymethyl)aminomethane (Tris- HCl [Sigma, UK]) pH 7.5; 10 mM NaF (Sigma, UK); 150 
mM NaCl (VWR, UK); 1% nonyl-phenoxylpolyethoxylethanol (NP-40, Sigma, UK); 1 mM 
Phenylmethanesulfonyl fluoride (PMSF, Sigma, UK); 1 mM Na3VO4 (Sigma, UK); 10 mg/ml 
proteinase inhibitor (Roche, UK), was added to each well and the plates incubated on ice for 30 
minutes. Using a cell scraper lysates were removed from the wells and the supernatants collected 
following centrifugation at 100,000g for 15 minutes at 4oC. Samples were stored at -80oC until use.  
 
184B2.8.2. BCA protein assay 
The protein concentrations of cell lysates were determined using the Pierce bicinchoninic acid 
(BCA) protein assay kit (Thermo Scientific, UK), performed in accordance to the instructions 
provided by the manufacturer and using bovine serum albumin (BSA 2mg/ml, Sigma, UK) as a 
standard. Briefly the two provided reagents, A (Na2CO3, NaHCO3, BCA and Na2C4H4O6 in 0.1M 
NaOH) and B (CuSO4) are mixed together in a ratio of 50:1, 200µl of the resulting solution are 
added to 10µl of each sample, in duplicate, in a 96-well culture plate (Nunc, Germany). Following a 
30 minute incubation in the absence of light, light absorbance at 563nm was measure using a 
Flexstation (Molecular Devices, USA). A standard curve was generated from the BSA standards and 
the protein concentrations of samples calculated from this. 
 
185B2.8.3. Gel electrophoresis 
Equal amounts of protein were mixed with loading buffer (10% w/v SDS [Sigma, UK], 10mM β-
mercaptoethanol [Sigma, UK], 20% v/v glycerol [VWR, UK], 200mM Tris-HCL [Sigma, UK] and 0.05% 
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w/v bromophenol blue [Sigma, UK]) in a 5:1 ratio and the protein denatured by heating to 95oC for 
5 minutes. Protein samples were separated on 8-12% SDS-polyacrylamide gels, alongside a 
complete protein marker (Fermentas, UK), in running buffer (25mM Tris-HCl [Sigma, UK], 200mM 
glycine [Sigma, UK], 10% w/v SDS [Sigma, UK]) at 90-100V for approximately 70-100 minutes using 
a PowerPac 200 (BioRad, UK). 
 
186B2.8.4. Visualisation of proteins 
To allow visualisation, proteins were transferred to PVDF membranes (Immobilon 0.45µm, 
Millipore, UK) in ice cold transfer buffer (25mM Tris-HCl [Sigma, UK], 200mM glycine [Sigma, UK], 
20% v/v methanol [VWR, UK], pH7.4) at 100V for 60 minutes. Membranes were then blocked in 
TBS-T (tris buffered saline) containing 5% w/v non-fat dried milk at room temperature for 60 
minutes, before being incubated overnight at 4oC in the presence of a primary antibody, goat anti-
human CX3CL1 (1:500, R&D Systems, UK). Membranes were then incubated with the appropriate 
horseradish peroxidase-conjugated secondary antibody (1:2000, anti-goat HRP conjugate [Dako, 
UK]) at room temperature for 60 minutes. Blots were washed three times with TBS-T and twice 
with PBS before being developed using Amersham ECL Plus western blotting detection system (GE 
Healthcare, UK) and exposed to Amersham Hyperfilm ECL (GE Healthcare, UK). Blots were then 
scanned and the density of the protein bands quantified using Quantity-One 1D Analysis Software 
(BioRad, UK). 
 
187B2.8.5. Membrane stripping 
To allow re-probing of a loading control, western blot membranes were stripped of their initial 
primary/secondary/ECL complex. Membranes were incubated in stripping buffer (TBS-T containing 
1% SDS and 0.1% β-mercaptoethanol) at 60oC for 30 minutes before being washed under running 
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dH20 for 5 minutes, washed three times in TBS-T, blocked for 60 minutes in TBS-T containing 10% 
non-fat dried milk and incubated in a primary antibody against GAPDH (1:500 rabbit anti-GAPDH 
[Sigma, UK]) and secondary antibody (1:2000, anti-rabbit HRP conjugate [Dako, UK]) as above. 
 
188B2.8.6. Statistical analysis of western blot data 
All densometric values were normalised to GAPDH bands, which was used to adjust for any 
uneven protein loading. Statistical analysis for western blots was carried out on this normalised 
data, using SigmaPlot 12.0 software (Systat Software Inc, UK). A mean value for each experimental 
group was then calculated, and the groups compared to one another using a Student’s t-test. 
Group difference with a P value of less than 0.05 (P<0.05) was considered significant. Data shown 





39B . Results 
 
In chapter three we established a role for the chemokine receptor CX3CR1 in the development of 
VCR-induced painful peripheral neuropathy; mice lacking this receptor show a delayed onset of 
pain. Here we have performed a series of experiments to determine the expression profile and 
role in the development of pain of this receptors ligand, CX3CL1. 
  
97B3.1. Inhibiting the cleavage of CX3CL1’s chemokine domain prevents the development of 
mechanical allodynia induced by VCR 
 
A wealth of literature exists describing the relationship of membrane bound CX3CL1 with its 
receptor CX3CR1 and their role in the transmigration of monocyte/macrophage; indeed we have 
shown that this relationship is essential for the development of pain following VCR treatment. 
However it is in its cleaved form that CX3CL1 is able to activate intracellular signalling pathways 
downstream of CX3CR1. To determine the necessity for this cleavage on the development of VCR-
induced mechanical allodynia we blocked this process with the irreversible CatS inhibitor LHVS. To 
determine the potential of this inhibitor as a prophylactic, LHVS was administered one hour prior 




Figure 4.5. Chronic administration of a Cathepsin S inhibitor (LHVS) delays the onset of VCR-induced 
mechanical allodynia. Development of mechanical allodynia following i.p. VCR (0.5mg/kg/day; 0-4 and 7-11; 
black horizontal bars), when administered with twice daily i.p. LHVS (or vehicle). (A) Time course of the 
development of mechanical allodynia shown as 50% paw withdrawal threshold (PWT), data are mean ± SEM. 
N=8 per group, ***P<0.001 vs baseline threshold, ### P<0.001 vs saline threshold, ††† P<0.001 vs vehicle 
threshold, two-way repeated measures ANOVA with post-hoc Holm-Sidak test. (B) Area under the curve 
(AUC) analysis with data expressed as allodynia index. All time is the analysis of AUC for baseline-day 24, first 
cycle baseline-day 4, second cycle day 7-day 11 and recovery day 11-day 24. Data shown are mean ± SEM. 
N=8 per group, ### P<0.001 compared to saline threshold, ††† P<0.001 compared to vehicle threshold with 







































































































































0 1 65 15 2172 17 19 2313
VCR






















































The data presented in figure 4.5 confirms that administration of VCR (0.5mg/kg i.p.) for five 
consecutive days (days 0-4; first cycle, cumulative dose 2.5mg/kg), followed by a two day pause 
and second subsequent cycle of treatment (five consecutive days; 7-11, cumulative dose 
5.0mg/kg) was associated with significant and severe hind-paw mechanical hypersensitivity (figure 
4.5A; VEH-VCR). However, mice receiving twice daily LHVS (LHVS-VCR) failed to develop significant 
allodynia for the first cycle of chemotherapy (figure 4.5A; LHVS-VCR), exhibiting only a 14.8% 
(±10.9) reduction in allodynia index (figure 4.5B; first cycle) compared to a 76.9% (±2.1) reduction 
in vehicle-VCR treated animals. It should be noted that the mechanical thresholds of LHVS-VCR 
mice are not statistically significant from those of saline-treated control animals during this first 
cycle.  
 
Following the cessation of LHVS treatment, during the administration of a second cycle of VCR, 
these mice (LHVS-VCR) went on to develop mechanical allodynia comparable to the same extent 
as vehicle treated animals (figure 4.5A day 14). However the decline in mechanical threshold they 
experience was much more gradual than that which occurred in vehicle treated animals during the 
first VCR cycle, and the allodynia index of LHVS-VCR animals remains significantly higher than that 
of VEH-VCR mice during the second cycle; this is demonstrated by the area under the curve 
analysis of the second VCR cycle time-points, where a significant difference is seen in the allodynia 
indices of VEH-VCR and LHVS-VCR mice (figure 4.5B; second cycle). No difference between the 
rates of recovery was seen between these two groups. These data show that the systemic 





98B3.2. VCR treatment does not alter CX3CL1 expression in vivo 
 
In the periphery CX3CL1 is constitutively expressed on endothelial cells. It has been established 
that spinal CX3CL1 plays a key role in the development of neuropathic pain; inhibiting its cleavage 
or neutralising its action with an antibody attenuates pain behaviours in models of peripheral 
nerve injury. We set out to determine whether or not VCR treatment alters the level of expression 
of this protein on endothelial cells within the nerve, using a mouse expressing CX3CL1 with an 
mCherry tag. 
 
                                                
 
Figure 4.6. Genotyping electrophoresis of PCR samples from CX3CL1-mCherry mice. Representative image 
of agarose gel following electrophoresis of PCR products with homozygous knock-in mice (lane 1) and wild-
type mice (lane 3) yielding a 300bp product, yielding a 1000bp product and heterozygous mice yielding both 
(lane 2).  
 
Prior to all experiments, mice were genotyped to confirm expression of wild-type CX3CL1 protein 
and CX3CL1-mCherry protein. As figure 4.6 demonstrates wild-type mice (CX3CL1






single transcript of approximately 300bp and homozygous mCherry (CX3CR1
mCherry/mCherry) mice 
express a single, larger transcript of approximately 1000bp, whilst heterozygous CX3CR1
+/mCherry 
mice express one wild-type (300bp) and one mCherry transcript (1000bp). Genotyping was 
performed twice (to remove false positives) and only heterozygous mice selected for 
experimentation. 
 
Whilst previous assessment of the function of CX3CL1 in these mice has suggested that the 
mCherry tag does not affect function, we have demonstrated that the normal interaction between 
this protein and its receptor CX3CR1 is critical for the development of pain in our model. Thus we 
first assessed the mechanical thresholds in CX3CR1
+/mCherry mice to ensure the mCherry expression 
was not influencing the function of this protein. This was indeed the case; the systemic 
administration of multiple VCR cycles to CX3CL1-mCherry mice was associated with the 
development of severe and sustained hind-paw mechanical allodynia (figure 4.7A) with 
mechanical thresholds and allodynia indexes (area under curve analysis; figure 4.7B) being 
comparable to those of all previously tested wild-type mice (see chapter two). The maximum 
reduction in thresholds was also comparable to the reductions shown in wild-type (CX3CR1
+/+) mice 
(CX3CR1
+/mCherry 98.20% ± 0.27, CX3CR1




    
Figure 4.7. Heterozygous CX3CL1-mCherry mice develop severe sustained mechanical allodynia following 
VCR treatment. Development of mechanical allodynia following i.p. VCR (0.5mg/kg/day; days 0-4 and 7-11; 
black horizontal bars). (A) Time course of the development of mechanical allodynia shown as 50% paw 
withdrawal threshold (PWT), data shown as mean ± SEM. N=8 per group, ***P<0.001 vs baseline threshold, 
### P<0.001 vs saline threshold, two-way repeated measures ANOVA with post-hoc Holm-Sidak test. (B) 
Area under the curve (AUC) analysis showing data expressed as allodynia index. All time = BL-day 11, first 
cycle = Bl-day 4, second cycle = day 7-11. Data shown are mean ± SEM. N=8 per group, ### P<0.001 

































































































































             
 
Figure 4.8. VCR administration does not alter the number of endothelial cells expressing CX3CL1 in the 
nerve. (A) Representative images showing CD31+ (green) and mCherry+ / CX3CL1
+ (red) cells in the 
(transverse) sciatic nerve in vehicle (SAL) and VCR (day 11) treated animals. Scale bars equal 100µm and 
50µm in inserts. (B) Quantification of the number of CD31+ cells that are mCherry+ (CX3CL1
+) in the whole 
nerve section. Data shown are mean ± SEM and N=4 per group. No significant difference found (one-way 












































Using mice expressing CX3CL1-mCherry we set out to test the hypothesis that VCR administration 
causes an increase in CX3CL1 expression on endothelial cells which allows increased 
monocyte/macrophage transmigration; however the null hypothesis is in fact true. As figure 4.8 
demonstrates, under normal physiological conditions CX3CL1 is expressed by approximately 54% 
(54.07% ± 2.64) of endothelial cells found in the nerve, and whilst this trends slightly towards an 
increase following two cycles of VCR (Day 11; 60.62% ± 3.63) it is far from significant (P=0.319), 
indicating that VCR does not increase CX3CL1 expression.  
 
We next hypothesised that an increase in CX3CL1 was occurring but that the protein was being 
subjected to an increased rate of cleavage, so was subsequently released into the blood stream, 
where it would act as a chemoattractant to monocyte/macrophages. Thus we used a CX3CL1 ELISA 
to determine the blood plasma concentrations of CX3CL1 in vehicle treated animals (saline) and 
compared this to CX3CL1 plasma concentrations of mice following a single injection, a single cycle 
or two cycles of VCR (day 1,4 and 11 respectively). As figure 4.9 demonstrates no increase in 
plasma CX3CL1 concentration was observed at any time point tested, confirming the observation 




                                                  
 
Figure 4.9. VCR administration does not alter plasma concentration of CX3CL1. Plasma concentration of 
CX3CL1 as determined by ELISA following i.p. VCR (0.5mg/kg/day; days0-4 and 7-11). Data shown are mean ± 





99B3.3. VCR treatment alters endothelial cell morphology and expression of adhesion molecules, 
but not CX3CL1, in vitro 
 
To further assess changes to endothelial cells caused by VCR we established a culture system using 
a primary HUVEC line.  We first assessed the viability of cells treated with varying concentrations 
of VCR over increasing incubation times. As figure 4.9A/B demonstrates, no concentration of VCR 
tested had a significant impact of the viability of cells, however a reduction in the number of cells 
present was seen at the highest concentration tested (1000nm; figure 4.10C), albeit without a 
significant reduction in protein concentration of the cell lysates (figure 4.11); thus this 




























                  
 
Figure 4.10. Incubation with VCR does not affect viability of endothelial cells in vitro. (A) Representative 
images showing live (green) and dead (red) HUVEC/endothelial cells following incubation in 1000nM VCR for 
1-24 hours or 70% methanol (positive control). Scale bar equal 100µm. (B) Quantification of the percentage 
of live cells in each condition. Data shown are mean ± SEM and N=4 cultures. No significant difference found 
between VCR groups. (C) Quantification of the number of cells in each condition. Data shown are mean ± 
SEM per 2 x 105µm2. N=4 cultures, two way ANOVA followed by Holm-Sidak post-hoc. ***P<0.001, *P<0.05 
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Figure 4.11. Incubation with VCR does not affect protein concentrations of HUVEC lysates. Protein 
concentrations of HUVEC lysates following incubation with VCR (1000nm, 100nm, 10nm) for varying times 
(shown in hours), assessed by BCA protein assay. Data shown are mean ± SEM and N=5 culture. No 
significant difference found (two way ANOVA). 
 
 
Whilst not an accurate marker of cell morphology, the live/dead assay appeared to demonstrate 
that incubation with VCR caused endothelial cells to take on a more hypertrophied morphology 
than they possessed under control conditions. To further examine this change, endothelial cells 
that had been incubated with either 10nm or 100nm of VCR were stained for the structural 
protein β-tubulin. As figure 4.12 demonstrates, under control conditions endothelial cells 
associate closely with one another, forming a confluent monolayer, and under high magnification 
(figure 4.12C) the β-tubulin itself appears quite evenly distributed throughout the cell. However 
following incubation with VCR (in particular for 24 hours at a concentration of 100nm), cells take 
on a hypertrophied appearance and the β-tubulin appears less well defined and more 



























Figure legend to follow.   
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Figure 4.12. Incubation with VCR alters tubulin organisation and morphology of HUVEC in vitro. 
Representative images showing β-tubulin in HUVEC/endothelial cells following incubation in VCR for 0.5-24 
hours. (A) Low magnification images of 10nm VCR treated cells. Scale bar equal to 100µm (B) Low 
magnification images of 100nm VCR treated cells. Scale bar equal to 100µm (C) High magnification images of 
cells treated with 10nm and 100nm VCR or control media for 24 hours Scale bar equal to 20µm. 
  
















Western blot analysis of the protein content of endothelial cells treated with either 10nm or 
100nm VCR has demonstrated that, as in vivo, VCR does not increase the expression of CX3CL1 
(figure 4.13); these data are supported by FACS analysis of VCR treated primary HUVEC in which 
very little expression of CX3CL1 was almost undetectable under all conditions examined (figure 
4.15). Additionally, CX3CL1 could not be detected (by ELISA) in the media of these cells, indicating 
this VCR does not cause significant shedding of this protein from the cell membrane. What FACS 
analysis did reveal, however, is that incubation with VCR (10nm for 18 hours) significantly 
increased the number of endothelial cells expressing the adhesion molecule VCAM-1 (figure 
4.14C). As virtually all HUVECs express CD31 and ICAM-1, we measured the expression of these 
adhesion molecules on the single cell level, looking for changes in the degree of expression. 
Incubation of HUVEC with VCR (10nm, 18hours) produced a trend towards an increase in ICAM-1 
expression of the cell surface (figure 4.15C), and was associated with a moderate but significant 
decrease in CD31 expression (figure 4.14D). The positive control, TNFα, produced a marked 
increase in the number of VCAM-1+ cells and in the expression of ICAM-1 as well as a substantial 
reduction in CD31 expression (figure 4.14C/D and 4.15C). 
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Figure 4.13. Incubation with VCR does not alter CX3CL1 protein levels in endothelial cells in vitro.  (A) 
Representative blot showing CX3CL1 expression (chemokine domain) in HUVEC/endothelial cell lysates 
following incubation with 10nM VCR. CX3CL1 band size 90kDa; GAPDH band size 37kDa. (B) Quantification of 
protein expression normalised to GAPDH loading control. Data shown are mean ± SEM. N=3 cultures, no 
significant difference found (one way ANOVA). 
  





























         
 
 
Figure 4.14. Incubation with VCR alters adhesion molecule expression in endothelial cells in vitro.  (A/B) 
Representative FACS and frequency plots of cells stained for CD31 and VCAM-1 following incubation with 
VCR (10nM) or TNFα (10ng/ml; positive control). (C) Quantification of VCAM-1 levels on endothelial cells 
(CD31+). Data shown are mean ± SEM, N=3 mice per group, one way ANOVA with Tukey post-hoc. (D) 
Quantification of CD31 levels on endothelial cells. Data shown are mean ± SEM, N=3 mice per group, one 




























































       
 
 
Figure 4.15. Incubation with VCR does not alter ICAM-1 expression in endothelial cells in vitro.  (A/B) 
Representative FACS and frequency plots of cells stained for FKN (CX3CL1; not detected) and ICAM-1 
following incubation with VCR (10nM) or TNFα (10ng/ml; positive control). (C) Quantification of ICAM-1 







































100B3.4. CX3CR1-mediates ROS production in macrophages 
 
The data above demonstrates that although its expression is not altered by VCR treatment, CX3CL1 
is expressed by endothelial cells in vitro and in vivo, and we have demonstrated in chapter three 
that infiltrating monocyte/macrophages express CX3CR1, the receptor for this ligand. But is CX3CL1 
able to activate CX3CR1 in a pro-nociceptive fashion following transmigration? In order the test the 
hypothesis that monocyte/macrophages do indeed produce pro-nociceptive mediators following 
exposure to CX3CL1, we evaluated the production of reactive oxygen species (ROS) in these cells. 
Oxidative stress is known to occur as a result of chemotherapy treatment, and it has been 
demonstrated that ROS are able to activate TRPA1 receptors, a receptor known to contribute 
significantly to the aberrant transmission of pain.  
 
Here we show that treatment of peritoneal monocyte/macrophages, with the chemokine domain 
of CX3CL1 (200ng/ml, amino acids 25-100 mouse-recombinant protein) induces the rapid 
production of ROS which reaches significance after 12 minutes of incubation (figure 4.16; 
CX3CR1
+/+). This response was absent in monocyte/macrophages lacking CX3CR1 (taken from the 
peritoneal cavity of CX3CR1






        
 
Figure 4.16. Treatment with CX3CL1 stimulates the production of ROS in macrophages in vitro.  ROS 
production by peritoneal macrophages (CX3CR1
+/+ and CX3CR1
-/- ) induced by CX3CL1 (recombinant mouse 
chemokine domain 200ng/ml) as determined by change in luminol bioluminescence over time expressed as 
a percentage of positive control response (PMA 100ng/ml). Data shown are mean ± SEM, N=3 animals per 





































101B3.5. TRPA1-deficiency reduces the severity of and aids recovery of VCR-induced mechanical 
allodynia  
 
ROS are known to activate TRPA1 receptor channels located on the terminals and axons of sensory 
neurons on the peripheral nerves, resulting in the generation of action potentials and contributing 
to the generation of pain. To determine whether or not this mechanism may contribute to the 
development of pain in VCR-induced painful peripheral neuropathy we evaluated the profile of the 
development of allodynia in TRPA1-/- mice following the administration of VCR. As figure 4.17A 
demonstrates, the mechanical thresholds of TRPA1-deficient mice decrease following the daily 
administration of VCR, however this was to a lesser extent than that occurring in wild-type mice 
(TRPA1+/+) during the first cycle of treatment (days 0-4); during the first cycle wild-type mice 
experience a decrease in allodynia index of 57.10% (±2.07; figure 4.17B) whilst knock-outs 
experience a decrease of 32.79% (±3.19; figure 4.17B). Furthermore, during the break between 
treatment cycles (figure 4.17A; day 7) TRPA1-/- mice exhibited significant signs of recovery; the 
mechanical thresholds of TRPA1-/- mice, whilst still significantly lower than those of saline-treated 
animals, were more than double their thresholds from day 4 at the end of the first VCR cycle 
previous (day 4; figure 4.17A). This effect is not seen in wild-type mice. The thresholds of TRPA1-/- 
mice during the second cycle of chemotherapy follow a similar pattern to those seen in the first 
cycle; a substantial reduction (TRPA1-/- 83.62% ±1.44 vs. TRPA1+/+ 98.87% ± 0.07) in threshold is 
observed, however these mice do not show allodynia as severe as wild-type mice (figure 4.17B 
allodynia index second cycle: TRPA1-/- 55.68% ±5.69 reduction, TRPA1+/+ 98.73% ±0.07 reduction).  
Following the cessation of treatment, TRPA1-/- mice show marked acceleration of recovery in 
comparison to TRPA1+/+ mice; their mechanical thresholds return to baseline levels four day earlier 
than those of wild-type mice. 
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Conversely, TRPA1-deficiency appears to offer no protection from the development of VCR-
induced cold allodynia; in both TRPA1-/- and TRPA1+/+ mice cold-induced withdrawal latency is 
reduced by VCR treatment to approximately 5.5 seconds (figure 4.18A). However TRPA1-/- mice 
have a significantly higher baseline withdrawal threshold than TRPA1+/+, and as such, they 
reduction in allodynia index they experience during the second cycle of VCR treatment is 
considerably greater (figure 4.18B; TRPA1-/- 58.60% ±1.86 reduction vs. TRPA1+/+ 41.03% ±3.97). 
Thus due to their higher baseline withdrawal latencies (to cold), TRPA1 knock-out mice show more 





     
 
Figure 4.17. TRPA1-deficiency reduces the severity and aids recovery of mechanical allodynia induced by 
repeated systemic administration of VCR.  Development of mechanical allodynia in TRPA1-/- (KO) mice or 
TRPA1+/+ (WT) control receiving i.p. VCR (0.5mg/kg/day), days 0-4 and 7-11; black horizontal bars (or vehicle 
[SA]). (A) Temporal profile of mechanical allodynia development shown as 50% PWT, data shown as mean ± 
SEM. N=8 per group, *P<0.05 / ***P<0.001 vs baseline threshold, ## P<0.01 / ### P<0.001 vs saline 
threshold, † P<0.05 / ††† P<0.001 vs WT threshold, two-way RM ANOVA with post-hoc Holm-Sidak test. (B) 
Area under the curve (AUC) analysis data expressed as allodynia index. All time = BL-day 24, first cycle= BL-
day 4, second cycle = 7-11, recovery = 11-24. Data shown are mean ± SEM. N=8 per group, ### P<0.001 vs 
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Figure 4.18. TRPA1 knock-out mice have a more pronounced cold hypersensitivity than wild-type mice 
following repeated systemic administration of VCR due to their higher baseline withdrawal latency.  
Development of cold allodynia in TRPA1-/- (KO) mice or TRPA1+/+ (WT) control receiving i.p. VCR 
(0.5mg/kg/day), days 0-4 and 7-11; black horizontal bars (or vehicle [SAL]). (A) Temporal profile of cold 
allodynia development shown as paw withdrawal latency (seconds), data shown as mean ± SEM. N=8 per 
group, *P<0.05 / ***P<0.001 vs baseline threshold, # P<0.05 / ### P<0.001 vs saline threshold, ††† P<0.001 
vs WT threshold, two-way RM ANOVA with post-hoc Holm-Sidak test. (B) Area under the curve (AUC) 
analysis data expressed as allodynia index. All time = BL-day 24, first cycle= BL-day 4, second cycle = 7-11, 
recovery = 11-24. Data shown are mean ± SEM. N=8 per group, ### P<0.001 vs saline index, ††† P<0.001 
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40B . Discussion 
Here, in this chapter, we set out to test the hypothesis that VCR reacts with endothelial cells to 
push the endothelium towards an activated state, which is associated with the increased 
expression of adhesion molecules, including the transmembrane chemokine CX3CL1. Furthermore, 
we hypothesise that soluble CX3CL1 activates monocytes as they transmigrate across the 
endothelium, causing them to produce factors (ROS) that act upon the nerve (via TRPA1) to 
enhance nociceptive transmission. The principle finding of the work described here is that 
treatment VCR does indeed activate endothelial cells; altering the expression of some of the 
adhesion molecules required for the adhesion and transmigration of leukocytes. Additionally these 
data demonstrate that whilst the expression of CX3CL1 is not altered by VCR treatment, it is 
expressed by endothelial cells both in vivo and in vitro, and inhibition of the solubilisation of this 
protein remains a viable therapeutic target for the treatment of VCR-induced painful peripheral 
neuropathy. Moreover, we demonstrate that a soluble form of CX3CL1 (aa25-100), such as that 
arising from the cleavage of the membrane bound chemokine, is able to activate 
monocyte/macrophages, causing them to produce ROS. ROS are known to activate TRPA1 
receptors along the axons of sensory neurons. Finally, we demonstrate that this TRPA1-dependent 
mechanism does indeed contribute to the development and maintenance of mechanical allodynia 
arising as a result of VCR treatment, as mice deficient in this receptor-channel protein show a 
significant attenuation of mechanical allodynia. 
 
The treatment of pain arising as the result of chronic treatment with chemotherapeutic agents 
such as VCR represents a major unmet clinical need. However without fully understanding the 
mechanism by which this neuropathy occurs, we have been unable to provide suitable targets for 
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the development of preventative agents. Following evidence described in chapter three, which 
indicates a prevalent role for the CX3CR1
+ monocyte/macrophage in the development of VCR-
induced neuropathy, here, we delineated the cellular and molecular players mediating VCR-pain 
mechanisms. A series of elegant experiments have established that whilst full length membrane 
bound CX3CL1 is able to mediate the adhesion of CX3CR1
+ monocyte/macrophages to the 
endothelial surface, the activation of these cells, demonstrated by calcium fluxes within the cell, 
requires binding of a soluble form of the protein to the receptor (Schwarz et al., 2010). This 
indicates that the solubilisation of transmembrane CX3CL1 is an essential process in the CX3CL1-
CX3CR1 dependent activation of leukocytes. Previous work in our laboratory has focused 
extensively on the role of the cysteine protease Cathepsin S (CatS) in the cleavage of neuronal 
CX3CL1, and contribution of CatS to the development of pain in a number of neuropathic and 
inflammatory disease models. We have demonstrated that inhibition of CX3CL1 cleavage by this 
enzyme, with the irreversible CatS inhibitor LHVS, is sufficient to attenuate mechanical allodynia in 
both models of inflammatory arthritis (Clark et al., 2012) and peripheral nerve injury (Clark et al., 
2007b) . In both of these chronic pain models significant immune cell infiltration/proliferation and 
activation is observed within the spinal cord. These cells can be activated by soluble forms of 
CX3CL1; CatS inhibitors significantly reduce microglial activation, and it has been demonstrated 
several times that microglial activation contributes to the development of a pain phenotype in 
neuropathic and inflammatory models (Ledeboer et al., 2005;Lin et al., 2007;Raghavendra et al., 
2003;Hua et al., 2005). As well as being expressed in the microglia of the CNS, CatS is expressed in 
monocyte/macrophages in the periphery. In the peripheral nerve and DRG CatS co-localises with 
the macrophage marker OX6 and is upregulated following nerve injury (Barclay et al., 2007). 
Furthermore, expression of CatS has been demonstrated in cultured primary 
monocyte/macrophages and is substantially upregulated by exposure of the cells to the 
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inflammatory cytokine IFNγ (Geraghty et al., 2007). Expression of CatS has also been reported in 
F4/80+ macrophages in the inflamed intestine, where the secretion of active CatS is associated 
with neuronal hyperexcitability and the development of visceral hyperalgesia (Cattaruzza et al., 
2011). In line with this evidence, we observed that the development of mechanical allodynia 
occurring as a result of VCR treatment was prevented by the CatS inhibitor LHVS. Therefore, our 
data support the possibility that the CatS-dependent cleavage of CX3CL1 is critical for the 
development of VCR-pain and indicate that the inhibition of CatS is a viable therapeutic option for 
the prophylaxis of this condition. It should be noted that endothelial CX3CL1 can also be cleaved by 
ADAM10 and ADAM17, which are constitutively expressed by endothelial cells; the effect of the 
inhibition of these proteases on the development of VCR-induced allodynia remains to be 
assessed. 
 
Within the CNS, CX3CL1 is expressed primarily on neurons, and it is the cleavage of this that has 
been shown to contribute to the development of pain in several neuropathic and inflammatory 
pain models (albeit in rats not mice); intrathecally administered LHVS attenuates pain (Clark et al., 
2012;Clark et al., 2007b). However, the reduction in pain seen observed in the VCR model arises as 
a result of the inhibition of peripheral CatS found in macrophages, as LHVS administered 
systemically does not reach the CNS (Barclay et al., 2007). Peripherally CX3CL1 is expressed 
predominantly on endothelial cells; here its expression is constitutive, but it can be substantially 
increased by inflammatory stimuli such as exposure to LPS or inflammatory cytokines (Harrison et 
al., 1999;Pan et al., 1997;Muehlhoefer et al., 2000). Thus we next hypothesised that treatment 
with VCR provides an inflammatory stimulus that induces the upregulation of CX3CL1 on 
endothelial cells. We first assessed the expression of CX3CL1 on endothelial cells in vivo using a 
genetically manipulated mouse that co-expresses the mCherry reporter protein with CX3CL1. Using 
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this mouse we visualised CX3CL1 in the small blood vessels of the sciatic nerve by co-staining 
transverse sections with the endothelial marker CD31. As the literature suggested, there was 
almost complete co-localization of CX3CL1 (mCherry) with CD31, however in control vehicle 
treated animals, not all CD31+ cells expressed CX3CL1. Analysis of the expression of these proteins 
revealed no difference in the immunoreactivity of CX3CL1-mCherry between vehicle and VCR 
treated tissue; thus to establish whether or not a there was a difference in CX3CL1 expression we 
assessed the number of CD31+ endothelial cells that expressed CX3CL1-mCherry. No increase in the 
number of CX3CL1-mCherry expression CD31
+ cells was observed in animals treated with VCR 
when assessed after a single dose, a single cycle or two full cycles of treatment. In this mouse the 
sequence encoding the mCherry reporter is inserted into the first exon of the cx3cl1 gene (Kim et 
al., 2011); this corresponds to the N-terminal region of the translated protein (Pan et al., 
1997;Bazan et al., 1997), which forms part of the soluble protein cleaved from the membrane 
tether by CatS (and ADAM-10/17). To assess the possibility that upregulation of CX3CL1-mCherry 
might not be detected due to enhanced cleavage of the protein, we determined the plasma 
concentration of CX3CL1 in vehicle and VCR treated mice, hypothesizing that if there was indeed 
enhanced expression and cleavage of CX3CL1 this would be reflected in the plasma concentration 
of soluble CX3CL1. This was not the case, the plasma concentration of CX3CL1, as determined by 
ELISA, was not altered by VCR treatment when assessed after a single dose, a single cycle or two 
cycles of treatment. To evaluate the endothelial expression of CX3CL1 in a more controlled 
environment, the effect of VCR on CX3CL1 expression and cell morphology was examined in vitro 
using a primary HUVEC (human umbilical vascular endothelial cell) line. 
 
Due to the know toxicity of VCR, prior to assessing the effect of VCR on CX3CL1 in vitro, we 
assessed the viability of HUVEC incubated with VCR. Our data demonstrate that whilst incubation 
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with VCR for increasing times does not alter the ratio of live to dead cells, at the highest 
concentration tested (1000nM) it does significantly reduce the number of cells in culture; thus the 
highest concentration was not used in further experiments. VCR exerts its cytotoxic effects via the 
binding to and disruption of the cytoskeleton protein tubulin. To determine whether or not VCR 
was able to exert this effect on HUVECs at the concentrations tested, we stained the cells with a 
pan β-tubulin antibody and observed their morphology after incubation with VCR for increasing 
times; VCR does indeed affect the tubulin structure in cultured HUVECs. Whilst this was not an 
affect that could be suitably quantified, a distinct qualitative difference can be observed between 
VCR and vehicle treated cells. Incubation with VCR causes a dramatic collapse in the tubulin 
structure of HUVECs, and was associated with the development of a hypertrophied appearance 
and reduction in cell to cell contact; however it did not alter the expression of CX3CL1 in these 
cells, and no soluble CX3CL1 was detected in the culture media in which these cells were treated. 
 
Overall our data indicate that exposure to VCR does not alter the CX3CL1 expression in endothelial 
cells; nonetheless VCR has a dramatic effect on the morphology of the cells, suggesting VCR may 
be able to induce endothelial activation. To assess this possibility we returned to our hypothesis 
that VCR provided an inflammatory stimulus to endothelial cells, thus pushing them towards an 
activated (type II) state. To address this hypothesis we phenotyped primary HUVEC cells using the 
expression of two key adhesion molecules: ICAM-1 and VCAM-1. These molecules play a critical 
role in the adhesion and transendothelial migration of leukocytes, however in the resting 
endothelium the transcription of many endothelial molecules, including VCAM-1, is suppressed 
(Pober and Sessa, 2007), and it is not until the endothelium undergoes prolonged activation, such 
as that triggered by the release of pro-inflammatory cytokines from leukocytes, that these 
proteins are upregulated on the luminal surface of the endothelium (Hadad et al., 2011;Kjaergaard 
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et al., 2013;Collins et al., 1995). As counter-receptors for the leukocyte β2 integrins the 
upregulation of ICAM-1 and VCAM-1 on inflammatory cytokine activated endothelial cells plays a 
critical role in the targeting of leukocyte transmigration to areas of inflammation (Min et al., 
2005); thus the enhanced expression of these adhesion molecules can be used as a surrogate 
marker for ‘pro-inflammatory’ activation of endothelial cells. FACS analysis of the expression of 
ICAM-1 and VCAM-1 on VCR treated HUVECs demonstrated that whilst constitutively expressed on 
all cells, there was a trend towards an increase in the expression of ICAM-1. Although this was not 
a significant increase, the increase in VCAM-1 expression observed was; incubation of HUVEC with 
VCR significantly increased the number of cells expressing VCAM-1, and together, these data 
suggest that the endothelial cells are indeed becoming activated. 
 
Whilst based on these data we must accept the null hypothesis, that VCR does not cause an 
increase in the expression of CX3CL1 on endothelial cells, our FACS analysis does provide evidence 
that VCR induces activation of endothelial cells. Despite the lack of increase in CX3CL1 on 
endothelial cells, its constitutive expression means that it may still be able to promote the 
transmigration of and activate monocyte/macrophages as they adhere to the endothelium via 
VCAM-1 (and ICAM-1) which, as a result of VCR acting upon the endothelium, is now expressed on 
the cells. We can hypothesise that CX3CL1 is able to activate these cells in a way that contributes 
to the development of pain, despite needing to be solubilised to activate the CX3CR1 receptor; we 
have demonstrated that inhibiting the solubilisation of this protein prevents the development of 
mechanical allodynia arising as a result of VCR chemotherapy. Furthermore, we provide evidence 
that soluble CX3CL1, at a concentration similar to those shown previously in our laboratory to 
activate the CX3CR1 receptor in microglia (Staniland et al., 2010), is able to activate 
monocyte/macrophages in a CX3CR1-dependent manner. In this instance assessed 
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monocyte/macrophage activation in terms of the production of reactive oxygen species (ROS). 
ROS are produced as a consequence of oxidative stress, which is known to occur as a result of 
chemotherapy; ROS scavengers are able to ablate cellular calcium fluxes induced by oxaliplatin 
(Nassini et al., 2011), and the reduction of superoxide production by the administration of an 
NADPH-oxidase inhibitor attenuates chemotherapy induced mechanical allodynia (Doyle et al., 
2012), as does the administration of the anti-oxidant acetyl-L-carnitine (Flatters et al., 
2006;Ghirardi et al., 2005a;Ghirardi et al., 2005b;Pisano et al., 2003).  
 
But how does an increase in ROS production equate to the development of pain following VCR 
chemotherapy? Recent evidence has demonstrated that ROS are able to activate the TRPA1 
receptor found on the axons and terminals of sensory neurons (Takahashi et al., 2008;Nilius et al., 
2012;Andersson et al., 2008;Weller et al., 2011). The expression of TRPA1 is upregulated in a 
number of models of chronic pain and inflammation, and is associated with the development of 
hyperalgesia; both cold and mechanical hyperalgesia occurring as a result of CFA-induced 
inflammation are reduced by the systemic administration of selective TRPA1 antagonists (Obata et 
al., 2005;da Costa et al., 2010;Petrus et al., 2007;Eid et al., 2008). Chemotherapeutic pain models 
are no exception to this; TRPA1 upregulation has been demonstrated following exposure of 
cultured DRG neurons to cisplatin or oxaliplatin in a similar pattern to that seen in vivo in the 
trigeminal ganglia of cisplatin treated mice (Windebank and Grisold, 2008;Ta et al., 2010). 
Furthermore the calcium currents induced in cells by ROS are TRPA1 dependent (Materazzi et al., 
2012;Nassini et al., 2011), and oxaliplatin and cisplatin induced pain behaviours are attenuated by 
the administration of TRPA1 antagonists (Materazzi et al., 2012;Nassini et al., 2011;Barriere et al., 
2012). This evidence led us to develop the hypothesis that ROS generated by 
monocyte/macrophages that have infiltrated the peripheral nerve are able to induce mechanical 
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allodynia via the activation of TRPA1, thus TRPA1 deficient mice should exhibit attenuated pain 
behaviours following the induction of VCR-neuropathy. 
 
As our data demonstrate, TRPA1 knock-out mice exhibit a reduction in the development of 
mechanical allodynia occurring as a result of VCR chemotherapy; whilst the mechanical thresholds 
in these mice do decline following treatment, it is to a lesser extent than that observed in wild-
type mice. Furthermore, we provide evidence of both earlier and more rapid recovery of 
mechanical thresholds in TRPA1 deficient mice in comparison to their wild-type littermate 
controls. Conversely, TRPA1-deficiency appears to offer no protection from the development of 
VCR-induced cold allodynia; due to higher baseline withdrawal latencies to a cold stimulus, TRPA1 
knock-out mice show more pronounced cold allodynia as a result of VCR treatment than wild-type 
mice. These data indicate that the development and maintenance of cold and mechanical 
hypersensitivity in VCR treated mice may occur via different mechanisms, and that whilst TRPA1 is 
a viable target for the development of analgesics for this condition, these drugs may not alleviate 
all symptoms of the neuropathy. Additionally, it should be noted that the attenuation of 
mechanical allodynia seen as a result of TRPA1 absence is only partial and does not prevent the 













41B . Thesis aims and summary of findings 
 
The treatment of pain arising as the result of chronic treatment with chemotherapeutic agents 
such as vincristine sulphate (VCR) represents a major unmet clinical need. Thus, the aim of the 
work presented in this thesis was to investigate possible mechanisms by which repeated cycles of 
chemotherapy with the anti-neoplastic drug VCR causes enhanced nociception, with the 
secondary aim of identify novel therapeutic targets for the prevention of this condition.  
 
Establishing a murine model of VCR-induced neuropathic pain, we used several in vivo and in vitro 
approaches to assess the pathological changes occurring as the result of two cycles of VCR 
treatment at both a gross behavioural and more detailed cellular level. The main findings of this 
work are summarised below: 
 
1. The systemic administration of two five day cycles of VCR results rapid in the development 
of severe mechanical allodynia and mild cold hypersensitivity. This behavioural phenotype 
is fully established by the end of the first cycle of treatment and is sustained throughout 
the second, but recovers approximately two weeks after the cessation of treatment. 
2. Whilst not associated with signs of sensory neuron damage, the development of allodynia 
is associated with astrogliosis in the spinal cord and significant monocyte/macrophage 
infiltration in the peripheral nerve. Astrogliosis is evident at the end of the first cycle of 
VCR treatment, peaks at the end of the second cycle, and is no longer observable once 
allodynia has recovered. Monocyte/macrophage infiltration is evident twenty-four hours 
after the first administration of VCR and continues to increase throughout the duration of 
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the treatment cycles, before returning to baseline levels by the time allodynia has 
recovered. 
3. Monocyte/macrophage infiltration of the peripheral nerve represents a critical and early 
step in the development of enhanced nociception, occurring within twenty-hour hours of 
the first VCR administration; depletion of these cells prevents the development of 
allodynia. Infiltrating monocyte/macrophages display a shift towards pro-inflammatory 
phenotype; the percentage of monocyte/macrophages that are Gr1+ increases following 
the administration of a cycle of VCR. Furthermore, we suggest that the expression of the 
CX3CR1 receptor is critical for monocyte/macrophage infiltration of the peripheral nerve as 
in the absence of this protein, this infiltration does not occur and the development of 
allodynia is delayed. 
4. VCR treatment has a substantial impact on the integrity of endothelial cells; VCR 
dramatically disrupts the tubulin cytoskeleton and morphology of these cells and induces 
an up-regulation of the adhesion molecule VCAM-1, indicative of a shift towards a type II 
activated state. 
5. CX3CR1 mediates the activation of monocyte/macrophages by CX3CL1, which results in the 
production of reactive oxygen species (ROS); ROS are known to evoke pain by activating 
neuronal TRPA1 channels, and indeed TRPA1-deficiency attenuates allodynia in this 
model. TRPA1-/- mice exhibit a reduction in the severity of allodynia experienced 
following the first cycle of VCR. Partial recovery is observed between treatment cycles and 
these animals recover at an accelerated rate, compared to wild-types, following cessation 





Here we demonstrate that VCR-induced neuropathic allodynia is the result of a cascade of events 
in the peripheral nerve (figure 5.1) that begins with an alteration in endothelial cell adhesion 
properties as a consequence of a shift towards a type II activated state; this promotes the 
recruitment and trafficking of CX3CR1-expressing monocyte/macrophages. The CX3CR1-dependent 
activation of monocyte/macrophage by endothelial CX3CL1 results in pro-nociceptive effects 
mediated by the production of ROS and the activation of TRPA1 receptors on the axons of sensory 
neurons, which enhances nociceptive transmission. Due to their involvement in this mechanism 
the following targets may offer viable therapeutic targets for the prevention of VCR-induced 
painful peripheral neuropathy: 
1. Peripheral CX3CR1 (in monocyte/macrophages) 
2. Enzymes capable of solubilizing CX3CL1 (e.g. CatS in macrophages or endothelial 
ADAM10/17) 
3. Anti-oxidants or ROS scavengers (targeting ROS released from macrophages) 
4. TRPA1 channels in sensory neurons 
 
This pathway is, to the best of our knowledge, the first detailed description of the molecular 
mechanisms that cause the important treatment-limiting painful peripheral neuropathy associated 























Figure 5.1. A novel pathway for VCR-
induced neuropathy. (1) VCR causes binds 
tubulin in endothelial cells, including those 
lining the small blood vessels within the 
peripheral nerve, causing activation and 
dysfunction that enhances the expression 
of selected adhesion molecules. (2) These, 
in turn, mediate transendothelial 
migration of monocytes. As monocytes 
undergo this process CX3CR1 on their 
surface binds its ligand, CX3CL1 on the 
endothelium, resulting in the activation of 
the cells as they migrate into the nerve. (3) 
The activation of monocyte/macrophages 
triggers the synthesis and release of a 
number of pro-inflammatory and pro-
nociceptive mediators, including ROS. (4) 
ROS activate TRPA1 receptors on the axon 
of primary afferent fibers, resulting in 
enhanced nociceptive transmission that 




43B2. General Discussion 
 
Chemotherapy-induced painful peripheral neuropathy is the dose-limited side-effect of several 
classes of chemotherapeutic agents, including the vinca alkaloids, taxanes and platinum-
containing compounds. Depending on the agent and regimen used, this side-effect occurs in up to 
97% of patients (Tanabe et al., 2013), is dose-limiting in an excess of 70% (Postma et al., 1995) and 
results in treatment cessation in between 20% and 40% of patients (Briani et al., 2013;Dougherty 
et al., 2007;Bennett et al., 2012). Symptoms of the neuropathy are almost exclusively sensory 
(suggesting it is the sensory neurons that are prone to this neuropathy) and most severe in the 
hands and feet. Currently chemotherapy-induced neuropathy is primarily managed in the clinic by 
way of symptomatic treatment with classical analgesics; however the efficacy of this approach is 
quite varied and often leaves many patients continuing to report pain severe enough to interfere 
with the activities of daily living. It has recently been reported that the average pain score of 
patients suffering from vinca alkaloid induced neuropathy receiving doses of morphine in excess of 
85mg/day only declines to three out of ten; in some individuals this score is as high as eight out of 
ten. Patients prescribed gabapentin, codeine, paracetamol, tramadol and/or fentanyl report 
maximum daily pain scores as high as ten out of ten (average 8.2 ± 1.7) (Dougherty et al., 2007). 
Furthermore, only 75% of patients with bortezomib-induced neuropathy report any decrease in 
pain intensity at all with ongoing oxycodone treatment (Cartoni et al., 2012). Not only is this pain 
management approach ineffective, it does nothing to prevent or treat the underlying cause of 
pain, the development of peripheral neuropathy. 
 
In the last two decades basic scientists, working alongside clinicians, have established a set of 
animal models of chemotherapy-induced neuropathy that mimic the human condition and allow 
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the mechanisms that underlie this condition to be investigated. Early research focused on the 
changes occurring to the properties of neurons as a consequence of chemotherapy; repeatedly 
patients report pain and mechanical and cold hypersensitivity that correlates with 
electrophysiological changes. For example, symptomatic VCR-neuropathy patients show abnormal 
amplitudes of sural sensory nerve action potentials and a decrease in sensory nerve conduction 
velocity; these electrophysiological changes are not observed in patients with no symptoms of 
neuropathy (Krishnan et al., 2005). These changes are a common finding across chemotherapeutic 
regimens (Krarup-Hansen et al., 2007) and it has been demonstrated that they persist, along with 
pain, beyond the cessation of the chemotherapy (Argyriou et al., 2007;Ramchandren et al., 2009). 
The same electrophysiological abnormalities are reproduced in rodent models of this 
chemotherapy-induced pain; the (single) administration of PTX, oxaliplatin, cisplatin and VCR is 
associated with the development of both mechanical and cold hypersensitivity in the extremities 
(hind paw), a decrease in sensory nerve conduction velocities and hyper-responsitivity of subsets 
of C-fibres in the tail, digital,  saphenous and sciatic nerves (Polomano et al., 2001;Gilardini et al., 
2012;Wozniak et al., 2011;Guindon et al., 2013;Aley et al., 1996;Tanner et al., 2003).  Interestingly 
the neuropathy arising as a result of chemotherapy is predominantly sensory; motor symptoms 
occur rarely and tend to be associated with extended periods of treatment and more advanced 
cancers. As a result a series of electrophysiological observations (see above) and 
chemotherapeutics tropism for sensory neurons, most of the early research in this field was based 
on the assumption that it was in these cells that the initial damage was occurring. Certainly there 
is evidence for damage to primary afferent fibres occurring as a result of treatment with 
chemotherapeutic agents; an increase in the expression of ATF-3 in the cell bodies in the DRG, a 
classical marker of neuronal stress/damage, has been observed in several laboratories (Hansen et 
al., 2011;Khasabova et al., 2012). Additionally evidence has been presented demonstrating 
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disruption of tubulin structure in sensory neurons in the saphenous nerve (Tanner et al., 2003), a 
decrease in the density of myelinated fibres in the sciatic nerve (Kawashiri et al., 2009;Callizot et 
al., 2008) and a decrease in intra-epidermal nerve fibre density in the glabrous skin of the hind 
paw (Siau et al., 2006) in several models of chemotherapy-pain. However, these changes are not 
observed concomitantly with the generation of pain, rather they are observed between 1 and 3 
weeks after the start of chemotherapy treatment, when pain (hypersensitivity) is well established. 
Specifically when we examined neuronal stress, by assessment of ATF-3 expression in the DRG, we 
were unable to observe a significant increase at an early time point (day 4) despite the severe 
mechanical allodynia observed in these animals. Furthermore, no microglial response was 
observed in the dorsal horn of the spinal cord at this time, or any later time points examined. This 
data indicates that neuronal damage is unlikely to be the initial step in the development of 
chemotherapy-induced neuropathy, and VCR may cause neuronal damage via an indirect 
mechanism. Indeed we demonstrate here that significant infiltration of monocyte/macrophages 
occurs rapidly in the sciatic nerve within the first cycle of VCR treatment, with a temporal profile 
similar to that of the development of mechanical allodynia. Furthermore, the prevention of this 
infiltration substantially delays the onset of this pain behaviour. In light of this, we suggest that the 
first step in the development VCR-induced pain is an inflammatory reaction; 
monocyte/macrophages infiltrate in response to damage to the endothelial cells that line the 
blood vessels within the nerve. Certainly our data show that VCR induces the activation of 
endothelial cells, which we propose to be the first site of action of VCR; the upregulation of 
adhesion molecules demonstrated here is indicative of type II endothelial activation in response to 
an inflammatory stimulus. Furthermore, our data indicate that immune cell infiltration of the 
nerve is critical for the development of allodynia in this model; retarding infiltration by reducing 
the circulating population of monocyte/macrophages or by knocking out the CX3CR1 receptor 
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prevents the development of mechanical allodynia. Additionally the onset of mechanical allodynia 
can be delayed by the administration of the cathepsin S inhibitor LHVS, which we hypothesise 
inhibits CX3CR1-dependent monocyte/macrophage activation by soluble forms of CX3CL1 by 
preventing the liberation of these soluble forms from membrane bound CX3CL1.  The activation of 
immune cells by CX3CL1 has been shown, in other models and in an in vitro setting, to cause the 
upregulation of pro-inflammatory mediators (e.g. IL-1β and TNFα (Ishida et al., 2008b)). These, in 
turn, are able to activate their neuronally expressed receptors and sensitise peripheral 
nociceptors; this is observed behaviorally as mechanical hypersensitivity (Reeve et al., 
2000;Kawasaki et al., 2008;Gruber-Schoffnegger et al., 2013;Liu et al., 2013b). 
 
As we propose that one of the initial processes in the development of VCR-induced mechanical 
allodynia is the infiltration of monocyte/macrophages we must consider the biological importance 
of the infiltration we observe. In our model the number of monocyte/macrophages in the sciatic 
nerve increases from 1.6 (± 0.1) to 3.0 (± 0.2) cells per 104µm2 after the first 24 hours and to 4.7 (± 
0.1) at its peak (this represents a 3 fold increase). Certainly data obtained from the study whereby 
we depleted these cells indicate that this infiltration is highly biologically significant; if we prevent 
infiltration by depleting monocyte/macrophages we substantially delay the onset of mechanical 
allodynia. Additionally, the degree of monocyte/macrophage infiltration that we demonstrate is 
consistent with observations previously published in this model; Uceyler et al report an 
approximate threefold increase in macrophages in the sciatic nerve of mice treated with two 
cycles of VCR. Furthermore, this degree of monocyte/macrophage infiltration is comparable to 
that previously reported in a model of chronic nerve compression; Gray et al observe 
approximately 3.5 macrophages per 104µm2 in the sciatic nerve four weeks after injury (Gray et al., 
2007). Whilst this is the first instance in which our laboratory has examined macrophage 
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infiltration in a model of chemotherapy-neuropathy, we have previously examined this process in 
a severe surgical injury model; seven days after partial ligation of the sciatic nerve approximately 
20 macrophages are seen per 104µm2. This level of infiltration is substantially greater than we 
observe in the VCR model; however then mechanism by which it occurs is likely different as, whilst 
CX3CR1-/- mice exhibit an attenuated mechanical and thermal hypersensitivity following PNL, the 
number of macrophages in the nerve of these animals is comparable to that of wild-types 
(Staniland et al., 2010). 
 
In this set of experiments we have examined the contribution to VCR-induced allodynia of 
infiltrating monocyte/macrophages in the peripheral nerve, and have not yet assessed the 
contribution of other infiltrating immune cells, in particular neutrophils. Neutrophils respond 
rapidly to injury or infection and their numbers peak as early as 24 hours after insult (Perkins and 
Tracey, 2000). Indeed the temporal profile of the development of mechanical allodynia doesn’t 
negate a role for these cells in the development of pain in our model; the involvement of these 
cells certainly warrants investigation. However, the development of mechanical allodynia 
following VCR administration is completely prevented by the pre-treatment of mice with liposome 
clodronate which depletes monocyte/macrophages and not neutrophils, and by the deficiency of 
the CX3CR1 receptor which is also exclusively a monocytic effect. Additionally, VCR-chemotherapy 
is classically associated with the development of neutropenia, a decrease in circulating 
neutrophils; a reduction in neutrophils has been demonstrated to be anti-nociceptive in models of 
neuropathic pain, yet pain remains the most prevalent side-effect of VCR in patients. Regardless, a 
contribution of neutrophils to the development of pain the recruitment of monocyte/macrophage 




The mechanism by which VCR causes allodynia that we describe here indicates that the initial site 
of action of VCR, rather than the sensory neurons, is the endothelial cells lining the blood vessels 
of the nerve. We hypothesise that it is this that allows enhanced monocyte/macrophage adhesion 
and subsequent infiltration of the nerve. Evidence suggests VCR has a tropism for sensory neurons 
as the blood nerve barrier in peripheral nerve is relatively permeable, and it is likely that this 
results in preferential accumulation of monocyte/macrophages in the nerve. However as VCR is 
administered systemically it is possible that endothelial disruption evoked by VCR might affect 
other organs. Indeed, our data indicate that there is infiltration of monocyte/macrophages into 
the peritoneal cavity of VCR-treated mice as well as the sciatic nerve; however we would need to 
assess monocyte/macrophages infiltration into other tissues to draw firm conclusions. A literature 
search for endothelial disruption following chemotherapy reveals that there is evidence to indicate 
that VCR-induced endothelial disruption contributes to the development of the non-neuronal side-
effects of this drug, specifically cardiovascular toxicity. It has been demonstrated that a number of 
chemotherapeutic agents are toxic to the cardiovascular system; their administration results in the 
development of vascular complications such as ischemia, myocardial infarction, thrombosis and 
hypertension (Daher and Yeh, 2008). The administration of both 5-fluorouracil and bevacizumab 
to endothelial cells in culture and to rodents have resulted in a number of effects consistent with 
endothelial cell injury, including endothelial cell specific decreases in DNA synthesis, increased 
prostacyclin release, inhibition of VEGF-induced tubule formation and reduced cell migration and 
angiogenesis (Daher and Yeh, 2008). Moreover, in a recent set of experiments Mikaelian and 
colleagues were able to demonstrate that the mechanism of cardiotoxicity of tubulin binding 
drugs is primary endothelial damage (Mikaelian et al., 2010); here they assessed endothelial 
damage induced by both VCR and vinblastine, providing evidence to support this process occurring 
as a result of vinca alkaloid treatment.  
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Whilst investigation into endothelial dysfunction as a result of treatment with chemotherapeutic 
agents (vinca alkaloids, 5-fluorouracil and bevacizumab [anti-VEGF antibody]) is underway, the 
evidence collected is not yet strong enough to apply this mechanism to chemotherapeutic agents 
of all classes (which have very varied mechanisms of action).  Similarly, the same can be said of our 
proposed mechanism for the initiation of VCR-induced mechanical allodynia. VCR functions as an 
anti-neoplastic by disrupting tubulin and causing the disassembly of microtubules. Whilst we have 
demonstrated here that it is capable of causing severe morphological changes in endothelial cells, 
not all chemotherapeutic agents exert their anti-cancer effects in this way. The taxane class of 
compounds are also considered tubulin binders, however rather than causing disassembly of 
microtubules they promote microtubule stability. Whilst this may indicate that these compounds, 
the most well known of which is PTX, are unlikely to cause pain via the same mechanism as the 
vinca alkaloids, monocyte/macrophage infiltration of the peripheral nerve has been demonstrated 
following intravenous PTX administration (Peters et al., 2007a). The platinum based compounds 
exert their anti-neoplastic effects by cross-linking DNA strands, thus preventing its replication and 
RNA and protein synthesis. Whilst both cisplatin and oxaliplatin induce the development of pain in 
both patients and animal models, enhanced monocyte/macrophage infiltration of the nerve has 
not yet been reported following the administration of these compounds.  
 
The evidence we provide here to support the hypothesis that VCR treatment causing endothelial 
damage is in an in vitro setting, and further work is required to determine the degree to which this 
occurs in vivo; for example immunohistochemical analysis of adhesion molecule expression in  the 
endothelial cells of VCR-treated animals. However, by comparing the VCR concentrations used in 
vitro to those achieved in vivo, we can predict that endothelial damage is likely to be observed in 
vivo. In the studies presented here VCR was administered to mice intraperitoneally; whilst we did 
317 
 
not assess the serum concentration of VCR in our mice this has been reported previously. Using 
toxicity based assays Dixon et al demonstrated that, in the mouse, the VCR content of the serum is 
approximately 0.35% of the original quantity given intraperitoneally (Dixon et al., 1969). Using this 
value we can predict the blood concentration of VCR in our mouse model system; a single 
administration of 0.5mg/kg of VCR in a 25g mouse results in a blood concentration of VCR of 
approximately 30nM; this is comparable with the concentrations we have used to investigate the 
effect of VCR on endothelial cells in vitro (10 and 100nM). In the adult human the maximum dose 
of VCR administered is 2mg, given intravenously into a blood volume of approximately 4.7L; this 
equates to a blood concentration of VCR in an adult human of approximately 450nM. This value is 
substantially greater than the predicted blood concentration of VCR in the mouse and the 
concentrations used in vitro, thus provide a basis for the hypothesis that the VCR-induced 
endothelial damage that we see in vitro occurs in man. It should be noted that this dose in humans 
represents a total cycle over a week, whilst the calculations presented for a mouse represent only 
a single dose in our study protocol, as an accurate rate of elimination of VCR in the mouse is not 
known. 
 
The mechanism outlined here proposes that the infiltration of CX3CR1
+ monocyte/macrophages 
into the nerve as a result of endothelial dysfunction represent the initiating steps in the 
development of chemotherapy pain. However, as demonstrated by studies undertaken using the 
CX3CR1 knock-out mouse, deficiency of this receptor delays the onset of pain, rather than 
preventing it altogether, indicating that CX3CR1-dependent migration of monocyte/macrophages 
may be important in the development of pain rather than its maintenance. Our data indicate that 
monocyte/macrophage infiltration remains a critical step in the development of VCR-induced 
mechanical allodynia, as even in CX3CR1 knock-out mice after a four day delay in pain onset; 
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mechanical allodynia develops concomitantly with monocyte/macrophage infiltration of the sciatic 
nerve. This indicates that the blockade of CX3CR1 function alone may not be sufficient to prevent 
the development of VCR-pain after several cycles of chemotherapy, and that a multi-drug 
approach may be required. The interaction of CX3CR1 and its ligand CX3CL1 is vital for the survival 
of CX3CR1
high resident monocyte/macrophages and for the early infiltration of these cells into the 
nerve. However a second population of monocyte/macrophages is far less dependent on this 
mechanism for function: the CX3CR
intCCR2+ monocyte/macrophages. Whilst these cells express 
CX3CR1, its expression is not critical for survival; the population persists in mice deficient of this 
protein (Jung et al., 2000). Furthermore, migration of these cells is CCR2 dependent rather than 
CX3CR1; thus this later infiltration might be mediated by the interaction between CCR2 and its 
ligand CCL2 (MCP-1) and that these proteins will provide further targets for the development of 
analgesics specifically for VCR-induced pain, that will likely be most efficacious when used in 
combination with inhibitors of CX3CR1 activation.  
 
Following the first cycle of VCR chemotherapy, CX3CR1 knock-out mice show an almost complete 
attenuation of mechanical allodynia; however TRPA1 knock-out mice show only a partial 
attenuation, and whilst our data indicate that TRPA1-deficiency aids recovery from VCR-induced 
hypersensitivity, it does not prevent the onset of this condition. We hypothesise that this 
difference in attenuation arises from TRPA1 having a role in the development of pain in a later 
stage of the mechanistic pathway than CX3CR1. Inhibiting monocyte/macrophage infiltration and 
CX3CR1 signalling in this model is highly effective at preventing the development of pain occurring 
as a result of VCR therapy; however these processes, whilst not hypothesised to be causative, 
occur early in our proposed mechanism. The activation of neuronal TRPA1 by ROS however, is 
proposed to be the final process in this mechanism, when it is likely that several signalling 
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pathways have been recruited to enhance nociceptive transmission. For example, once activated 
monocyte/macrophages are able to synthesise and release a host of pro-nociceptive mediators, 
including TNF and IL-6 (Niu et al., 2012;Dumitru et al., 2000). The increased expression of these 
mediators following chemotherapy has been demonstrated (Pusztai et al., 2004;Starkweather, 
2010), and antibody neutralisation of these proteins are anti-nociceptive when administered 
peripherally (Kiguchi et al., 2008b). Additionally, following its release from macrophages, CatS, as 
well as cleaving CX3CL1, is able to activate the PAR2 receptor. This receptor is expressed on sciatic 
nerve and DRG (Liu et al., 2013a) and can be upregulated by pro-inflammatory cytokines including 
IL-6 (Shinohara et al., 2012). It has been demonstrated that activation of PAR2 can sensitise 
neurons, contributes to inflammation-induced pain responses (Hoogerwerf et al., 2001) and is 
critical for the induction of nerve-injury induced neuronal hyperexcitability (Huang et al., 2012). 
Thus, whilst we have presented here a mechanism by which initial endothelial damage and 
monocyte/macrophage infiltration of the nerve results in the pro-nociceptive activation of 
neurons following the administration of VCR, we hypothesise that due to a divergence of signalling 
pathway subsequent to monocyte/macrophage infiltration, targeting the recruitment of these 
cells represents the most favourable opportunity to prevent chemotherapy-induced painful 
peripheral neuropathy. 
 
The model used here examines the consequences of chemotherapy in the absence of cancer; 
whilst this does not accurately approximate the clinical situation, it does allows the mechanisms 
by which CX3CR1 monocyte/macrophages contribute to the development of vincristine-induced 
painful peripheral neuropathy to be investigated in a controlled manner. What must be 
considered however is how, in a cancer baring patient, modulation of monocyte/macrophage 
function would influence tumour burden and/or progression. This can be investigated, in a similar 
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fashion to the experiments performed here, by administering liposome encapsulate clodronate to 
deplete monocyte/macrophages in cancer bearing mice. Such experiments have provided 
evidence that indicates that monocyte/macrophages actually promote tumour progression and 
the development of metastasis; several groups have reported that liposome encapsulated 
clodronate has significant anti-tumour activity. For example in a mouse model of colon cancer 
macrophage depleted animals displayed significantly smaller primary tumours, and did not go on 
to develop liver or peritoneal metastases which were evident in over 80% of untreated mice 
(Kruse et al., 2013). Similarly weekly administration of liposome encapsulated clodronate to 
fibrosarcoma or colon carcinoma bearing mice substantially inhibited tumour growth and 
significantly increased survival the survival rate of these mice (Guth et al., 2012). This approach to 
depleting macrophages also reduces tumour growth in models of melanoma (Gazzaniga et al., 
2007), ovarian (Robinson-Smith et al., 2007), lung (Kimura et al., 2007), teratocarcinoma 
(Zeisberger et al., 2006) and prostate (Halin et al., 2009) models of cancers. Additionally the 
administration of an anti-Gr-1 antibody to otherwise immunocompetent mice, resulting in the 
depletion of granulocytes and macrophages, reduced the growth of a UV-light induced tumour 
(Seung et al., 1995).  
 
It is now widely accepted in the oncology field that solid tumours contain a multitude of non-
malignant as well as malignant cells; leukocytes were observed within tumours as early as the mid-
nineteenth century (Balkwill and Mantovani, 2001). One of the most notable populations of non-
malignant cells within the tumour is macrophages. These cells are typically referred to as tumour-
associated macrophages (TAMs), however are predominantly derived from peripheral blood 
monocytes (Stephens et al., 1978) that proliferate locally (McBride, 1986). TAMs are recruited to 
tumours by chemokines, cytokines and growth factors that are released from the malignant cells 
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themselves (Pollard, 2004); CCL2 (MCP-1), macrophage colony stimulating factor (M-CSF/CSF-1) 
and vascular endothelial growth factor (VEGF) are thought to contribute most substantially (Bingle 
et al., 2002), whilst IL-4 and IL-10 promote differentiation to an M2/alternatively-activated 
phenotype (Qian and Pollard, 2010). In fact CCL2 is widely expressed in tumours of many types 
(Scotton et al., 2001;Pollard, 2004) and the role of CCL2-CCR2 signalling in monocyte-macrophage 
mobilisation and recruitment is well established. Furthermore high levels of this chemokine 
correlate with poor prognosis (Leek and Harris, 2002;Saji et al., 2001), as does over-expression of 
CSF-1 (Lin et al., 2002;Scholl et al., 1994;Kacinski, 1995). Experimental over-expression of CSF-1 
results in earlier macrophage infiltration, accelerated tumour progression and increased 
metastasis, whilst the genetic ablation or pharmacological blockade of CSF-1 has opposing effects 
(Lin et al., 2001;Oguma et al., 2008;Abraham et al., 2010). In patients a correlation is observed 
between TAM density and poor prognosis; a recent meta-analysis demonstrated this correlation is 
evident in over 80% of studies (Bingle et al., 2002;Scholl et al., 1994). For example, in non-small 
cell lung cancer patients there is a positive correlation between intratumoural macrophage density 
and tumour grade/stage (Bonde et al., 2012). In prostate carcinoma patients a high density of 
TAMs is associated with shorter survival time (Lissbrant et al., 2000), in breast cancer patients a 
high TAM density is associated with reduced relapse-free and overall survival time (Leek et al., 
1996) and there is a strong association between increased macrophage density and poor survival 
in lung (Chen et al., 2005), hepatocellular (Zhou et al., 2009) and thyroid cancers (Ryder et al., 
2008). Conversely TAM density has been shown to be associated with good prognosis in a small 
study of colorectal cancer (Nakayama et al., 2002) and contradictory data have been obtained 
from studies of stomach cancer (Bingle et al., 2002;Scholl et al., 1994). The current understanding 
of these findings is that it is not just the density of the TAMs that is important in determining 
prognosis, rather the phenotype of these cells is also critically important. In the majority of 
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tumours TAMs take on an M2/alternatively-activated phenotype which promotes 
immunosubversion by the cancer via inhibition of cytotoxic T-cell responses (Zitvogel et al., 
2006;Kuang et al., 2009) and results in poor prognosis, whilst in a small number of cancers an 
M1/classically activated phenotype of TAMs predominates and take on a protective role by 
activating tumour-killing mechanisms, antagonise the immunosuppressive actions of M2 
macrophages and amplify beneficial T-cell responses (Murray and Wynn, 2011;Biswas and 
Mantovani, 2010;Sica and Bronte, 2007). 
 
So the majority of TAMs are M2-like and contribute to tumour progression, but how do they 
achieve this? Once within the tumour, TAMs contribute to the local microenvironment in a 
number of ways, and it is this microenvironment that is responsible for the regulation of tumour 
growth and the development of metastases. Firstly, TAMs produce a number of trophic factors 
that directly promote the survival and proliferation of cancer cells, including (but not limited to) 
endothelial growth factor (EGF), platelet-derived growth factor (PDGF) and transforming growth 
factor-β (TGF-β) (Richards et al., 2013). Secondly, due to the physiological function of 
macrophages to initiate and/or support angiogenesis, TAMs promote neovascularisation and 
angiogenesis of tumours via the synthesis and release angiogenic factors such as VEGF and 
angiopoietins (Bando and Toi, 2000;Leek and Harris, 2002). Additionally TAMs also increase the 
bioavailability of constitutively expressed VEGF as they produced matrix metalloprotease-9 
(MMP9) which releases VEGF from intracellular stores (Qian and Pollard, 2010). Macrophage 
depletion reduces angiogenesis in cancer models (Kubota et al., 2009) and inhibits angiogenesis in 
transplanted tumours (Gazzaniga et al., 2007;Halin et al., 2009;Kimura et al., 2007), conversely 
over-expression of VEGF in macrophage-depleted mice restores vascularisation capacity and 
accelerates tumour progression (Lin and Pollard, 2007). Finally TAMs are metastases-promoting; 
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the ablation of macrophages, both genetic and chemical, indicates that TAMs are required for 
efficient metastatic growth (Qian et al., 2009). Initially the interaction between TAMs and tumour 
cells promote the migration of tumours cells out of the primary tumour as TAMs respond to 
chemotactic gradients of growth factors (Wyckoff et al., 2004). TAMs also produce proteases such 
as matrix metalloproteases and cathepsins that facilitate the escape of cells from the primary 
tumour and tissue invasion into secondary sites by breaking down basement membranes (Qian 
and Pollard, 2010;Condeelis and Pollard, 2006). These cells promote intravasation of tumour cells 
into blood vessels by clustering on the abluminal side of vessels and releasing TNF-α which impairs 
the endothelial barrier (Wyckoff et al., 2007;Zervantonakis et al., 2012) and promote extravasation 
into tissues where CCL2 produced by tumour and target site stromal cells stimulates the release of 
VEGF (Qian et al., 2011). 
 
Overall the observations made in the above studies indicated that the majority of macrophages do 
indeed contribute significantly to the progression of tumour growth and that inhibiting their 
function may be beneficial rather than enhance tumour burden. Thus the modulation of 
monocyte/macrophage function that here we propose will attenuate the development of 




44B3. Future Directions 
 
Whilst the work presented here provides us with a mechanism by which VCR chemotherapy 
results in the development of chronic pain, there is much space for further investigation, not only 
into the precise cellular changes occurring but also into the divergence of pathways that this data 
hints are important. In addition the mechanism described here provides us with several novel 
targets for the development of disease specific analgesics that require further attention. These 
further avenues of investigation are described briefly below: 
 
1. An investigation of VCR-induced endothelial damage and the effect of this on 
monocyte/macrophage infiltration and activation in vivo. This can be achieved with a 
series of immunohistochemical studies examining the expression of adhesion molecules 
associated with type II endothelial activation and by assessing the structure of the 
endothelium in vivo. Similarly monocyte/macrophage activation can be assessed 
immunohistochemically by assessment of the expression of the phosphorylated forms of 
the MAP kinases known to be activated in these cells and by changes in the expression and 
release of pro-nociceptive mediators from these cells.  
2. An investigation into the role of CX3CR
intCCR2+ monocyte/macrophages in a VCR model of 
chemotherapy pain, and the potential of combined CX3CR1/CCR2 antagonism as a 
prophylactic treatment for the development of this condition. This can be achieved using a 
similar approach that used to establish the role of CX3CR1
high monocyte/macrophages 
here. 
3. Thirdly, an investigation into the contribution to pain made by central sensitisation 
induced by VCR-treatment. Here we demonstrate astrogliosis in our model in a temporal 
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profile similar to that of the development of mechanical allodynia, however reversing this 
with the glial inhibitor fluorocitrate does not impact the behavioural phenotype; do these 
cells significantly contribute to dysfunctions in nociceptive transmission in this model? 
Additionally are there changes in dorsal horn neurons as a result of chemotherapy 
treatment? Is there an increase in expression of glutamate or neuropeptide receptors? Is 
there a decrease in inhibitory input such as that seen in nerve injury models of 
neuropathic pain? Alternatively, could the astrogliosis seen here be anti- rather than pro-
nociceptive or inflammatory phenotype?  If so could this phenotype be enhanced to assist 
recovery in patients in whom this pain is already well established? 
4. Finally it is important to assess how translational this proposed mechanism is. This can be 
achieved by first assessing the contribution to pain of endothelial damage, 
monocyte/macrophage infiltration and activation, and TRPA1 activation in models of pain 
induced by chemotherapeutic agents with differing mechanisms of action (i.e. not tubulin 
disrupters). Additionally the contribution of this proposed mechanism could be assessed 
humans; however this would require either the identification of surrogate markers for 
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